
<html lang="en"     class="pb-page"  data-request-id="3e6d5c23-c03b-4397-925a-d32524a51086"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.8b00886;issue:issue:10.1021/jmcmar.2018.61.issue-15;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Unraveling the Prenylation–Cancer Paradox in Multiple Myeloma with Novel Geranylgeranyl Pyrophosphate Synthase (GGPPS) Inhibitors" /></meta><meta name="dc.Creator" content="Cyrus&#xA;M.  Lacbay" /></meta><meta name="dc.Creator" content="Daniel D.  Waller" /></meta><meta name="dc.Creator" content="Jaeok  Park" /></meta><meta name="dc.Creator" content="Mònica  Gómez Palou" /></meta><meta name="dc.Creator" content="Félix  Vincent" /></meta><meta name="dc.Creator" content="Xian Fang  Huang" /></meta><meta name="dc.Creator" content="Viviane  Ta" /></meta><meta name="dc.Creator" content="Albert M.  Berghuis" /></meta><meta name="dc.Creator" content="Michael  Sebag" /></meta><meta name="dc.Creator" content="Youla S.  Tsantrizos" /></meta><meta name="dc.Description" content="Post-translational prenylation of the small GTP-binding proteins (GTPases) is vital to a plethora of biological processes, including cellular proliferation. We have identified a new class of thieno..." /></meta><meta name="Description" content="Post-translational prenylation of the small GTP-binding proteins (GTPases) is vital to a plethora of biological processes, including cellular proliferation. We have identified a new class of thieno..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 17, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b00886" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00886" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b00886" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00886" /></link>
        
    
    

<title>Unraveling the Prenylation–Cancer Paradox in Multiple Myeloma with Novel Geranylgeranyl Pyrophosphate Synthase (GGPPS) Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b00886" /></meta><meta property="og:title" content="Unraveling the Prenylation–Cancer Paradox in Multiple Myeloma with Novel Geranylgeranyl Pyrophosphate Synthase (GGPPS) Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0008.jpeg" /></meta><meta property="og:description" content="Post-translational prenylation of the small GTP-binding proteins (GTPases) is vital to a plethora of biological processes, including cellular proliferation. We have identified a new class of thienopyrimidine-based bisphosphonate (ThP-BP) inhibitors of the human geranylgeranyl pyrophosphate synthase (hGGPPS) that block protein prenylation in multiple myeloma (MM) cells leading to cellular apoptosis. These inhibitors are also effective in blocking the proliferation of other types of cancer cells. We confirmed intracellular target engagement, demonstrated the mechanism of action leading to apoptosis, and determined a direct correlation between apoptosis and intracellular inhibition of hGGPPS. Administration of a ThP-BP inhibitor to a MM mouse model confirmed in vivo downregulation of Rap1A geranylgeranylation and reduction of monoclonal immunoglobulins (M-protein, a biomarker of disease burden) in the serum. These results provide the first proof-of-principle that hGGPPS is a valuable therapeutic target in oncology and more specifically for the treatment of multiple myeloma." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b00886"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00886">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b00886&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b00886&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b00886&amp;href=/doi/10.1021/acs.jmedchem.8b00886" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 15</span><span class="cit-fg-pageRange">, 6904-6917</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/15" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b00813" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b00908" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Unraveling the Prenylation–Cancer Paradox in Multiple Myeloma with Novel Geranylgeranyl Pyrophosphate Synthase (GGPPS) Inhibitors</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Cyrus M. Lacbay</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cyrus M. Lacbay</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry, McGill University, Montreal, QC H3A 0B8, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cyrus%0AM.++Lacbay">Cyrus M. Lacbay</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Daniel D. Waller</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daniel D. Waller</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicine, McGill University, Montreal, QC H3A 1A1, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daniel+D.++Waller">Daniel D. Waller</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jaeok Park</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jaeok Park</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry, McGill University, Montreal, QC H3G 1Y6, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jaeok++Park">Jaeok Park</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8180-3950" title="Orcid link">http://orcid.org/0000-0002-8180-3950</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mònica Gómez Palou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mònica Gómez Palou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicine, McGill University, Montreal, QC H3A 1A1, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=M%C3%B2nica++G%C3%B3mez+Palou">Mònica Gómez Palou</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Félix Vincent</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Félix Vincent</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry, McGill University, Montreal, QC H3A 0B8, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=F%C3%A9lix++Vincent">Félix Vincent</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xian Fang Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xian Fang Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicine, McGill University, Montreal, QC H3A 1A1, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xian+Fang++Huang">Xian Fang Huang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Viviane Ta</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Viviane Ta</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry, McGill University, Montreal, QC H3A 0B8, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Viviane++Ta">Viviane Ta</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Albert M. Berghuis</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Albert M. Berghuis</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry, McGill University, Montreal, QC H3G 1Y6, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Albert+M.++Berghuis">Albert M. Berghuis</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael Sebag</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Sebag</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicine, McGill University, Montreal, QC H3A 1A1, Canada</div><div class="loa-info-affiliations-info">Division of Hematology, McGill University Health Center, Montreal, QC H4A 3J1, Canada</div></div><span class="conrtib-corresp"><strong>*</strong>M.S.: e-mail, <a href="/cdn-cgi/l/email-protection#125f7b717a73777e3c6177707375527f71757b7e7e3c7173"><span class="__cf_email__" data-cfemail="94d9fdf7fcf5f1f8bae7f1f6f5f3d4f9f7f3fdf8f8baf7f5">[email protected]</span></a>; phone, + 514-843-1558.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Sebag">Michael Sebag</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Youla S. Tsantrizos</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Youla S. Tsantrizos</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry, McGill University, Montreal, QC H3A 0B8, Canada</div><div class="loa-info-affiliations-info">Department of Biochemistry, McGill University, Montreal, QC H3G 1Y6, Canada</div></div><span class="conrtib-corresp"><strong>*</strong>Y.S.T.: e-mail, <a href="/cdn-cgi/l/email-protection#0b52647e676a257f786a657f79627164784b66686c62676725686a"><span class="__cf_email__" data-cfemail="4811273d2429663c3b29263c3a2132273b08252b2f212424662b29">[email protected]</span></a>; phone, +514-398-3638.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Youla+S.++Tsantrizos">Youla S. Tsantrizos</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6231-7498" title="Orcid link">http://orcid.org/0000-0002-6231-7498</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00886&amp;href=/doi/10.1021%2Facs.jmedchem.8b00886" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 15</span><span class="cit-pageRange">, 6904–6917</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 17, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>4 June 2018</li><li><span class="item_label"><b>Published</b> online</span>17 July 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 August 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b00886" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00886</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6904%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DCyrus%250AM.%2BLacbay%252C%2BDaniel%2BD.%2BWaller%252C%2BJaeok%2BPark%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D15%26contentID%3Dacs.jmedchem.8b00886%26title%3DUnraveling%2Bthe%2BPrenylation%25E2%2580%2593Cancer%2BParadox%2Bin%2BMultiple%2BMyeloma%2Bwith%2BNovel%2BGeranylgeranyl%2BPyrophosphate%2BSynthase%2B%2528GGPPS%2529%2BInhibitors%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6917%26publicationDate%3DAugust%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b00886"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1227</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">16</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b00886" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Unraveling the Prenylation–Cancer Paradox in Multiple Myeloma with Novel Geranylgeranyl Pyrophosphate Synthase (GGPPS) Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Cyrus\nM.&quot;,&quot;last_name&quot;:&quot;Lacbay&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;D. Waller&quot;},{&quot;first_name&quot;:&quot;Jaeok&quot;,&quot;last_name&quot;:&quot;Park&quot;},{&quot;first_name&quot;:&quot;Mònica&quot;,&quot;last_name&quot;:&quot;Gómez Palou&quot;},{&quot;first_name&quot;:&quot;Félix&quot;,&quot;last_name&quot;:&quot;Vincent&quot;},{&quot;first_name&quot;:&quot;Xian&quot;,&quot;last_name&quot;:&quot;Fang Huang&quot;},{&quot;first_name&quot;:&quot;Viviane&quot;,&quot;last_name&quot;:&quot;Ta&quot;},{&quot;first_name&quot;:&quot;Albert&quot;,&quot;last_name&quot;:&quot;M. Berghuis&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Sebag&quot;},{&quot;first_name&quot;:&quot;Youla&quot;,&quot;last_name&quot;:&quot;S. Tsantrizos&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;17&quot;,&quot;issue&quot;:&quot;15&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;6904-6917&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b00886&quot;},&quot;abstract&quot;:&quot;Post-translational prenylation of the small GTP-binding proteins (GTPases) is vital to a plethora of biological processes, including cellular proliferation. We have identified a new class of thienopyrimidine-based bisphosphonate (ThP-BP) inhibitors of the human geranylgeranyl pyrophosphate synthase (hGGPPS) that block protein prenylation in multiple myeloma (MM) cells leading to cellular apoptosis. These inhibitors are also effective in blocking the proliferation of other types of cancer cells. We confirmed intracellular target engagement, demonstrated the mechanism of action leading to apoptosis, and determined a direct correlation between apoptosis and intracellular inhibition of hGGPPS. Administration of a ThP-BP inhibitor to a MM mouse model confirmed in vivo downregulation of Rap1A geranylgeranylation and reduction of monoclonal immunoglobulins (M-protein, a biomarker of disease burden) in the serum. These results provide the first proof-of-principle that hGGPPS is a valuable therapeutic target in oncolo&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00886&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00886" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00886&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00886" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00886&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00886" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00886&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00886&amp;href=/doi/10.1021/acs.jmedchem.8b00886" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b00886" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b00886" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b00886%26sid%3Dliteratum%253Aachs%26pmid%3D30016091%26genre%3Darticle%26aulast%3DLacbay%26date%3D2018%26atitle%3DUnraveling%2Bthe%2BPrenylation%25E2%2580%2593Cancer%2BParadox%2Bin%2BMultiple%2BMyeloma%2Bwith%2BNovel%2BGeranylgeranyl%2BPyrophosphate%2BSynthase%2B%2528GGPPS%2529%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D15%26spage%3D6904%26epage%3D6917%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/15" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/jmcmar.2018.61.issue-15/20180809/jmcmar.2018.61.issue-15.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/medium/jm-2018-00886c_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00886&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Post-translational prenylation of the small GTP-binding proteins (GTPases) is vital to a plethora of biological processes, including cellular proliferation. We have identified a new class of thienopyrimidine-based bisphosphonate (ThP-BP) inhibitors of the human geranylgeranyl pyrophosphate synthase (hGGPPS) that block protein prenylation in multiple myeloma (MM) cells leading to cellular apoptosis. These inhibitors are also effective in blocking the proliferation of other types of cancer cells. We confirmed intracellular target engagement, demonstrated the mechanism of action leading to apoptosis, and determined a direct correlation between apoptosis and intracellular inhibition of hGGPPS. Administration of a ThP-BP inhibitor to a MM mouse model confirmed in vivo downregulation of Rap1A geranylgeranylation and reduction of monoclonal immunoglobulins (M-protein, a biomarker of disease burden) in the serum. These results provide the first proof-of-principle that hGGPPS is a valuable therapeutic target in oncology and more specifically for the treatment of multiple myeloma.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63467" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63467" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Post-translationally modified proteins, with either farnesyl pyrophosphate (FPP) or geranylgeranyl pyrophosphate (GGPP), constitute approximately 2% of the total mammalian proteome.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Known farnesylated proteins include members of the small GTP-binding proteins (GTPases), such as the Ras superfamily (e.g., H/K/N-Ras),<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> DnaJ chaperone proteins,<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> and the precursor of the nuclear lamin A.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Geranylgeranylated GTPases include the Rho family of proteins (e.g., RhoA/B/C), the Ras-related proteins Rap1A and Rac-1, and Cdc42. Prenylation of small GTPases provides them with the ability to associate specifically with cellular membranes and participate in a plethora of cellular functions, including cell signaling and proliferation.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_p">There is a growing awareness that dysregulation of the mevalonate pathway plays a crucial role in oncogenesis and tumor cell survival.<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7−9)</a> In the past, targeting this pathway has focused mainly on inhibiting the human farnesyl pyrophosphate synthase (hFPPS) and the prenyl transferases FTase and GGTase I (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>a). Indirect inhibition of prenylation with statins<a onclick="showRef(event, 'ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12">(10−12)</a> has also been under clinical investigation and implicated in better survival of patients with multiple myeloma (MM).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Nitrogen-containing bisphosphonates (<i>N</i>-BPs; <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>b), such as zoledronic acid (<b>1</b>; ZOL) and risedronic acid (<b>2</b>; RIS), are clinically validated inhibitors of hFPPS that are used mainly for the treatment of skeletal disorders.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> Additionally, the potential value of <i>N</i>-BPs as antitumor agents has been explored in numerous studies both in vitro and in vivo. For example, clinical trials in breast cancer<a onclick="showRef(event, 'ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref19">(16−19)</a> and MM<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> have shown improved outcomes for patients treated with standard of care chemotherapy plus zoledronic acid (<b>1</b>) and the effects appeared to be unrelated to the skeletal benefits of this drug. However, there is an ongoing debate as to whether <i>N</i>-BPs are bona fide antitumor agents, since their antitumor effects in humans are minimal when used in monotherapy. The modest clinical antitumoral efficacy of <b>1</b> has been attributed to its poor cell-membrane permeability, rapid clearance from the systemic circulation, and almost negligible distribution to nonskeletal tissues.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> Consequently, more recent drug discovery efforts have focused toward the identification of non-bisphosphonate allosteric inhibitors of hFPPS.<a onclick="showRef(event, 'ref24 ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26 ref27">(24−27)</a> Numerous structurally diverse compounds have been reported; unfortunately, none of them exhibit any significant antitumor potency. Efforts directed at blocking the prenyl transferase enzymes FTase and GGTase I have also received significant attention. Several compounds, including the dual FTase/GGTase I inhibitors L-778,123 (<b>3</b>),<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> were advanced to clinical development. However, after a number of disappointing clinical trials with FTase inhibitors, it was realized that a biochemical redundancy mechanism allows cross prenylation and activation of Ras proteins (which are common drivers of oncogenesis) by GGTPase I, when FTase is inhibited.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/medium/jm-2018-00886c_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Isoprenoid substrates and inhibitors of prenylation. (a) Sequence of biochemical steps involved in the biosynthesis of isoprenoids. (b) Structures of inhibitors zoledronic acid (<b>1</b>) and risedronic acid (<b>2</b>) of hFPPS. L-778,123 (<b>3</b>) is a dual inhibitor of FTase and GGTase I. Compound <b>4</b> is a dual inhibitor of hFPPS and hGGPPS. Compounds <b>5</b> and <b>6</b> are selective inhibitors of hGGPPS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00886&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The human geranylgeranyl pyrophosphate synthase (hGGPPS) is not yet a clinically validated therapeutic target. Only a few selective inhibitors of this enzyme have been reported, and none advanced to clinical development. The precision with which hGGPPS identifies its substrates surpasses our current understanding of the molecular recognition elements required to design potent and highly selective inhibitors for this target. Although the volume of the hGGPPS active site cavity is larger than that of its functionally related upstream enzyme, hFPPS, this information alone does not provide sufficient guidance in the design of selective and drug-like inhibitors. Known inhibitors of hGGPPS include the pyridinium bisphosphonate <b>4</b><a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> and the substrate bioisosteres <b>5</b><a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> and <b>6</b><a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>b). Compound <b>4</b> exhibits negligible selectivity between hFPPS and hGGPPS,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> whereas <b>5</b> and <b>6</b> are much more selective in inhibiting hGGPPS. Triazole <i>E</i>/<i>Z</i>-<b>6</b> is currently the most potent hGGPPS inhibitor known (IC<sub>50</sub> value of 45 nM).<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35,36)</a> Interestingly, the <i>E</i>/<i>Z</i> mixture of <b>6</b> is more potent than either one of its pure isomers and presumed to bind cooperatively in both the FPP substrate and the GGPP product subpockets of hGGPPS.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> However, crystallographic confirmation of the exact binding mode of this compound has yet to be realized.</div><div class="NLM_p">In this report, we present a novel chemotype of thienopyrimide-based bisphosphonate (ThP-BP; <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) inhibitors of hGGPPS. Analogs <b>10a</b>–<b>d</b> and <b>11a</b>–<b>c</b> were identified that exhibit toxicity in various cancer cell lines and are particularly toxic to human myeloma cells, blocking prenylation and inducing apoptosis. The antimyeloma potency of some ThP-BP analogs is equivalent to that of doxorubicin while exhibiting far lower toxicity to healthy cells. Strong evidence of intracellular engagement of hGGPPS (by these inhibitors) was observed that correlates with their antimyeloma activity both in cellular assays and in vivo. The antimyeloma effects of prenylation inhibitors is a topic of significant interest. However, the necessity to develop selective inhibitors of hGGPPS has been intensely debated.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> In principle, inhibitors of hFPPS are expected to directly block activation of FPP-dependent and indirectly GGPP-dependent GTPases; the latter as a consequence of intracellular depletion of the FPP substrate of hGGPPS (e.g., zoledronic acid blocks geranylgeranylation of Rap 1A<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a>). In this report, we provide data from a large panel of human MM cell lines and MM patient bone marrow specimens suggesting that hGGPPS is a far more valuable therapeutic target for multiple myeloma than hFPPS.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/medium/jm-2018-00886c_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Examples of thienopyrimidine-based inhibitors of hFPPS/hGGPPS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00886&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18738" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18738" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Identification of hGGPPS Inhibitors and Confirmation of Binding to the Active Site</h3><div class="NLM_p">Libraries of structurally diverse thienopyrimidine-based bisphosphonates (ThP-BPs), substituted at the C-2, C-5, and/or the C-6 carbon of the parent molecule <b>7</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), were synthesized in order to probe the molecular recognition elements differentiating between binding to hFPPS versus hGGPPS.<a onclick="showRef(event, 'ref25 ref38 ref40'); return false;" href="javascript:void(0);" class="ref ref25 ref38 ref40">(25,38,40)</a> Approximately 200 analogs were screened in our in vitro assays for their ability to inhibit hFPPS and/or hGGPPS. In general, compounds substituted at C-5 (∼20 analogs) were found to be poor inhibitors of both enzymes; analogs more potent in inhibiting hFPPS were usually substituted at C-6 (∼100 analogs), whereas analogs substituted at C-2 (∼60 analogs) were inhibitors of hGGPPS with IC<sub>50</sub> potency in the nanomolar range and exhibited selectivity against hFPPS. The synthesis of compounds having a C-2 substituent is briefly described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The synthesis of this library was achieved using slightly modified literature procedures, as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>; select examples are shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/medium/jm-2018-00886c_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0007.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Parallel Synthesis of a 60-Member Compound Library<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00886&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Pathway A: Synthesis of key intermediates <b>17a,b</b>. Pathway B: Synthesis of compound library, including analogs <b>10a</b>–<b>d</b> and <b>11a</b>–<b>c</b>. Conditions: (a) MeSCN, HCl, dioxane, 70 °C, 63%; (b) diethyl phosphite, CH(OEt)<sub>3</sub>, toluene, 130 °C, 40%; (c) arylboronic acid, Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, CuTC, dioxane, 50 °C, 80–83%; (d) SnCl<sub>2</sub>·H<sub>2</sub>O, EtOH, 80 °C, 83%; (e) aryl/heteroaryl acid chloride, Et<sub>3</sub>N, DCM, 0 °C to rt or aryl/heteroaryl carboxylic acid, HBTU, DIPEA, DMF, rt, 60–80%; (f) TMSBr, DCM, 0 °C to rt, then MeOH; (g) TFA, 80 °C; >95%; (h) H<sub>2</sub>N-aryl/heteroaryl, HBTU, DIPEA, DMF, rt, 60–80%.</p></p></figure><div class="NLM_p">Initial structure–activity relationship (SAR) studies suggested that small substituents at either the C-2 or the C-6 position resulted in inhibitors with equivalent potency for both enzymes.<a onclick="showRef(event, 'ref25 ref38'); return false;" href="javascript:void(0);" class="ref ref25 ref38">(25,38)</a> For example, the phenyl derivatives <b>8</b> and <b>9</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) exhibited the same potency in inhibiting hGGPPS, with a narrow window of selectivity for hFPPS (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). On the basis of these data, we initially presumed that rotation around the C-4 amino linker, connecting the thienopyrimidine scaffold to the bisphosphonate moiety, could allow the side chains of <b>8</b> and <b>9</b> to adopt similar enzyme-bound conformations. However, SAR optimization proved that higher selectivity for hGGPPS could be achieved by extending the side chain attached to the C-2 position. Inhibitor <b>10a</b> was found to exhibit in vitro potency (IC<sub>50</sub>) of 64 nM in inhibiting hGGPPS and a selectivity window of approximately 30-fold against hFPPS (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). In contrast, when the C-2 side chain of <b>10a</b> was transferred to the C-6 position of the thienopyrimidine core <b>7</b>, the resulting analog <b>12</b> was completely inactive in both in vitro inhibition assays at the highest concentration tested of 10 μM. These results confirmed that the molecular recognition elements involved in binding to hGGPPS (vs hFPPS) are not <i>simply</i> dictated by the presence of a bisphosphonate pharmacophore or the size and length of the side chain or the binding orientation of the thienopyrimidine scaffold. Further optimization of this class of compounds led to the identification of several hGGPPS inhibitors with IC<sub>50</sub> values below 100 nM and a selectivity window of ≥15-fold. It is noteworthy that biological profiling of a 200-member library of ThP-BP compounds (a collection from this work and our previous studies<a onclick="showRef(event, 'ref25 ref38 ref40'); return false;" href="javascript:void(0);" class="ref ref25 ref38 ref40">(25,38,40)</a>) clearly demonstrated that high potency in inhibiting hGGPPS, rather than hFPPS, is the critical factor in achieving nanomolar antitumor activity in human MM cells. Representative examples of ThP-BP hGGPPS inhibitors include analogs <b>10a</b>–<b>d</b> and the reversed amides <b>11a</b>–<b>c</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Enzyme Inhibition (IC<sub>50</sub>) and Antiproliferation Activity (EC<sub>50</sub>) in MM RPMI-8226 Cells of Representative ThP-BP Analogs<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">IC<sub>50</sub> (μM)</th><th class="rowsep1 colsep0" align="center">EC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">hFPPS<a class="ref internalNav" href="#t1fn1" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">hGGPPS<a class="ref internalNav" href="#t1fn1" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">hGGPPS Y246D</th><th class="colsep0 rowsep0" align="center">RPMI-8226<a class="ref internalNav" href="#t1fn2" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">0.004</td><td class="colsep0 rowsep0" align="left">>100,000</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">0.43<a class="ref internalNav" href="#t1fn5" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">0.59</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">∼0.8<a class="ref internalNav" href="#t1fn6" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">>1.0<a class="ref internalNav" href="#t1fn6" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">0.55</td><td class="colsep0 rowsep0" align="left">0.082</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">0.20</td><td class="colsep0 rowsep0" align="left">0.094</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10a</b></td><td class="colsep0 rowsep0" align="left">2.0</td><td class="colsep0 rowsep0" align="left">0.064</td><td class="colsep0 rowsep0" align="left">0.039</td><td class="colsep0 rowsep0" align="left">0.50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10b</b></td><td class="colsep0 rowsep0" align="left">2.6</td><td class="colsep0 rowsep0" align="left">0.10</td><td class="colsep0 rowsep0" align="left">0.037</td><td class="colsep0 rowsep0" align="left">0.72</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10c</b></td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">0.085</td><td class="colsep0 rowsep0" align="left">0.092</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10d</b></td><td class="colsep0 rowsep0" align="left">>1.0<a class="ref internalNav" href="#t1fn7" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">0.042</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">0.70</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11a</b></td><td class="colsep0 rowsep0" align="left">3.0</td><td class="colsep0 rowsep0" align="left">0.049</td><td class="colsep0 rowsep0" align="left">0.050</td><td class="colsep0 rowsep0" align="left">0.46</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11b</b></td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">0.075</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">0.23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11c</b></td><td class="colsep0 rowsep0" align="left">1.4</td><td class="colsep0 rowsep0" align="left">0.086</td><td class="colsep0 rowsep0" align="left">0.075</td><td class="colsep0 rowsep0" align="left">0.14<a class="ref internalNav" href="#t1fn8" aria-label="g">g</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">IN</td><td class="colsep0 rowsep0" align="left">IN</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">IN</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">0.023</td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">>100</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup><sup>a</sup></sup><p class="last">IN: inactive at the highest concentration tested of 10 μM. nd: not determined</p></div><div class="footnote" id="t1fn1"><sup><sup>b</sup></sup><p class="last">IC<sub>50</sub> values were determined with 10 min preincubation of the enzyme with each inhibitor; the values shown are average of <i>n</i> ≥ 3 determinations with standard deviation of ±5–10%.</p></div><div class="footnote" id="t1fn2"><sup><sup>c</sup></sup><p class="last">EC<sub>50</sub> values were determined using an MTT assay after 72 h of incubation of the cells with or without an inhibitor; the values shown are average of <i>n</i> ≥ 4 determinations with standard deviation of ≤2-fold.</p></div><div class="footnote" id="t1fn5"><sup><sup>d</sup></sup><p class="last">IC<sub>50</sub> value obtained in our own in vitro inhibition assays, when compounds were tested in parallel with several other analogs in above table.</p></div><div class="footnote" id="t1fn6"><sup><sup>e</sup></sup><p class="last">Estimated values based on 70% and 40% inhibition observed for hFPPS and hGGPPS, respectively, at 1 μM.</p></div><div class="footnote" id="t1fn7"><sup><sup>f</sup></sup><p class="last">20% inhibition was observed at 1 μM.</p></div><div class="footnote" id="t1fn8"><sup><sup>g</sup></sup><p class="last">Average of five independent determinations, each run in quadruplicate.</p></div></div></div><div class="NLM_p">Binding of the ThP-BP inhibitors to the active site of hGGPPS was confirmed by crystallography and DSF studies. Crystallization of the wild-type human GGPPS has proven to be very challenging, with only one structure reported so far.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> We assumed that the multimeric organization of this enzyme, forming a trimer of homodimers (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a), may be responsible for this challenge. A more readily crystallizable Y246D mutant was created, disrupting the interdimer contacts mediated by Tyr 246 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a).<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> This mutant is dimeric; it retains the same overall structure as the wild type enzyme (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>b; PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6C56">6C56</a>; 2.80 Å resolution) and is catalytically competent (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). We solved the cocrystal structure of inhibitor <b>10d</b> bound to the Y246D mutant, and despite lower resolution (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6C57">6C57</a>; 3.50 Å resolution), we could observe the electron density for the inhibitor, as well as the anomalous signal from its sulfur atom, bound in the active site of one subunit (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>c). While the exact binding conformation is unclear, the bisphosphonate of <b>10d</b> appears to bind between the aspartate-rich motifs, competing with the pyrophosphate of FPP (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>d). Additionally, the <i>p</i>-fluorophenyl tail of <b>10d</b> appears to insert into the hydrophobic cavity formed between α<sub>D</sub> and α<sub>F</sub>, which typically accommodates the isoprenyl tail of FPP in the catalytic cycle. Binding of <b>10d</b> may also interfere with IPP binding, as the inhibitor’s thienopyrimidine core extends into the second substrate site (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>d). Binding of <b>10d</b> did not appear to involve Mg<sup>2+</sup> ions (likely due to the low resolution), and it is plausible that direct interactions with residues Arg73, Gln185, and Lys212 can contribute to the stabilization of the charged bisphosphonate (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>c). However, DSF studies clearly indicated that Mg<sup>2+</sup> ions are required for the formation of the Y246D mutant/<b>10d</b> complex and an increase in thermal stability of the protein/inhibitor complex (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00886/suppl_file/jm8b00886_si_001.pdf" class="ext-link">Figure S3</a>). Thus, our DSF data further corroborate that inhibitor <b>10d</b> binds to the active site of hGGPPS and must compete for binding with FPP.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/medium/jm-2018-00886c_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Crystal structure of wild type and mutant hGGPS. (a) Hexameric wild type hGGPPS (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2Q80">2Q80</a>). Monomer units are indicated by different colors. (b) Dimeric hGGPPS mutant (Y246D; cyan and green; PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6C56">6C56</a>). A dimer of the wild type enzyme (gray) is superposed (the inset highlights the single amino acid mutation disrupting the dimer–dimer contact). (c) Dimeric hGGPPS in complex with <b>10d</b> (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6C57">6C57</a>). The green and orange meshes represent the ligand discovery map (<i>F</i><sub>o</sub> - <i>F</i><sub>c</sub> contoured at 3σ) and the anomalous signal map (3σ), respectively. (d) Superposition of <b>10d</b>. GGPPS substrate with the structure of a sulfur derivative of FPP (FsPP) and IPP bound to the yeast enzyme (ligands in magenta; protein in semitransparent wheat; PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2E8T">2E8T</a>) are superimposed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00886&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Inhibition of Cancer Cell Proliferation and Rap1A Prenylation</h3><div class="NLM_p">Inhibitors of hGGPPS are known to block the proliferation of MM RPMI-8226 cells (e.g., <i>E</i>/<i>Z</i>-<b>6</b> was reported to exhibit an EC<sub>50</sub> of 190 ± 58 nM).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Initial profiling of our ThP-BP library was carried out only for analogs exhibiting IC<sub>50</sub> ≤ 100 nM in inhibiting hGGPPS and a minimum of a 10-fold selectivity against hFPPS. Compounds were tested up to a maximum concentration of 10 μM; higher concentrations can lead to aggregation and artifacts.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Several compounds were identified exhibiting submicromolar potency in inhibiting the proliferation of RPMI-8226 cells with inhibitors <b>11b</b> and <b>11c</b> identified as the most potent analogs (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>; <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>a). As was expected, no inhibition was observed with the structurally related, inactive compound <b>12</b> or with ThP-BP inhibitors that preferentially target hFPPS, such as analog <b>13</b>, despite similar lipophilicity (as estimated by their relative retention on a C<sub>18</sub> reversed phase HPLC column). These results strongly suggest that neither the bisphosphonate moiety nor inhibition of hFPPS are responsible for the antiproliferation activity observed with our hGGPPS inhibitors.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/medium/jm-2018-00886c_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Antimyeloma properties of thienopyrimidine-based hGGPPS inhibitors. (a) Comparison of hGGPPS inhibitor <b>11c</b>, selective hFPPS inhibitor <b>13</b>, and inactive ThP-BP compound <b>12</b>. Doxorubicin was used as a positive control. (b) Toxicity effects on normal human bronchial cells (NHBE) induced by inhibitors <b>11b</b>, <b>11c</b>, and doxorubicin. Apoptosis of MM RPMI-8226 cells after 72 h of incubation with (c) vehicle, (d) inhibitor <b>11c</b>, (e) GGOH and inhibitor <b>11c</b>, (f) GGOH alone, (g) ZOL (<b>1</b>) at the same concentration as <b>11c</b>, and (h) bortezomib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00886&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The hGGPPS inhibitor <b>11c</b> was approximately equally toxic to RPMI-8226 cells as doxorubicin (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>a) and ∼80-fold more potent than zoledronic acid (EC<sub>50</sub> ∼ 11 μM). However, <b>11c</b> was significantly less toxic to normal bronchial cells (NHBE) than doxorubicin, which exhibited an EC<sub>50</sub> of ∼300 nM (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>b). Antimyeloma potency (EC<sub>50</sub> ∼ 100–500 nM) was also observed in a genetically diverse panel of MM cell lines characteristic of the human disease, including cells carrying NF-κB activation mutations, RAS mutations, and p53 mutations/deletions (e.g., <a href="/doi/suppl/10.1021/acs.jmedchem.8b00886/suppl_file/jm8b00886_si_001.pdf" class="ext-link">Figure S4a</a>).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Given that cancers harboring genetic anomalies in p53 are commonly resistant to standard chemotherapy,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> the latter is an important observation. The antitumor effects of inhibitors <b>11b</b> and <b>11c</b> were also evaluated in a variety of other cancer cell lines with K-Ras/N-Ras overexpression and/or activating mutations, as well as an ovarian cancer cell line expressing high levels of multidrug resistant pumps (e.g., ADR-RES), along with doxorubicin as a control. In spite of their lower toxicity in normal cells, inhibitors <b>11b</b>/<b>11c</b> appeared to be as effective as (<i>or better than</i>) doxorubicin in blocking the proliferation of ADR-RES cells (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00886/suppl_file/jm8b00886_si_001.pdf" class="ext-link">Figure S4b</a>). Antitumor activity was also observed in pancreatic cancer (MiaPaCa-2) and other cancer cells with several ThP-BP analogs (examples shown in <a href="/doi/suppl/10.1021/acs.jmedchem.8b00886/suppl_file/jm8b00886_si_001.pdf" class="ext-link">Figure S4c</a>). Interestingly, the toxicity of analog <b>11b</b> in MiaPaCa-2 cells was stronger than that of L-778,123 (<b>3</b>), in spite of its bisphosphonate chemical nature. L-778,123 was advanced to phase I clinical trials in patients with pancreatic cancer (90% K-Ras mutations, but was withdrawn from development due to toxicity.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Intracellular Engagement of hGGPPS, Induction of Cell Apoptosis, and Inhibition of Rap 1A Prenylation</h3><div class="NLM_p">Evaluation of several ThP-BP analogs by flow cytometry confirmed that they induce apoptosis in RPMI-8226 cells in a dose-depended manner; zoledronic acid (<b>1</b>) and the antimyeloma drug bortezomib (a proteosome inhibitor) were used as controls. Apoptosis of RPMI-8226 cells was observed with many hGGPPS inhibitors, including compounds <b>10b</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00886/suppl_file/jm8b00886_si_001.pdf" class="ext-link">Figure S5</a>) and <b>11c</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>d). In contrast, no apoptosis was observed with <b>1</b>, when tested in parallel at the same concentration (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>g). Although induction of apoptosis in cancer cells treated with <i>N</i>-BP inhibitors of hFPPS has been previously reported (e.g., with incadronate in MM<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> and breast cancer<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> and with <b>1</b> in renal carcinoma<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> and mesothelioma<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> cells), these observations were possible only at very high concentrations of compound. Interestingly, in many of these studies greater reduction of toxicity was observed when cells were co-treated with geranylgeraniol (GGOH) than with farnesol (FOH).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> However, such observations cannot be interpreted as proof that intracellular depletion of GGPP is more toxic to cancer cells than depletion of FPP, since neither the relative cell permeability of FOH and GGOH nor their relative rates of bioconversion to their corresponding pyrophosphate metabolites are known. In our studies, complete rescue from apoptosis was observed when cells were simultaneously treated with a toxic dose of inhibitor <b>11c</b> and a nontoxic dose of geranylgeraniol (GGOH; <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>e and <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>f, respectively). These results are consistent with selective intracellular target engagement and a mechanism-based toxicity due to inhibition of hGGPPS. However, since bisphosphonates act as bioisosteres of isoprenoid metabolites, it is conceivable that in addition to inhibiting hGGPPS, our ThP-BP compounds could also potentially inhibit the transferase enzymes (e.g., GGTase I and II), an effect that may be possible to overcome by high concentrations of GGOH. More in-depth studies are required to completely rule out any additional off-target effects. We also used bortezomib to induce apoptosis (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>h) and observed no rescue when cells were co-treated with this drug and GGOH (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00886/suppl_file/jm8b00886_si_001.pdf" class="ext-link">Figure S5</a>), consistent with a mechanism of action that is independent of protein prenylation.</div><div class="NLM_p">The ability of our hGGPPS inhibitors to disrupt intracellular geranylgeranylation of small GTPases was confirmed. For example, RPMI-8226 cells were incubated with increasing concentrations of inhibitor <b>11c</b> and their lysate was analyzed by Western Blotting, using a Rap 1A antibody that specifically binds to the unprenylated form of the protein. Dose-dependent inhibition of Rap 1A prenylation was observed at concentrations as low as 150–200 nM; similar results were observed with zoledronic acid (<b>1</b>) at approximately 0.5 μM concentration (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00886/suppl_file/jm8b00886_si_001.pdf" class="ext-link">Figure S6</a>).</div><div class="NLM_p">Impairment of isoprenoid biosynthesis has been previously reported to also disrupt secretory pathway function in MM cells, leading to the accumulation of intracellular immunoglobulins and/or light chains in the endoplasmic reticulum (ER) that leads to ER stress-induced apoptosis.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> We confirmed similar results with inhibitor <b>11c</b>, which induced increased splicing of XBP1 mRNA, as a consequence of ER stress (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00886/suppl_file/jm8b00886_si_001.pdf" class="ext-link">Figure S7a</a>). Moreover, the increased XBP1 mRNA splicing caused by <b>11c</b> was largely subverted by simultaneous co-treatment with GGOH, consistent with ER stress induction due to hGGPPS inhibition. Western blot analysis also demonstrated that XBP1s (the protein product of spliced XBP1 mRNA) increased with hGGPPS inhibitor treatment, and this effect was also mitigated by GGOH co-treatment (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00886/suppl_file/jm8b00886_si_001.pdf" class="ext-link">Figure S7b</a>). Increased and decreased phosphorylation of ERK and AKT, respectively, was also observed (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00886/suppl_file/jm8b00886_si_001.pdf" class="ext-link">Figure S7b</a>). Collectively, these results suggest that intracellular inhibition of hGGPPS produces proapoptotic ERK signaling and concomitant loss of prosurvival AKT signaling in MM cells.</div><div class="NLM_p">From a biochemical perspective, a reasonable first assumption is that the inhibition of hFPPS should block all downstream events in the mevalonate pathway, thus blocking prenylation of GTPases and inducing cell apoptosis. However, our results suggest that hGGPPS plays a more important role in cancer cell biology than hFPPS. Although the low cell-based potency of zoledronic acid (<b>1</b>) may be attributed to its poor physicochemical properties, we observed a dramatic difference in antimyeloma efficacy with structurally very similar ThP-BP compounds that preferentially inhibit hGGPPS vs hFPPS (e.g., hFPPS inhibitor <b>13</b> vs hGGPPS inhibitor <b>11c</b>; <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>a), suggesting that hGGPPS may be a better therapeutic target for oncology. To gain some insight into the reasons for our observations, we analyzed the intracellular level of these biological targets that potentially need to be engaged by an inhibitor, as can be inferred from the abundance of mRNA transcripts of each enzyme in cells.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> We found that the mRNA levels of hFPPS are consistently higher than those of hGGPPS in all human MM cells (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>a). Similar differences in the mRNA levels were observed in primary cancer cells, taken from bone marrow specimens (obtained at diagnosis) of over 700 MM patients participating in a large clinical trial (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>b; CoMMpass IA10 clinical trial data (NCT01454297)].<a onclick="showRef(event, 'ref50 ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref50 ref51 ref52">(50−52)</a> Collectively, the mRNA data strongly suggest that a lower dose of a drug would be required to achieve a much higher level of intracellular engagement of hGGPPS (thus potentially leading to better clinical efficacy and greater therapeutic index) than with an inhibitor of hFPPS. This conclusion is based on the assumption that the two inhibitors (for hGGPPS vs hFPPS) have equivalent potency and similar overall biopharmaceutical profiles.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/medium/jm-2018-00886c_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. RNA transcript level (RNAseq) of hFPPS and hGGPPS. (a) mRNA expression (Log<sub>2</sub> RPKM) of hFPPS and hGGPPS in various human MM cell lines. (b) mRNA expression levels (FPKM) of hFPPS and hGGPPS in CD138-selected MM cells from patients’ bone marrow specimens obtained at diagnosis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00886&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Preclinical Evaluation of a ThP-BP Inhibitor: Metabolic Stability, Bone Affinity, and Proof-of-Principle Studies</h3><div class="NLM_p">The half-life clearance of inhibitor <b>11c</b> in male CD-1 mouse (MLM), Sprague-Dawley rat (RLM), and human (HLM) liver microsomes was found to be 128 min, 187 min, and 154 min, respectively. Given the strong association between the MM malignancy and lytic bone disease, as well as the relationship between protein geranylgeranylation and bone resorbing osteoclasts,<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> the affinity of our ThP-BP compounds for the bone mineral hydroxyapatite (HAP) was of significant importance. A validated <sup>1</sup>H NMR protocol was used to estimate the affinity of our compounds for bone.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> The relative affinity of analogs <b>11a</b> and <b>11c</b> for hydroxyapatite (HAP) was found to be equivalent to that of zoledronic acid and slightly stronger than that of risedronic acid (<sup>1</sup>H NMR data in <a href="/doi/suppl/10.1021/acs.jmedchem.8b00886/suppl_file/jm8b00886_si_001.pdf" class="ext-link">Figure S8</a>).</div><div class="NLM_p">Encouraged by the above data, the in vivo efficacy of inhibitor <b>11c</b> was subsequently investigated in a validated MM mouse model that recapitulates the characteristics of the human MM disease and mimics the therapeutic responses of MM patients to clinically validate drugs.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Vk*MYC transgenic mice were bred and maintained in a pathogen-free standard animal facility with a light/dark cycle of 12 h and provided with food and water ad libitum. They were observed daily for any signs of overt toxicity, such as significant weight loss, decreased mobility, skin lesions, inflammation at the site of injection, or morbidity, according to the Facility Animal Care Committees Protocol Number 2012-7242 from the Research Institute of McGill University Health Center (RI MUHC; Glen site) and in accordance with the Policies and Guidelines of the Canadian Council on Animal Care (CCAC).</div><div class="NLM_p">Aged mice (average 50 weeks old)<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> with disease measurable by serum protein electrophoresis (i.e., M-protein levels higher than 15% of total serum proteins, a biomarker of MM disease burden) were treated with 3 mg kg<sup>–1</sup> day<sup>–1</sup> of compound <b>11c</b> or vehicle (phosphate buffered saline; PBS) by intraperitoneal injection (ip; <i>n</i> = 8 per group, age and gender matched) over a period of 14 days (a total of 12 doses, with a drug holiday during the weekends). Weight loss was observed in all animals over the treatment period, ranging from ∼10% (<i>n</i> = 4) to 16% (<i>n</i> = 2) in the control group and 15% (<i>n</i> = 4) to 28% (<i>n</i> = 1) for the animals treated with <b>11c</b> (two of the animals in the latter group were euthanized on day 13). Some of the weight loss was attributed to stress induced by daily intraperitoneal injections and manipulation of the animals. At the end of treatment with <b>11c</b>, Western blot analysis of peripheral blood mononuclear cell (PBMC) lysates clearly showed inhibition of Rap 1A geranylgeranylation, which is the expected and desired outcome of hGGPPS inhibition, providing evidence of systemic exposure and in vivo target engagement (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>a). Encouraging antimyeloma efficacy was also observed with a decrease in serum M-protein for the mice treated with <b>11c</b> as compared to an increase for animals treated with vehicle (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>b,c). Since the half-life of mouse immunoglobulins (i.e., M-protein) is approximately 7 days,<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> the observed decrease in M-protein after less than 2 weeks of treatment (<i>albeit moderate</i>) is an exciting result that clearly proves the in vivo antimyeloma efficacy of inhibitor <b>11c</b>. It is noteworthy that for this study, daily dosing of compound <b>11c</b> (or vehicle) was carried out by ip injection, since daily dosing of mice by iv is impractical and requires implanted slow delivery iv pumps. A disadvantage to ip administration of drugs is lower systemic exposure (as compared to iv dosing) and increased absorption into the liver (due to direct transport from the peritoneal cavity into the portal vein system); the latter leads to higher potential for hepatic toxicity. Blood chemistry assessment of plasma samples (collected at the end of the study) confirmed increased alanine transaminase (ALT) and aspartate transaminase (AST) levels in some animals treated with <b>11c</b>, although the levels were highly variable (see <a href="/doi/suppl/10.1021/acs.jmedchem.8b00886/suppl_file/jm8b00886_si_001.pdf" class="ext-link">Table S3</a>). However, there was no correlation between the increase of liver enzymes, extent of weight loss, and decrease of M-protein levels for the animals treated with <b>11c</b> that could potentially imply a mechanism-based toxicity.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/medium/jm-2018-00886c_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (a) Western blot analysis of two representative PBMC samples from vehicle (lanes 1 and 2) and inhibitor <b>11c</b> treated mice (lanes 3 and 4). (b) Serum protein electrophoresis from animals treated with vehicle or inhibitor <b>11c</b>. Arrows indicated location of M-protein. (c) Analysis of M-protein as a percentage of total serum protein and expressed as a change from baseline (day 0) to day 14 for each respective mouse. Statistical analysis was performed using unpaired two-tailed Student’s <i>t</i> test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00886&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14418" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14418" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Multiple myeloma (MM) is a malignancy of B lymphocytes, characterized by the accumulation of malignant plasma cells in the bone marrow that secrete monoclonal immunoglobulins (M-protein) and give rise to a constellation of target organ damage known as CRAB (hypercalcemia, renal failure, anemia, bone disease).<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> In the past, inhibition of protein prenylation of small GTPases that are intimately involved in oncogenesis was proposed as a plausible mechanism of MM therapy. However, strong clinical proof of efficacy with inhibitors of hFPPS, FTase, and GGTase I inhibitors has been elusive. Currently, there are no known clinically validated inhibitors of hGGPPS. A new chemotype of hGGPPS inhibitors, represented by compound <b>11c</b>, was identified and found to induce antimyeloma effects both in vitro and in a reliable MM disease mouse model, which has been shown to accurately predict human drug response.</div><div class="NLM_p last">The studies herein also provide substantial evidence that the hGGPPS is a better therapeutic target for the treatment of MM than the upstream enzyme of the isoprenoid biosynthetic cascade (hFPPS). Support for this hypothesis was provided by antiproliferation data in human MM cells, which clearly showed a stronger response to compounds inhibiting hGGPPS, as compared to structurally related analogs (i.e., having very similar physicochemical properties) that are more potent at inhibiting hFPPS. Additionally, analysis of the mRNA levels of hFPPS and hGGPPS in MM cancer cells and bone marrow specimens of MM patients indicated much higher intracellular mRNA levels of hFPPS than hGGPPS. Collectively, these observations suggest that assuming selective hFPPS and hGGPPS inhibitors were identified that possessed equivalent biopharmaceutical properties, a more effective target engagement and better clinical outcome would be expected with therapeutic agents targeting hGGPPS. Furthermore, it has been proposed that the beneficial effects of <i>N</i>-BPs on bone resorption are more likely the result of indirect inhibition of geranylgeranylation (rather than direct farnesylation) of proteins in osteoclasts.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> As one of the salient features of human MM is osteolytic bone disease, compounds such as <b>11c</b> that bind to bone with high affinity (thereby concentrating in the milieu of the MM disease), inhibit geranylgeranylation (thus blocking bone resorption), and exhibit strong antimyeloma activity may provide the ideal set of therapeutic properties for the treatment of multiple myeloma.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80821" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80821" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> General Chemistry</h3><div class="NLM_p last">Chemicals and solvents were purchased from commercial suppliers and used without further purification. Normal phase column chromatography on silica gel was performed using a CombiFlash instrument using the solvent gradient, as indicated. Reverse phase preparative HPLC was carried out using a Waters Atlantis Prep T3 OBD C18 5 μm, 19 mm × 50 mm column. Solvent A: H<sub>2</sub>O, 0.1% formic acid. Solvent B: CH<sub>3</sub>CN, 0.1% formic acid. Mobile phase: gradient from 95% A and 5% B to 5% A and 95% B in 17 min acquisition time. Flow rate: 1 mL/min. The homogeneity of final inhibitors was confirmed to be ≥95% by reversed-phase HPLC using a Waters ALLIANCE instrument (e2695 with 2489 UV detector, 3100 mass spectrometer, C18 5 μm column). Solvent A: H<sub>2</sub>O, 0.1% formic acid. Solvent B: CH<sub>3</sub>CN, 0.1% formic acid. Mobile phase: linear gradient from 95% A and 5% B to 0% A and 100% B in 13 min. Key compounds were fully characterized by <sup>1</sup>H, <sup>13</sup>C, <sup>31</sup>P NMR and HRMS. Chemical shifts (δ) are reported in ppm relative to the internal deuterated solvent. The NMR spectra of all final bisphosphonate inhibitors were acquired in D<sub>2</sub>O (either after conversion to their corresponding trisodium salt or by addition of ∼2% ND<sub>4</sub>OD) or in DMSO-<i>d</i><sub>6</sub>. In some cases, the Cα to the bisphosphonate was broad and overlapped with the solvent peak, as confirmed by HSQC NMR studies. The high resolution MS spectra of final products were recorded using electrospray ionization (ESI<sup>±</sup>) and Fourier transform ion cyclotron resonance mass analyzer (FTMS). The HRMS data for inhibitors <b>10a</b>–<b>c</b>, <b>11a</b>–<b>c</b>, and <b>12</b> were acquired from the corresponding trisodium salt of the bisphosphonic acid.</div></div><div id="sec4_1_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> General Protocols for the Synthesis of Inhibitors <b>10</b> and <b>11</b>. Amide Bond Formation. Method A</h3><div class="NLM_p last">To a stirring solution of intermediate <b>18</b> (80 mg, 0.15 mmol) in dry DCM (1.5 mL) at 0 °C, dry Et<sub>3</sub>N (97 μL, 0.45 mmol) was added, followed by an acid chloride (aryl-COCl or heteroary-COCl; 0.18 mmol), which was added dropwise. The solution was stirred and allowed to warm to rt (reaction progress was monitored by TLC or LC–MS). Once complete (typically, after ∼1 h), the reaction was poured into sat. NaHCO<sub>3</sub> solution and extracted with EtOAc (2×), washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. Crude product was purified by silica gel column chromatography using a gradient from 25% EtOAc in hexanes to 100% EtOAc and then to 20% MeOH in EtOAc. Product typically eluted with 10–20% MeOH in EtOAc. Isolated yields typically ranged from 75% to quantitative.</div></div><div id="sec4_1_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Amide Bond Formation. Method B</h3><div class="NLM_p last">Alternatively, to a mixture of intermediate <b>19</b> (50 mg, 0.09 mmol) and an amine (aryl-NH<sub>2</sub> or heteroaryl-NH<sub>2</sub>) (0.1 mmol) in dry DMF (2.0 mL), DIPEA (31 μL, 0.18 mmol) was added, followed by HBTU (37.4 mg, 0.1 mmol). The solution was stirred at rt until complete conversion was observed by TLC (typically after ∼1–2 h). The reaction mixture was then diluted with brine and was extracted with EtOAc. The organic phase was washed with sat. NH<sub>4</sub>Cl solution, brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. Crude product was purified by silica-gel column chromatography as described for method A above. Isolated yields typically ranged from 60% to 80%.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Step 2. General Protocol for Conversion of the Bisphosphonate Esters to the Bisphosphonic Acids</h3><div class="NLM_p last">Deprotection was carried out using TMSBr, followed by methanolysis previously described.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Isolated yields ranged from 40% to 90%.</div></div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> (((2-(3-Benzamidophenyl)thieno[2,3-<i>d</i>]pyrimidin-4-yl)amino)methylene)bis(phosphonic acid) (<b>10a</b>)</h3><div class="NLM_p">The tetraethyl (((2-(3-benzamidophenyl)thieno[2,3-<i>d</i>]pyrimidin-4-yl)amino)methylene)bis(phosphonate) was isolated as a light yellow solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.43 (s, -NH), 8.86 (t, <i>J</i> = 1.7 Hz, 1H), 8.65 (d, <i>J</i> = 9.7 Hz, -NH), 8.12 (d, <i>J</i> = 7.9 Hz, 1H), 8.10 (d, <i>J</i> = 6.0 Hz, 1H), 8.01 (d, <i>J</i> = 7.1 Hz, 2H), 7.91 (dd, <i>J</i> = 8.1, 1.1 Hz, 1H), 7.64 (d, <i>J</i> = 6.0 Hz, 1H), 7.63–7.59 (m, 1H), 7.57–7.53 (m, 2H), 7.51 (t, <i>J</i> = 7.9 Hz, 1H), 6.06 (td, <i>J</i> = 23.3, 9.5 Hz, 1H), 4.18–4.07 (m, 8H), 1.19–1.10 (m, 12H). <sup>31</sup>P NMR (203 MHz, DMSO-<i>d</i><sub>6</sub>) δ 17.01 (s).</div><div class="NLM_p last">Inhibitor <b>10a</b> was isolated as a pale yellow solid. <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O): δ 8.36 (s, 1H), 8.18 (d, <i>J</i> = 7.9 Hz, 1H), 7.95 (d, <i>J</i> = 7.3 Hz, 2H), 7.89 (d, <i>J</i> = 8.2 Hz, 1H), 7.70–7.57 (m, 5H), 7.49 (d, <i>J</i> = 6.0 Hz, 1H), 5.13 (t, <i>J</i> = 18.6 Hz, 1H). <sup>31</sup>P NMR (162 MHz, D<sub>2</sub>O): δ 13.79 (s). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O): δ 169.8, 165.5, 159.8, 157.0, 138.7, 137.5, 133.9, 132.4, 129.5, 128.8, 127.4, 125.3, 124.3, 123.1, 122.0, 119.0, 115.9. C-α to the bisphosphonate was observed by HSQC. HSQC (<sup>1</sup>H–<sup>13</sup>C): <sup>1</sup>H at δ 5.13 correlates to <sup>13</sup>C-α at δ 49.5. HRMS [ESI<sup>+</sup>] calculated for C<sub>20</sub>H<sub>16</sub>N<sub>4</sub>Na<sub>3</sub>O<sub>7</sub>P<sub>2</sub>S <i>m</i>/<i>z</i>, 586.9903; found 586.9898 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> (((2-(3-(4-Methylbenzamido)phenyl)thieno[2,3-<i>d</i>]pyrimidin-4-yl)amino)methylene)bis(phosphonic acid) (<b>10b</b>)</h3><div class="NLM_p">The tetraethyl (((2-(3-(4-methylbenzamido)phenyl)thieno[2,3-<i>d</i>]pyrimidin-4-yl)amino)methylene)bis(phosphonate) was isolated as a pale yellow solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.34 (s, -NH), 8.85 (t, <i>J</i> = 1.8 Hz, 1H), 8.65 (d, <i>J</i> = 9.7 Hz, -NH), 8.12–8.09 (m, 2H), 7.93 (d, <i>J</i> = 8.2 Hz, 2H), 7.91 (ddd, <i>J</i> = 8.1, 2.1, 1.0 Hz, 1H), 7.64 (d, <i>J</i> = 6.0 Hz, 1H), 7.50 (t, <i>J</i> = 7.9 Hz, 1H), 7.35 (d, <i>J</i> = 7.9 Hz, 2H), 6.06 (td, <i>J</i> = 23.4, 9.7 Hz, 1H), 4.18–4.05 (m, 8H), 2.40 (s, 3H), 1.19–1.10 (m, 12H). <sup>31</sup>P NMR (203 MHz, DMSO-<i>d</i><sub>6</sub>): δ 17.00 (s). MS [ESI<sup>+</sup>] <i>m</i>/<i>z</i>: 647.2 [M + H<sup>+</sup>]<sup>+</sup>.</div><div class="NLM_p last">Inhibitor <b>10b</b> was isolated as a pale yellow solid. <sup>1</sup>H NMR (500 MHz, D<sub>2</sub>O): δ 8.38 (s, 1H), 8.20 (d, <i>J</i> = 7.6 Hz, 1H), 7.93 (d, <i>J</i> = 7.1 Hz, 1H), 7.89 (d, <i>J</i> = 7.9 Hz, 2H), 7.68–7.63 (m, 2H), 7.51 (d, <i>J</i> = 5.9 Hz, 1H), 7.46 (d, <i>J</i> = 7.9 Hz, 2H), 5.15 (t, <i>J</i> = 18.9 Hz, 1H), 2.47 (s, 3H). <sup>31</sup>P NMR (203 MHz, D<sub>2</sub>O) δ 13.82 (s). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O): δ 169.3, 165.6, 159.5, 156.8, 143.5, 138.3, 137.5, 130.7, 129.4, 129.3, 127.5, 125.0, 124.1, 123.3, 121.6, 118.8, 115.8, 48.9 (t, <i>J</i> = 124.8 Hz), 20.6. HRMS [ESI<sup>+</sup>] calculated for C<sub>21</sub>H<sub>18</sub>N<sub>4</sub>Na<sub>3</sub>O<sub>7</sub>P<sub>2</sub>S <i>m</i>/<i>z</i>, 601.00590; found 601.00773 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> (((2-(3-(4-Methoxybenzamido)phenyl)thieno[2,3-<i>d</i>]pyrimidin-4-yl)amino)methylene)bis(phosphonic acid) (<b>10c</b>)</h3><div class="NLM_p">The tetraethyl (((2-(3-(4-methoxybenzamido)phenyl)thieno[2,3-<i>d</i>]pyrimidin-4-yl)amino)methylene)bis(phosphonate) was isolated as a pale yellow solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.27 (s, -NH), 8.84 (t, <i>J</i> = 1.7 Hz, 1H), 8.65 (d, <i>J</i> = 9.7 Hz, -NH), 8.11–8.09 (m, 2H), 8.02 (d, <i>J</i> = 8.8 Hz, 2H), 7.90 (dd, <i>J</i> = 6.9, 1.2 Hz, 1H), 7.64 (d, <i>J</i> = 6.0 Hz, 1H), 7.49 (t, <i>J</i> = 7.9 Hz, 1H), 7.08 (d, <i>J</i> = 8.9 Hz, 2H), 6.06 (td, <i>J</i> = 23.4, 9.7 Hz, 1H), 4.18–4.07 (m, 8H), 3.85 (s, 3H), 1.19–1.10 (m, 12H). <sup>31</sup>P NMR (203 MHz, DMSO-<i>d</i><sub>6</sub>): δ 17.01 (s). MS [ESI<sup>+</sup>] <i>m</i>/<i>z</i>: 663.2 [M + H<sup>+</sup>]<sup>+</sup>.</div><div class="NLM_p last">Inhibitor <b>10c</b> was isolated as pale yellow solid. <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O): δ 8.36 (s, 1H), 8.19 (d, <i>J</i> = 7.8 Hz, 1H), 7.98 (d, <i>J</i> = 8.8 Hz, 2H), 7.91 (d, <i>J</i> = 8.1 Hz, 1H), 7.68–7.60 (m, 2H), 7.50 (d, <i>J</i> = 6.0 Hz, 1H), 7.17 (d, <i>J</i> = 8.9 Hz, 2H), 5.11 (t, <i>J</i> = 19.0 Hz, 1H), 3.94 (s, 3H). <sup>31</sup>P NMR (162 MHz, D<sub>2</sub>O) δ 13.78 (s). <sup>13</sup>C NMR (126 MHz, D<sub>2</sub>O): δ 169.1, 165.0, 162.2, 160.0, 156.8, 138.7, 137.6, 129.6, 129.5, 126.3, 125.1, 124.4, 122.6, 122.0, 119.2, 116.0, 114.1, 55.5. C-α to the bisphosphonate was observed by HSQC. HSQC (<sup>1</sup>H–<sup>13</sup>C): <sup>1</sup>H at δ 5.11 correlates to <sup>13</sup>C-α at δ 50.0. HRMS [ESI<sup>+</sup>] calculated for C<sub>21</sub>H<sub>18</sub>N<sub>4</sub>Na<sub>3</sub>O<sub>8</sub>P<sub>2</sub>S <i>m</i>/<i>z</i>, 617.000 82; found 617.001 81 [M + H]<sup>+</sup></div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> (((2-(3-(4-Fluorobenzamido)phenyl)thieno[2,3-<i>d</i>]pyrimidin-4-yl)amino)methylene)bis(phosphonic acid) (<b>10d</b>)</h3><div class="NLM_p">The tetraethyl (((2-(3-(4-fluorobenzamido)phenyl)thieno[2,3-<i>d</i>]pyrimidin-4-yl)amino)methylene)bis(phosphonate) was isolated as a pale yellow solid (48 mg, 65%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.39 (s, 1H), 8.28 (d, <i>J</i> = 7.9 Hz, 1H), 8.14 (d, <i>J</i> = 7.6 Hz, 1H), 8.03–7.90 (m, 3H), 7.52 (t, <i>J</i> = 8.0 Hz, 1H), 7.37 (d, <i>J</i> = 6.0 Hz, 1H), 7.21 (t, <i>J</i> = 8.5 Hz, 2H), 5.97 (d, <i>J</i> = 9.9 Hz, 1H), 5.78 (s, 1H), 4.35–4.08 (m, 8H), 1.29–1.19 (m, 12H). <sup>31</sup>P NMR (203 MHz, CDCl<sub>3</sub>): δ 16.84.</div><div class="NLM_p last">Inhibitor <b>10d</b> was isolated as a light beige solid (26.1 mg, 63%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O): δ 8.37 (s, 1H), 8.20 (d, <i>J</i> = 7.9 Hz, 1H), 8.05–7.98 (m, 2H), 7.93 (d, <i>J</i> = 8.1 Hz, 1H), 7.70–7.60 (m, 2H), 7.51 (d, <i>J</i> = 6.0 Hz, 1H), 7.39–7.29 (m, 2H), 5.17 (t, <i>J</i> = 19.0 Hz, 1H). <sup>31</sup>P NMR (162 MHz, D<sub>2</sub>O): δ 13.93 (s). <sup>13</sup>C NMR (126 MHz, D<sub>2</sub>O): δ 168.5, 165.8, 165.4, 163.8, 159.7, 156.9, 138.5, 137.4, 130.1, 130.0, 129.4, 125.1, 124.1, 122.9, 121.7, 118.9, 115.8, 115.7, 115.5, 49.5 (t, <i>J</i> = 122.7 Hz). HRMS [ESI<sup>–</sup>] calculated for C<sub>20</sub>H<sub>15</sub>FN<sub>4</sub>NaO<sub>7</sub>P<sub>2</sub>S <i>m</i>/<i>z</i> [M – 2H + Na]<sup>−</sup> 559.0024; found 559.0010 [M – 2H + Na]<sup>−</sup>.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> (((2-(3-(Phenylcarbamoyl)phenyl)thieno[2,3-<i>d</i>]pyrimidin-4-yl)amino)methylene)bis(phosphonic acid) (<b>11a</b>)</h3><div class="NLM_p">The tetraethyl (((2-(3-(phenylcarbamoyl)phenyl)thieno[2,3-<i>d</i>]pyrimidin-4-yl)amino)methylene)bis(phosphonate) was isolated as a light yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.47 (s, -NH), 8.95 (s, 1H), 8.75 (d, <i>J</i> = 9.6 Hz, -NH), 8.57 (d, <i>J</i> = 7.9 Hz, 1H), 8.10 (d, <i>J</i> = 5.7 Hz, 1H), 8.07 (d, <i>J</i> = 7.9 Hz, 1H), 7.82 (d, <i>J</i> = 7.7 Hz, 2H), 7.71–7.66 (m, 2H), 7.39–7.35 (m, 2H), 7.12 (t, <i>J</i> = 7.4 Hz, 1H), 6.03 (br, 1H), 4.18–4.00 (m, 8H), 1.19–1.08 (m, 12H). <sup>31</sup>P NMR (162 MHz, DMSO-<i>d</i><sub>6</sub>) δ 17.05 (s). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.6, 165.5, 157.5, 156.0 (t, <i>J</i> = 3.7 Hz), 139.2, 137.7, 135.5, 130.4, 129.4, 128.7, 128.6, 127.1, 123.8, 123.7, 120.3, 120.2, 115.5, 62.9–62.7 (m), 16.2–16.1 (m). C-α to the bisphosphonate was observed by HSQC. HSQC (<sup>1</sup>H–<sup>13</sup>C): <sup>1</sup>H at δ 6.03 correlates to <sup>13</sup>C-α at δ 45.1. MS [ESI<sup>+</sup>] <i>m</i>/<i>z</i>: 633.2 [M + H<sup>+</sup>]<sup>+</sup>.</div><div class="NLM_p last">Inhibitor <b>11a</b> was isolated as off-white solid. <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O): δ 8.81 (s, 1H), 8.58 (d, <i>J</i> = 7.9 Hz, 1H), 8.06 (d, <i>J</i> = 7.8 Hz, 1H), 7.76 (t, <i>J</i> = 7.8 Hz, 1H), 7.66–7.63 (m, 3H), 7.56–7.52 (m, 3H), 7.36 (t, <i>J</i> = 7.4 Hz, 1H), 5.20 (t, <i>J</i> = 19.0 Hz, 1H). <sup>31</sup>P NMR (203 MHz, D<sub>2</sub>O): δ 13.91 (s). <sup>13</sup>C NMR (126 MHz, D<sub>2</sub>O): δ 169.4, 165.5, 159.7, 157.0, 138.3, 136.9, 134.4, 132.0, 129.4, 129.3, 129.2, 126.9, 126.0, 123.2, 123.0, 119.0, 115.9, 49.3 (<sup>13</sup>C-α observed by HSQC). HSQC (<sup>1</sup>H–<sup>13</sup>C): <sup>1</sup>H at δ 5.20 correlates to <sup>13</sup>C-α at δ 49.3. HRMS [ESI<sup>+</sup>] calculated for C<sub>20</sub>H<sub>16</sub>N<sub>4</sub>Na<sub>3</sub>O<sub>7</sub>P<sub>2</sub>S <i>m</i>/<i>z</i>, 586.9903; found 586.9903 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> (((2-(3-((4-Methoxyphenyl)carbamoyl)phenyl)thieno[2,3-<i>d</i>]pyrimidin-4-yl)amino)methylene)bis(phosphonic acid) (<b>11b</b>)</h3><div class="NLM_p">The tetraethyl (((2-(3-((4-methoxyphenyl)carbamoyl)phenyl)thieno[2,3-<i>d</i>]pyrimidin-4-yl)amino)methylene)bis(phosphonate) was isolated as a light yellow solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub> with ∼0.1% CD<sub>3</sub>OD): δ 9.01 (s, 1H), 8.67 (br_s, 1H), 8.59 (d, <i>J</i> = 7.8 Hz, 1H), 8.11 (d, <i>J</i> = 7.6 Hz, 1H), 7.68 (d, <i>J</i> = 8.8 Hz, 2H), 7.61 (t, <i>J</i> = 7.7 Hz, 1H), 7.45 (d, <i>J</i> = 5.3 Hz, 1H), 7.37 (d, <i>J</i> = 6.0 Hz, 1H), 6.92 (d, <i>J</i> = 9.0 Hz, 2H), 5.86 (t, <i>J</i> = 22.3 Hz, 1H), 4.27–4.10 (m, 8H), 3.82 (s, 3H), 1.26 (t, <i>J</i> = 7.1 Hz, 6H), 1.21 (t, <i>J</i> = 7.1 Hz, 6H). <sup>31</sup>P NMR (203 MHz, CDCl<sub>3</sub>): δ 17.10 (s). MS [ESI<sup>+</sup>] <i>m</i>/<i>z</i>: 663.4 [M + H<sup>+</sup>]<sup>+</sup>.</div><div class="NLM_p last">Inhibitor <b>11b</b> was isolated as off-white solid. <sup>1</sup>H NMR (500 MHz, D<sub>2</sub>O): δ 8.74 (s, 1H), 8.54 (d, <i>J</i> = 7.8 Hz, 1H), 8.00 (d, <i>J</i> = 7.7 Hz, 1H), 7.72 (t, <i>J</i> = 7.8 Hz, 1H), 7.62 (d, <i>J</i> = 5.9 Hz, 1H), 7.51–7.49 (m, 3H), 7.06 (d, <i>J</i> = 8.9 Hz, 2H), 5.18 (t, <i>J</i> = 18.9 Hz, 1H), 3.86 (s, 3H). <sup>13</sup>C NMR (126 MHz, D<sub>2</sub>O): δ 169.3, 165.5, 159.7, 157.0, 156.7, 138.3, 134.3, 132.0, 130.1, 129.3, 129.3, 126.8, 124.8, 123.2, 118.9, 115.9, 114.4, 55.5, 49.3 (<sup>13</sup>C-α observed by HSQC). HSQC (<sup>1</sup>H–<sup>13</sup>C): <sup>1</sup>H at δ 5.18 correlates to <sup>13</sup>C-α at δ 49.3. <sup>31</sup>P NMR (203 MHz, D<sub>2</sub>O): δ 13.91 (s). HRMS [ESI<sup>+</sup>] calculated for C<sub>21</sub>H<sub>18</sub>N<sub>4</sub>Na<sub>3</sub>O<sub>8</sub>P<sub>2</sub>S <i>m</i>/<i>z</i>, 617.000 82; found 617.000 90 [M + H<sup>+</sup>]<sup>+</sup>.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> (((2-(3-((3-Fluoro-4-methoxyphenyl)carbamoyl)phenyl)thieno[2,3-<i>d</i>]pyrimidin-4-yl)amino)methylene)bis(phosphonic acid) (<b>11c</b>)</h3><div class="NLM_p">The tetraethyl (((2-(3-((3-fluoro-4-methoxyphenyl)carbamoyl)phenyl)thieno[2,3-<i>d</i>]pyrimidin-4-yl)amino)methylene)bis(phosphonate) was isolated as a yellow solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 9.28 (s, 1H), 9.10 (br_s, 1H), 8.62 (d, <i>J</i> = 7.8 Hz, 1H), 8.14 (d, <i>J</i> = 7.7 Hz, 1H), 7.70 (dd, <i>J</i> = 13.1, 2.3 Hz, 1H), 7.66 (d, <i>J</i> = 8.7 Hz, 1H), 7.59 (t, <i>J</i> = 7.7 Hz, 1H), 7.42 (d, <i>J</i> = 5.8 Hz, 1H), 7.27 (d, <i>J</i> = 6.0 Hz, 1H), 6.94 (t, <i>J</i> = 9.1 Hz, 1H), 6.77 (br_s, 1H), 5.63 (td, <i>J</i> = 22.9, 7.7 Hz, 1H), 4.24–4.11 (m, 8H), 1.24–1.20 (m, 12H). <sup>31</sup>P NMR (203 MHz, CDCl<sub>3</sub>) δ 17.27 (s). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 168.4, 165.3, 158.5, 155.8 (t, <i>J</i> = 3.3 Hz), 152.2 (d, <sup>1</sup><i>J</i><sub>CF</sub> = 244.1 Hz), 144.3 (d, <i>J</i> = 10.9 Hz), 138.0, 134.7, 132.6 (d, <i>J</i> = 9.4 Hz), 131.1, 130.2, 129.1, 126.8, 123.9, 117.9, 116.3 (d, <i>J</i> = 3.4 Hz), 115.5, 113.7 (d, <i>J</i> = 2.5 Hz), 109.7 (d, <i>J</i> = 22.6 Hz), 63.9–63.7 (m), 56.7, 46.9 (t, <i>J</i> = 147.9 Hz), 16.5–16.4 (m). MS [ESI<sup>+</sup>] <i>m</i>/<i>z</i>: 681.3 [M + H<sup>+</sup>]<sup>+</sup>.</div><div class="NLM_p last">Inhibitor <b>11c</b> was isolated as a pale yellow solid. <sup>1</sup>H NMR (500 MHz, D<sub>2</sub>O): δ 8.77 (s, 1H), 8.55 (d, <i>J</i> = 7.8 Hz, 1H), 8.03 (d, <i>J</i> = 7.8 Hz, 1H), 7.74 (t, <i>J</i> = 7.8 Hz, 1H), 7.64 (d, <i>J</i> = 5.9 Hz, 1H), 7.53–7.51 (m, 2H), 7.34 (d, <i>J</i> = 8.5 Hz, 1H), 7.23 (t, <i>J</i> = 9.1 Hz, 1H), 5.21 (t, <i>J</i> = 18.5 Hz, 1H), 3.95 (s, 3H). <sup>31</sup>P NMR (203 MHz, D<sub>2</sub>O): δ 13.90 (s). <sup>13</sup>C NMR (126 MHz, D<sub>2</sub>O): δ 168.8, 165.5, 159.5, 157.0, 151.3 (d, <sup>1</sup><i>J</i><sub>CF</sub> = 242.1 Hz), 144.3 (d, <i>J</i> = 10.9 Hz), 138.1, 133.9, 132.0, 130.5 (d, <i>J</i> = 9.4 Hz), 129.3, 129.2, 126.8, 123.2, 118.7, 118.7 (d, <i>J</i> = 3.1 Hz), 115.8, 113.9 (d, <i>J</i> = 1.9 Hz), 111.0 (d, <i>J</i> = 21.8 Hz), 56.3, 49.0 (<sup>13</sup>C-α observed by HSQC) . HSQC (<sup>1</sup>H–<sup>13</sup>C): <sup>1</sup>H at δ 5.19 correlates to <sup>13</sup>C-α at δ 49.0. HRMS [ESI<sup>+</sup>] calculated for C<sub>21</sub>H<sub>17</sub>O<sub>8</sub>N<sub>4</sub>FNa<sub>3</sub>P<sub>2</sub>S <i>m</i>/<i>z</i>, 634.991 40; found 634.991 64 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> (((6-(3-Benzamidophenyl)thieno[2,3-<i>d</i>]pyrimidin-4-yl)amino)methylene)bis(phosphonic acid) (<b>12</b>)</h3><div class="NLM_p">Suzuki cross-coupling between intermediate tetraethyl (((6-bromothieno[2,3-<i>d</i>]pyrimidin-4-yl)amino)methylene)bis(phosphonate), which was previously reported,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> and (3-benzamidophenyl)boronic acid (prepared as previously reported<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a>) gave the tetraethyl (((6-(3-benzamidophenyl)thieno[2,3-<i>d</i>]pyrimidin-4-yl)amino)methylene)bis(phosphonate), isolated as a light yellow solid (82%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.43 (s, -NH), 8.71 (d, <i>J</i> = 9.7 Hz, -NH), 8.54 (s, 1H), 8.45 (s, 1H), 8.31 (d, <i>J</i> = 2.3 Hz, 1H), 8.03–7.99 (m, 2H), 7.77 (d, <i>J</i> = 7.5 Hz, 1H), 7.64–7.44 (m, 5H), 5.81 (td, <i>J</i> = 23.5, 9.1 Hz, 1H), 4.16–4.02 (m, 8H), 1.23–1.11 (m, 12H). <sup>31</sup>P NMR (162 MHz, DMSO-<i>d</i><sub>6</sub>) δ 16.88 (s). MS [ESI<sup>+</sup>] <i>m</i>/<i>z</i>: 633.2 [M + H<sup>+</sup>]<sup>+</sup>.</div><div class="NLM_p last">Inhibitor <b>12</b> was isolated as a pale yellow solid. <sup>1</sup>H NMR (500 MHz, D<sub>2</sub>O): δ 8.27 (s, 1H), 7.92–7.89 (m, 4H), 7.67–7.63 (m, 2H), 7.59–7.56 (m, 3H), 7.52 (t, <i>J</i> = 7.9 Hz, 1H). α-CH to the bisphosphonate overlaps with the solvent peak. <sup>31</sup>P NMR (203 MHz, D<sub>2</sub>O): δ 13.53 (s). <sup>13</sup>C NMR (126 MHz, D<sub>2</sub>O): δ 169.3, 163.2, 156.2, 153.5, 138.7, 137.9, 133.9, 133.5, 132.4, 129.9, 128.7, 127.3, 122.8, 121.8, 119.0, 118.6, 115.1, 50.8 (t, <i>J</i> = 125.7 Hz). HRMS [ESI<sup>+</sup>] calculated for C<sub>20</sub>H<sub>16</sub>N<sub>4</sub>Na<sub>3</sub>O<sub>7</sub>P<sub>2</sub>S <i>m</i>/<i>z</i>, 586.9903; found 586.9906 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 2-(Methylthio)thieno[2,3-<i>d</i>]pyrimidin-4-amine (<b>15</b>)</h3><div class="NLM_p last">2-Amino-5-methylthiophene-3-carbonitrile (<b>14</b>; 2.5 g, 20 mmol) was added to HCl (4 M in dioxane; 30.2 mL, 121 mmol), followed by methyl thiocyanate (1.4 mL, 20 mmol). The resulting suspension was heated to 70 °C in a sealed pressure tube for 36 h. The mixture was allowed to cool to rt, and the resulting green precipitate was collected by vacuum filtration. The solid was dissolved in EtOAc, washed with saturated aqueous NaHCO<sub>3</sub>, and the aqueous phase was extracted further with EtOAc. The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. Intermediate <b>15</b> was obtained as a light brown solid (2.52g, 63%) and was used in the next step without further purification. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.55 (br_s, 2H), 7.47 (d, <i>J</i> = 5.9 Hz, 1H), 7.36 (d, <i>J</i> = 5.9 Hz, 1H), 2.46 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.5, 166.5, 158.3, 120.7, 120.2, 113.4, 13.8. MS [ESI<sup>+</sup>] <i>m</i>/<i>z</i>: 198.0 [M + H<sup>+</sup>]<sup>+</sup>.</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Tetraethyl (((2-(Methylthio)thieno[2,3-<i>d</i>]pyrimidin-4-yl)amino)methylene)bis(phosphonate) (<b>16</b>)</h3><div class="NLM_p last">In a pressure vessel, diethyl phosphite (5.5 mL, 43 mmol) and triethyl orthoformate (1.7 mL, 10 mmol) were added to a solution of <b>15</b> (1.2 g, 6.1 mmol) in dry toluene (5.0 mL). The resulting mixture was heated at 130 °C for 40 h (monitored by TLC and/or LC–MS). The mixture was then cooled to rt and concentrated in vacuo. Crude product was purified by silica gel column chromatography. The product, intermediate <b>16</b>, eluted from the column with 10–20% MeOH in EtOAC and obtained as a light yellow solid (1.2 g, 41%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.70 (d, <i>J</i> = 9.7 Hz, -NH), 7.97 (d, <i>J</i> = 6.0 Hz, 1H), 7.45 (d, <i>J</i> = 6.0 Hz, 1H), 5.70 (td, <i>J</i> = 23.6, 9.7 Hz, 1H), 4.14–4.02 (m, 8H), 2.50 (s, 3H), 1.21 (t, <i>J</i> = 7.1 Hz, 6H), 1.14 (t, <i>J</i> = 7.0 Hz, 6H). <sup>31</sup>P NMR (203 MHz, DMSO-<i>d</i><sub>6</sub>): δ 16.77 (s). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.3, 165.4, 155.12 (t, <i>J</i> = 4.1 Hz), 121.1, 120.1, 113.6, 62.9–62.7 (m), 44.4 (t, <i>J</i> = 147.3 Hz), 16.2–16.1 (m), 13.5. MS [ESI<sup>+</sup>] <i>m</i>/<i>z</i>: 484.1 [M + H<sup>+</sup>]<sup>+</sup>.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> General Protocol for the Synthesis of Intermediates <b>17a</b> and <b>17b</b></h3><div class="NLM_p last">This cross-coupling reaction was based on the literature with slight modifications.<a onclick="showRef(event, 'ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref60 ref61">(60,61)</a> Intermediate <b>16</b> (880 mg, 1.8 mmol), the arylboronic acid (4.6 mmol; obtained commercially or prepared using well established methods), CuTC (1.04 g, 5.5 mmol), and Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub> (150 mg, 0.18 mmol) were charged into an oven-dried round-bottom flask. The flask was evacuated and purged with Ar, followed by addition of dry dioxane (10.0 mL). The flask was sealed and heated at 50 °C for 4–16 h (under Ar balloon; monitored by TLC or LC–MS). The reaction mixture was cooled to rt, diluted with EtOAc, and filtered through Celite. The filtrate was collected and washed with 10% aqueous NH<sub>4</sub>OH (thrice), followed by brine. The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. Crude product was purified by silica gel column chromatography with a gradient from 25% EtOAc in hexanes to 100% EtOAc and then to 20% MeOH in EtOAc. Product typically eluted from the column with 10–20% MeOH in EtOAc and isolated in ∼80–85% yield.</div></div><div id="sec4_3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Tetraethyl (((2-(3-Nitrophenyl)thieno[2,3-<i>d</i>]pyrimidin-4-yl)amino)methylene)bis(phosphonate) (<b>17a</b>)</h3><div class="NLM_p last">Isolated as light brown solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.12 (t, <i>J</i> = 1.9 Hz, 1H), 8.85 (d, <i>J</i> = 9.6 Hz, -NH), 8.80 (d, <i>J</i> = 7.9 Hz, 1H), 8.35 (ddd, <i>J</i> = 8.2, 2.4, 0.9 Hz, 1H), 8.14 (d, <i>J</i> = 6.0 Hz, 1H), 7.84 (t, <i>J</i> = 8.0 Hz, 1H), 7.72 (d, <i>J</i> = 6.0 Hz, 1H), 5.99 (td, <i>J</i> = 23.5, 9.6 Hz, 1H), 4.23–4.02 (m, 8H), 1.20 (t, <i>J</i> = 7.0 Hz, 6H), 1.12 (t, <i>J</i> = 7.0 Hz, 6H). <sup>31</sup>P NMR (203 MHz, DMSO-<i>d</i><sub>6</sub>): δ 16.9. <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.8, 156.5 (t, <i>J</i> = 4.0 Hz), 156.4, 148.7, 139.6, 134.1, 130.8, 125.3, 124.9, 122.4, 120.8, 116.4, 63.4–63.2 (m), 45.0 (t, <i>J</i> = 147.2 Hz), 16.7–16.6 (m). MS [ESI<sup>+</sup>] <i>m</i>/<i>z</i>: 559.1 [M + H<sup>+</sup>]<sup>+</sup>.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Benzyl 3-(4-((Bis(diethoxyphosphoryl)methyl)amino)thieno[2,3-<i>d</i>]pyrimidin-2-yl)benzoate (<b>17b</b>)</h3><div class="NLM_p last">Isolated as a light yellow solid. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ 9.09 (s, 1H), 8.66 (d, <i>J</i> = 7.8 Hz, 1H), 8.14 (dd, <i>J</i> = 7.7, 1.1 Hz, 1H), 7.72 (d, <i>J</i> = 6.0 Hz, 1H), 7.64–7.58 (m, 1H), 7.55 (dd, <i>J</i> = 6.0, 1.5 Hz, 1H), 7.49 (d, <i>J</i> = 7.9 Hz, 2H), 7.41 (t, <i>J</i> = 7.5 Hz, 2H), 7.36–7.32 (m, 1H), 6.19 (t, <i>J</i> = 23.5 Hz, 1H), 5.42 (s, 2H), 4.24–4.18 (m, 8H), 1.27–1.21 (m, 12H). <sup>31</sup>P NMR (203 MHz, CD<sub>3</sub>OD): δ 17.17 (s). <sup>13</sup>C NMR (126 MHz, CD<sub>3</sub>OD): δ 169.5, 167.5, 159.4, 157.4 (t, <i>J</i> = 3.9 Hz), 139.7, 137.6, 133.6, 132.2, 131.8, 130.1, 129.9, 129.7, 129.3, 129.3, 125.3, 119.8, 117.1, 67.9, 65.2–65.1 (m), 45.5 (t, <i>J</i> = 150.0 Hz), 16.7–16.6 (m). MS [ESI<sup>–</sup>] <i>m</i>/<i>z</i>: 648.3 [M – H<sup>+</sup>]<sup>−</sup>.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Tetraethyl (((2-(3-Aminophenyl)thieno[2,3-<i>d</i>]pyrimidin-4-yl)amino)methylene)bis(phosphonate) (<b>18</b>)</h3><div class="NLM_p last">In a pressure vessel containing intermediate <b>17a</b> (500 mg, 0.90 mmol) in EtOH (9.0 mL), SnCl<sub>2</sub>·2H<sub>2</sub>O (1.01 g, 4.5 mmol) was added, and the mixture was stirred at 80 °C for 2–3 h. The reaction mixture was cooled to rt and then slowly poured into sat. NaHCO<sub>3</sub> solution (9.0 mL). It was then extracted with EtOAc (3×), brine (once), dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated in vacuo. Intermediate <b>18</b> was obtained as a light yellow solid (392 mg, 83% yield) and was used in the next step without further purification. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.52 (d, <i>J</i> = 9.7 Hz, 1H), 8.06 (d, <i>J</i> = 6.0 Hz, 1H), 7.64–7.62 (m, 1H), 7.58 (d, <i>J</i> = 6.0 Hz, 1H), 7.53 (d, <i>J</i> = 7.7 Hz, 1H), 7.14 (t, <i>J</i> = 7.8 Hz, 1H), 6.67 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H), 6.01 (td, <i>J</i> = 23.5, 9.7 Hz, 1H), 5.22 (s, 2H), 4.15–4.05 (m, 8H), 1.16 (t, <i>J</i> = 7.0 Hz, 6H), 1.11 (t, <i>J</i> = 7.0 Hz, 6H). <sup>31</sup>P NMR (203 MHz, DMSO-<i>d</i><sub>6</sub>): δ 17.18 (s). MS [ESI<sup>+</sup>] <i>m</i>/<i>z</i>: 529.1 [M + H<sup>+</sup>]<sup>+</sup>.</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 3-(4-((Bis(diethoxyphosphoryl)methyl)amino)thieno[2,3-<i>d</i>]pyrimidin-2-yl)benzoic Acid (<b>19</b>)</h3><div class="NLM_p last">A solution of intermediate <b>17b</b> (271 mg, 0.42 mmol) in neat TFA (4.6 mL) was stirred at 80 °C for 14 h (monitored by TLC). TFA was then removed by evaporation in vacuo, and the residue was dissolved in DCM, and the solvent was evaporated again under reduced pressure (done at least twice). Crude product was purified by silica gel column chromatography using a gradient of 50% EtOAc in hexanes to 100% EtOAc and then to 15% MeOH in EtOAc. Product was isolated as a light brown solid (quantitative yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub> with ∼0.1% CD<sub>3</sub>OD): δ 9.20 (s, 1H), 8.70 (d, <i>J</i> = 7.9 Hz, 1H), 8.19 (d, <i>J</i> = 7.7 Hz, 1H), 7.70 (d, <i>J</i> = 6.0 Hz, 1H), 7.59 (t, <i>J</i> = 7.8 Hz, 1H), 7.40 (d, <i>J</i> = 6.0 Hz, 1H), 6.08 (t, <i>J</i> = 22.2 Hz, 1H), 4.29–4.18 (m, 8H), 1.29 (t, <i>J</i> = 7.0 Hz, 6H), 1.20 (t, <i>J</i> = 7.0 Hz, 6H). <sup>31</sup>P NMR (203 MHz, CDCl<sub>3</sub>): δ 17.50 (s). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub> with ∼0.1% CD<sub>3</sub>OD) δ 169.2, 168.3, 158.4, 155.8, 138.4, 132.7, 131.5, 129.8, 128.6, 123.8, 118.8, 115.9, 115.8, 64.2 (br), 44.1 (t, <i>J</i> = 147.0 Hz, 1H), 16.2 (br). MS [ESI<sup>+</sup>] <i>m</i>/<i>z</i>: 558.1 [M + H<sup>+</sup>]<sup>+</sup>.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i31"><a href="/doi/suppl/10.1021/acs.jmedchem.8b00886" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84001" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84001" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the ACS Publications Web site at DOI:10.1021/acs.jmedchem- .  (CSV). The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b00886" class="ext-link">10.1021/acs.jmedchem.8b00886</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Experimental procedures for (a) the expression, purification, and in vitro assay of recombinant hGGPPS, (b) creation of the dimeric Y246D mutant of hGGPPS and crystallographic studies with inhibitor <b>10d</b>, (c) cell culture and viability assays for MM cell lines, (d) cell culture for various other cancer cell lines (non-MM), (e) determination of cancer cell viability for non-MM cancer cells, (f) annexin-V apoptosis assays, (g) Western blot analysis, (h) XBP1 mRNA splicing, (i) metabolic stability, (j) in vivo experiments with MM mouse diseases model, (k) serum protein electrophoresis (SPEP), (l) isolation of peripheral blood mononuclear cells (PBMCs), (m) DSF studies; Figures S1–S8; Tables S1–S3; <sup>1</sup>H, <sup>31</sup>C, <sup>31</sup>P NMR spectra and HPLC chromatograms for inhibitors <b>10a</b>–<b>d</b> and <b>11a</b>–<b>c</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00886/suppl_file/jm8b00886_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and biological data (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00886/suppl_file/jm8b00886_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00886/suppl_file/jm8b00886_si_001.pdf">jm8b00886_si_001.pdf (2.61 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00886/suppl_file/jm8b00886_si_002.csv">jm8b00886_si_002.csv (1.25 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The PDB accession codes for the X-ray structures of the dimeric hGGPPS Y245D mutant and the structure of <b>10d</b> bound to this mutant are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6C56">6C56</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6C57">6C57</a>, respectively. Authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.8b00886" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84434" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84434" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Sebag</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicine, McGill University, Montreal, QC H3A 1A1, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Division
of Hematology, McGill University Health
Center, Montreal, QC H4A 3J1, Canada</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c68bafa5aea7a3aae8b5a3a4a7a186aba5a1afaaaae8a5a7"><span class="__cf_email__" data-cfemail="fcb1959f949d9990d28f999e9d9bbc919f9b959090d29f9d">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Youla S. Tsantrizos</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, McGill University, Montreal, QC H3A 0B8, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Biochemistry, McGill University, Montreal, QC H3G 1Y6, Canada</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6231-7498" title="Orcid link">http://orcid.org/0000-0002-6231-7498</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4811273d2429663c3b29263c3a2132273b08252b2f212424662b29"><span class="__cf_email__" data-cfemail="61380e140d004f1512000f1513081b0e12210c0206080d0d4f0200">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cyrus
M. Lacbay</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, McGill University, Montreal, QC H3A 0B8, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel D. Waller</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicine, McGill University, Montreal, QC H3A 1A1, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jaeok Park</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry, McGill University, Montreal, QC H3G 1Y6, Canada</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8180-3950" title="Orcid link">http://orcid.org/0000-0002-8180-3950</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mònica Gómez Palou</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicine, McGill University, Montreal, QC H3A 1A1, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Félix Vincent</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, McGill University, Montreal, QC H3A 0B8, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xian Fang Huang</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicine, McGill University, Montreal, QC H3A 1A1, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Viviane Ta</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, McGill University, Montreal, QC H3A 0B8, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Albert M. Berghuis</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry, McGill University, Montreal, QC H3G 1Y6, Canada</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>C.M.L., D.D.W., and M.G.P contributed equally. Author contributions are the following: conceptualization and coordination of project (Y.S.T.); design of hematology, cellular, and in vivo studies (M.S.); library synthesis and in vitro evaluation of inhibitors (C.M.L.); biology experiments (D.D.W., M.G.P., X.F.H., J.P); cloning, protein production, and crystallography (J.P., V.T., A.M.B.); DSF and bone affinity studies (F.V.)</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e3555-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02830" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02830" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Financial support for this work was provided by the Canadian Institute of Health Research (CIHR) and Fonds Québécois de la Research sur la Nature et les Technologies (FRQNT) research grants to A.M.B., M.S. and Y.S.T. Data in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>b was generated as part of the Multiple Myeloma Research Foundation Personalized Medicine Initiatives (<a href="https://research.themmrf.org" class="extLink">https://research.themmrf.org</a> and <a href="http://www.themmrf.org" class="extLink">www.themmrf.org</a>). The authors thank Opher Gileadi of the Structural Genomics Consortium (SGC) at the University of Oxford for providing the wild-type human GGPPS pNIC28-Bsa4 vector.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">hFPPS</td><td class="NLM_def"><p class="first last">human farnesyl pyrophosphate synthase</p></td></tr><tr><td class="NLM_term">hGGPPS</td><td class="NLM_def"><p class="first last">human geranylgeranyl pyrophosphate synthase</p></td></tr><tr><td class="NLM_term">FTase</td><td class="NLM_def"><p class="first last">farnesyl transferase</p></td></tr><tr><td class="NLM_term">GGTase I and II</td><td class="NLM_def"><p class="first last">geranylgeranyl transferase I and II</p></td></tr><tr><td class="NLM_term">GTPase</td><td class="NLM_def"><p class="first last">small GTP-binding protein</p></td></tr><tr><td class="NLM_term">MM</td><td class="NLM_def"><p class="first last">multiple myeloma</p></td></tr><tr><td class="NLM_term">MLM</td><td class="NLM_def"><p class="first last">mouse liver microsome</p></td></tr><tr><td class="NLM_term">RLM</td><td class="NLM_def"><p class="first last">rat liver microsome</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">huma liver microsome</p></td></tr><tr><td class="NLM_term">SPEP</td><td class="NLM_def"><p class="first last">serum protein electrophoresis</p></td></tr><tr><td class="NLM_term">PBMC</td><td class="NLM_def"><p class="first last">peripheral blood mononuclear cell</p></td></tr><tr><td class="NLM_term">DSF</td><td class="NLM_def"><p class="first last">differential scanning fluorimetry</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate buffered saline</p></td></tr><tr><td class="NLM_term">ip</td><td class="NLM_def"><p class="first last">intraperitoneal injection</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55142" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55142" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 62 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, U. T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deraeve, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fränzel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bon, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blankenfeldt, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goody, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolters, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexandrov, K.</span></span> <span> </span><span class="NLM_article-title">Analysis of the eukaryotic prenylome by isoprenoid affinity tagging <i>Nature</i></span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">227</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.1038/nchembio.149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1038%2Fnchembio.149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=19219049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvFKju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=227-235&author=U.+T.+T.+Nguyenauthor=Z.+Guoauthor=C.+Delonauthor=Y.+Wuauthor=C.+Deraeveauthor=B.+Fr%C3%A4nzelauthor=R.+S.+Bonauthor=W.+Blankenfeldtauthor=R.+S.+Goodyauthor=H.+Waldmannauthor=D.+Woltersauthor=K.+Alexandrov&title=Analysis+of+the+eukaryotic+prenylome+by+isoprenoid+affinity+tagging+Nature&doi=10.1038%2Fnchembio.149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of the eukaryotic prenylome by isoprenoid affinity tagging</span></div><div class="casAuthors">Nguyen, Uyen T. T.; Guo, Zhong; Delon, Christine; Wu, Yaowen; Deraeve, Celine; Fraenzel, Benjamin; Bon, Robin S.; Blankenfeldt, Wulf; Goody, Roger S.; Waldmann, Herbert; Wolters, Dirk; Alexandrov, Kirill</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">227-235</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein prenylation is a widespread phenomenon in eukaryotic cells that affects many important signaling mols.  The authors describe the structure-guided design of engineered protein prenyltransferases and their universal synthetic substrate, biotin-geranylpyrophosphate.  These new tools allowed the authors to detect femtomolar amts. of prenylatable proteins in cells and organs and to identify their cognate protein prenyltransferases.  Using this approach, the authors analyzed the in vivo effects of protein prenyltransferase inhibitors.  Whereas some of the inhibitors displayed the expected activities, others lacked in vivo activity or targeted a broader spectrum of prenyltransferases than previously believed.  To quantitate the in vivo effect of the prenylation inhibitors, the authors profiled biotin-geranyl-tagged Rab-GTPases across the proteome by mass spectrometry.  The authors also demonstrate that sites of active vesicular transport carry most of the Rab-GTPases.  This approach enables a quant. proteome-wide anal. of the regulation of protein prenylation and its modulation by therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtjML3f4rJZLVg90H21EOLACvtfcHk0liJEIDTGShxMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvFKju7g%253D&md5=55c806fee6cd3e6276bf9e5f92571352</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.149%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DU.%2BT.%2BT.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DDelon%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DDeraeve%26aufirst%3DC.%26aulast%3DFr%25C3%25A4nzel%26aufirst%3DB.%26aulast%3DBon%26aufirst%3DR.%2BS.%26aulast%3DBlankenfeldt%26aufirst%3DW.%26aulast%3DGoody%26aufirst%3DR.%2BS.%26aulast%3DWaldmann%26aufirst%3DH.%26aulast%3DWolters%26aufirst%3DD.%26aulast%3DAlexandrov%26aufirst%3DK.%26atitle%3DAnalysis%2520of%2520the%2520eukaryotic%2520prenylome%2520by%2520isoprenoid%2520affinity%2520tagging%2520Nature%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D5%26spage%3D227%26epage%3D235%26doi%3D10.1038%2Fnchembio.149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kho, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaunbergs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinbaum, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamanoi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span> <span> </span><span class="NLM_article-title">A tagging-via-substrate technology for detection and proteomics of farnesylated proteins</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">12479</span>– <span class="NLM_lpage">12484</span>, <span class="refDoi"> DOI: 10.1073/pnas.0403413101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1073%2Fpnas.0403413101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=15308774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsVens7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=12479-12484&author=Y.+Khoauthor=S.+C.+Kimauthor=C.+Jiangauthor=D.+Barmaauthor=S.+W.+Kwonauthor=J.+Chengauthor=J.+Jaunbergsauthor=C.+Weinbaumauthor=F.+Tamanoiauthor=J.+Falckauthor=Y.+Zhao&title=A+tagging-via-substrate+technology+for+detection+and+proteomics+of+farnesylated+proteins&doi=10.1073%2Fpnas.0403413101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">A tagging-via-substrate technology for detection and proteomics of farnesylated proteins</span></div><div class="casAuthors">Kho, Yoonjung; Kim, Sung Chan; Jiang, Chen; Barma, Deb; Kwon, Sung Won; Cheng, Jinke; Jaunbergs, Janis; Weinbaum, Carolyn; Tamanoi, Fuyuhiko; Falck, John; Zhao, Yingming</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">12479-12484</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A recently developed proteomics strategy, designated tagging-via-substrate (TAS) approach, is described for the detection and proteomic anal. of farnesylated proteins.  TAS technol. involves metabolic incorporation of a synthetic azido-farnesyl analog and chemoselective derivatization of azido-farnesyl-modified proteins by an elegant version of Staudinger reaction, pioneered by the Bertozzi group, using a biotinylated phosphine capture reagent.  The resulting protein conjugates can be specifically detected and/or affinity-purified by streptavidin-linked horseradish peroxidase or agarose beads, resp.  Thus, the technol. enables global profiling of farnesylated proteins by enriching farnesylated proteins and reducing the complexity of farnesylation subproteome.  Azido-farnesylated proteins maintain the properties of protein farnesylation, including promoting membrane assocn., Ras-dependent mitogen-activated protein kinase k activation, and inhibition of lovastatin-induced apoptosis.  A proteomic anal. of farnesylated proteins by TAS technol. revealed 18 farnesylated proteins, including those with potentially novel farnesylation motifs, suggesting that future use of this method is likely to yield novel insight into protein farnesylation.  TAS technol. can be extended to other posttranslational modifications, such as geranylgeranylation and myristoylation, thus providing powerful tools for detection, quantification, and proteomic anal. of posttranslationally modified proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6gC0ZaOzxhbVg90H21EOLACvtfcHk0liJEIDTGShxMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsVens7Y%253D&md5=e0c77d3d0eadf7c244402094e7de62a4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0403413101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0403413101%26sid%3Dliteratum%253Aachs%26aulast%3DKho%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DS.%2BC.%26aulast%3DJiang%26aufirst%3DC.%26aulast%3DBarma%26aufirst%3DD.%26aulast%3DKwon%26aufirst%3DS.%2BW.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DJaunbergs%26aufirst%3DJ.%26aulast%3DWeinbaum%26aufirst%3DC.%26aulast%3DTamanoi%26aufirst%3DF.%26aulast%3DFalck%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DY.%26atitle%3DA%2520tagging-via-substrate%2520technology%2520for%2520detection%2520and%2520proteomics%2520of%2520farnesylated%2520proteins%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26spage%3D12479%26epage%3D12484%26doi%3D10.1073%2Fpnas.0403413101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stark, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehla, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaika, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acton, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montelione, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, R.</span></span> <span> </span><span class="NLM_article-title">Structure and function of human DnaJ homologues subfamily A member 1 (DNAJA1) and its relationship to pancreatic cancer</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1360</span>– <span class="NLM_lpage">1372</span>, <span class="refDoi"> DOI: 10.1021/bi401329a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi401329a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=1360-1372&author=J.+L.+Starkauthor=K.+Mehlaauthor=N.+Chaikaauthor=T.+B.+Actonauthor=R.+Xiaoauthor=P.+K.+Singhauthor=G.+T.+Montelioneauthor=R.+Powers&title=Structure+and+function+of+human+DnaJ+homologues+subfamily+A+member+1+%28DNAJA1%29+and+its+relationship+to+pancreatic+cancer&doi=10.1021%2Fbi401329a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fbi401329a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi401329a%26sid%3Dliteratum%253Aachs%26aulast%3DStark%26aufirst%3DJ.%2BL.%26aulast%3DMehla%26aufirst%3DK.%26aulast%3DChaika%26aufirst%3DN.%26aulast%3DActon%26aufirst%3DT.%2BB.%26aulast%3DXiao%26aufirst%3DR.%26aulast%3DSingh%26aufirst%3DP.%2BK.%26aulast%3DMontelione%26aufirst%3DG.%2BT.%26aulast%3DPowers%26aufirst%3DR.%26atitle%3DStructure%2520and%2520function%2520of%2520human%2520DnaJ%2520homologues%2520subfamily%2520A%2520member%25201%2520%2528DNAJA1%2529%2520and%2520its%2520relationship%2520to%2520pancreatic%2520cancer%26jtitle%3DBiochemistry%26date%3D2014%26volume%3D53%26spage%3D1360%26epage%3D1372%26doi%3D10.1021%2Fbi401329a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kampinga, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craig, E. A.</span></span> <span> </span><span class="NLM_article-title">The HSP70 chaperone machinery J proteins as drivers of functional specificity</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">579</span>– <span class="NLM_lpage">592</span>, <span class="refDoi"> DOI: 10.1038/nrm2941</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1038%2Fnrm2941" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=20651708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1arsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=579-592&author=H.+H.+Kampingaauthor=E.+A.+Craig&title=The+HSP70+chaperone+machinery+J+proteins+as+drivers+of+functional+specificity&doi=10.1038%2Fnrm2941"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The HSP70 chaperone machinery: J proteins as drivers of functional specificity</span></div><div class="casAuthors">Kampinga, Harm H.; Craig, Elizabeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">579-592</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Heat-shock 70-kDa proteins (HSP70s) are ubiquitous mol. chaperones that function in a myriad of biol. processes, modulating polypeptide folding, degrdn., and translocation across membranes, and protein-protein interactions.  This multitude of roles is not easily reconciled with the universality of the activity of HSP70s in ATP-dependent client protein-binding and release cycles.  Much of the functional diversity of the HSP70s is driven by a diverse class of cofactors: J proteins.  Often, multiple J proteins function with a single HSP70.  Some target HSP70 activity to clients at precise locations in cells and others bind client proteins directly, thereby delivering specific clients to HSP70 and directly detg. their fate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqr-hItdN33vLVg90H21EOLACvtfcHk0lipHcq4PQxbWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1arsLo%253D&md5=06ca9d96bfb6878abbb9facadebc32c8</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrm2941&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2941%26sid%3Dliteratum%253Aachs%26aulast%3DKampinga%26aufirst%3DH.%2BH.%26aulast%3DCraig%26aufirst%3DE.%2BA.%26atitle%3DThe%2520HSP70%2520chaperone%2520machinery%2520J%2520proteins%2520as%2520drivers%2520of%2520functional%2520specificity%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2010%26volume%3D11%26spage%3D579%26epage%3D592%26doi%3D10.1038%2Fnrm2941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaelis, S.</span></span> <span> </span><span class="NLM_article-title">Prelamin A, Zmpste24, misshapen cell nuclei, and progeria – new evidence suggesting that protein farnesylation could be important for diseases pathogenesis</span>. <i>J. Lipid Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">2531</span>– <span class="NLM_lpage">2558</span>, <span class="refDoi"> DOI: 10.1194/jlr.R500011-JLR200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1194%2Fjlr.R500011-JLR200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2005&pages=2531-2558&author=S.+G.+Youngauthor=L.+G.+Fongauthor=S.+Michaelis&title=Prelamin+A%2C+Zmpste24%2C+misshapen+cell+nuclei%2C+and+progeria+%E2%80%93+new+evidence+suggesting+that+protein+farnesylation+could+be+important+for+diseases+pathogenesis&doi=10.1194%2Fjlr.R500011-JLR200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1194%2Fjlr.R500011-JLR200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1194%252Fjlr.R500011-JLR200%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DS.%2BG.%26aulast%3DFong%26aufirst%3DL.%2BG.%26aulast%3DMichaelis%26aufirst%3DS.%26atitle%3DPrelamin%2520A%252C%2520Zmpste24%252C%2520misshapen%2520cell%2520nuclei%252C%2520and%2520progeria%2520%25E2%2580%2593%2520new%2520evidence%2520suggesting%2520that%2520protein%2520farnesylation%2520could%2520be%2520important%2520for%2520diseases%2520pathogenesis%26jtitle%3DJ.%2520Lipid%2520Res.%26date%3D2005%26volume%3D46%26spage%3D2531%26epage%3D2558%26doi%3D10.1194%2Fjlr.R500011-JLR200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matozaki, T.</span></span> <span> </span><span class="NLM_article-title">Small GTP-binding roteins</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1152/physrev.2001.81.1.153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1152%2Fphysrev.2001.81.1.153" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2001&pages=153-208&author=Y.+Takaiauthor=T.+Sasakiauthor=T.+Matozaki&title=Small+GTP-binding+roteins&doi=10.1152%2Fphysrev.2001.81.1.153"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.2001.81.1.153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.2001.81.1.153%26sid%3Dliteratum%253Aachs%26aulast%3DTakai%26aufirst%3DY.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DMatozaki%26aufirst%3DT.%26atitle%3DSmall%2520GTP-binding%2520roteins%26jtitle%3DPhysiol.%2520Rev.%26date%3D2001%26volume%3D81%26spage%3D153%26epage%3D208%26doi%3D10.1152%2Fphysrev.2001.81.1.153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mullen, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archer, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penn, L. Z.</span></span> <span> </span><span class="NLM_article-title">The interplay between cell signaling and the mevalonate pathway in cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">718</span>– <span class="NLM_lpage">731</span>, <span class="refDoi"> DOI: 10.1038/nrc.2016.76</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1038%2Fnrc.2016.76" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=27562463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVSrur%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=718-731&author=P.+J.+Mullenauthor=R.+Yuauthor=J.+Longoauthor=M.+C.+Archerauthor=L.+Z.+Penn&title=The+interplay+between+cell+signaling+and+the+mevalonate+pathway+in+cancer&doi=10.1038%2Fnrc.2016.76"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The interplay between cell signalling and the mevalonate pathway in cancer</span></div><div class="casAuthors">Mullen, Peter J.; Yu, Rosemary; Longo, Joseph; Archer, Michael C.; Penn, Linda Z.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">718-731</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The mevalonate (MVA) pathway is an essential metabolic pathway that uses acetyl-CoA to produce sterols and isoprenoids that are integral to tumor growth and progression.  In recent years, many oncogenic signalling pathways have been shown to increase the activity and/or the expression of MVA pathway enzymes.  This Review summarizes recent advances and discusses unique opportunities for immediately targeting this metabolic vulnerability in cancer with agents that have been approved for other therapeutic uses, such as the statin family of drugs, to improve outcomes for cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprCFV9_aKCv7Vg90H21EOLACvtfcHk0lipHcq4PQxbWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVSrur%252FN&md5=4a692b82d8eb6fc1547db5c45a36cae4</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2016.76&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2016.76%26sid%3Dliteratum%253Aachs%26aulast%3DMullen%26aufirst%3DP.%2BJ.%26aulast%3DYu%26aufirst%3DR.%26aulast%3DLongo%26aufirst%3DJ.%26aulast%3DArcher%26aufirst%3DM.%2BC.%26aulast%3DPenn%26aufirst%3DL.%2BZ.%26atitle%3DThe%2520interplay%2520between%2520cell%2520signaling%2520and%2520the%2520mevalonate%2520pathway%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2016%26volume%3D16%26spage%3D718%26epage%3D731%26doi%3D10.1038%2Fnrc.2016.76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clendening, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandyra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boutros, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghamrasni, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khosravi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trentin, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martirosyan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakem, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakem, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurisica, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penn, L. Z.</span></span> <span> </span><span class="NLM_article-title">Dysregulation of the mevalonate pathway promotes transformation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">15051</span>– <span class="NLM_lpage">15056</span>, <span class="refDoi"> DOI: 10.1073/pnas.0910258107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1073%2Fpnas.0910258107" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=15051-15056&author=J.+W.+Clendeningauthor=A.+Pandyraauthor=P.+C.+Boutrosauthor=S.+E.+Ghamrasniauthor=F.+Khosraviauthor=G.+A.+Trentinauthor=A.+Martirosyanauthor=A.+Hakemauthor=R.+Hakemauthor=I.+Jurisicaauthor=L.+Z.+Penn&title=Dysregulation+of+the+mevalonate+pathway+promotes+transformation&doi=10.1073%2Fpnas.0910258107"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0910258107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0910258107%26sid%3Dliteratum%253Aachs%26aulast%3DClendening%26aufirst%3DJ.%2BW.%26aulast%3DPandyra%26aufirst%3DA.%26aulast%3DBoutros%26aufirst%3DP.%2BC.%26aulast%3DGhamrasni%26aufirst%3DS.%2BE.%26aulast%3DKhosravi%26aufirst%3DF.%26aulast%3DTrentin%26aufirst%3DG.%2BA.%26aulast%3DMartirosyan%26aufirst%3DA.%26aulast%3DHakem%26aufirst%3DA.%26aulast%3DHakem%26aufirst%3DR.%26aulast%3DJurisica%26aufirst%3DI.%26aulast%3DPenn%26aufirst%3DL.%2BZ.%26atitle%3DDysregulation%2520of%2520the%2520mevalonate%2520pathway%2520promotes%2520transformation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D15051%26epage%3D15056%26doi%3D10.1073%2Fpnas.0910258107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sorrentino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Specchia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordenonsi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupont, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfrin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingallina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommaggio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piazza, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccolo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Sal, G.</span></span> <span> </span><span class="NLM_article-title">Metabolic control of YAP and TAZ by the mevalonate pathway</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">366</span>, <span class="refDoi"> DOI: 10.1038/ncb2936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1038%2Fncb2936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=24658687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC2cXks12rtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=357-366&author=G.+Sorrentinoauthor=N.+Ruggeriauthor=V.+Specchiaauthor=M.+Cordenonsiauthor=M.+Manoauthor=S.+Dupontauthor=A.+Manfrinauthor=E.+Ingallinaauthor=R.+Sommaggioauthor=S.+Piazzaauthor=A.+Rosatoauthor=S.+Piccoloauthor=G.+Del+Sal&title=Metabolic+control+of+YAP+and+TAZ+by+the+mevalonate+pathway&doi=10.1038%2Fncb2936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic control of YAP and TAZ by the mevalonate pathway</span></div><div class="casAuthors">Sorrentino, Giovanni; Ruggeri, Naomi; Specchia, Valeria; Cordenonsi, Michelangelo; Mano, Miguel; Dupont, Sirio; Manfrin, Andrea; Ingallina, Eleonora; Sommaggio, Roberta; Piazza, Silvano; Rosato, Antonio; Piccolo, Stefano; Del Sal, Giannino</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">357-366</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The YAP and TAZ mediators of the Hippo pathway (hereafter called YAP/TAZ) promote tissue proliferation and organ growth.  However, how their biol. properties intersect with cellular metab. remains unexplained.  Here, we show that YAP/TAZ activity is controlled by the SREBP/mevalonate pathway.  Inhibition of the rate-limiting enzyme of this pathway (HMG-CoA reductase) by statins opposes YAP/TAZ nuclear localization and transcriptional responses.  Mechanistically, the geranylgeranyl pyrophosphate produced by the mevalonate cascade is required for activation of Rho GTPases that, in turn, activate YAP/TAZ by inhibiting their phosphorylation and promoting their nuclear accumulation.  The mevalonate-YAP/TAZ axis is required for proliferation and self-renewal of breast cancer cells.  In Drosophila melanogaster, inhibition of mevalonate biosynthesis and geranylgeranylation blunts the eye overgrowth induced by Yorkie, the YAP/TAZ orthologue.  In tumor cells, YAP/TAZ activation is promoted by increased levels of mevalonic acid produced by SREBP transcriptional activity, which is induced by its oncogenic cofactor mutant p53.  These findings reveal an addnl. layer of YAP/TAZ regulation by metabolic cues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXxh8AtqF2PbVg90H21EOLACvtfcHk0liUG3VIiL9CZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXks12rtLY%253D&md5=417c52cd08ff2d532f10875140445bdd</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fncb2936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb2936%26sid%3Dliteratum%253Aachs%26aulast%3DSorrentino%26aufirst%3DG.%26aulast%3DRuggeri%26aufirst%3DN.%26aulast%3DSpecchia%26aufirst%3DV.%26aulast%3DCordenonsi%26aufirst%3DM.%26aulast%3DMano%26aufirst%3DM.%26aulast%3DDupont%26aufirst%3DS.%26aulast%3DManfrin%26aufirst%3DA.%26aulast%3DIngallina%26aufirst%3DE.%26aulast%3DSommaggio%26aufirst%3DR.%26aulast%3DPiazza%26aufirst%3DS.%26aulast%3DRosato%26aufirst%3DA.%26aulast%3DPiccolo%26aufirst%3DS.%26aulast%3DDel%2BSal%26aufirst%3DG.%26atitle%3DMetabolic%2520control%2520of%2520YAP%2520and%2520TAZ%2520by%2520the%2520mevalonate%2520pathway%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2014%26volume%3D16%26spage%3D357%26epage%3D366%26doi%3D10.1038%2Fncb2936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordestgaard, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bojesen, S. E.</span></span> <span> </span><span class="NLM_article-title">Statin use and reduced cancer-related mortality</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">1792</span>– <span class="NLM_lpage">1802</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1201735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1056%2FNEJMoa1201735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=23134381" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1ekt73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=1792-1802&author=S.+F.+Nielsenauthor=B.+G.+Nordestgaardauthor=S.+E.+Bojesen&title=Statin+use+and+reduced+cancer-related+mortality&doi=10.1056%2FNEJMoa1201735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Statin use and reduced cancer-related mortality</span></div><div class="casAuthors">Nielsen, Sune F.; Nordestgaard, Boerge G.; Bojesen, Stig E.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1792-1802</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A redn. in the availability of cholesterol may limit the cellular proliferation required for cancer growth and metastasis.  We tested the hypothesis that statin use begun before a cancer diagnosis is assocd. with reduced cancer-related mortality.  We assessed mortality among patients from the entire Danish population who had received a diagnosis of cancer between 1995 and 2007, with follow-up until Dec. 31, 2009.  Among patients 40 years of age or older, 18,721 had used statins regularly before the cancer diagnosis and 277,204 had never used statins.  Multivariable-adjusted hazard ratios for statin users, as compared with patients who had never used statins, were 0.85 (95% confidence interval [CI], 0.83 to 0.87) for death from any cause and 0.85 (95% CI, 0.82 to 0.87) for death from cancer.  Adjusted hazard ratios for death from any cause according to the defined daily statin dose (the assumed av. maintenance dose per day) were 0.82 (95% CI, 0.81 to 0.85) for a dose of 0.01 to 0.75 defined daily dose per day, 0.87 (95% CI, 0.83 to 0.89) for 0.76 to 1.50 defined daily dose per day, and 0.87 (95% CI, 0.81 to 0.91) for higher than 1.50 defined daily dose per day; the corresponding hazard ratios for death from cancer were 0.83 (95% CI, 0.81 to 0.86), 0.87 (95% CI, 0.83 to 0.91), and 0.87 (95% CI, 0.81 to 0.92).  The reduced cancer-related mortality among statin users as compared with those who had never used statins was obsd. for each of 13 cancer types.  Statin use in patients with cancer is assocd. with reduced cancer-related mortality.  This suggests a need for trials of statins in patients with cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRi4ePb4X5TbVg90H21EOLACvtfcHk0liUG3VIiL9CZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1ekt73N&md5=cb3c50e51082614338f3c11f0078252e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1201735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1201735%26sid%3Dliteratum%253Aachs%26aulast%3DNielsen%26aufirst%3DS.%2BF.%26aulast%3DNordestgaard%26aufirst%3DB.%2BG.%26aulast%3DBojesen%26aufirst%3DS.%2BE.%26atitle%3DStatin%2520use%2520and%2520reduced%2520cancer-related%2520mortality%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D1792%26epage%3D1802%26doi%3D10.1056%2FNEJMoa1201735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garwood, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baehner, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Au, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hylton, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flowers, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnikoski, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olopade, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Port, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esserman, L. J.</span></span> <span> </span><span class="NLM_article-title">Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.1007/s10549-009-0507-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1007%2Fs10549-009-0507-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=19728082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFaqtrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2010&pages=137-144&author=E.+R.+Garwoodauthor=A.+S.+Kumarauthor=F.+L.+Baehnerauthor=D.+H.+Mooreauthor=A.+Auauthor=N.+Hyltonauthor=C.+I.+Flowersauthor=J.+Garberauthor=B.+A.+Lesnikoskiauthor=E.+S.+Hwangauthor=O.+Olopadeauthor=E.+R.+Portauthor=M.+Campbellauthor=L.+J.+Esserman&title=Fluvastatin+reduces+proliferation+and+increases+apoptosis+in+women+with+high+grade+breast+cancer&doi=10.1007%2Fs10549-009-0507-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer</span></div><div class="casAuthors">Garwood, Elisabeth R.; Kumar, Anjali S.; Baehner, Frederick L.; Moore, Dan H.; Au, Alfred; Hylton, Nola; Flowers, Chris I.; Garber, Judy; Lesnikoski, Beth-Ann; Hwang, E. Shelley; Olopade, Olofunmilao; Port, Elisa Rush; Campbell, Michael; Esserman, Laura J.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">137-144</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The purpose of this study is to det. the biol. impact of short-term lipophilic statin exposure on in situ and invasive breast cancer through paired tissue, blood and imaging-based biomarkers.  A perioperative window trial of fluvastatin was conducted in women with a diagnosis of DCIS or stage 1 breast cancer.  Patients were randomized to high dose (80 mg/day) or low dose (20 mg/day) fluvastatin for 3-6 wk before surgery.  Tissue (diagnostic core biopsy/final surgical specimen), blood, and magnetic resonance images were obtained before/after treatment.  The primary endpoint was Ki-67 (proliferation) redn.  Secondary endpoints were change in cleaved caspase-3 (CC3, apoptosis), MRI tumor vol., and serum C-reactive protein (CRP, inflammation).  Planned subgroup analyses compared disease grade, statin dose, and estrogen-receptor status.  Forty of 45 patients who enrolled completed the protocol; 29 had paired Ki-67 primary endpoint data.  Proliferation of high grade tumors decreased by a median of 7.2% (P = 0.008), which was statistically greater than the 0.3% decrease for low grade tumors.  Paired data for CC3 showed tumor apoptosis increased in 38%, remained stable in 41%, and decreased in 21% of subjects.  More high grade tumors had an increase in apoptosis (60 vs. 13%; P = 0.015).  Serum CRP did not change, but cholesterol levels were significantly lower post statin exposure (P < 0.001).  Fluvastatin showed measurable biol. changes by reducing tumor proliferation and increasing apoptotic activity in high-grade, stage 0/1 breast cancer.  Effects were only evident in high grade tumors.  These results support further evaluation of statins as chemoprevention for ER-neg. high grade breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYjyXK6k7NN7Vg90H21EOLACvtfcHk0ljJO_q_MN9C_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFaqtrrO&md5=0376bbe6cebf6545ff9b1066c43ee240</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs10549-009-0507-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-009-0507-x%26sid%3Dliteratum%253Aachs%26aulast%3DGarwood%26aufirst%3DE.%2BR.%26aulast%3DKumar%26aufirst%3DA.%2BS.%26aulast%3DBaehner%26aufirst%3DF.%2BL.%26aulast%3DMoore%26aufirst%3DD.%2BH.%26aulast%3DAu%26aufirst%3DA.%26aulast%3DHylton%26aufirst%3DN.%26aulast%3DFlowers%26aufirst%3DC.%2BI.%26aulast%3DGarber%26aufirst%3DJ.%26aulast%3DLesnikoski%26aufirst%3DB.%2BA.%26aulast%3DHwang%26aufirst%3DE.%2BS.%26aulast%3DOlopade%26aufirst%3DO.%26aulast%3DPort%26aufirst%3DE.%2BR.%26aulast%3DCampbell%26aufirst%3DM.%26aulast%3DEsserman%26aufirst%3DL.%2BJ.%26atitle%3DFluvastatin%2520reduces%2520proliferation%2520and%2520increases%2520apoptosis%2520in%2520women%2520with%2520high%2520grade%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2010%26volume%3D119%26spage%3D137%26epage%3D144%26doi%3D10.1007%2Fs10549-009-0507-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kubatka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruzliak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotrekl, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jelinkova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mladosievicova, B.</span></span> <span> </span><span class="NLM_article-title">Statins in oncological research: from experimental studies to clinical practice</span>. <i>Crit. Rev. Oncol. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">296</span>– <span class="NLM_lpage">311</span>, <span class="refDoi"> DOI: 10.1016/j.critrevonc.2014.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1016%2Fj.critrevonc.2014.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=25220658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A280%3ADC%252BC2M7htl2lsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2014&pages=296-311&author=P.+Kubatkaauthor=P.+Kruzliakauthor=V.+Rotreklauthor=S.+Jelinkovaauthor=B.+Mladosievicova&title=Statins+in+oncological+research%3A+from+experimental+studies+to+clinical+practice&doi=10.1016%2Fj.critrevonc.2014.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Statins in oncological research: from experimental studies to clinical practice</span></div><div class="casAuthors">Kubatka Peter; Kruzliak Peter; Rotrekl Vladimir; Jelinkova Sarka; Mladosievicova Beata</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">296-311</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Statins, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors are commonly used drugs in the treatment of dyslipidemias, primarily raised cholesterol.  Recently, many epidemiological and preclinical studies pointed to anti-tumor properties of statins, including anti-proliferative activities, apoptosis, decreased angiogenesis and metastasis.  These processes play an important role in carcinogenesis and, therefore, the role of statins in cancer disease is being seriously discussed among oncologists.  Anti-neoplastic properties of statins combined with an acceptable toxicity profile in the majority of individuals support their further development as anti-tumor drugs.  The mechanism of action, current preclinical studies and clinical efficacy of statins are reviewed in this paper.  Moreover, promising results have been reported regarding the statins' efficacy in some cancer types, especially in esophageal and colorectal cancers, and hepatocellular carcinoma.  Statins' hepatotoxicity has traditionally represented an obstacle to the prescription of this class of drugs and this issue is also discussed in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRlg2H7p3p9vEewzGPswiWOfW6udTcc2ebwMif9hU3yn7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M7htl2lsg%253D%253D&md5=d8aa97da1562828e3917630c41b1cd75</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2014.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2014.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DKubatka%26aufirst%3DP.%26aulast%3DKruzliak%26aufirst%3DP.%26aulast%3DRotrekl%26aufirst%3DV.%26aulast%3DJelinkova%26aufirst%3DS.%26aulast%3DMladosievicova%26aufirst%3DB.%26atitle%3DStatins%2520in%2520oncological%2520research%253A%2520from%2520experimental%2520studies%2520to%2520clinical%2520practice%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2014%26volume%3D92%26spage%3D296%26epage%3D311%26doi%3D10.1016%2Fj.critrevonc.2014.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanfilippo, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gage, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moskowitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gumbel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blue, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brian, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, K.</span></span> <span> </span><span class="NLM_article-title">Statins are associated with reduced mortality in multiple myeloma</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">4008</span>– <span class="NLM_lpage">4014</span>, <span class="refDoi"> DOI: 10.1200/JCO.2016.68.3482</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1200%2FJCO.2016.68.3482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=27646948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmtlGh" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=4008-4014&author=K.+M.+Sanfilippoauthor=J.+Kellerauthor=B.+F.+Gageauthor=S.+Luoauthor=T.-F.+Wangauthor=G.+Moskowitzauthor=J.+Gumbelauthor=B.+Blueauthor=K.+O%E2%80%99Brianauthor=K.+Carson&title=Statins+are+associated+with+reduced+mortality+in+multiple+myeloma&doi=10.1200%2FJCO.2016.68.3482"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Statins are associated with reduced mortality in multiple myeloma</span></div><div class="casAuthors">Sanfilippo, Kristen Marie; Keller, Jesse; Gage, Brian F.; Luo, Suhong; Wang, Tzu-Fei; Moskowitz, Gerald; Gumbel, Jason; Blue, Brandon; O'Brian, Katiuscia; Carson, Kenneth R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">4008-4014</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) have activity in one of the pathways influenced by nitrogen-contg. bisphosphonates, which are assocd. with improved survival in multiple myeloma (MM).  To understand the benefit of statins in MM, we evaluated the assocn. between statin use and mortality in a large cohort of patients with MM.  Patients and Methods From the Veterans Administration Central Cancer Registry, we identified patients diagnosed with MM between 1999 and 2013.  We defined statin use as the presence of any prescription for a statin within 3 mo before or any time after MM diagnosis.  Cox proportional hazards regression assessed the assocn. of statin use with mortality, while controlling for known MM prognostic factors.  Results We identified a cohort of 4,957 patients, of whom 2,294 received statin therapy.  Statin use was assocd. with a 21% decrease in all-cause mortality (adjusted hazard ratio, 0.79; 95% CI, 0.73 to 0.86; P < .001) as well as a 24% decrease in MM-specific mortality (adjusted hazard ratio, 0.76; 95% CI, 0.67 to 0.86; P < .001).  This assocn. remained significant across all sensitivity analyses.  In addn. to redns. in mortality, statin use was assocd. with a 31% decreased risk of developing a skeletal-related event.  Conclusion In this cohort study of US veterans with MM, statin therapy was assocd. with a reduced risk of both all-cause and MM-specific mortality.  Our findings suggest a potential role for statin therapy in patients with MM.  The putative benefit of statin therapy in MM should be corroborated in prospective studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBKXz8mCQuDrVg90H21EOLACvtfcHk0ljJO_q_MN9C_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmtlGh&md5=4e499c400e7a33c7e187b7b515a5c759</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.68.3482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.68.3482%26sid%3Dliteratum%253Aachs%26aulast%3DSanfilippo%26aufirst%3DK.%2BM.%26aulast%3DKeller%26aufirst%3DJ.%26aulast%3DGage%26aufirst%3DB.%2BF.%26aulast%3DLuo%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DT.-F.%26aulast%3DMoskowitz%26aufirst%3DG.%26aulast%3DGumbel%26aufirst%3DJ.%26aulast%3DBlue%26aufirst%3DB.%26aulast%3DO%25E2%2580%2599Brian%26aufirst%3DK.%26aulast%3DCarson%26aufirst%3DK.%26atitle%3DStatins%2520are%2520associated%2520with%2520reduced%2520mortality%2520in%2520multiple%2520myeloma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26spage%3D4008%26epage%3D4014%26doi%3D10.1200%2FJCO.2016.68.3482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dunford, J. E.</span></span> <span> </span><span class="NLM_article-title">Molecular targets of the nitrogen containing bisphosphonates: The molecular pharmacology of prenyl synthase inhibition</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2961</span>– <span class="NLM_lpage">2969</span>, <span class="refDoi"> DOI: 10.2174/138161210793563617</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.2174%2F138161210793563617" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=2961-2969&author=J.+E.+Dunford&title=Molecular+targets+of+the+nitrogen+containing+bisphosphonates%3A+The+molecular+pharmacology+of+prenyl+synthase+inhibition&doi=10.2174%2F138161210793563617"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2174%2F138161210793563617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161210793563617%26sid%3Dliteratum%253Aachs%26aulast%3DDunford%26aufirst%3DJ.%2BE.%26atitle%3DMolecular%2520targets%2520of%2520the%2520nitrogen%2520containing%2520bisphosphonates%253A%2520The%2520molecular%2520pharmacology%2520of%2520prenyl%2520synthase%2520inhibition%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2010%26volume%3D16%26spage%3D2961%26epage%3D2969%26doi%3D10.2174%2F138161210793563617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ebetino, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogan, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsoumpra, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triffitt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwaasi, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunford, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnett, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oppermann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundy, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashemirov, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenna, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, R. G.</span></span> <span> </span><span class="NLM_article-title">The relationship between the chemistry and biological activity of the bisphosphonates</span>. <i>Bone</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1016/j.bone.2011.03.774</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1016%2Fj.bone.2011.03.774" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=21497677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsVSgsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2011&pages=20-33&author=F.+H.+Ebetinoauthor=A.-M.+Hoganauthor=S.+Sunauthor=M.+K.+Tsoumpraauthor=X.+Duanauthor=J.+T.+Triffittauthor=A.+A.+Kwaasiauthor=J.+E.+Dunfordauthor=B.+L.+Barnettauthor=U.+Oppermannauthor=M.+W.+Lundyauthor=A.+Boydeauthor=B.+A.+Kashemirovauthor=C.+E.+McKennaauthor=R.+G.+Russell&title=The+relationship+between+the+chemistry+and+biological+activity+of+the+bisphosphonates&doi=10.1016%2Fj.bone.2011.03.774"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The relationship between the chemistry and biological activity of the bisphosphonates</span></div><div class="casAuthors">Ebetino, Frank H.; Hogan, Anne-Marie L.; Sun, Shuting; Tsoumpra, Maria K.; Duan, Xuchen; Triffitt, James T.; Kwaasi, Aaron A.; Dunford, James E.; Barnett, Bobby L.; Oppermann, Udo; Lundy, Mark W.; Boyde, Alan; Kashemirov, Boris A.; McKenna, Charles E.; Russell, R. Graham G.</div><div class="citationInfo"><span class="NLM_cas:title">Bone (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-33</span>CODEN:
                <span class="NLM_cas:coden">BONEDL</span>;
        ISSN:<span class="NLM_cas:issn">8756-3282</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The ability of bisphosphonates ((HO)2P(O)CR1R2P(O)(OH)2) to inhibit bone resorption has been known since the 1960s, but it is only recently that a detailed mol. understanding of the relationship between chem. structures and biol. activity has begun to emerge.  The early development of chem. in this area was largely empirical and based on modifying R2 groups in a variety of ways.  Apart from the general ability of bisphosphonates to chelate Ca2+ and thus target the calcium phosphate mineral component of bone, attempts to refine clear structure-activity relationships had led to ambiguous or seemingly contradictory results.  However, there was increasing evidence for cellular effects, and eventually the earliest bisphosphonate drugs, such as clodronate (R1 = R2 = Cl) and etidronate (R1 = OH, R2 = CH3), were shown to exert intracellular actions via the formation in vivo of drug derivs. of ATP.  The observation that pamidronate, a bisphosphonate with R1 = OH and R2 = CH2CH2NH2, exhibited higher potency than previously known bisphosphonate drugs represented the first step towards the later recognition of the crit. importance of having nitrogen in the R2 side chain.  The synthesis and biol. evaluation of a large no. of nitrogen-contg. bisphosphonates took place particularly in the 1980s, but still with an incomplete understanding of their structure-activity relationships.  A major advance was the discovery that the anti-resorptive effects of the nitrogen-contg. bisphosphonates (including alendronate, risedronate, ibandronate, and zoledronate) on osteoclasts appear to result from their potency as inhibitors of the enzyme farnesyl pyrophosphate synthase (FPPS), a key branch-point enzyme in the mevalonate pathway.  FPPS generates isoprenoid lipids utilized in sterol synthesis and for the post-translational modification of small GTP-binding proteins essential for osteoclast function.  Effects on other cellular targets, such as osteocytes, may also be important.  Over the years many hundreds of bisphosphonates have been synthesized and studied.  Interest in expanding the structural scope of the bisphosphonate class has also motivated new approaches to the chem. synthesis of these compds.  Recent chem. innovations include the synthesis of fluorescently labeled bisphosphonates, which has enabled studies of the biodistribution of these drugs.  As a class, bisphosphonates share common properties.  However, as with other classes of drugs, there are chem., biochem., and pharmacol. differences among the individual compds.  Differences in mineral binding affinities among bisphosphonates influence their differential distribution within bone, their biol. potency, and their duration of action.  The overall pharmacol. effects of bisphosphonates on bone, therefore, appear to depend upon these two key properties of affinity for bone mineral and inhibitory effects on osteoclasts.  The relative contributions of these properties differ among individual bisphosphonates and help det. their clin. behavior and effectiveness.  This article is part of a Special Issue entitled Bisphosphonates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkW3DAKvbJe7Vg90H21EOLACvtfcHk0lh6wmbrE345jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsVSgsLk%253D&md5=0bba79f40512f2df89bd0ee36459e264</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bone.2011.03.774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bone.2011.03.774%26sid%3Dliteratum%253Aachs%26aulast%3DEbetino%26aufirst%3DF.%2BH.%26aulast%3DHogan%26aufirst%3DA.-M.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DTsoumpra%26aufirst%3DM.%2BK.%26aulast%3DDuan%26aufirst%3DX.%26aulast%3DTriffitt%26aufirst%3DJ.%2BT.%26aulast%3DKwaasi%26aufirst%3DA.%2BA.%26aulast%3DDunford%26aufirst%3DJ.%2BE.%26aulast%3DBarnett%26aufirst%3DB.%2BL.%26aulast%3DOppermann%26aufirst%3DU.%26aulast%3DLundy%26aufirst%3DM.%2BW.%26aulast%3DBoyde%26aufirst%3DA.%26aulast%3DKashemirov%26aufirst%3DB.%2BA.%26aulast%3DMcKenna%26aufirst%3DC.%2BE.%26aulast%3DRussell%26aufirst%3DR.%2BG.%26atitle%3DThe%2520relationship%2520between%2520the%2520chemistry%2520and%2520biological%2520activity%2520of%2520the%2520bisphosphonates%26jtitle%3DBone%26date%3D2011%26volume%3D49%26spage%3D20%26epage%3D33%26doi%3D10.1016%2Fj.bone.2011.03.774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodwell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkinshaw, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houston, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grieve, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett-Lee, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pugh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaunt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rea, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiley, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, R.</span></span> <span> </span><span class="NLM_article-title">Breast-cancer adjuvant therapy with zoledronic acid</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">1396</span>– <span class="NLM_lpage">1405</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1105195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1056%2FNEJMoa1105195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=21995387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlals7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2011&pages=1396-1405&author=R.+E.+Colemanauthor=H.+Marshallauthor=D.+Cameronauthor=D.+Dodwellauthor=R.+Burkinshawauthor=M.+Keaneauthor=M.+Gilauthor=S.+J.+Houstonauthor=R.+J.+Grieveauthor=P.+J.+Barrett-Leeauthor=D.+Ritchieauthor=J.+Pughauthor=C.+Gauntauthor=U.+Reaauthor=J.+Petersonauthor=C.+Daviesauthor=V.+Hileyauthor=W.+Gregoryauthor=R.+Bell&title=Breast-cancer+adjuvant+therapy+with+zoledronic+acid&doi=10.1056%2FNEJMoa1105195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Breast-cancer adjuvant therapy with zoledronic acid</span></div><div class="casAuthors">Coleman, Robert E.; Marshall, Helen; Cameron, David; Dodwell, David; Burkinshaw, Roger; Keane, Maccon; Gil, Miguel; Houston, Stephen.; Grieve, Robert J.; Barrett-Lee, Peter J.; Ritchie, Diana; Pugh, Julia; Gaunt, Claire; Rea, Una; Peterson, Jennifer; Davies, Claire; Hiley, Victoria; Gregory, Walter; Bell, Richard</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1396-1405</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Data suggest that the adjuvant use of bisphosphonates reduces rates of recurrence and death in patients with early-stage breast cancer.  We conducted a study to det. whether treatment with zoledronic acid, in addn. to std. adjuvant therapy, would improve disease outcomes in such patients.  METHODS: In this open-label phase 3 study, we randomly assigned 3360 patients to receive std. adjuvant systemic therapy either with or without zoledronic acid.  The zoledronic acid was administered every 3 to 4 wk for 6 doses and then every 3 to 6 mo to complete 5 years of treatment.  The primary end point of the study was disease-free survival.  A second interim anal. revealed that a prespecified boundary for lack of benefit had been crossed.  RESULTS: At a median follow-up of 59 mo, there was no significant between-group difference in the primary end point, with a rate of disease-free survival of 77% in each group (adjusted hazard ratio in the zoledronic acid group, 0.98; 95% confidence interval [CI], 0.85 to 1.13; P = 0.79). Disease recurrence or death occurred in 377 patients in the zoledronic acid group and 375 of those in the control group.  The nos. of deaths - 243 in the zoledronic acid group and 276 in the control group - were also similar, resulting in rates of overall survival of 85.4% in the zoledronic acid group and 83.1% in the control group (adjusted hazard ratio, 0.85; 95% CI, 0.72 to 1.01; P = 0.07).  In the zoledronic acid group, there were 17 confirmed cases of osteonecrosis of the jaw (cumulative incidence, 1.1%; 95% CI, 0.6 to 1.7; P < 0.001) and 9 suspected cases; there were no cases in the control group.  Rates of other adverse effects were similar in the two study groups.  CONCLUSIONS: These findings do not support the routine use of zoledronic acid in the adjuvant management of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpISmlJLPnAebVg90H21EOLACvtfcHk0lh6wmbrE345jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlals7jP&md5=3c61150ab39db154b5370ea59896c73f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1105195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1105195%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DR.%2BE.%26aulast%3DMarshall%26aufirst%3DH.%26aulast%3DCameron%26aufirst%3DD.%26aulast%3DDodwell%26aufirst%3DD.%26aulast%3DBurkinshaw%26aufirst%3DR.%26aulast%3DKeane%26aufirst%3DM.%26aulast%3DGil%26aufirst%3DM.%26aulast%3DHouston%26aufirst%3DS.%2BJ.%26aulast%3DGrieve%26aufirst%3DR.%2BJ.%26aulast%3DBarrett-Lee%26aufirst%3DP.%2BJ.%26aulast%3DRitchie%26aufirst%3DD.%26aulast%3DPugh%26aufirst%3DJ.%26aulast%3DGaunt%26aufirst%3DC.%26aulast%3DRea%26aufirst%3DU.%26aulast%3DPeterson%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DC.%26aulast%3DHiley%26aufirst%3DV.%26aulast%3DGregory%26aufirst%3DW.%26aulast%3DBell%26aufirst%3DR.%26atitle%3DBreast-cancer%2520adjuvant%2520therapy%2520with%2520zoledronic%2520acid%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D365%26spage%3D1396%26epage%3D1405%26doi%3D10.1056%2FNEJMoa1105195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gnant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mlineritsch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoeger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luschin-Ebengreuth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heck, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakesz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seifert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubalek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pristauz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauernhofer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eidtmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiermann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwasny, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochreiner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forsthuber, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fesl, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greil, R.</span></span> <span> </span><span class="NLM_article-title">Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">631</span>– <span class="NLM_lpage">641</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(11)70122-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1016%2FS1470-2045%2811%2970122-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=21641868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC3MXot1ejtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=631-641&author=M.+Gnantauthor=B.+Mlineritschauthor=H.+Stoegerauthor=G.+Luschin-Ebengreuthauthor=D.+Heckauthor=C.+Menzelauthor=R.+Jakeszauthor=M.+Seifertauthor=M.+Hubalekauthor=G.+Pristauzauthor=T.+Bauernhoferauthor=H.+Eidtmannauthor=W.+Eiermannauthor=G.+Stegerauthor=W.+Kwasnyauthor=P.+Dubskyauthor=G.+Hochreinerauthor=E.+P.+Forsthuberauthor=C.+Feslauthor=R.+Greil&title=Adjuvant+endocrine+therapy+plus+zoledronic+acid+in+premenopausal+women+with+early-stage+breast+cancer%3A+62-month+follow-up+from+the+ABCSG-12+randomised+trial&doi=10.1016%2FS1470-2045%2811%2970122-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial</span></div><div class="casAuthors">Gnant, Michael; Mlineritsch, Brigitte; Stoeger, Herbert; Luschin-Ebengreuth, Gero; Heck, Dietmar; Menzel, Christian; Jakesz, Raimund; Seifert, Michael; Hubalek, Michael; Pristauz, Gunda; Bauernhofer, Thomas; Eidtmann, Holger; Eiermann, Wolfgang; Steger, Guenther; Kwasny, Werner; Dubsky, Peter; Hochreiner, Gerhard; Forsthuber, Ernst-Pius; Fesl, Christian; Greil, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">631-641</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Anal. of the Austrian Breast and Colorectal Cancer Study Group trial-12 (ABCSG-12) at 48 mo' follow-up showed that addn. of zoledronic acid to adjuvant endocrine therapy significantly improved disease-free survival.  We have now assessed long-term clin. efficacy including disease-free survival and disease outcomes in patients receiving anastrozole or tamoxifen with or without zoledronic acid.  ABSCG-12 is a randomised, controlled, open-label, two-by-two factorial, multicentre trial in 1803 premenopausal women with endocrine-receptor-pos. early-stage (stage I-II) breast cancer receiving goserelin (3.6 mg every 28 days), comparing the efficacy and safety of anastrozole (1 mg per day) or tamoxifen (20 mg per day) with or without zoledronic acid (4 mg every 6 mo) for 3 years.  Randomisation (1:1:1:1 ratio) was computerized and based on the Pocock and Simon minimisation method to balance the four treatment arms across eight prognostic variables (age, neoadjuvant chemotherapy, pathol. tumor stage; lymph-node involvement, type of surgery or locoregional therapy, complete axillary dissection, intraoperative radiation therapy, and geog. region).  Treatment allocation was not masked.  The primary endpoint was disease-free survival (defined as disease recurrence or death) and anal. was by intention to treat.  This trial is registered with ClinicalTrials.gov, no. NCT00295646; follow-up is ongoing.  At a median follow-up of 62 mo (range 0-114.4 mo), more than 2 years after treatment completion, 186 disease-free survival events had been reported (53 events in 450 patients on tamoxifen alone, 57 in 453 patients on anastrozole alone, 36 in 450 patients on tamoxifen plus zoledronic acid, and 40 in 450 patients on anastrozole plus zoledronic acid).  Zoledronic acid reduced risk of disease-free survival events overall (HR 0.68, 95% CI 0.51-0.91; p=0.009), although the difference was not significant in the tamoxifen (HR 0.67, 95% CI 0.44-1.03; p=0.067) and anastrozole arms (HR 0.68, 95% CI 0.45-1.02; p=0.061) assessed sep.  Zoledronic acid did not significantly affect risk of death (30 deaths with zoledronic acid vs 43 deaths without; HR 0.67, 95% CI 0.41-1.07; p=0.09).  There was no difference in disease-free survival between patients on tamoxifen alone vs. anastrozole alone (HR 1.08, 95% CI 0.81-1.44; p=0.591), but overall survival was worse with anastrozole than with tamoxifen (46 vs 27 deaths; HR 1.75, 95% CI 1.08-2.83; p=0.02).  Treatments were generally well tolerated, with no reports of renal failure or osteonecrosis of the jaw.  Bone pain was reported in 601 patients (33%; 349 patients on zoledronic acid vs 252 not on the drug), fatigue in 361 (20%; 192 vs 169), headache in 280 (16%; 147 vs 133), and arthralgia in 266 (15%; 145 vs 121).  Addn. of zoledronic acid improved disease-free survival in the patients taking anastrozole or tamoxifen.  There was no difference in disease-free survival between patients receiving anastrozole and tamoxifen overall, but those on anastrozole alone had inferior overall survival.  These data show persistent benefits with zoledronic acid and support its addn. to adjuvant endocrine therapy in premenopausal patients with early-stage breast cancer.  Funding: AstraZeneca; Novartis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgMLLmua064rVg90H21EOLACvtfcHk0liFelxDVr5MEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXot1ejtLc%253D&md5=4755e1a85528b14accc4cc95bfa3d6b3</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2811%2970122-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252811%252970122-X%26sid%3Dliteratum%253Aachs%26aulast%3DGnant%26aufirst%3DM.%26aulast%3DMlineritsch%26aufirst%3DB.%26aulast%3DStoeger%26aufirst%3DH.%26aulast%3DLuschin-Ebengreuth%26aufirst%3DG.%26aulast%3DHeck%26aufirst%3DD.%26aulast%3DMenzel%26aufirst%3DC.%26aulast%3DJakesz%26aufirst%3DR.%26aulast%3DSeifert%26aufirst%3DM.%26aulast%3DHubalek%26aufirst%3DM.%26aulast%3DPristauz%26aufirst%3DG.%26aulast%3DBauernhofer%26aufirst%3DT.%26aulast%3DEidtmann%26aufirst%3DH.%26aulast%3DEiermann%26aufirst%3DW.%26aulast%3DSteger%26aufirst%3DG.%26aulast%3DKwasny%26aufirst%3DW.%26aulast%3DDubsky%26aufirst%3DP.%26aulast%3DHochreiner%26aufirst%3DG.%26aulast%3DForsthuber%26aufirst%3DE.%2BP.%26aulast%3DFesl%26aufirst%3DC.%26aulast%3DGreil%26aufirst%3DR.%26atitle%3DAdjuvant%2520endocrine%2520therapy%2520plus%2520zoledronic%2520acid%2520in%2520premenopausal%2520women%2520with%2520early-stage%2520breast%2520cancer%253A%252062-month%2520follow-up%2520from%2520the%2520ABCSG-12%2520randomised%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2011%26volume%3D12%26spage%3D631%26epage%3D641%26doi%3D10.1016%2FS1470-2045%2811%2970122-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gnant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mlineritsch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schippinger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luschin-Ebengreuth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pöstlberger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakesz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seifert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubalek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjelic-Radisic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samonigg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tausch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eidtmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwasny, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridrik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzal, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stierer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rücklinger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greil, R.</span></span> <span> </span><span class="NLM_article-title">Endocrine therapy plus zoledronic acid in premenopaisal breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">691</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa0806285</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1056%2FNEJMoa0806285" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=19213681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVyisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2009&pages=679-691&author=M.+Gnantauthor=B.+Mlineritschauthor=W.+Schippingerauthor=G.+Luschin-Ebengreuthauthor=S.+P%C3%B6stlbergerauthor=C.+Menzelauthor=R.+Jakeszauthor=M.+Seifertauthor=M.+Hubalekauthor=V.+Bjelic-Radisicauthor=H.+Samoniggauthor=C.+Tauschauthor=H.+Eidtmannauthor=G.+Stegerauthor=W.+Kwasnyauthor=P.+Dubskyauthor=M.+Fridrikauthor=F.+Fitzalauthor=M.+Stiererauthor=E.+R%C3%BCcklingerauthor=R.+Greil&title=Endocrine+therapy+plus+zoledronic+acid+in+premenopaisal+breast+cancer&doi=10.1056%2FNEJMoa0806285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Endocrine therapy plus zoledronic acid in premenopausal breast cancer</span></div><div class="casAuthors">Gnant, Michael; Mlineritsch, Brigitte; Schippinger, Walter; Luschin-Ebengreuth, Gero; Postlberger, Sabine; Menzel, Christian; Jakesz, Raimund; Seifert, Michael; Hubalek, Michael; Bjelic-Radisic, Vesna; Samonigg, Hellmut; Tausch, Christoph; Eidtmann, Holger; Steger, Gunther; Kwasny, Werner; Dubsky, Peter; Fridrik, Michael; Fitzal, Florian; Stierer, Michael; Rucklinger, Ernst; Greil, Richard</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">679-691</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Ovarian suppression plus tamoxifen is a std. adjuvant treatment in premenopausal women with endocrine-responsive breast cancer.  Aromatase inhibitors are superior to tamoxifen in postmenopausal patients, and preclin. data suggest that zoledronic acid has antitumor properties.  We examd. the effect of adding zoledronic acid to a combination of either goserelin and tamoxifen or goserelin and anastrozole in premenopausal women with endocrine-responsive early breast cancer.  We randomly assigned 1803 patients to receive goserelin (3.6 mg given s.c. every 28 days) plus tamoxifen (20 mg per day given orally) or anastrozole (1 mg per day given orally) with or without zoledronic acid (4 mg given i.v. every 6 mo) for 3 years.  The primary end point was disease-free survival; recurrence-free survival and overall survival were secondary end points.  After a median follow-up of 47.8 mo, 137 events had occurred, with disease-free survival rates of 92.8% in the tamoxifen group, 92.0% in the anastrozole group, 90.8% in the group that received endocrine therapy alone, and 94.0% in the group that received endocrine therapy with zoledronic acid.  There was no significant difference in disease-free survival between the anastrozole and tamoxifen groups (hazard ratio for disease progression in the anastrozole group, 1.10; 95% confidence interval [CI], 0.78 to 1.53; P = 0.59).  The addn. of zoledronic acid to endocrine therapy, as compared with endocrine therapy without zoledronic acid, resulted in an abs. redn. of 3.2 percentage points and a relative redn. of 36% in the risk of disease progression (hazard ratio, 0.64; 95% CI, 0.46 to 0.91; P = 0.01); the addn. of zoledronic acid did not significantly reduce the risk of death (hazard ratio, 0.60; 95% CI, 0.32 to 1.11; P = 0.11).  Adverse events were consistent with known drug-safety profiles.  The addn. of zoledronic acid to adjuvant endocrine therapy improves disease-free survival in premenopausal patients with estrogen-responsive early breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqWZL1vqoy7LVg90H21EOLACvtfcHk0liFelxDVr5MEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVyisbk%253D&md5=f2c9103a7cfd4b4d14bf30f8a2e679d7</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0806285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0806285%26sid%3Dliteratum%253Aachs%26aulast%3DGnant%26aufirst%3DM.%26aulast%3DMlineritsch%26aufirst%3DB.%26aulast%3DSchippinger%26aufirst%3DW.%26aulast%3DLuschin-Ebengreuth%26aufirst%3DG.%26aulast%3DP%25C3%25B6stlberger%26aufirst%3DS.%26aulast%3DMenzel%26aufirst%3DC.%26aulast%3DJakesz%26aufirst%3DR.%26aulast%3DSeifert%26aufirst%3DM.%26aulast%3DHubalek%26aufirst%3DM.%26aulast%3DBjelic-Radisic%26aufirst%3DV.%26aulast%3DSamonigg%26aufirst%3DH.%26aulast%3DTausch%26aufirst%3DC.%26aulast%3DEidtmann%26aufirst%3DH.%26aulast%3DSteger%26aufirst%3DG.%26aulast%3DKwasny%26aufirst%3DW.%26aulast%3DDubsky%26aufirst%3DP.%26aulast%3DFridrik%26aufirst%3DM.%26aulast%3DFitzal%26aufirst%3DF.%26aulast%3DStierer%26aufirst%3DM.%26aulast%3DR%25C3%25BCcklinger%26aufirst%3DE.%26aulast%3DGreil%26aufirst%3DR.%26atitle%3DEndocrine%2520therapy%2520plus%2520zoledronic%2520acid%2520in%2520premenopaisal%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D360%26spage%3D679%26epage%3D691%26doi%3D10.1056%2FNEJMoa0806285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Boer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eidtmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llombart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neven, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Minckwitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sleeboom, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forbes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrios, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frassoldati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paija, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bundred, N.</span></span> <span> </span><span class="NLM_article-title">Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): 60-months results</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">398</span>– <span class="NLM_lpage">405</span>, <span class="refDoi"> DOI: 10.1093/annonc/mds277</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1093%2Fannonc%2Fmds277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=23047045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A280%3ADC%252BC3s%252FjsFGjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=398-405&author=R.+E.+Colemanauthor=R.+de+Boerauthor=H.+Eidtmannauthor=A.+Llombartauthor=N.+Davidsonauthor=P.+Nevenauthor=G.+von+Minckwitzauthor=H.+P.+Sleeboomauthor=J.+Forbesauthor=C.+Barriosauthor=A.+Frassoldatiauthor=I.+Campbellauthor=O.+Paijaauthor=N.+Martinauthor=A.+Modiauthor=N.+Bundred&title=Zoledronic+acid+%28zoledronate%29+for+postmenopausal+women+with+early+breast+cancer+receiving+adjuvant+letrozole+%28ZO-FAST+study%29%3A+60-months+results&doi=10.1093%2Fannonc%2Fmds277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results</span></div><div class="casAuthors">Coleman R; de Boer R; Eidtmann H; Llombart A; Davidson N; Neven P; von Minckwitz G; Sleeboom H P; Forbes J; Barrios C; Frassoldati A; Campbell I; Paija O; Martin N; Modi A; Bundred N</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">398-405</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Aromatase inhibitors are the preferred adjuvant endocrine therapy for the majority of postmenopausal women with hormone-responsive early breast cancer.  Although generally more effective than tamoxifen, aromatase inhibitor therapy is associated with increased bone loss and fracture risk.  PATIENTS AND METHODS:  Postmenopausal women receiving adjuvant letrozole (2.5 mg/day for 5 years; N = 1065) were randomly assigned to immediate zoledronic acid (zoledronate) 4 mg every 6 months for 5 years, or delayed zoledronate (initiated for fracture or on-study bone mineral density [BMD] decrease).  The primary end point was the change in lumbar spine BMD at 12 months.  Lumbar spine and total hip BMD at subsequent follow-up, disease-free survival (DFS), and overall survival were assessed as secondary end points.  RESULTS:  At 60 months (final analysis), the mean change in lumbar spine BMD was +4.3% with immediate zoledronate and -5.4% with delayed intervention (P < 0.0001).  Immediate zoledronate reduced the risk of DFS events by 34% (hazard ratio [HR] = 0.66; P = 0.0375) with fewer local (0.9% versus 2.3%) and distant (5.5% versus 7.7%) recurrences versus delayed zoledronate.  In the delayed group, delayed initiation of zoledronate substantially improved DFS versus no zoledronate (HR = 0.46; P = 0.0334).  CONCLUSIONS:  Immediate zoledronate in postmenopausal women receiving letrozole preserved BMD and is associated with improved DFS compared with letrozole alone.  Clinical Trials Registration No NCT00171340.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSrF__4n9ssxlHFYivNCdPRfW6udTcc2ebhEk5RAxmq87ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s%252FjsFGjsg%253D%253D&md5=8c3ee5dd7ea24a157be353eca918044e</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmds277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmds277%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DR.%2BE.%26aulast%3Dde%2BBoer%26aufirst%3DR.%26aulast%3DEidtmann%26aufirst%3DH.%26aulast%3DLlombart%26aufirst%3DA.%26aulast%3DDavidson%26aufirst%3DN.%26aulast%3DNeven%26aufirst%3DP.%26aulast%3Dvon%2BMinckwitz%26aufirst%3DG.%26aulast%3DSleeboom%26aufirst%3DH.%2BP.%26aulast%3DForbes%26aufirst%3DJ.%26aulast%3DBarrios%26aufirst%3DC.%26aulast%3DFrassoldati%26aufirst%3DA.%26aulast%3DCampbell%26aufirst%3DI.%26aulast%3DPaija%26aufirst%3DO.%26aulast%3DMartin%26aufirst%3DN.%26aulast%3DModi%26aufirst%3DA.%26aulast%3DBundred%26aufirst%3DN.%26atitle%3DZoledronic%2520acid%2520%2528zoledronate%2529%2520for%2520postmenopausal%2520women%2520with%2520early%2520breast%2520cancer%2520receiving%2520adjuvant%2520letrozole%2520%2528ZO-FAST%2520study%2529%253A%252060-months%2520results%26jtitle%3DAnn.%2520Oncol.%26date%3D2013%26volume%3D24%26spage%3D398%26epage%3D405%26doi%3D10.1093%2Fannonc%2Fmds277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocks, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szubert, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro-Coy, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drayson, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feyler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashcroft, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roddie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Child, J. A.</span></span> <span> </span><span class="NLM_article-title">First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomized controlled trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">1989</span>– <span class="NLM_lpage">1999</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(10)62051-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1016%2FS0140-6736%2810%2962051-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=21131037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFCqsLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2010&pages=1989-1999&author=G.+J.+Morganauthor=F.+E.+Daviesauthor=W.+M.+Gregoryauthor=K.+Cocksauthor=S.+E.+Bellauthor=A.+J.+Szubertauthor=N.+Navarro-Coyauthor=M.+T.+Draysonauthor=R.+G.+Owenauthor=S.+Feylerauthor=A.+J.+Ashcroftauthor=F.+Rossauthor=J.+Byrneauthor=H.+Roddieauthor=C.+Rudinauthor=G.+Cookauthor=G.+H.+Jacksonauthor=J.+A.+Child&title=First-line+treatment+with+zoledronic+acid+as+compared+with+clodronic+acid+in+multiple+myeloma+%28MRC+Myeloma+IX%29%3A+a+randomized+controlled+trial&doi=10.1016%2FS0140-6736%2810%2962051-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial</span></div><div class="casAuthors">Morgan, Gareth J.; Davies, Faith E.; Gregory, Walter M.; Cocks, Kim; Bell, Sue E.; Szubert, Alex J.; Navarro-Coy, Nuria; Drayson, Mark T.; Owen, Roger G.; Feyler, Sylvia; Ashcroft, A. John; Ross, Fiona; Byrne, Jennifer; Roddie, Huw; Rudin, Claudius; Cook, Gordon; Jackson, Graham H.; Child, J. Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">9757</span>),
    <span class="NLM_cas:pages">1989-1999</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Bisphosphonates reduce the risk of skeletal events in patients with malignant bone disease, and zoledronic acid has shown potential anticancer effects in preclin. and clin. studies.  We aimed to establish whether bisphosphonates can affect clin. outcomes in patients with multiple myeloma.  Patients of age 18 years or older with newly diagnosed multiple myeloma were enrolled from 120 centers in the UK.  Computer-generated randomisation sequence was used to allocate patients equally, via an automated telephone service, to receive 4 mg zoledronic acid as an infusion every 3-4 wk or 1600 mg oral clodronic acid daily.  Patients also received intensive or non-intensive induction chemotherapy.  No investigators, staff, or patients were masked to treatment allocation, and bisphosphonate and maintenance therapy continued at least until disease progression.  The primary endpoints were overall survival, progression-free survival, and overall response rate.  We assessed between-group differences with Cox proportional hazards models for progression-free survival and overall survival, and with logistic regression models for overall response rate.  Anal. was by intention to treat.  This trial is registered, no. ISRCTN68454111.  1970 patients were enrolled between May, 2003, and Nov., 2007, of whom 1960 were eligible for intention-to-treat anal.: 981 in the zoledronic acid group (555 on intensive chemotherapy, 426 on non-intensive chemotherapy); and 979 on clodronic acid (556 on intensive chemotherapy, 423 on non-intensive chemotherapy).  The treatment cutoff was Oct 5, 2009, with patients receiving bisphosphonates for a median of 350 days (IQR 137-632) before disease progression, with a median of 3.7 years' follow-up (IQR 2.9-4.7).  Zoledronic acid reduced mortality by 16% (95% CI 4-26) vs. clodronic acid (hazard ratio [HR] 0.84, 95% CI 0.74-0.96; p=0.0118), and extended median overall survival by 5.5 mo (50.0 mo, IQR 21.0 to not reached vs 44.5 mo, IQR 16.5 to not reached; p=0.04).  Zoledronic acid also significantly improved progression-free survival by 12% (95% CI 2-20) vs. clodronic acid (HR 0.88, 95% CI 0.80-0.98; p=0.0179), and increased median progression-free survival by 2.0 mo (19.5 mo, IQR 9.0-38.0 vs 17.5 mo, IQR 8.5-34.0; p=0.07).  Rates of complete, very good partial, or partial response did not differ significantly between the zoledronic acid and clodronic acid groups for patients receiving intensive induction chemotherapy (432 patients [78%] vs 422 [76%]; p=0.43) or non-intensive induction chemotherapy (215 [50%] vs 195 [46%]; p=0.18).  Both bisphosphonates were generally well tolerated, with similar occurrence of acute renal failure and treatment-emergent serious adverse events, but zoledronic acid was assocd. with higher rates of confirmed osteonecrosis of the jaw (35 [4%]) than was clodronic acid (3 [<1%]).  Consistent with the potential anticancer activity of zoledronic acid, overall survival improved independently of prevention of skeletal-related events, showing that zoledronic acid has treatment benefits beyond bone health.  These findings support immediate treatment with zoledronic acid in patients with newly diagnosed multiple myeloma, not only for prevention of skeletal-related events, but also for potential antimyeloma benefits.  Funding: Medical Research Council (London, UK), with unrestricted educational grants from Novartis, Schering Health Care, Chugai, Pharmion, Celgene, and Ortho Biotech.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXS5ilaeyX3rVg90H21EOLACvtfcHk0ljJULT8sh8RRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFCqsLnL&md5=53e25efc3a82b57d286c73f7fba6a611</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2810%2962051-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252810%252962051-X%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DG.%2BJ.%26aulast%3DDavies%26aufirst%3DF.%2BE.%26aulast%3DGregory%26aufirst%3DW.%2BM.%26aulast%3DCocks%26aufirst%3DK.%26aulast%3DBell%26aufirst%3DS.%2BE.%26aulast%3DSzubert%26aufirst%3DA.%2BJ.%26aulast%3DNavarro-Coy%26aufirst%3DN.%26aulast%3DDrayson%26aufirst%3DM.%2BT.%26aulast%3DOwen%26aufirst%3DR.%2BG.%26aulast%3DFeyler%26aufirst%3DS.%26aulast%3DAshcroft%26aufirst%3DA.%2BJ.%26aulast%3DRoss%26aufirst%3DF.%26aulast%3DByrne%26aufirst%3DJ.%26aulast%3DRoddie%26aufirst%3DH.%26aulast%3DRudin%26aufirst%3DC.%26aulast%3DCook%26aufirst%3DG.%26aulast%3DJackson%26aufirst%3DG.%2BH.%26aulast%3DChild%26aufirst%3DJ.%2BA.%26atitle%3DFirst-line%2520treatment%2520with%2520zoledronic%2520acid%2520as%2520compared%2520with%2520clodronic%2520acid%2520in%2520multiple%2520myeloma%2520%2528MRC%2520Myeloma%2520IX%2529%253A%2520a%2520randomized%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2010%26volume%3D376%26spage%3D1989%26epage%3D1999%26doi%3D10.1016%2FS0140-6736%2810%2962051-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szubert, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drayson, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashcroft, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Child, J. A.</span></span> <span> </span><span class="NLM_article-title">Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">5374</span>– <span class="NLM_lpage">5383</span>, <span class="refDoi"> DOI: 10.1182/blood-2011-11-392522</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1182%2Fblood-2011-11-392522" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=22498739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFantLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2012&pages=5374-5383&author=G.+J.+Morganauthor=F.+E.+Daviesauthor=W.+M.+Gregoryauthor=A.+J.+Szubertauthor=S.+E.+Bellauthor=M.+T.+Draysonauthor=R.+G.+Owenauthor=A.+J.+Ashcroftauthor=G.+H.+Jacksonauthor=J.+A.+Child&title=Effects+of+induction+and+maintenance+plus+long-term+bisphosphonates+on+bone+disease+in+patients+with+multiple+myeloma%3A+the+Medical+Research+Council+Myeloma+IX+Trial&doi=10.1182%2Fblood-2011-11-392522"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial</span></div><div class="casAuthors">Morgan, Gareth J.; Davies, Faith E.; Gregory, Walter M.; Szubert, Alex J.; Bell, Sue E.; Drayson, Mark T.; Owen, Roger G.; Ashcroft, A. John; Jackson, Graham H.; Child, J. Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5374-5383</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The Medical Research Council Myeloma IX Trial (ISRCTNG8454111) examd. traditional and thalidomide-based induction and maintenance regimens and IV zoledronic acid (ZOL) and oral clodronate (CLO) in 1960 patients with newly diagnosed multiple myeloma.  Overall survival (OS) and skeletal-related event (SRE) data have been reported for the overall trial population.  The present anal. investigated optimal therapy regimens for different patient populations in Myeloma IX.  Patients were assigned to intensive or nonintensive treatment pathways and randomized to induction cyclophosphamide, vincristine, doxorubicin, and dexamethasone (CVAD) vs. cyclophosphamide, thalidomide, and dexamethasone (CTD; intensive) or melphalan and prednisolone vs. attenuated oral CTD (CTDa; nonintensive).  Patients were also randomized to ZOL or CLO.  In the nonintensive pathway, CTDa produced better responses and lower SRE rates than melphalan and prednisolone.  ZOL improved OS compared with CLO independently of sex, stage, or myeloma subtype, most profoundly in patients with baseline bone disease or other SREs.  In patients treated for ≥ 2 years, ZOL improved OS compared with CLO from randomization (median not reached for either; P = .02) and also from first on-study disease progression (median, 34 mo for ZOL vs 27 mo for CLO; P = .03).  Thalidomide-contg. regimens had better efficacy than traditional regimens, and ZOL demonstrated greater benefits than CLO.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn6bsYwhGflrVg90H21EOLACvtfcHk0ljJULT8sh8RRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFantLg%253D&md5=b908fa4236bbad0d7585647e43a02fbf</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-11-392522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-11-392522%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DG.%2BJ.%26aulast%3DDavies%26aufirst%3DF.%2BE.%26aulast%3DGregory%26aufirst%3DW.%2BM.%26aulast%3DSzubert%26aufirst%3DA.%2BJ.%26aulast%3DBell%26aufirst%3DS.%2BE.%26aulast%3DDrayson%26aufirst%3DM.%2BT.%26aulast%3DOwen%26aufirst%3DR.%2BG.%26aulast%3DAshcroft%26aufirst%3DA.%2BJ.%26aulast%3DJackson%26aufirst%3DG.%2BH.%26aulast%3DChild%26aufirst%3DJ.%2BA.%26atitle%3DEffects%2520of%2520induction%2520and%2520maintenance%2520plus%2520long-term%2520bisphosphonates%2520on%2520bone%2520disease%2520in%2520patients%2520with%2520multiple%2520myeloma%253A%2520the%2520Medical%2520Research%2520Council%2520Myeloma%2520IX%2520Trial%26jtitle%3DBlood%26date%3D2012%26volume%3D119%26spage%3D5374%26epage%3D5383%26doi%3D10.1182%2Fblood-2011-11-392522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skerjanec, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berenson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Major, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. H.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schran, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seaman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldmeier, F.</span></span> <span> </span><span class="NLM_article-title">The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">154</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1177/0091270002239824</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1177%2F0091270002239824" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=12616668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD3sXht1eqsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2003&pages=154-162&author=A.+Skerjanecauthor=J.+Berensonauthor=C.+Hsuauthor=P.+Majorauthor=W.+H.+Millerauthor=C.+Raveraauthor=H.+Schranauthor=J.+Seamanauthor=F.+Waldmeier&title=The+pharmacokinetics+and+pharmacodynamics+of+zoledronic+acid+in+cancer+patients+with+varying+degrees+of+renal+function&doi=10.1177%2F0091270002239824"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function</span></div><div class="casAuthors">Skerjanec, Andrej; Berenson, James; Hsu, ChyiHung; Major, Pierre; Miller, Wilson H., Jr.; Ravera, Christina; Schran, Horst; Seaman, John; Waldmeier, Felix</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">154-162</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">An open-label pharmacokinetic and pharmacodynamic study of zoledronic acid (Zometa) was performed in 19 cancer patients with bone metastases and known, varying levels of renal function.  Patients were stratified according to creatinine clearance (CLcr) into different groups of normal (CLcr > 80 mL/min), mildly (CLcr = 50-80 mL/min), or moderately/severely impaired (CLcr = 10-50 mL/min) renal function.  Three i.v. infusions of 4 mg zoledronic acid were administered at 1-mo intervals between doses.  Plasma concns. and amts. excreted in urine were detd. in all subjects, and 4 patients were administered 14C-labeled zoledronic acid to assess excretion and distribution of drug in whole blood.  In general, the drug was well tolerated by the patients.  Mean area under the plasma concn. vs. time curve and mean concn. immediately after cessation of drug infusion were lower, and mean amts. excreted in urine over 24 h from start of infusion were higher in normal subjects than in those with impaired renal function (36% vs. 28% of excreted dose), although the differences were not significant.  Furthermore, with repeated doses, there was no evidence of drug accumulation in plasma or changes in drug exposure in any of the groups, nor was there any evidence of changes in renal function status.  Serum levels of markers of bone resorption (serum C-telopeptide and N-telopeptide) were noticeably reduced after each dose of zoledronic acid across all three renal groups.  It was concluded that in patients with mildly to moderately reduced renal function, dosage adjustment of zoledronic acid is likely not necessary.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVyx9dbcD7JbVg90H21EOLACvtfcHk0ljJULT8sh8RRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXht1eqsLo%253D&md5=48a5725e25414d6532f3f7d68ffbbd76</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1177%2F0091270002239824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270002239824%26sid%3Dliteratum%253Aachs%26aulast%3DSkerjanec%26aufirst%3DA.%26aulast%3DBerenson%26aufirst%3DJ.%26aulast%3DHsu%26aufirst%3DC.%26aulast%3DMajor%26aufirst%3DP.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26aulast%3DRavera%26aufirst%3DC.%26aulast%3DSchran%26aufirst%3DH.%26aulast%3DSeaman%26aufirst%3DJ.%26aulast%3DWaldmeier%26aufirst%3DF.%26atitle%3DThe%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520zoledronic%2520acid%2520in%2520cancer%2520patients%2520with%2520varying%2520degrees%2520of%2520renal%2520function%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2003%26volume%3D43%26spage%3D154%26epage%3D162%26doi%3D10.1177%2F0091270002239824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfaar, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweitzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiegand, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skerjanec, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schran, H.</span></span> <span> </span><span class="NLM_article-title">Biodistribution and plasma protein binding of zoledronic acid</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">2043</span>– <span class="NLM_lpage">2049</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.021071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1124%2Fdmd.108.021071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=18625688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtF2jtLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=2043-2049&author=H.+M.+Weissauthor=U.+Pfaarauthor=A.+Schweitzerauthor=H.+Wiegandauthor=A.+Skerjanecauthor=H.+Schran&title=Biodistribution+and+plasma+protein+binding+of+zoledronic+acid&doi=10.1124%2Fdmd.108.021071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Biodistribution and plasma protein binding of zoledronic acid</span></div><div class="casAuthors">Weiss, H. Markus; Pfaar, Ulrike; Schweitzer, Alain; Wiegand, Hansjorg; Skerjanec, Andrej; Schran, Horst</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2043-2049</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The bisphosphonate zoledronic acid is a potent inhibitor of osteoclast-mediated bone resorption.  To investigate drug biodistribution and elimination, 14C-zoledronic acid was administered i.v. to rats and dogs in single or multiple doses and assessed for its in vitro blood distribution and plasma protein binding in rat, dog, and human.  Drug exposure in plasma, bones, and noncalcified tissues was investigated up to 240 days in rats and 96 h in dogs using radiometry after dissection.  Drug biodistribution in the rat and within selected bones from dog was assessed by autoradiog.  Concns. of radioactivity showed a rapid decline in plasma and noncalcified tissue but only a slow decline in bone, to ∼50% of peak at 240 days post dose, whereas the terminal half-lives (50-200 days) were similar in bone and noncalcified tissues, suggesting redistribution of drug from the former rather than prolonged retention in the latter.  Uptake was highest in cancellous bone and axial skeleton.  At 96 h after dose, the fraction of dose excreted was 36% in rat and 60% in dog; 94 to 96% of the excreted radioactivity was found in urine.  Blood/plasma concn. ratios were 0.52 to 0.59, and plasma protein binding of zoledronic acid was moderate to low in all species.  The results suggest that a fraction of zoledronic acid is reversibly taken up by the skeleton, the elimination of drug is mainly by renal excretion, and the disposition in blood and noncalcified tissue is governed by extensive uptake into and slow release from bone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhdoRU-4CE8bVg90H21EOLACvtfcHk0lhGo63ZWSAspQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtF2jtLbF&md5=50e294a82b4649e2951f759d4788c7f8</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.021071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.021071%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DH.%2BM.%26aulast%3DPfaar%26aufirst%3DU.%26aulast%3DSchweitzer%26aufirst%3DA.%26aulast%3DWiegand%26aufirst%3DH.%26aulast%3DSkerjanec%26aufirst%3DA.%26aulast%3DSchran%26aufirst%3DH.%26atitle%3DBiodistribution%2520and%2520plasma%2520protein%2520binding%2520of%2520zoledronic%2520acid%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26spage%3D2043%26epage%3D2049%26doi%3D10.1124%2Fdmd.108.021071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rondeau, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotesta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzinzik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellé, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geiser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strauss, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Götte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitsch, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemmig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glickman, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roddy, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stout, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J. R.</span></span> <span> </span><span class="NLM_article-title">Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">660</span>– <span class="NLM_lpage">666</span>, <span class="refDoi"> DOI: 10.1038/nchembio.421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1038%2Fnchembio.421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=20711197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVaisLzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=660-666&author=W.+Jahnkeauthor=J.-M.+Rondeauauthor=S.+Cotestaauthor=A.+Marzinzikauthor=X.+Pell%C3%A9author=M.+Geiserauthor=A.+Straussauthor=M.+G%C3%B6tteauthor=F.+Bitschauthor=R.+Hemmigauthor=C.+Henryauthor=S.+Lehmannauthor=J.+F.+Glickmanauthor=T.+P.+Roddyauthor=S.+J.+Stoutauthor=J.+R.+Green&title=Allosteric+non-bisphosphonate+FPPS+inhibitors+identified+by+fragment-based+discovery&doi=10.1038%2Fnchembio.421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery</span></div><div class="casAuthors">Jahnke, Wolfgang; Rondeau, Jean-Michel; Cotesta, Simona; Marzinzik, Andreas; Pelle, Xavier; Geiser, Martin; Strauss, Andre; Goette, Marjo; Bitsch, Francis; Hemmig, Rene; Henry, Chrystele; Lehmann, Sylvie; Glickman, J. Fraser; Roddy, Thomas P.; Stout, Steven J.; Green, Jonathan R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">660-666</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bisphosphonates are potent inhibitors of farnesyl pyrophosphate synthase (FPPS) and are highly efficacious in the treatment of bone diseases such as osteoporosis, Paget's disease and tumor-induced osteolysis.  In addn., the potential for direct antitumor effects has been postulated on the basis of in vitro and in vivo studies and has recently been demonstrated clin. in early breast cancer patients treated with the potent bisphosphonate zoledronic acid.  However, the high affinity of bisphosphonates for bone mineral seems suboptimal for the direct treatment of soft-tissue tumors.  Here we report the discovery of the first potent non-bisphosphonate FPPS inhibitors.  These new inhibitors bind to a previously unknown allosteric site on FPPS, which was identified by fragment-based approaches using NMR and X-ray crystallog.  This allosteric and druggable pocket allows the development of a new generation of FPPS inhibitors that are optimized for direct antitumor effects in soft tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZFyA6x-XeY7Vg90H21EOLACvtfcHk0lhGo63ZWSAspQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVaisLzO&md5=72e1bc45a05733c2748a2138d0e0824f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.421%26sid%3Dliteratum%253Aachs%26aulast%3DJahnke%26aufirst%3DW.%26aulast%3DRondeau%26aufirst%3DJ.-M.%26aulast%3DCotesta%26aufirst%3DS.%26aulast%3DMarzinzik%26aufirst%3DA.%26aulast%3DPell%25C3%25A9%26aufirst%3DX.%26aulast%3DGeiser%26aufirst%3DM.%26aulast%3DStrauss%26aufirst%3DA.%26aulast%3DG%25C3%25B6tte%26aufirst%3DM.%26aulast%3DBitsch%26aufirst%3DF.%26aulast%3DHemmig%26aufirst%3DR.%26aulast%3DHenry%26aufirst%3DC.%26aulast%3DLehmann%26aufirst%3DS.%26aulast%3DGlickman%26aufirst%3DJ.%2BF.%26aulast%3DRoddy%26aufirst%3DT.%2BP.%26aulast%3DStout%26aufirst%3DS.%2BJ.%26aulast%3DGreen%26aufirst%3DJ.%2BR.%26atitle%3DAllosteric%2520non-bisphosphonate%2520FPPS%2520inhibitors%2520identified%2520by%2520fragment-based%2520discovery%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D6%26spage%3D660%26epage%3D666%26doi%3D10.1038%2Fnchembio.421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Schutter, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gormley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berghuis, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poirier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsantrizos, Y. S.</span></span> <span> </span><span class="NLM_article-title">Multistage screening reveals chameleon ligands of human farnesyl pyrophosphate synthase: Implications to drug discovery for neurodegenerative diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5764</span>– <span class="NLM_lpage">5776</span>, <span class="refDoi"> DOI: 10.1021/jm500629e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500629e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5764-5776&author=J.+W.+De%0ASchutterauthor=J.+Parkauthor=C.+Y.+Leungauthor=P.+Gormleyauthor=Y.+S.+Linauthor=Z.+Huauthor=A.+M.+Berghuisauthor=J.+Poirierauthor=Y.+S.+Tsantrizos&title=Multistage+screening+reveals+chameleon+ligands+of+human+farnesyl+pyrophosphate+synthase%3A+Implications+to+drug+discovery+for+neurodegenerative+diseases&doi=10.1021%2Fjm500629e"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm500629e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500629e%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSchutter%26aufirst%3DJ.%2BW.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DLeung%26aufirst%3DC.%2BY.%26aulast%3DGormley%26aufirst%3DP.%26aulast%3DLin%26aufirst%3DY.%2BS.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DBerghuis%26aufirst%3DA.%2BM.%26aulast%3DPoirier%26aufirst%3DJ.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26atitle%3DMultistage%2520screening%2520reveals%2520chameleon%2520ligands%2520of%2520human%2520farnesyl%2520pyrophosphate%2520synthase%253A%2520Implications%2520to%2520drug%2520discovery%2520for%2520neurodegenerative%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5764%26epage%3D5776%26doi%3D10.1021%2Fjm500629e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marzinzik, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amstutz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bold, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourgier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotesta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glickman, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Götte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartwieg, J. C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ofner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellé, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roddy, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rondeau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stout, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel allostetic non-bisphosphonate inhibitors of farnesyl pyrophosphate synthase by integrated lead finding</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1884</span>– <span class="NLM_lpage">1891</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1002%2Fcmdc.201500338" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1884-1891&author=A.+L.+Marzinzikauthor=R.+Amstutzauthor=G.+Boldauthor=E.+Bourgierauthor=S.+Cotestaauthor=J.+F.+Glickmanauthor=M.+G%C3%B6tteauthor=C.+Henryauthor=S.+Lehmannauthor=J.+C.+D.+Hartwiegauthor=S.+Ofnerauthor=X.+Pell%C3%A9author=T.+P.+Roddyauthor=M.+Rondeauauthor=F.+Staufferauthor=S.+J.+Stoutauthor=A.+Widmerauthor=J.+Zimmermannauthor=T.+Zollerauthor=W.+Jahnke&title=Discovery+of+novel+allostetic+non-bisphosphonate+inhibitors+of+farnesyl+pyrophosphate+synthase+by+integrated+lead+finding&doi=10.1002%2Fcmdc.201500338"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500338%26sid%3Dliteratum%253Aachs%26aulast%3DMarzinzik%26aufirst%3DA.%2BL.%26aulast%3DAmstutz%26aufirst%3DR.%26aulast%3DBold%26aufirst%3DG.%26aulast%3DBourgier%26aufirst%3DE.%26aulast%3DCotesta%26aufirst%3DS.%26aulast%3DGlickman%26aufirst%3DJ.%2BF.%26aulast%3DG%25C3%25B6tte%26aufirst%3DM.%26aulast%3DHenry%26aufirst%3DC.%26aulast%3DLehmann%26aufirst%3DS.%26aulast%3DHartwieg%26aufirst%3DJ.%2BC.%2BD.%26aulast%3DOfner%26aufirst%3DS.%26aulast%3DPell%25C3%25A9%26aufirst%3DX.%26aulast%3DRoddy%26aufirst%3DT.%2BP.%26aulast%3DRondeau%26aufirst%3DM.%26aulast%3DStauffer%26aufirst%3DF.%26aulast%3DStout%26aufirst%3DS.%2BJ.%26aulast%3DWidmer%26aufirst%3DA.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DZoller%26aufirst%3DT.%26aulast%3DJahnke%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520novel%2520allostetic%2520non-bisphosphonate%2520inhibitors%2520of%2520farnesyl%2520pyrophosphate%2520synthase%2520by%2520integrated%2520lead%2520finding%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D1884%26epage%3D1891%26doi%3D10.1002%2Fcmdc.201500338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matralis, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacbay, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsakos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez De Troconiz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berghuis, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsantrizos, Y. S.</span></span> <span> </span><span class="NLM_article-title">Pharmacophore mapping of thienopyrimidine-based monophosphonate (ThP-MP) inhibitors of the human farnesyl pyrophosphate synthase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2119</span>– <span class="NLM_lpage">2134</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01888</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01888" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC2sXivFSru74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2119-2134&author=J.+Parkauthor=C.+Y.+Leungauthor=A.+N.+Matralisauthor=C.+M.+Lacbayauthor=M.+Tsakosauthor=G.+Fernandez+De+Troconizauthor=A.+M.+Berghuisauthor=Y.+S.+Tsantrizos&title=Pharmacophore+mapping+of+thienopyrimidine-based+monophosphonate+%28ThP-MP%29+inhibitors+of+the+human+farnesyl+pyrophosphate+synthase&doi=10.1021%2Facs.jmedchem.6b01888"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacophore Mapping of Thienopyrimidine-Based Monophosphonate (ThP-MP) Inhibitors of the Human Farnesyl Pyrophosphate Synthase</span></div><div class="casAuthors">Park, Jaeok; Leung, Chun Yuen; Matralis, Alexios N.; Lacbay, Cyrus M.; Tsakos, Michail; Fernandez De Troconiz, Guillermo; Berghuis, Albert M.; Tsantrizos, Youla S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2119-2134</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The human farnesyl pyrophosphate synthase (hFPPS), a key regulatory enzyme in the mevalonate pathway, catalyzes the biosynthesis of the C-15 isoprenoid farnesyl pyrophosphate (FPP).  FPP plays a crucial role in the post-translational prenylation of small GTPases that perform a plethora of cellular functions.  Although hFPPS is a well-established therapeutic target for lytic bone diseases, the currently available bisphosphonate drugs exhibit poor cellular uptake and distribution into non-skeletal tissues.  Recent drug discovery efforts have focused primarily on allosteric inhibition of hFPPS and the discovery of non-bisphosphonate drugs for potentially treating non-skeletal diseases.  Hit-to-lead optimization of a new series of thienopyrimidine-based monosphosphonates (ThP-MPs) led to the identification of analogs with nanomolar potency in inhibiting hFPPS.  Their interactions with the allosteric pocket of the enzyme were characterized by crystallog. and the results provide further insight into the pharmacophore requirements for allosteric inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyhrW7fwd66bVg90H21EOLACvtfcHk0lhsnkl9uwq1Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXivFSru74%253D&md5=ac44083a7b20a199cd1cfb59bec71be1</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01888%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DLeung%26aufirst%3DC.%2BY.%26aulast%3DMatralis%26aufirst%3DA.%2BN.%26aulast%3DLacbay%26aufirst%3DC.%2BM.%26aulast%3DTsakos%26aufirst%3DM.%26aulast%3DFernandez%2BDe%2BTroconiz%26aufirst%3DG.%26aulast%3DBerghuis%26aufirst%3DA.%2BM.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26atitle%3DPharmacophore%2520mapping%2520of%2520thienopyrimidine-based%2520monophosphonate%2520%2528ThP-MP%2529%2520inhibitors%2520of%2520the%2520human%2520farnesyl%2520pyrophosphate%2520synthase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2119%26epage%3D2134%26doi%3D10.1021%2Facs.jmedchem.6b01888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lobell, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buser, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davide, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePuy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblan, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motzel, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbruzzese, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowinsky, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deutsch, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazina, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildonger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, S.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohl, N. E.</span></span> <span> </span><span class="NLM_article-title">Preclinical and clinical pharmacodynamic assessment of L-778, 123, a dual inhibitor of farnesyl:protein transfgerase and geranylgeranyl:ptotein tansferase type-I</span>. <i>Mol. Cancer Ther</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">747</span>– <span class="NLM_lpage">758</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=12479371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsFSmtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=747-758&author=R.+B.+Lobellauthor=D.+Liuauthor=C.+A.+Buserauthor=J.+P.+Davideauthor=E.+DePuyauthor=K.+Hamiltonauthor=K.+S.+Koblanauthor=Y.+Leeauthor=S.+Mosserauthor=S.+L.+Motzelauthor=J.+L.+Abbruzzeseauthor=C.+S.+Fuchsauthor=E.+K.+Rowinskyauthor=E.+H.+Rubinauthor=S.+Sharmaauthor=P.+J.+Deutschauthor=K.+E.+Mazinaauthor=B.+W.+Morrisonauthor=L.+Wildongerauthor=S.-L.+Yaoauthor=N.+E.+Kohl&title=Preclinical+and+clinical+pharmacodynamic+assessment+of+L-778%2C+123%2C+a+dual+inhibitor+of+farnesyl%3Aprotein+transfgerase+and+geranylgeranyl%3Aptotein+tansferase+type-I"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I</span></div><div class="casAuthors">Lobell, Robert B.; Liu, Dongming; Buser, Carolyn A.; Davide, Joseph P.; DePuy, Elizabeth; Hamilton, Kelly; Koblan, Kenneth S.; Lee, Yih; Mosser, Scott; Motzel, Sherri L.; Abbruzzese, James L.; Fuchs, Charles S.; Rowinsky, Eric K.; Rubin, Eric H.; Sharma, Sunil; Deutsch, Paul J.; Mazina, Kathryn E.; Morrison, Briggs W.; Wildonger, Lynne; Yao, Siu-Long; Kohl, Nancy E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">747-758</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Farnesyl:protein transferase (FPTase) inhibitors were developed as anti-Ras drugs, but they fail to inhibit Ki-Ras activity because Ki-Ras can be modified by geranylgeranyl:protein transferase type-I (GGPTase-I).  L-778,123, an inhibitor of FPTase and GGPTase-I, was developed in part because it can completely inhibit Ki-Ras prenylation.  To support the clin. development of L-778,123, we developed pharmacodynamic assays using peripheral blood mononuclear cells (PBMCs) to measure the inhibition of prenylation of HDJ2 and Rap1A, proteins that are FPTase- and GGPTase-I substrates, resp.  We validated these assays in animal models and show that inhibition of HDJ2 prenylation in mouse PBMCs correlates with the concn. of FPTase inhibitors in blood.  In dogs, continuous infusion of L-778,123 inhibited both HDJ2 and Rap1A prenylation in PBMCs, but we did not detect inhibition of Ki-Ras prenylation.  We reported previously results from the first L-778,123 Phase I trial that showed a dose-dependent inhibition of HDJ2 farnesylation in PBMCs.  In this report, we present addnl. anal. of patient samples from this trial and a second Phase I trial of L-778, 123, and demonstrate the inhibition of both HDJ2 and Rap1A prenylation in PBMC samples.  This study represents the first demonstration of GGPTase-I inhibition in humans.  However, no inhibition of Ki-Ras prenylation by L-778,123 was detected in patient samples.  These results confirm the pharmacol. profile of L-778, 123 in humans as a dual inhibitor of FPTase and GGPTase-I, but indicate that the intended target of the drug, Ki-Ras, was not inhibited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogSDhxZmacjrVg90H21EOLACvtfcHk0lhsnkl9uwq1Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsFSmtb8%253D&md5=082f75d70280294811cdf665b880b692</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLobell%26aufirst%3DR.%2BB.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DBuser%26aufirst%3DC.%2BA.%26aulast%3DDavide%26aufirst%3DJ.%2BP.%26aulast%3DDePuy%26aufirst%3DE.%26aulast%3DHamilton%26aufirst%3DK.%26aulast%3DKoblan%26aufirst%3DK.%2BS.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DMosser%26aufirst%3DS.%26aulast%3DMotzel%26aufirst%3DS.%2BL.%26aulast%3DAbbruzzese%26aufirst%3DJ.%2BL.%26aulast%3DFuchs%26aufirst%3DC.%2BS.%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26aulast%3DRubin%26aufirst%3DE.%2BH.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DDeutsch%26aufirst%3DP.%2BJ.%26aulast%3DMazina%26aufirst%3DK.%2BE.%26aulast%3DMorrison%26aufirst%3DB.%2BW.%26aulast%3DWildonger%26aufirst%3DL.%26aulast%3DYao%26aufirst%3DS.-L.%26aulast%3DKohl%26aufirst%3DN.%2BE.%26atitle%3DPreclinical%2520and%2520clinical%2520pharmacodynamic%2520assessment%2520of%2520L-778%252C%2520123%252C%2520a%2520dual%2520inhibitor%2520of%2520farnesyl%253Aprotein%2520transfgerase%2520and%2520geranylgeranyl%253Aptotein%2520tansferase%2520type-I%26jtitle%3DMol.%2520Cancer%2520Ther%26date%3D2002%26volume%3D1%26spage%3D747%26epage%3D758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiel, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLaney, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regine, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohiuddin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosato, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haller, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pramanik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tepper, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deutsch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muschel, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenna, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhard, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, S. M.</span></span> <span> </span><span class="NLM_article-title">A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">5447</span>– <span class="NLM_lpage">5454</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-04-0248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1158%2F1078-0432.CCR-04-0248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=15328183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvFSltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=5447-5454&author=N.+E.+Martinauthor=T.+B.+Brunnerauthor=K.+D.+Kielauthor=T.+F.+DeLaneyauthor=W.+F.+Regineauthor=M.+Mohiuddinauthor=E.+F.+Rosatoauthor=D.+G.+Hallerauthor=J.+P.+Stevensonauthor=D.+Smithauthor=B.+Pramanikauthor=J.+Tepperauthor=W.+K.+Tanakaauthor=B.+Morrisonauthor=P.+Deutschauthor=A.+K.+Guptaauthor=R.+J.+Muschelauthor=G.+McKennaauthor=E.+J.+Bernhardauthor=S.+M.+Hahn&title=A+phase+I+trial+of+the+dual+farnesyltransferase+and+geranylgeranyltransferase+inhibitor+L-778%2C123+and+radiotherapy+for+locally+advanced+pancreatic+cancer&doi=10.1158%2F1078-0432.CCR-04-0248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer</span></div><div class="casAuthors">Martin, Neil E.; Brunner, Thomas B.; Kiel, Krystina D.; DeLaney, Thomas F.; Regine, William F.; Mohiuddin, Mohammed; Rosato, Ernest F.; Haller, Daniel G.; Stevenson, James P.; Smith, Debbie; Pramanik, Barnali; Tepper, Joel; Tanaka, Wesley K.; Morrison, Briggs; Deutsch, Paul; Gupta, Anjali K.; Muschel, Ruth J.; McKenna, W. Gillies; Bernhard, Eric J.; Hahn, Stephen M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5447-5454</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Preclin. and clin. studies have demonstrated that inhibition of prenylation can radiosensitize cell lines with activation of Ras and produce clin. response in patients with cancer.  The aim of this study was to det. the maximally tolerated dose of the dual farnesyltransferase and geranylgeranyltransferase I inhibitor L-778,123 in combination with radiotherapy for patients with locally advanced pancreatic cancer.  L-778,123 was given by continuous i.v. infusion with concomitant radiotherapy to 59.4 Gy in std. fractions.  Two L-778,123 dose levels were tested: 280 mg/m2/day over weeks 1, 2, 4, and 5 for dose level 1; and 560 mg/m2/day over weeks 1, 2, 4, 5, and 7 for dose level 2.  There were no dose-limiting toxicities obsd. in the eight patients treated on dose level 1.  Two of the four patients on dose level 2 experienced dose-limiting toxicities consisting of grade 3 diarrhea in one case and grade 3 gastrointestinal hemorrhage assocd. with grade 3 thrombocytopenia and neutropenia in the other case.  Other common toxicities were mild neutropenia, dehydration, hyperglycemia, and nausea/vomiting.  One patient on dose level 1 showed a partial response of 6 mo in duration.  Both reversible inhibition of HDJ2 farnesylation and radiosensitization of a study patient-derived cell line were demonstrated in the presence of L-778,123.  K-RAS mutations were found in three of the four patients evaluated.  The combination of L-778,123 and radiotherapy at dose level 1 showed acceptable toxicity in patients with locally advanced pancreatic cancer.  Radiosensitization of a patient-derived pancreatic cancer cell line was obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-CjOMRzk8JLVg90H21EOLACvtfcHk0lglqX35rvfXtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvFSltLg%253D&md5=cb80a9340dbafafced681366cceaf51c</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-0248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-0248%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DN.%2BE.%26aulast%3DBrunner%26aufirst%3DT.%2BB.%26aulast%3DKiel%26aufirst%3DK.%2BD.%26aulast%3DDeLaney%26aufirst%3DT.%2BF.%26aulast%3DRegine%26aufirst%3DW.%2BF.%26aulast%3DMohiuddin%26aufirst%3DM.%26aulast%3DRosato%26aufirst%3DE.%2BF.%26aulast%3DHaller%26aufirst%3DD.%2BG.%26aulast%3DStevenson%26aufirst%3DJ.%2BP.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DPramanik%26aufirst%3DB.%26aulast%3DTepper%26aufirst%3DJ.%26aulast%3DTanaka%26aufirst%3DW.%2BK.%26aulast%3DMorrison%26aufirst%3DB.%26aulast%3DDeutsch%26aufirst%3DP.%26aulast%3DGupta%26aufirst%3DA.%2BK.%26aulast%3DMuschel%26aufirst%3DR.%2BJ.%26aulast%3DMcKenna%26aufirst%3DG.%26aulast%3DBernhard%26aufirst%3DE.%2BJ.%26aulast%3DHahn%26aufirst%3DS.%2BM.%26atitle%3DA%2520phase%2520I%2520trial%2520of%2520the%2520dual%2520farnesyltransferase%2520and%2520geranylgeranyltransferase%2520inhibitor%2520L-778%252C123%2520and%2520radiotherapy%2520for%2520locally%2520advanced%2520pancreatic%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D5447%26epage%3D5454%26doi%3D10.1158%2F1078-0432.CCR-04-0248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelb, M. H.</span></span> <span> </span><span class="NLM_article-title">Differential prenyl pyrophosphate binding to mammalian protein geranylgeranyltransferase-I and protein farnesyltransferase and its consequence on the specificity of protein prenylation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>272</i></span>,  <span class="NLM_fpage">3944</span>– <span class="NLM_lpage">3952</span>, <span class="refDoi"> DOI: 10.1074/jbc.272.7.3944</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1074%2Fjbc.272.7.3944" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=9020098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADyaK2sXht1Oltr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=3944-3952&author=K.+Yokoyamaauthor=K.+Zimmermanauthor=J.+Scholtenauthor=M.+H.+Gelb&title=Differential+prenyl+pyrophosphate+binding+to+mammalian+protein+geranylgeranyltransferase-I+and+protein+farnesyltransferase+and+its+consequence+on+the+specificity+of+protein+prenylation&doi=10.1074%2Fjbc.272.7.3944"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Differential prenyl pyrophosphate binding to mammalian protein geranylgeranyltransferase-I and protein farnesyltransferase and its consequence on the specificity of protein prenylation</span></div><div class="casAuthors">Yokoyama, Kohei; Zimmerman, Karen; Scholten, Jeffrey; Gelb, Michael H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3944-3952</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Protein geranylgeranyltransferase-I (PGGT-I) and protein farnesyltransferase (PET) attach geranylgeranyl and farnesyl groups, resp., to the C termini of eukaryotic cell proteins.  In vitro, PGGT-I and PFT can transfer both geranylgeranyl and farnesyl groups from geranylgeranyl pyrophosphate (GGPP) and farnesyl pyrophosphate (FPP) to their protein or peptide prenyl acceptor substrates.  In the present study it is shown that PGGT-I binds GGPP 330-fold tighter than FPP and that PFT binds FPP 15-fold tighter than GGPP.  Therefore, in vivo, where both GGPP and FPP compete for the binding to prenyltransferases, PGGT-I and PFT will likely be bound predominantly to GGPP and FPP, resp.  Previous studies have shown that K-Ras4B and the Ras-related GTPase TC21 are substrates for both PGGT-I and PFT in vitro.  It is shown that TC21 can compete with the C-terminal peptide of the γ subunit of heterotrimeric G proteins and with the C-terminal peptide of lamin B for geranylgeranylation by PGGT-I and for farnesylation by PFT, resp.  K-Ras4B competes in both cases but is almost exclusively farnesylated by PFT in the presence of the lamin B peptide competitor.  Rapid and single turnover kinetic studies indicate that the rate const. for the PGGT-I-catalyzed geranylgeranyl transfer step of the reaction cycle is 14-fold larger than the steady-state turnover no., which indicates that the rate of the overall reaction is limited by a step subsequent to prenyl transfer such as release of products from the enzyme.  PGGT-I-catalyzed farnesylation is 37-fold slower than geranylgeranylation and is limited by the farnesyl transfer step.  These results together with earlier studies provide a paradigm for the substrate specificity of PGGT-I and PFT and provide information that is crit. for the design of prenyltransferase inhibitors as anti-cancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFtK1IiaHPBbVg90H21EOLACvtfcHk0lglqX35rvfXtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXht1Oltr4%253D&md5=4e6ccafc175458dc5306c58288ac10c6</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1074%2Fjbc.272.7.3944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.272.7.3944%26sid%3Dliteratum%253Aachs%26aulast%3DYokoyama%26aufirst%3DK.%26aulast%3DZimmerman%26aufirst%3DK.%26aulast%3DScholten%26aufirst%3DJ.%26aulast%3DGelb%26aufirst%3DM.%2BH.%26atitle%3DDifferential%2520prenyl%2520pyrophosphate%2520binding%2520to%2520mammalian%2520protein%2520geranylgeranyltransferase-I%2520and%2520protein%2520farnesyltransferase%2520and%2520its%2520consequence%2520on%2520the%2520specificity%2520of%2520protein%2520prenylation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26spage%3D3944%26epage%3D3952%26doi%3D10.1074%2Fjbc.272.7.3944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rowinsky, E. K.</span></span> <span> </span><span class="NLM_article-title">Lately, it occurs to me what a long, strange trip it’s been for the farnesyltransferase inhibitors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2981</span>– <span class="NLM_lpage">2984</span>, <span class="refDoi"> DOI: 10.1200/JCO.2006.05.9808</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1200%2FJCO.2006.05.9808" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=16769983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD28XnslKhsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=2981-2984&author=E.+K.+Rowinsky&title=Lately%2C+it+occurs+to+me+what+a+long%2C+strange+trip+it%E2%80%99s+been+for+the+farnesyltransferase+inhibitors&doi=10.1200%2FJCO.2006.05.9808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors</span></div><div class="casAuthors">Rowinsky, Eric K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2981-2984</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The research of Sparano et al. (2006) entitled "Targeted inhibition of farnesyltransferase in locally advanced breast cancer: A phase I and II trial incorporating tipifarnib plus dose-dense doxorubicin and cyclophosphamide", is reviewed with commentary and refs.  The study of Sparano et al. have shown that the farnesyltransferase (FTase) inhibitors are capable of inhibiting FTase in tumors.  The pathol. complete response rate of 33% reported by Sparano et al. exceeds the threshold rate of 15% defined a priori for proceeding to the next stage of the study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq39i56qUmuhbVg90H21EOLACvtfcHk0lgICgxG0PESuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnslKhsro%253D&md5=02a13916c995ebf1cbccfc783a32aae6</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1200%2FJCO.2006.05.9808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2006.05.9808%26sid%3Dliteratum%253Aachs%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26atitle%3DLately%252C%2520it%2520occurs%2520to%2520me%2520what%2520a%2520long%252C%2520strange%2520trip%2520it%25E2%2580%2599s%2520been%2520for%2520the%2520farnesyltransferase%2520inhibitors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D2981%26epage%3D2984%26doi%3D10.1200%2FJCO.2006.05.9808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krysiak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">No, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukkamala, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houlihan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldfield, E.</span></span> <span> </span><span class="NLM_article-title">Lipophilic pyridinium bisphosphonates: Potent γδ T cell stimulators</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1136</span>– <span class="NLM_lpage">1138</span>, <span class="refDoi"> DOI: 10.1002/anie.200905933</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1002%2Fanie.200905933" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=1136-1138&author=Y.+Zhangauthor=R.+Caoauthor=F.+Yinauthor=F.-Y.+Linauthor=H.+Wangauthor=K.+Krysiakauthor=J.-H.+Noauthor=D.+Mukkamalaauthor=K.+Houlihanauthor=J.+Liauthor=C.+T.+Moritaauthor=E.+Oldfield&title=Lipophilic+pyridinium+bisphosphonates%3A+Potent+%CE%B3%CE%B4+T+cell+stimulators&doi=10.1002%2Fanie.200905933"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fanie.200905933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200905933%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DR.%26aulast%3DYin%26aufirst%3DF.%26aulast%3DLin%26aufirst%3DF.-Y.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DKrysiak%26aufirst%3DK.%26aulast%3DNo%26aufirst%3DJ.-H.%26aulast%3DMukkamala%26aufirst%3DD.%26aulast%3DHoulihan%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMorita%26aufirst%3DC.%2BT.%26aulast%3DOldfield%26aufirst%3DE.%26atitle%3DLipophilic%2520pyridinium%2520bisphosphonates%253A%2520Potent%2520%25CE%25B3%25CE%25B4%2520T%2520cell%2520stimulators%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2010%26volume%3D49%26spage%3D1136%26epage%3D1138%26doi%3D10.1002%2Fanie.200905933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudock, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, R.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krysiak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">No, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cass, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goddard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, T.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Beek, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papapoulos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukkamala, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldfield, E.</span></span> <span> </span><span class="NLM_article-title">Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: An X-ray and NMR investigation</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">5153</span>– <span class="NLM_lpage">5162</span>, <span class="refDoi"> DOI: 10.1021/ja808285e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja808285e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjsFKnsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2009&pages=5153-5162&author=Y.+Zhangauthor=R.+Caoauthor=F.+Yinauthor=M.+P.+Hudockauthor=R.-T.+Guoauthor=K.+Krysiakauthor=S.+Mukherjeeauthor=Y.-G.+Gaoauthor=H.+Robinsonauthor=Y.+Songauthor=J.+H.+Noauthor=K.+Berganauthor=A.+Leonauthor=L.+Cassauthor=A.+Goddardauthor=T.-K.+Changauthor=F.-Y.+Linauthor=E.+Van+Beekauthor=S.+Papapoulosauthor=A.H.-J.+Wangauthor=T.+Kuboauthor=M.+Ochiauthor=D.+Mukkamalaauthor=E.+Oldfield&title=Lipophilic+bisphosphonates+as+dual+farnesyl%2Fgeranylgeranyl+diphosphate+synthase+inhibitors%3A+An+X-ray+and+NMR+investigation&doi=10.1021%2Fja808285e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Lipophilic Bisphosphonates as Dual Farnesyl/Geranylgeranyl Diphosphate Synthase Inhibitors: An X-ray and NMR Investigation</span></div><div class="casAuthors">Zhang, Yonghui; Cao, Rong; Yin, Fenglin; Hudock, Michael P.; Guo, Rey-Ting; Krysiak, Kilannin; Mukherjee, Sujoy; Gao, Yi-Gui; Robinson, Howard; Song, Yongcheng; No, Joo Hwan; Bergan, Kyle; Leon, Annette; Cass, Lauren; Goddard, Amanda; Chang, Ting-Kai; Lin, Fu-Yang; Van Beek, Ermond; Papapoulos, Socrates; Wang, Andrew H.-J.; Kubo, Tadahiko; Ochi, Mitsuo; Mukkamala, Dushyant; Oldfield, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5153-5162</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Considerable effort has focused on the development of selective protein farnesyl transferase (FTase) and protein geranylgeranyl transferase (GGTase) inhibitors as cancer chemotherapeutics.  Here, we report a new strategy for anticancer therapeutic agents involving inhibition of farnesyl diphosphate synthase (FPPS) and geranylgeranyl diphosphate synthase (GGPPS), the two enzymes upstream of FTase and GGTase, by lipophilic bisphosphonates.  Due to dual site targeting and decreased polarity, the compds. have activities far greater than do current bisphosphonate drugs in inhibiting tumor cell growth and invasiveness, both in vitro and in vivo.  We explore how these compds. inhibit cell growth and how cell activity can be predicted based on enzyme inhibition data, and using X-ray diffraction, solid state NMR, and isothermal titrn. calorimetry, we show how these compds. bind to FPPS and/or GGPPS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHhFMAMouc-rVg90H21EOLACvtfcHk0lgICgxG0PESuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjsFKnsLw%253D&md5=373a71c889ed9f0ae6510d2503127e94</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fja808285e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja808285e%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DR.%26aulast%3DYin%26aufirst%3DF.%26aulast%3DHudock%26aufirst%3DM.%2BP.%26aulast%3DGuo%26aufirst%3DR.-T.%26aulast%3DKrysiak%26aufirst%3DK.%26aulast%3DMukherjee%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DY.-G.%26aulast%3DRobinson%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DNo%26aufirst%3DJ.%2BH.%26aulast%3DBergan%26aufirst%3DK.%26aulast%3DLeon%26aufirst%3DA.%26aulast%3DCass%26aufirst%3DL.%26aulast%3DGoddard%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DT.-K.%26aulast%3DLin%26aufirst%3DF.-Y.%26aulast%3DVan%2BBeek%26aufirst%3DE.%26aulast%3DPapapoulos%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DA.H.-J.%26aulast%3DKubo%26aufirst%3DT.%26aulast%3DOchi%26aufirst%3DM.%26aulast%3DMukkamala%26aufirst%3DD.%26aulast%3DOldfield%26aufirst%3DE.%26atitle%3DLipophilic%2520bisphosphonates%2520as%2520dual%2520farnesyl%252Fgeranylgeranyl%2520diphosphate%2520synthase%2520inhibitors%253A%2520An%2520X-ray%2520and%2520NMR%2520investigation%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2009%26volume%3D131%26spage%3D5153%26epage%3D5162%26doi%3D10.1021%2Fja808285e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shull, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiemer, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohl, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiemer, D. F.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological activity of isoprenoid bisphosphonates</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">4130</span>– <span class="NLM_lpage">4136</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2006.02.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1016%2Fj.bmc.2006.02.010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=4130-4136&author=L.+W.+Shullauthor=A.+J.+Wiemerauthor=R.+J.+Hohlauthor=D.+F.+Wiemer&title=Synthesis+and+biological+activity+of+isoprenoid+bisphosphonates&doi=10.1016%2Fj.bmc.2006.02.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2006.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2006.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DShull%26aufirst%3DL.%2BW.%26aulast%3DWiemer%26aufirst%3DA.%2BJ.%26aulast%3DHohl%26aufirst%3DR.%2BJ.%26aulast%3DWiemer%26aufirst%3DD.%2BF.%26atitle%3DSynthesis%2520and%2520biological%2520activity%2520of%2520isoprenoid%2520bisphosphonates%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D4130%26epage%3D4136%26doi%3D10.1016%2Fj.bmc.2006.02.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wills, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holstein, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiemer, D. F.</span></span> <span> </span><span class="NLM_article-title">Potent triazole bisphosphonate inhibitor of geranylgeranyl diphosphate synthase</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1195</span>– <span class="NLM_lpage">1198</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00334</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00334" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1195-1198&author=V.+S.+Willsauthor=C.+Allenauthor=S.+A.+Holsteinauthor=D.+F.+Wiemer&title=Potent+triazole+bisphosphonate+inhibitor+of+geranylgeranyl+diphosphate+synthase&doi=10.1021%2Facsmedchemlett.5b00334"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00334%26sid%3Dliteratum%253Aachs%26aulast%3DWills%26aufirst%3DV.%2BS.%26aulast%3DAllen%26aufirst%3DC.%26aulast%3DHolstein%26aufirst%3DS.%2BA.%26aulast%3DWiemer%26aufirst%3DD.%2BF.%26atitle%3DPotent%2520triazole%2520bisphosphonate%2520inhibitor%2520of%2520geranylgeranyl%2520diphosphate%2520synthase%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D1195%26epage%3D1198%26doi%3D10.1021%2Facsmedchemlett.5b00334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wills, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzger, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varney, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiemer, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holstein, S. A.</span></span> <span> </span><span class="NLM_article-title">Bishomoisoprenoid triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2437</span>– <span class="NLM_lpage">2444</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.02.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1016%2Fj.bmc.2017.02.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=28302510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1OnsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=2437-2444&author=V.+S.+Willsauthor=J.+I.+Metzgerauthor=C.+Allenauthor=M.+L.+Varneyauthor=D.+F.+Wiemerauthor=S.+A.+Holstein&title=Bishomoisoprenoid+triazole+bisphosphonates+as+inhibitors+of+geranylgeranyl+diphosphate+synthase&doi=10.1016%2Fj.bmc.2017.02.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Bishomoisoprenoid triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase</span></div><div class="casAuthors">Wills, Veronica S.; Metzger, Joseph I.; Allen, Cheryl; Varney, Michelle L.; Wiemer, David F.; Holstein, Sarah A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2437-2444</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Protein geranylgeranylation reactions are dependent on the availability of geranylgeranyl diphosphate (GGDP), which serves as the isoprenoid donor.  Inhibition of GGDP synthase (GGDPS) is of interest from a drug development perspective as GGDPS inhibition results in impaired protein geranylgeranylation, which in multiple myeloma, disrupts monoclonal protein trafficking and induces apoptosis.  We have recently reported a series of isoprenoid triazole bisphosphonates and have demonstrated that a 3:1 mixt. of homogeranyl and homoneryl isomers potently, and in a synergistic manner, inhibits GGDPS.  We now present the synthesis and biol. evaluation of a novel series of bishomoisoprenoid triazoles which furthers our understanding of the structure-function relationship of this class.  These studies demonstrate the importance of chain length and olefin stereochem. on inhibitory activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa9eWy7qvSRbVg90H21EOLACvtfcHk0lie1IvbncYXPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1OnsL4%253D&md5=8aaa35d9ab8ae37bf288169d749eb10c</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.02.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.02.066%26sid%3Dliteratum%253Aachs%26aulast%3DWills%26aufirst%3DV.%2BS.%26aulast%3DMetzger%26aufirst%3DJ.%2BI.%26aulast%3DAllen%26aufirst%3DC.%26aulast%3DVarney%26aufirst%3DM.%2BL.%26aulast%3DWiemer%26aufirst%3DD.%2BF.%26aulast%3DHolstein%26aufirst%3DS.%2BA.%26atitle%3DBishomoisoprenoid%2520triazole%2520bisphosphonates%2520as%2520inhibitors%2520of%2520geranylgeranyl%2520diphosphate%2520synthase%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D2437%26epage%3D2444%26doi%3D10.1016%2Fj.bmc.2017.02.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guenther, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakker, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roelofs, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gramatzki, M.</span></span> <span> </span><span class="NLM_article-title">The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">246</span>, <span class="refDoi"> DOI: 10.1002/ijc.24758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1002%2Fijc.24758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=19621390" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVamt7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2010&pages=239-246&author=A.+Guentherauthor=S.+Gordonauthor=M.+Tiemannauthor=R.+Burgerauthor=F.+Bakkerauthor=J.+R.+Greenauthor=W.+Baumauthor=A.+J.+Roelofsauthor=M.+J.+Rogersauthor=M.+Gramatzki&title=The+bisphosphonate+zoledronic+acid+has+antimyeloma+activity+in+vivo+by+inhibition+of+protein+prenylation&doi=10.1002%2Fijc.24758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation</span></div><div class="casAuthors">Guenther, Andreas; Gordon, Sharon; Tiemann, Markus; Burger, Renate; Bakker, Frank; Green, Jonathan R.; Baum, Wolfgang; Roelofs, Anke J.; Rogers, Michael J.; Gramatzki, Martin</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">239-246</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Nitrogen-contg. bisphosphonates (N-BPs) are effective antiosteolytic agents in patients with multiple myeloma.  Preclin. studies have also demonstrated that these agents have direct antitumor effects in vitro and can reduce tumor burden in a variety of animal models, although it is not clear whether such effects are caused by direct actions on tumor cells or by inhibition of bone resorption.  N-BPs prevent bone destruction in myeloma by inhibiting the enzyme farnesyl pyrophosphate synthase in osteoclasts, thereby preventing the prenylation of small GTPase signaling proteins.  In this study, utilizing a plasmacytoma xenograft model without complicating skeletal lesions, treatment with zoledronic acid (ZOL) led to significant prolongation of survival in severe combined immunodeficiency mice inoculated with human INA-6 plasma cells.  Following treatment with a clin. relevant dose of ZOL, histol. anal. of INA-6 tumors from the peritoneal cavity revealed extensive areas of apoptosis assocd. with poly (ADP-ribose) polymerase cleavage.  Furthermore, Western blot anal. of tumor homogenates demonstrated the accumulation of unprenylated Rap1A, indicative of the uptake of ZOL by nonskeletal tumors and inhibition of farnesyl pyrophosphate synthase.  These studies provide, for the first time, clear evidence that N-BPs have direct antitumor effects in plasma cell tumors in vivo and this is executed by a mol. mechanism similar to that obsd. in osteoclasts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHg7sfa313ubVg90H21EOLACvtfcHk0lie1IvbncYXPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVamt7nJ&md5=7c58cef58f4cb5c7aab14bbd03a3058d</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2Fijc.24758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.24758%26sid%3Dliteratum%253Aachs%26aulast%3DGuenther%26aufirst%3DA.%26aulast%3DGordon%26aufirst%3DS.%26aulast%3DTiemann%26aufirst%3DM.%26aulast%3DBurger%26aufirst%3DR.%26aulast%3DBakker%26aufirst%3DF.%26aulast%3DGreen%26aufirst%3DJ.%2BR.%26aulast%3DBaum%26aufirst%3DW.%26aulast%3DRoelofs%26aufirst%3DA.%2BJ.%26aulast%3DRogers%26aufirst%3DM.%2BJ.%26aulast%3DGramatzki%26aufirst%3DM.%26atitle%3DThe%2520bisphosphonate%2520zoledronic%2520acid%2520has%2520antimyeloma%2520activity%2520in%2520vivo%2520by%2520inhibition%2520of%2520protein%2520prenylation%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2010%26volume%3D126%26spage%3D239%26epage%3D246%26doi%3D10.1002%2Fijc.24758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langille, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancuso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsantrizos, Y. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of thienopyrimidine-based inhibitors of the human farnesyl pyrophosphate synthase – Parallel synthesis of analogs via a thrimethylsilyl ylidene intermediate</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2229</span>– <span class="NLM_lpage">2240</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1016%2Fj.bmc.2013.02.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2229-2240&author=C.-Y.+Leungauthor=A.+M.+Langilleauthor=J.+Mancusoauthor=Y.+S.+Tsantrizos&title=Discovery+of+thienopyrimidine-based+inhibitors+of+the+human+farnesyl+pyrophosphate+synthase+%E2%80%93+Parallel+synthesis+of+analogs+via+a+thrimethylsilyl+ylidene+intermediate&doi=10.1016%2Fj.bmc.2013.02.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DC.-Y.%26aulast%3DLangille%26aufirst%3DA.%2BM.%26aulast%3DMancuso%26aufirst%3DJ.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26atitle%3DDiscovery%2520of%2520thienopyrimidine-based%2520inhibitors%2520of%2520the%2520human%2520farnesyl%2520pyrophosphate%2520synthase%2520%25E2%2580%2593%2520Parallel%2520synthesis%2520of%2520analogs%2520via%2520a%2520thrimethylsilyl%2520ylidene%2520intermediate%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D2229%26epage%3D2240%26doi%3D10.1016%2Fj.bmc.2013.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kavanagh, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunford, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunkoczi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, R. G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oppermann, U. J.</span></span> <span> </span><span class="NLM_article-title">The crystal structure of human geranylgeranyl pyrophosphate synthase reveals a novel hexameric arrangement and inhibitory product binding</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>281</i></span>,  <span class="NLM_fpage">22004</span>– <span class="NLM_lpage">22012</span>, <span class="refDoi"> DOI: 10.1074/jbc.M602603200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1074%2Fjbc.M602603200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=16698791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsVOmsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=22004-22012&author=K.+L.+Kavanaghauthor=J.+E.+Dunfordauthor=G.+Bunkocziauthor=R.+G.+G.+Russellauthor=U.+J.+Oppermann&title=The+crystal+structure+of+human+geranylgeranyl+pyrophosphate+synthase+reveals+a+novel+hexameric+arrangement+and+inhibitory+product+binding&doi=10.1074%2Fjbc.M602603200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The Crystal Structure of Human Geranylgeranyl Pyrophosphate Synthase Reveals a Novel Hexameric Arrangement and Inhibitory Product Binding</span></div><div class="casAuthors">Kavanagh, Kathryn L.; Dunford, James E.; Bunkoczi, Gabor; Russell, R. Graham G.; Oppermann, Udo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">22004-22012</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Modification of GTPases with isoprenoid mols. derived from geranylgeranyl pyrophosphate (GGPP) or farnesyl pyrophosphate (FPP) is an essential requisite for cellular signaling pathways.  The synthesis of these isoprenoids proceeds in mammals through the mevalonate pathway, and the final steps in the synthesis are catalyzed by the related enzymes farnesyl pyrophosphate synthase (FPPS) and geranylgeranyl pyrophosphate synthase (GGPS).  Both enzymes play crucial roles in cell survival, and inhibition of farnesyl pyrophosphate synthase by nitrogen-contg. bisphosphonates is an established concept in the treatment of bone disorders such as osteoporosis or certain forms of cancer in bone.  Here we report the crystal structure of human geranylgeranyl pyrophosphate synthase, the first mammalian ortholog to have its x-ray structure detd.  It reveals that three dimers join together to form a propeller-bladed hexameric mol. with a mass of ∼200 kDa.  Structure-based sequence alignments predict this quaternary structure to be restricted to mammalian and insect orthologs, whereas fungal, bacterial, archaeal, and plant forms exhibit the dimeric organization also obsd. in farnesyl pyrophosphate synthase.  Geranylgeranyl pyrophosphate derived from heterologous bacterial expression is tightly bound in a cavity distinct from the chain elongation site described for farnesyl pyrophosphate synthase.  The structure most likely represents an inhibitory complex, which is further corroborated by steady-state kinetics, suggesting a possible feedback mechanism for regulating enzyme activity.  Structural comparisons between members of this enzyme class give deeper insights into conserved features important for catalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppWvup7XisV7Vg90H21EOLACvtfcHk0ljQi3oCZWXnWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsVOmsLY%253D&md5=416cd4f9643c65dc1427cb70fac1c873</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M602603200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M602603200%26sid%3Dliteratum%253Aachs%26aulast%3DKavanagh%26aufirst%3DK.%2BL.%26aulast%3DDunford%26aufirst%3DJ.%2BE.%26aulast%3DBunkoczi%26aufirst%3DG.%26aulast%3DRussell%26aufirst%3DR.%2BG.%2BG.%26aulast%3DOppermann%26aufirst%3DU.%2BJ.%26atitle%3DThe%2520crystal%2520structure%2520of%2520human%2520geranylgeranyl%2520pyrophosphate%2520synthase%2520reveals%2520a%2520novel%2520hexameric%2520arrangement%2520and%2520inhibitory%2520product%2520binding%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D22004%26epage%3D22012%26doi%3D10.1074%2Fjbc.M602603200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Schutter, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebag, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berghuis, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsantrizos, Y. S.</span></span> <span> </span><span class="NLM_article-title">Thienopyrimidine bisphosphomates (ThPBP) inhibitors of the human farnesyl pyrophosphate synthase: Optimization and characterization of the mode of inhibition</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7939</span>– <span class="NLM_lpage">7950</span>, <span class="refDoi"> DOI: 10.1021/jm400946f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400946f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7939-7950&author=C.+Y.+Leungauthor=J.+Parkauthor=J.+W.+De+Schutterauthor=M.+Sebagauthor=A.+M.+Berghuisauthor=Y.+S.+Tsantrizos&title=Thienopyrimidine+bisphosphomates+%28ThPBP%29+inhibitors+of+the+human+farnesyl+pyrophosphate+synthase%3A+Optimization+and+characterization+of+the+mode+of+inhibition&doi=10.1021%2Fjm400946f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm400946f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400946f%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DC.%2BY.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DDe%2BSchutter%26aufirst%3DJ.%2BW.%26aulast%3DSebag%26aufirst%3DM.%26aulast%3DBerghuis%26aufirst%3DA.%2BM.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26atitle%3DThienopyrimidine%2520bisphosphomates%2520%2528ThPBP%2529%2520inhibitors%2520of%2520the%2520human%2520farnesyl%2520pyrophosphate%2520synthase%253A%2520Optimization%2520and%2520characterization%2520of%2520the%2520mode%2520of%2520inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7939%26epage%3D7950%26doi%3D10.1021%2Fjm400946f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span>For details
on the characterization
of MM cells lines, refer to Keats lab Web site: <a href="http://www.keatslab.org/projects/mm-cell-line-characterization/cell-line-characterization-status" class="extLink">http://www.keatslab.org/projects/mm-cell-line-characterization/cell-line-characterization-status</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=For+details%0Aon+the+characterization%0Aof+MM+cells+lines%2C+refer+to+Keats+lab+Web+site%3A+http%3A%2F%2Fwww.keatslab.org%2Fprojects%2Fmm-cell-line-characterization%2Fcell-line-characterization-status."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nozawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, H.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samur, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirstea, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massefski, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utsugi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhe-Paganon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span> <span> </span><span class="NLM_article-title">p53-Related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">1308</span>– <span class="NLM_lpage">1319</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-09-738500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1182%2Fblood-2016-09-738500" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=1308-1319&author=T.+Hideshimaauthor=F.+Cottiniauthor=Y.+Nozawaauthor=H.-S.+Seoauthor=H.+Ohguchiauthor=M.+K.+Samurauthor=D.+Cirsteaauthor=N.+Mimuraauthor=Y.+Iwasawaauthor=P.+G.+Richardsonauthor=N.+C.+Munshiauthor=D.+Chauhanauthor=W.+Massefskiauthor=T.+Utsugiauthor=S.+Dhe-Paganonauthor=K.+C.+Anderson&title=p53-Related+protein+kinase+confers+poor+prognosis+and+represents+a+novel+therapeutic+target+in+multiple+myeloma&doi=10.1182%2Fblood-2016-09-738500"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-09-738500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-09-738500%26sid%3Dliteratum%253Aachs%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DCottini%26aufirst%3DF.%26aulast%3DNozawa%26aufirst%3DY.%26aulast%3DSeo%26aufirst%3DH.-S.%26aulast%3DOhguchi%26aufirst%3DH.%26aulast%3DSamur%26aufirst%3DM.%2BK.%26aulast%3DCirstea%26aufirst%3DD.%26aulast%3DMimura%26aufirst%3DN.%26aulast%3DIwasawa%26aufirst%3DY.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DMunshi%26aufirst%3DN.%2BC.%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DMassefski%26aufirst%3DW.%26aulast%3DUtsugi%26aufirst%3DT.%26aulast%3DDhe-Paganon%26aufirst%3DS.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3Dp53-Related%2520protein%2520kinase%2520confers%2520poor%2520prognosis%2520and%2520represents%2520a%2520novel%2520therapeutic%2520target%2520in%2520multiple%2520myeloma%26jtitle%3DBlood%26date%3D2017%26volume%3D129%26spage%3D1308%26epage%3D1319%26doi%3D10.1182%2Fblood-2016-09-738500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shipman, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croucher, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russel, R. G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helfrich, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, M. J.</span></span> <span> </span><span class="NLM_article-title">The bisphosphnate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5294</span>– <span class="NLM_lpage">5297</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=5294-5297&author=C.+M.+Shipmanauthor=P.+I.+Croucherauthor=R.+G.+G.+Russelauthor=M.+H.+Helfrichauthor=M.+J.+Rogers&title=The+bisphosphnate+incadronate+%28YM175%29+causes+apoptosis+of+human+myeloma+cells+in+vitro+by+inhibiting+the+mevalonate+pathway"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShipman%26aufirst%3DC.%2BM.%26aulast%3DCroucher%26aufirst%3DP.%2BI.%26aulast%3DRussel%26aufirst%3DR.%2BG.%2BG.%26aulast%3DHelfrich%26aufirst%3DM.%2BH.%26aulast%3DRogers%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520bisphosphnate%2520incadronate%2520%2528YM175%2529%2520causes%2520apoptosis%2520of%2520human%2520myeloma%2520cells%2520in%2520vitro%2520by%2520inhibiting%2520the%2520mevalonate%2520pathway%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26spage%3D5294%26epage%3D5297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jagdev, S.
P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipman, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rostami-H, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croucher, P. I.</span></span> <span> </span><span class="NLM_article-title">The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">1126</span>– <span class="NLM_lpage">1134</span>, <span class="refDoi"> DOI: 10.1054/bjoc.2001.1727</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1054%2Fbjoc.2001.1727" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=11308265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktFymu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2001&pages=1126-1134&author=S.%0AP.+Jagdevauthor=R.+E.+Colemanauthor=C.+M.+Shipmanauthor=A.+Rostami-Hauthor=P.+I.+Croucher&title=The+bisphosphonate%2C+zoledronic+acid%2C+induces+apoptosis+of+breast+cancer+cells%3A+evidence+for+synergy+with+paclitaxel&doi=10.1054%2Fbjoc.2001.1727"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel</span></div><div class="casAuthors">Jagdev, S. P.; Coleman, R. E.; Shipman, C. M.; Rostami-H, A.; Croucher, P. I.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1126-1134</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Harcourt Publishers Ltd.</span>)
        </div><div class="casAbstract">Bisphosphonates are well established in the management of breast-cancer-induced bone disease.  Recent studies have suggested that these compds. are effective in preventing the development of bone metastases.  However, it is unclear whether this reflects an indirect effect via an inhibition of bone resorption or a direct antitumor effect.  The breast cancer cell lines, MCF-7 and MDA-MB-231 cells were treated with increasing concns. of the bisphosphonate, zoledronic acid, for varying time periods, in the presence or absence of paclitaxel.  The effects of zoledronic acid were detd. by assessing cell no. and rate of apoptosis by evaluating changes in nuclear morphol. and using a fluorescence nick translation assay.  Zoledronic acid caused a dose- and time-dependent decrease in cell no. (P < 0.001) and a concomitant increase in tumor cell apoptosis (P < 0.005).  Short-term exposure to zoledronic acid was sufficient to cause a significant redn. in cell no. and increase in apoptosis (P < 0.05).  These effects could be prevented by incubation with geranyl geraniol, suggesting that zoledronic acid-induced apoptosis is mediated by inhibiting the mevalonate pathway.  Treatment with zoledronic acid and clin. achievable concns. of paclitaxel resulted in a 4-5-fold increase in tumor cell apoptosis (P < 0.02).  Isobologram anal. revealed synergistic effects on tumor cell no. and apoptosis when zoledronic acid and paclitaxel were combined.  Short-term treatment with zoledronic acid, which closely resembles the clin. setting, has a clear antitumor effect on breast cancer cells.  Importantly, the commonly used anti-neoplastic agent, paclitaxel, potentiates the antitumor effects of zoledronic acid.  These data suggest that, in addn. to inhibiting bone resorption, zoledronic acid has a direct antitumor activity on breast cancer cells in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-FMJ3yV5xCrVg90H21EOLACvtfcHk0ljQi3oCZWXnWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktFymu7w%253D&md5=5cda9ff95bb2441029802c717eee076b</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1054%2Fbjoc.2001.1727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1054%252Fbjoc.2001.1727%26sid%3Dliteratum%253Aachs%26aulast%3DJagdev%26aufirst%3DS.%2BP.%26aulast%3DColeman%26aufirst%3DR.%2BE.%26aulast%3DShipman%26aufirst%3DC.%2BM.%26aulast%3DRostami-H%26aufirst%3DA.%26aulast%3DCroucher%26aufirst%3DP.%2BI.%26atitle%3DThe%2520bisphosphonate%252C%2520zoledronic%2520acid%252C%2520induces%2520apoptosis%2520of%2520breast%2520cancer%2520cells%253A%2520evidence%2520for%2520synergy%2520with%2520paclitaxel%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2001%26volume%3D84%26spage%3D1126%26epage%3D1134%26doi%3D10.1054%2Fbjoc.2001.1727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tohi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamura, N.</span></span> <span> </span><span class="NLM_article-title">Involvement of the mevalonate pathway in the antiproliferative effects of zoledronate on ACHN renal cell carcinoma cells</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1371</span>– <span class="NLM_lpage">1376</span>, <span class="refDoi"> DOI: 10.3892/or.2012.1683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.3892%2For.2012.1683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=22322451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt1Squ7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2012&pages=1371-1376&author=M.+Fujitaauthor=M.+Tohiauthor=K.+Sawadaauthor=Y.+Yamamotoauthor=T.+Nakamuraauthor=T.+Yagamiauthor=M.+Yamamoriauthor=N.+Okamura&title=Involvement+of+the+mevalonate+pathway+in+the+antiproliferative+effects+of+zoledronate+on+ACHN+renal+cell+carcinoma+cells&doi=10.3892%2For.2012.1683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of the mevalonate pathway in the antiproliferative effect of zoledronate on ACHN renal cell carcinoma cells</span></div><div class="casAuthors">Fujita, Megumi; Tohi, Makiko; Sawada, Kyoko; Yamamoto, Yasuhiro; Nakamura, Tsutomu; Yagami, Tatsurou; Yamamori, Motohiro; Okamura, Noboru</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1371-1376</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Oncology Reports</span>)
        </div><div class="casAbstract">Renal cell carcinoma (RCC) has been shown to be resistant to chemotherapy and radiotherapy.  In order to examine the potential of zoledronate(ZOL), abisphosphonate, as an anticancer agent, we investigated the effects of ZOL on RCC cells and the involvement of the mevalonate pathway in antiproliferative effects, as well as the effects of ZOL administration on mice inoculated with RCC.  ACHN cells were used and cell viability was measured via intracellular reductase activity.  Chromatin condensation was detected by Hoechst 33342 staining.  Proteins were detected by western blot anal.  Tumor vol. was measured bidimensionally in mice inoculated with ACHN cells after vehicle or ZOL s.c. administration.  ZOL exhibited antiproliferative effects with an IC50 value of 2.29±0.53 μM in ACHN cells and chromatin condensation was obsd. when treated with ZOL.  Farnesol (FOH) and geranylgeraniol (GGOH), precursors of farnesyl pyrophosphate and geranylgeranyl pyrophosphate, exhibited potency to rescue cells treated with ZOL.  Addnl., Ras and RhoA proteins located in the membrane fraction decreased when treated with ZOL and recovered by FOH or GGOH treatment, suggesting that ZOL inhibited the mevalonate pathway, thereby suppressing the translocation of prenylated Ras and RhoA proteins to membrane fractions.  An in vivo study showed the inhibitory potential of ZOL on tumor growth in mice without changes in body wt.  Our study showed that ZOL could be useful as an anticancer agent for the treatment of RCC, and the mevalonate pathway could be an efficient target for novel therapeutic agents against RCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRS_uSYJsrVrVg90H21EOLACvtfcHk0lgBtXtGCAdXeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt1Squ7w%253D&md5=31745485b904a62a3f6008f92d258712</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.3892%2For.2012.1683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2012.1683%26sid%3Dliteratum%253Aachs%26aulast%3DFujita%26aufirst%3DM.%26aulast%3DTohi%26aufirst%3DM.%26aulast%3DSawada%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DYagami%26aufirst%3DT.%26aulast%3DYamamori%26aufirst%3DM.%26aulast%3DOkamura%26aufirst%3DN.%26atitle%3DInvolvement%2520of%2520the%2520mevalonate%2520pathway%2520in%2520the%2520antiproliferative%2520effects%2520of%2520zoledronate%2520on%2520ACHN%2520renal%2520cell%2520carcinoma%2520cells%26jtitle%3DOncol.%2520Rep.%26date%3D2012%26volume%3D27%26spage%3D1371%26epage%3D1376%26doi%3D10.3892%2For.2012.1683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shingyoji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekine, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takiguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatsumi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiroshima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tagawa, M.</span></span> <span> </span><span class="NLM_article-title">Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e1517</span>, <span class="refDoi"> DOI: 10.1038/cddis.2014.475</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1038%2Fcddis.2014.475" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=25393473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFCiu7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=e1517&author=S.+Okamotoauthor=Y.+Jiangauthor=K.+Kawamuraauthor=M.+Shingyojiauthor=Y.+Tadaauthor=I.+Sekineauthor=Y.+Takiguchiauthor=K.+Tatsumiauthor=H.+Kobayashiauthor=H.+Shimadaauthor=K.+Hiroshimaauthor=M.+Tagawa&title=Zoledronic+acid+induces+apoptosis+and+S-phase+arrest+in+mesothelioma+through+inhibiting+Rab+family+proteins+and+topoisomerase+II+actions&doi=10.1038%2Fcddis.2014.475"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions</span></div><div class="casAuthors">Okamoto, S.; Jiang, Y.; Kawamura, K.; Shingyoji, M.; Tada, Y.; Sekine, I.; Takiguchi, Y.; Tatsumi, K.; Kobayashi, H.; Shimada, H.; Hiroshima, K.; Tagawa, M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e1517</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Zoledronic acid (ZOL), a nitrogen-contg. bisphosphonate, produced anti-tumor effects through apoptosis induction or S-phase arrest depending on human mesothelioma cells tested.  An addn. of isoprenoid, geranylgeraniol but not farnesol, negated these ZOL-induced effects, indicating that the ZOL-mediated effects were attributable to depletion of geranylgeranyl pyrophosphates which were substrates for prenylation processes of small guanine-nucleotide-binding regulatory proteins (small G proteins).  ZOL-treated cells decreased a ratio of membrane to cytoplasmic fractions in RhoA, Cdc42 and Rab6 but less significantly Rac1 proteins, indicating that these proteins were possible targets for ZOL-induced actions.  We further analyzed which small G proteins were responsible for the three ZOL-induced effects, caspase-mediated apoptosis, S-phase arrest and morphol. changes, using inhibitors for resp. small G proteins and siRNA for Cdc42.  ZOL-induced apoptosis is due to insufficient prenylation of Rab proteins because an inhibitor of geranlygeranyl transferase II that was specific for Rab family proteins prenylation, but not others inhibitors, activated the same apoptotic pathways that ZOL did.  ZOL suppressed an endogenous topoisomerase II activity, which was assocd. with apoptosis and S-phase arrest in resp. cells because we detected the same cell cycle changes in etoposide-treated cells.  Inhibitors for geranlygeranyl transferase I and for RhoA produced morphol. changes and disrupted actin fiber structures, both of which were similar to those by ZOL treatments.  These data demonstrated that anti-tumor effects by ZOL were attributable to inhibited functions of resp. small G proteins and topoisomerase II activity, and suggested that cellular factors were involved in the differential cell cycle changes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1V4pcnt-Xr7Vg90H21EOLACvtfcHk0lgBtXtGCAdXeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFCiu7%252FM&md5=58d19666aee80a93af63ffec9c373602</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2014.475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2014.475%26sid%3Dliteratum%253Aachs%26aulast%3DOkamoto%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DKawamura%26aufirst%3DK.%26aulast%3DShingyoji%26aufirst%3DM.%26aulast%3DTada%26aufirst%3DY.%26aulast%3DSekine%26aufirst%3DI.%26aulast%3DTakiguchi%26aufirst%3DY.%26aulast%3DTatsumi%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DH.%26aulast%3DShimada%26aufirst%3DH.%26aulast%3DHiroshima%26aufirst%3DK.%26aulast%3DTagawa%26aufirst%3DM.%26atitle%3DZoledronic%2520acid%2520induces%2520apoptosis%2520and%2520S-phase%2520arrest%2520in%2520mesothelioma%2520through%2520inhibiting%2520Rab%2520family%2520proteins%2520and%2520topoisomerase%2520II%2520actions%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2014%26volume%3D5%26spage%3De1517%26doi%3D10.1038%2Fcddis.2014.475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
de Donk, N. W. C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lokhorst, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nijhuis, E. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamphuis, M. M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloem, A. C.</span></span> <span> </span><span class="NLM_article-title">Geranylgeranylated proteins are involved in the regulation of myeloma cell growth</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">439</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=15701825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD2MXislWgtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=429-439&author=N.+W.+C.+J.+Van%0Ade+Donkauthor=H.+M.+Lokhorstauthor=E.+H.+J.+Nijhuisauthor=M.+M.+J.+Kamphuisauthor=A.+C.+Bloem&title=Geranylgeranylated+proteins+are+involved+in+the+regulation+of+myeloma+cell+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Geranylgeranylated proteins are involved in the regulation of myeloma cell growth</span></div><div class="casAuthors">van de Donk, Niels W. C. J.; Lokhorst, Henk M.; Nijhuis, Evert H. J.; Kamphuis, Marloes M. J.; Bloem, Andries C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2, Pt. 1</span>),
    <span class="NLM_cas:pages">429-439</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Prenylation is essential for membrane localization and participation of proteins in various signaling pathways.  This study examd. the role of farnesylated and geranylgeranylated proteins in the regulation of myeloma cell proliferation.  Antiproliferative and apoptotic effects of various modulators of farnesylated and geranylgeranylated proteins were investigated in myeloma cells.  Depletion of geranylgeranylpyrophosphate inhibited myeloma cell proliferation through accumulation of cells in G1 phase of the cell cycle and loss of cells in S phase.  In contrast, depletion of farnesylpyrophosphate had no or only minor effects.  Furthermore, inhibition of geranylgeranyl transferase I activity was more effective in reducing myeloma cell growth when compared with inhibition of farnesyl transferase activity.  This indicates that protein geranylgeranylation is important for myeloma cell proliferation and cell cycle progression through G1.  Geranylgeranylated target proteins involved in the control of proliferation include GTPases, such as Rac-1, Cdc42, and RhoA.  Inhibition of Rho, Rac, and Cdc42 GTPases by toxin B reduced proliferation, without affecting cell viability, whereas specific inhibition of Rho GTPases by C3 exoenzyme was without effect.  This suggests a role for Rac and/or Cdc42 GTPases in myeloma cell growth.  Rac-1 activity was found in all myeloma cell lines and was suppressed by the depletion of intracellular pools of geranylgeranylpyrophosphate, whereas interleukin-6 rapidly induced Rac-1 activation.  Furthermore, dominant-neg. Tat-Rac-1 reduced myeloma cell proliferation, whereas constitutively active Tat-Rac-1 enhanced proliferation.  These results indicate that protein geranylgeranylation is essential for myeloma cell proliferation and suggest that Rac-1 is a regulator of myeloma cell growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWXGCjQMNcbLVg90H21EOLACvtfcHk0lgBtXtGCAdXeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXislWgtrs%253D&md5=16cb7b0245ce22f3ee703e6adccbe4be</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bde%2BDonk%26aufirst%3DN.%2BW.%2BC.%2BJ.%26aulast%3DLokhorst%26aufirst%3DH.%2BM.%26aulast%3DNijhuis%26aufirst%3DE.%2BH.%2BJ.%26aulast%3DKamphuis%26aufirst%3DM.%2BM.%2BJ.%26aulast%3DBloem%26aufirst%3DA.%2BC.%26atitle%3DGeranylgeranylated%2520proteins%2520are%2520involved%2520in%2520the%2520regulation%2520of%2520myeloma%2520cell%2520growth%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D429%26epage%3D439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holstein, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohl, R. J.</span></span> <span> </span><span class="NLM_article-title">Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">551</span>– <span class="NLM_lpage">559</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2010.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1016%2Fj.leukres.2010.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=20828814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtV2ru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2011&pages=551-559&author=S.+A.+Holsteinauthor=R.+J.+Hohl&title=Isoprenoid+biosynthetic+pathway+inhibition+disrupts+monoclonal+protein+secretion+and+induces+the+unfolded+protein+response+pathway+in+multiple+myeloma+cells&doi=10.1016%2Fj.leukres.2010.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells</span></div><div class="casAuthors">Holstein, Sarah A.; Hohl, Raymond J.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">551-559</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Myeloma is characterized by the overprodn. and secretion of monoclonal protein.  Inhibitors of the isoprenoid biosynthetic pathway (IBP) have pleiotropic effects in myeloma cells.  To investigate whether IBP inhibition interferes with monoclonal protein secretion, human myeloma cells were treated with specific inhibitors of the IBP or prenyltransferases.  These studies demonstrate that agents that inhibit Rab geranylgeranylation disrupt light chain trafficking, lead to accumulation of light chain in the endoplasmic reticulum, activate the unfolded protein response pathway and induce apoptosis.  These studies provide a novel mechanism of action for IBP inhibitors and suggest that further exploration of Rab-targeted agents in myeloma is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoveCupAqPavrVg90H21EOLACvtfcHk0lirqU7DDaEkBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtV2ru7g%253D&md5=c7c2c8ba4025668eb4c83cba8c57b7d3</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2010.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2010.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DHolstein%26aufirst%3DS.%2BA.%26aulast%3DHohl%26aufirst%3DR.%2BJ.%26atitle%3DIsoprenoid%2520biosynthetic%2520pathway%2520inhibition%2520disrupts%2520monoclonal%2520protein%2520secretion%2520and%2520induces%2520the%2520unfolded%2520protein%2520response%2520pathway%2520in%2520multiple%2520myeloma%2520cells%26jtitle%3DLeuk.%2520Res.%26date%3D2011%26volume%3D35%26spage%3D551%26epage%3D559%26doi%3D10.1016%2Fj.leukres.2010.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">The
Cancer Cell Line Encyclopedia and Genomics of Drug Sensitivity in
Cancer Consortium.</span> <span> </span><span class="NLM_article-title">Pharmacogenomic
agreement between two cancer cell line data sets</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>528</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">87</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=528&publication_year=2015&pages=84-87&author=The%0ACancer+Cell+Line+Encyclopedia+and+Genomics+of+Drug+Sensitivity+in%0ACancer+Consortium.&title=Pharmacogenomic%0Aagreement+between+two+cancer+cell+line+data+sets"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DPharmacogenomic%250Aagreement%2520between%2520two%2520cancer%2520cell%2520line%2520data%2520sets%26jtitle%3DNature%26date%3D2015%26volume%3D528%26spage%3D84%26epage%3D87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craig, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurdoglu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auclair, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kidd, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagannath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vij, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orloff, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, T. M.</span></span>; <span class="NLM_contrib-group">Mmrf CoMMpass Network</span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capone, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonial, S.</span></span> <span> </span><span class="NLM_article-title">Interim analysis of the mmrf commpass trial, a longitudinal study in multiple myeloma relating clinical outcomes to genomic and immunophenotypic profiles</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">532</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=532&author=J.+J.+Keatsauthor=D.+W.+Craigauthor=W.+Liangauthor=Y.+Venkataauthor=A.+Kurdogluauthor=J.+Aldrichauthor=D.+Auclairauthor=K.+Allenauthor=B.+Harrisonauthor=S.+Jewellauthor=P.+G.+Kiddauthor=M.+Correllauthor=S.+Jagannathauthor=D.+S.+Siegelauthor=R.+Vijauthor=G.+Orloffauthor=T.+M.+Zimmermanauthor=Mmrf+CoMMpass+Networkauthor=W.+Caponeauthor=J.+Carptenauthor=S.+Lonial&title=Interim+analysis+of+the+mmrf+commpass+trial%2C+a+longitudinal+study+in+multiple+myeloma+relating+clinical+outcomes+to+genomic+and+immunophenotypic+profiles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKeats%26aufirst%3DJ.%2BJ.%26aulast%3DCraig%26aufirst%3DD.%2BW.%26aulast%3DLiang%26aufirst%3DW.%26aulast%3DVenkata%26aufirst%3DY.%26aulast%3DKurdoglu%26aufirst%3DA.%26aulast%3DAldrich%26aufirst%3DJ.%26aulast%3DAuclair%26aufirst%3DD.%26aulast%3DAllen%26aufirst%3DK.%26aulast%3DHarrison%26aufirst%3DB.%26aulast%3DJewell%26aufirst%3DS.%26aulast%3DKidd%26aufirst%3DP.%2BG.%26aulast%3DCorrell%26aufirst%3DM.%26aulast%3DJagannath%26aufirst%3DS.%26aulast%3DSiegel%26aufirst%3DD.%2BS.%26aulast%3DVij%26aufirst%3DR.%26aulast%3DOrloff%26aufirst%3DG.%26aulast%3DZimmerman%26aufirst%3DT.%2BM.%26aulast%3D%26aulast%3DCapone%26aufirst%3DW.%26aulast%3DCarpten%26aufirst%3DJ.%26aulast%3DLonial%26aufirst%3DS.%26atitle%3DInterim%2520analysis%2520of%2520the%2520mmrf%2520commpass%2520trial%252C%2520a%2520longitudinal%2520study%2520in%2520multiple%2520myeloma%2520relating%2520clinical%2520outcomes%2520to%2520genomic%2520and%2520immunophenotypic%2520profiles%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26spage%3D532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lonial, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yellapantula, V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurdoglu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legendre, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephenson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adkins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christofferson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuyugan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohrer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodges, M.</span></span>; <span class="NLM_contrib-group">Mmrf CoMMpass Network</span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derome, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auclair, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kidd, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craig, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J. J.</span></span> <span> </span><span class="NLM_article-title">Interim analysis of the Mmrf Commpass Trial: identification of novel rearrangements potentially associated with disease initiation and progression</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">722</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=722&author=S.+Lonialauthor=V.+D.+Yellapantulaauthor=W.+Liangauthor=A.+Kurdogluauthor=J.+Aldrichauthor=C.+M.+Legendreauthor=K.+Stephensonauthor=J.+Adkinsauthor=J.+McDonaldauthor=A.+Hellandauthor=M.+Russellauthor=A.+Christoffersonauthor=L.+Cuyuganauthor=D.+Rohrerauthor=A.+Blanskiauthor=M.+Hodgesauthor=Mmrf+CoMMpass+Networkauthor=M.+Deromeauthor=D.+Auclairauthor=P.+G.+Kiddauthor=S.+Jewellauthor=D.+Craigauthor=J.+Carptenauthor=J.+J.+Keats&title=Interim+analysis+of+the+Mmrf+Commpass+Trial%3A+identification+of+novel+rearrangements+potentially+associated+with+disease+initiation+and+progression"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLonial%26aufirst%3DS.%26aulast%3DYellapantula%26aufirst%3DV.%2BD.%26aulast%3DLiang%26aufirst%3DW.%26aulast%3DKurdoglu%26aufirst%3DA.%26aulast%3DAldrich%26aufirst%3DJ.%26aulast%3DLegendre%26aufirst%3DC.%2BM.%26aulast%3DStephenson%26aufirst%3DK.%26aulast%3DAdkins%26aufirst%3DJ.%26aulast%3DMcDonald%26aufirst%3DJ.%26aulast%3DHelland%26aufirst%3DA.%26aulast%3DRussell%26aufirst%3DM.%26aulast%3DChristofferson%26aufirst%3DA.%26aulast%3DCuyugan%26aufirst%3DL.%26aulast%3DRohrer%26aufirst%3DD.%26aulast%3DBlanski%26aufirst%3DA.%26aulast%3DHodges%26aufirst%3DM.%26aulast%3D%26aulast%3DDerome%26aufirst%3DM.%26aulast%3DAuclair%26aufirst%3DD.%26aulast%3DKidd%26aufirst%3DP.%2BG.%26aulast%3DJewell%26aufirst%3DS.%26aulast%3DCraig%26aufirst%3DD.%26aulast%3DCarpten%26aufirst%3DJ.%26aulast%3DKeats%26aufirst%3DJ.%2BJ.%26atitle%3DInterim%2520analysis%2520of%2520the%2520Mmrf%2520Commpass%2520Trial%253A%2520identification%2520of%2520novel%2520rearrangements%2520potentially%2520associated%2520with%2520disease%2520initiation%2520and%2520progression%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speyer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christofferson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legendre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuyugan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adkins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodges, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohrer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagannath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vij, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orloff, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niesvizky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fay, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rifkin, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, N. C.</span></span>; <span class="NLM_contrib-group">Mmrf CoMMpass Network</span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yesil, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derome, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kidd, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpten, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auclair, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonial, S.</span></span> <span> </span><span class="NLM_article-title">Molecular predictors of outcome and drug response in multiple myeloma: An interim analysis of the Mmrf CoMMpass study</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">194</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=194&author=J.+J.+Keatsauthor=G.+Speyerauthor=A.+Christoffersonauthor=C.+Legendreauthor=J.+Aldrichauthor=M.+Russellauthor=L.+Cuyuganauthor=J.+Adkinsauthor=A.+Blanskiauthor=M.+Hodgesauthor=D.+Rohrerauthor=S.+Jagannathauthor=R.+Vijauthor=G.+Orloffauthor=T.+Zimmermanauthor=R.+Niesvizkyauthor=D.+Lilesauthor=J.+W.+Fayauthor=J.+L.+Wolfauthor=R.+M.+Rifkinauthor=N.+C.+Gutierrezauthor=Mmrf+CoMMpass+Networkauthor=J.+Yesilauthor=M.+Deromeauthor=S.+Kimauthor=W.+Liangauthor=P.+G.+Kiddauthor=S.+Jewellauthor=J.+D.+Carptenauthor=D.+Auclairauthor=S.+Lonial&title=Molecular+predictors+of+outcome+and+drug+response+in+multiple+myeloma%3A+An+interim+analysis+of+the+Mmrf+CoMMpass+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKeats%26aufirst%3DJ.%2BJ.%26aulast%3DSpeyer%26aufirst%3DG.%26aulast%3DChristofferson%26aufirst%3DA.%26aulast%3DLegendre%26aufirst%3DC.%26aulast%3DAldrich%26aufirst%3DJ.%26aulast%3DRussell%26aufirst%3DM.%26aulast%3DCuyugan%26aufirst%3DL.%26aulast%3DAdkins%26aufirst%3DJ.%26aulast%3DBlanski%26aufirst%3DA.%26aulast%3DHodges%26aufirst%3DM.%26aulast%3DRohrer%26aufirst%3DD.%26aulast%3DJagannath%26aufirst%3DS.%26aulast%3DVij%26aufirst%3DR.%26aulast%3DOrloff%26aufirst%3DG.%26aulast%3DZimmerman%26aufirst%3DT.%26aulast%3DNiesvizky%26aufirst%3DR.%26aulast%3DLiles%26aufirst%3DD.%26aulast%3DFay%26aufirst%3DJ.%2BW.%26aulast%3DWolf%26aufirst%3DJ.%2BL.%26aulast%3DRifkin%26aufirst%3DR.%2BM.%26aulast%3DGutierrez%26aufirst%3DN.%2BC.%26aulast%3D%26aulast%3DYesil%26aufirst%3DJ.%26aulast%3DDerome%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLiang%26aufirst%3DW.%26aulast%3DKidd%26aufirst%3DP.%2BG.%26aulast%3DJewell%26aufirst%3DS.%26aulast%3DCarpten%26aufirst%3DJ.%2BD.%26aulast%3DAuclair%26aufirst%3DD.%26aulast%3DLonial%26aufirst%3DS.%26atitle%3DMolecular%2520predictors%2520of%2520outcome%2520and%2520drug%2520response%2520in%2520multiple%2520myeloma%253A%2520An%2520interim%2520analysis%2520of%2520the%2520Mmrf%2520CoMMpass%2520study%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26spage%3D194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Beek, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löwik, C. W. G.
M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papapoulos, S. E.</span></span> <span> </span><span class="NLM_article-title">Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors</span>. <i>Bone</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">64</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/S8756-3282(01)00655-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1016%2FS8756-3282%2801%2900655-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=64-70&author=E.+R.+Van%0ABeekauthor=C.+W.+G.%0AM.+L%C3%B6wikauthor=S.+E.+Papapoulos&title=Bisphosphonates+suppress+bone+resorption+by+a+direct+effect+on+early+osteoclast+precursors+without+affecting+the+osteoclastogenic+capacity+of+osteogenic+cells%3A+the+role+of+protein+geranylgeranylation+in+the+action+of+nitrogen-containing+bisphosphonates+on+osteoclast+precursors&doi=10.1016%2FS8756-3282%2801%2900655-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2FS8756-3282%2801%2900655-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS8756-3282%252801%252900655-X%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BBeek%26aufirst%3DE.%2BR.%26aulast%3DL%25C3%25B6wik%26aufirst%3DC.%2BW.%2BG.%2BM.%26aulast%3DPapapoulos%26aufirst%3DS.%2BE.%26atitle%3DBisphosphonates%2520suppress%2520bone%2520resorption%2520by%2520a%2520direct%2520effect%2520on%2520early%2520osteoclast%2520precursors%2520without%2520affecting%2520the%2520osteoclastogenic%2520capacity%2520of%2520osteogenic%2520cells%253A%2520the%2520role%2520of%2520protein%2520geranylgeranylation%2520in%2520the%2520action%2520of%2520nitrogen-containing%2520bisphosphonates%2520on%2520osteoclast%2520precursors%26jtitle%3DBone%26date%3D2002%26volume%3D30%26spage%3D64%26epage%3D70%26doi%3D10.1016%2FS8756-3282%2801%2900655-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, C.</span></span> <span> </span><span class="NLM_article-title">An <i>in vitro</i> assay to measure targeted drug delivery to bone mineral</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">770</span>– <span class="NLM_lpage">776</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201000016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1002%2Fcmdc.201000016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=770-776&author=W.+Jahnkeauthor=C.+Henry&title=An+in+vitro+assay+to+measure+targeted+drug+delivery+to+bone+mineral&doi=10.1002%2Fcmdc.201000016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201000016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201000016%26sid%3Dliteratum%253Aachs%26aulast%3DJahnke%26aufirst%3DW.%26aulast%3DHenry%26aufirst%3DC.%26atitle%3DAn%2520in%2520vitro%2520assay%2520to%2520measure%2520targeted%2520drug%2520delivery%2520to%2520bone%2520mineral%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D770%26epage%3D776%26doi%3D10.1002%2Fcmdc.201000016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chesi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbitt, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shortt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefebure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergsagel, P. L.</span></span> <span> </span><span class="NLM_article-title">Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">376</span>– <span class="NLM_lpage">385</span>, <span class="refDoi"> DOI: 10.1182/blood-2012-02-412783</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1182%2Fblood-2012-02-412783" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2012&pages=376-385&author=M.+Chesiauthor=G.+M.+Matthewsauthor=V.+M.+Garbittauthor=S.+E.+Palmerauthor=J.+Shorttauthor=M.+Lefebureauthor=A.+K.+Stewartauthor=R.+W.+Johnstoneauthor=P.+L.+Bergsagel&title=Drug+response+in+a+genetically+engineered+mouse+model+of+multiple+myeloma+is+predictive+of+clinical+efficacy&doi=10.1182%2Fblood-2012-02-412783"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1182%2Fblood-2012-02-412783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2012-02-412783%26sid%3Dliteratum%253Aachs%26aulast%3DChesi%26aufirst%3DM.%26aulast%3DMatthews%26aufirst%3DG.%2BM.%26aulast%3DGarbitt%26aufirst%3DV.%2BM.%26aulast%3DPalmer%26aufirst%3DS.%2BE.%26aulast%3DShortt%26aufirst%3DJ.%26aulast%3DLefebure%26aufirst%3DM.%26aulast%3DStewart%26aufirst%3DA.%2BK.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26aulast%3DBergsagel%26aufirst%3DP.%2BL.%26atitle%3DDrug%2520response%2520in%2520a%2520genetically%2520engineered%2520mouse%2520model%2520of%2520multiple%2520myeloma%2520is%2520predictive%2520of%2520clinical%2520efficacy%26jtitle%3DBlood%26date%3D2012%26volume%3D120%26spage%3D376%26epage%3D385%26doi%3D10.1182%2Fblood-2012-02-412783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Palou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebag, M.</span></span> <span> </span><span class="NLM_article-title">A transgenic model of multiple myeloma bone disease shows profound mesenchymal stem cell impairment</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">130</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2013&pages=130&author=M.+Gomez-Palouauthor=H.+Fangauthor=R.+Kremerauthor=M.+Sebag&title=A+transgenic+model+of+multiple+myeloma+bone+disease+shows+profound+mesenchymal+stem+cell+impairment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGomez-Palou%26aufirst%3DM.%26aulast%3DFang%26aufirst%3DH.%26aulast%3DKremer%26aufirst%3DR.%26aulast%3DSebag%26aufirst%3DM.%26atitle%3DA%2520transgenic%2520model%2520of%2520multiple%2520myeloma%2520bone%2520disease%2520shows%2520profound%2520mesenchymal%2520stem%2520cell%2520impairment%26jtitle%3DBlood%26date%3D2013%26volume%3D112%26spage%3D130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vieira, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajewsky, K.</span></span> <span> </span><span class="NLM_article-title">The half-lives of serum immunoglobulins in adult mice</span>. <i>Eur. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">313</span>– <span class="NLM_lpage">316</span>, <span class="refDoi"> DOI: 10.1002/eji.1830180221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1002%2Feji.1830180221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=3350037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADyaL1cXhvVCrs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1988&pages=313-316&author=P.+Vieiraauthor=K.+Rajewsky&title=The+half-lives+of+serum+immunoglobulins+in+adult+mice&doi=10.1002%2Feji.1830180221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">The half-lives of serum immunoglobulins in adult mice</span></div><div class="casAuthors">Vieira, Paulo; Rajewsky, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Immunology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">313-16</span>CODEN:
                <span class="NLM_cas:coden">EJIMAF</span>;
        ISSN:<span class="NLM_cas:issn">0014-2980</span>.
    </div><div class="casAbstract">The half-lives were detd. of several sets of murine monoclonal antibodies spanning all Ig isotypes in the serum.  The antibodies in each set possess the same V region.  With this approach, the differences in half-life obsd. between the different isotypes are independent of the V region carried by the monoclonal antibodies and therefore must relate to each other in the same way as the half-lives of each class of serum Igs.  The half-life of a monoclonal antibody of the γ2a isotype is identical to the av. half-life of serum IgG2a as previously detd. (6-8 days).  Therefore, the half-lives detd. with monoclonal antibodies possessing the same V region represent the half-life of the serum Igs.  In this way, the half-life of IgM was calcd. to be 2 days, IgG3 and IgG1 was 6-8 days, and IgG2b was 4-6 days.  IgE has a half-life of 12 h.  A polymeric form of IgA was eliminated from the serum with a half-life of 17-22 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0z6mWARTG1rVg90H21EOLACvtfcHk0lh8_LWkIvwlhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXhvVCrs7Y%253D&md5=2c644134b8964794b3391b7c796f8537</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Feji.1830180221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Feji.1830180221%26sid%3Dliteratum%253Aachs%26aulast%3DVieira%26aufirst%3DP.%26aulast%3DRajewsky%26aufirst%3DK.%26atitle%3DThe%2520half-lives%2520of%2520serum%2520immunoglobulins%2520in%2520adult%2520mice%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D1988%26volume%3D18%26spage%3D313%26epage%3D316%26doi%3D10.1002%2Feji.1830180221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span> For a recent review
on the biology/physiology and clinical characteristics of multiply
myeloma, refer to the following:<span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, N.</span></span> <span> </span><span class="NLM_article-title">Pathogenesis beyond the cancer clone(s) in multiple myeloma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">3049</span>– <span class="NLM_lpage">3058</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-11-568881</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1182%2Fblood-2014-11-568881" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=25838343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFGqsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=3049-3058&author=G.+Bianchiauthor=N.+Munshi&title=Pathogenesis+beyond+the+cancer+clone%28s%29+in+multiple+myeloma&doi=10.1182%2Fblood-2014-11-568881"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Pathogenesis beyond the cancer clone(s) in multiple myeloma</span></div><div class="casAuthors">Bianchi, Giada; Munshi, Nikhil C.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3049-3058</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  Over the past 4 decades, basic research has provided crucial information regarding the cellular and mol. biol. of cancer.  In particular, the relevance of cancer microenvironment (including both cellular and noncellular elements) and the concept of clonal evolution and heterogeneity have emerged as important in cancer pathogenesis, immunol. escape, and resistance to therapy.  Multiple myeloma (MM), a cancer of terminally differentiated plasma cells, is emblematic of the impact of cancer microenvironment and the role of clonal evolution.  Although genetic and epigenetic aberrations occur in MM and evolve over time under the pressure of exogenous stimuli, they are also largely present in premalignant plasma cell dyscrasia such as monoclonal gammopathy of undetd. significance (MGUS) and smoldering multiple myeloma (SMM), suggesting that genetic mutations alone are necessary, but not sufficient, for myeloma transformation.  The role of bone marrow microenvironment in mediating survival, proliferation, and resistance to therapy in myeloma is well established; and although an appealing speculation, its role in fostering the evolution of MGUS or SMM into MM is yet to be proven.  In this review, we discuss MM pathogenesis with a particular emphasis on the role of bone marrow microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrltD2PWpKFIbVg90H21EOLACvtfcHk0lgSgmJaPLAZMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFGqsLY%253D&md5=f82070898f2c44ea219884e64dc8f5c3</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-11-568881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-11-568881%26sid%3Dliteratum%253Aachs%26aulast%3DBianchi%26aufirst%3DG.%26aulast%3DMunshi%26aufirst%3DN.%26atitle%3DPathogenesis%2520beyond%2520the%2520cancer%2520clone%2528s%2529%2520in%2520multiple%2520myeloma%26jtitle%3DBlood%26date%3D2015%26volume%3D125%26spage%3D3049%26epage%3D3058%26doi%3D10.1182%2Fblood-2014-11-568881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coxon, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helfrich, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van’t
Hof, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ralston, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, M. J.</span></span> <span> </span><span class="NLM_article-title">Protein geranylgeranylation is required for osteoclast formation, function and survival: Inhibition by bisphosphonates and GGTI-298</span>. <i>J. Bone Miner. Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1467</span>– <span class="NLM_lpage">1476</span>, <span class="refDoi"> DOI: 10.1359/jbmr.2000.15.8.1467</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1359%2Fjbmr.2000.15.8.1467" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10934645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlvVSjsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2000&pages=1467-1476&author=F.+P.+Coxonauthor=M.+H.+Helfrichauthor=R.+van%E2%80%99t%0AHofauthor=S.+Sebtiauthor=S.+H.+Ralstonauthor=A.+Hamiltonauthor=M.+J.+Rogers&title=Protein+geranylgeranylation+is+required+for+osteoclast+formation%2C+function+and+survival%3A+Inhibition+by+bisphosphonates+and+GGTI-298&doi=10.1359%2Fjbmr.2000.15.8.1467"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298</span></div><div class="casAuthors">Coxon, Fraser P.; Helfrich, Miep H.; Van't Hof, Robert; Sebti, Said; Ralston, Stuart H.; Hamilton, Andrew; Rogers, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bone and Mineral Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1467-1476</span>CODEN:
                <span class="NLM_cas:coden">JBMREJ</span>;
        ISSN:<span class="NLM_cas:issn">0884-0431</span>.
    
            (<span class="NLM_cas:orgname">American Society for Bone and Mineral Research</span>)
        </div><div class="casAbstract">Bisphosphonates are the important class of antiresorptive drugs used in the treatment of metabolic bone diseases.  Although their mol. mechanism of action has not been fully elucidated, recent studies have shown that the nitrogen-contg. bisphosphonates can inhibit protein prenylation in macrophages in vitro.  In this study, we show that the nitrogen-contg. bisphosphonates risedronate, zoledronate, ibandronate, alendronate, and pamidronate (but not the non nitrogen-contg. bisphosphonates clodronate, etidronate, and tiludronate) prevent the incorporation of [14C]mevalonate into prenylated (farnesylated and geranylgeranylated) proteins in purified rabbit osteoclasts.  The inhibitory effect of nitrogen-contg. bisphosphonates on bone resorption is likely to result largely from the loss of geranylgeranylated proteins rather than loss of farnesylated proteins in osteoclasts, because concns. of GGTI-298 (a specific inhibitor of geranylgeranyl transferase I) that inhibited protein geranylgeranylation in purified rabbit osteoclasts prevented osteoclast formation in murine bone marrow cultures, disrupted the osteoclast cytoskeleton, inhibited bone resorption, and induced apoptosis in isolated chick and rabbit osteoclasts in vitro.  By contrast, concns. of FTI-277 (a specific inhibitor of farnesyl transferase) that prevented protein farnesylation in purified rabbit osteoclasts had little effect on osteoclast morphol. or apoptosis and did not inhibit bone resorption.  These results therefore show the mol. mechanism of action of nitrogen-contg. bisphosphonate drugs in osteoclasts and highlight the fundamental importance of geranylgeranylated proteins in osteoclast formation and function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDC_HEW6PkGrVg90H21EOLACvtfcHk0lgSgmJaPLAZMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlvVSjsLw%253D&md5=6dfe84e31fc6e121470fbd0185d993e5</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1359%2Fjbmr.2000.15.8.1467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1359%252Fjbmr.2000.15.8.1467%26sid%3Dliteratum%253Aachs%26aulast%3DCoxon%26aufirst%3DF.%2BP.%26aulast%3DHelfrich%26aufirst%3DM.%2BH.%26aulast%3Dvan%25E2%2580%2599t%2BHof%26aufirst%3DR.%26aulast%3DSebti%26aufirst%3DS.%26aulast%3DRalston%26aufirst%3DS.%2BH.%26aulast%3DHamilton%26aufirst%3DA.%26aulast%3DRogers%26aufirst%3DM.%2BJ.%26atitle%3DProtein%2520geranylgeranylation%2520is%2520required%2520for%2520osteoclast%2520formation%252C%2520function%2520and%2520survival%253A%2520Inhibition%2520by%2520bisphosphonates%2520and%2520GGTI-298%26jtitle%3DJ.%2520Bone%2520Miner.%2520Res.%26date%3D2000%26volume%3D15%26spage%3D1467%26epage%3D1476%26doi%3D10.1359%2Fjbmr.2000.15.8.1467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbay, J. K.</span>; <span class="NLM_string-name">Chakravarty, D.</span>; <span class="NLM_string-name">Shook, B.
C.</span>; <span class="NLM_string-name">Wang, A.</span></span> <span> </span><span class="NLM_article-title">Methylene Amines of Thieno[2,3-<i>d</i>]pyrimidine and Their Use as Adenosine a2a Receptor Antagonists</span>. <span class="NLM_patent">WO2010/045006 A1</span>, April 22, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+K.+Barbay&author=D.+Chakravarty&author=B.%0AC.+Shook&author=A.+Wang&title=Methylene+Amines+of+Thieno%5B2%2C3-d%5Dpyrimidine+and+Their+Use+as+Adenosine+a2a+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBarbay%26aufirst%3DJ.%2BK.%26atitle%3DMethylene%2520Amines%2520of%2520Thieno%255B2%252C3-d%255Dpyrimidine%2520and%2520Their%2520Use%2520as%2520Adenosine%2520a2a%2520Receptor%2520Antagonists%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liebeskind, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srogl, J.</span></span> <span> </span><span class="NLM_article-title">Heteroaromatic thioether-boronic acid cross-coupling under neutral reaction conditions</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">979</span>– <span class="NLM_lpage">981</span>, <span class="refDoi"> DOI: 10.1021/ol0200091</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol0200091" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD38Xht1Gktb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2002&pages=979-981&author=L.+S.+Liebeskindauthor=J.+Srogl&title=Heteroaromatic+thioether-boronic+acid+cross-coupling+under+neutral+reaction+conditions&doi=10.1021%2Fol0200091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Heteroaromatic Thioether-Boronic Acid Cross-Coupling under Neutral Reaction Conditions</span></div><div class="casAuthors">Liebeskind, Lanny S.; Srogl, Jiri</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">979-981</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">π-Deficient heteroarom. thioethers undergo efficient palladium-catalyzed cross-coupling with boronic acids, mediated by copper(I) thiophene-2-carboxylate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowmqoxHMYfLbVg90H21EOLACvtfcHk0lgSgmJaPLAZMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xht1Gktb0%253D&md5=ce42d2952572e0b36f0f60e6037a18f6</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fol0200091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol0200091%26sid%3Dliteratum%253Aachs%26aulast%3DLiebeskind%26aufirst%3DL.%2BS.%26aulast%3DSrogl%26aufirst%3DJ.%26atitle%3DHeteroaromatic%2520thioether-boronic%2520acid%2520cross-coupling%2520under%2520neutral%2520reaction%2520conditions%26jtitle%3DOrg.%2520Lett.%26date%3D2002%26volume%3D4%26spage%3D979%26epage%3D981%26doi%3D10.1021%2Fol0200091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wetzel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchais-Oberwinkler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, R.-W.</span></span> <span> </span><span class="NLM_article-title">17b-HSD2 inhibitors for the treatment of osteoporosis: Identification of a promising scaffold</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">807</span>– <span class="NLM_lpage">815</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.12.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1016%2Fj.bmc.2010.12.013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=807-815&author=M.+Wetzelauthor=S.+Marchais-Oberwinklerauthor=R.-W.+Hartmann&title=17b-HSD2+inhibitors+for+the+treatment+of+osteoporosis%3A+Identification+of+a+promising+scaffold&doi=10.1016%2Fj.bmc.2010.12.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.12.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.12.013%26sid%3Dliteratum%253Aachs%26aulast%3DWetzel%26aufirst%3DM.%26aulast%3DMarchais-Oberwinkler%26aufirst%3DS.%26aulast%3DHartmann%26aufirst%3DR.-W.%26atitle%3D17b-HSD2%2520inhibitors%2520for%2520the%2520treatment%2520of%2520osteoporosis%253A%2520Identification%2520of%2520a%2520promising%2520scaffold%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D807%26epage%3D815%26doi%3D10.1016%2Fj.bmc.2010.12.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 16 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Edyta Gendaszewska-Darmach, Malgorzata A. Garstka, <span class="NLM_string-name hlFld-ContribAuthor">Katarzyna M. Błażewska</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Small GTPases and Their Prenylation in Diabetes Mellitus. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (14)
                                     , 9677-9710. <a href="https://doi.org/10.1021/acs.jmedchem.1c00410" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00410</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00410%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252BSmall%252BGTPases%252Band%252BTheir%252BPrenylation%252Bin%252BDiabetes%252BMellitus%26aulast%3DGendaszewska-Darmach%26aufirst%3DEdyta%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D07032021%26date%3D08072021%26volume%3D64%26issue%3D14%26spage%3D9677%26epage%3D9710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alisa E.R.  Fairweather</span>, <span class="hlFld-ContribAuthor ">Daniel B.  Goetz</span>, <span class="hlFld-ContribAuthor ">Chloe M.  Schroeder</span>, <span class="hlFld-ContribAuthor ">Nazmul H.  Bhuiyan</span>, <span class="hlFld-ContribAuthor ">Michelle L.  Varney</span>, <span class="hlFld-ContribAuthor ">David F.  Wiemer</span>, <span class="hlFld-ContribAuthor ">Sarah A.  Holstein</span>. </span><span class="cited-content_cbyCitation_article-title">Impact of α-modifications on the activity of triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>44 </em>, 116307. <a href="https://doi.org/10.1016/j.bmc.2021.116307" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116307</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116307%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DImpact%252Bof%252B%2525CE%2525B1-modifications%252Bon%252Bthe%252Bactivity%252Bof%252Btriazole%252Bbisphosphonates%252Bas%252Bgeranylgeranyl%252Bdiphosphate%252Bsynthase%252Binhibitors%26aulast%3DFairweather%26aufirst%3DAlisa%2BE.R.%26date%3D2021%26volume%3D44%26spage%3D116307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiajia  Jin</span>, <span class="hlFld-ContribAuthor ">Hong  Qian</span>, <span class="hlFld-ContribAuthor ">Bing  Wan</span>, <span class="hlFld-ContribAuthor ">Li  Zhou</span>, <span class="hlFld-ContribAuthor ">Cen  Chen</span>, <span class="hlFld-ContribAuthor ">Yanling  Lv</span>, <span class="hlFld-ContribAuthor ">Meizi  Chen</span>, <span class="hlFld-ContribAuthor ">Suhua  Zhu</span>, <span class="hlFld-ContribAuthor ">Liang  Ye</span>, <span class="hlFld-ContribAuthor ">Xiaoxia  Wang</span>, <span class="hlFld-ContribAuthor ">Wujian  Xu</span>, <span class="hlFld-ContribAuthor ">Tangfeng  Lv</span>, <span class="hlFld-ContribAuthor ">Yong  Song</span>. </span><span class="cited-content_cbyCitation_article-title">Geranylgeranyl diphosphate synthase deficiency hyperactivates macrophages and aggravates lipopolysaccharide-induced acute lung injury. </span><span class="cited-content_cbyCitation_journal-name">American Journal of Physiology-Lung Cellular and Molecular Physiology</span><span> <strong>2021,</strong> <em>320 </em>
                                    (6)
                                     , L1011-L1024. <a href="https://doi.org/10.1152/ajplung.00281.2020" title="DOI URL">https://doi.org/10.1152/ajplung.00281.2020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1152/ajplung.00281.2020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1152%2Fajplung.00281.2020%26sid%3Dliteratum%253Aachs%26jtitle%3DAmerican%2520Journal%2520of%2520Physiology-Lung%2520Cellular%2520and%2520Molecular%2520Physiology%26atitle%3DGeranylgeranyl%252Bdiphosphate%252Bsynthase%252Bdeficiency%252Bhyperactivates%252Bmacrophages%252Band%252Baggravates%252Blipopolysaccharide-induced%252Bacute%252Blung%252Binjury%26aulast%3DJin%26aufirst%3DJiajia%26date%3D2021%26volume%3D320%26issue%3D6%26spage%3DL1011%26epage%3DL1024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thibaut  Legigan</span>, <span class="hlFld-ContribAuthor ">Evelyne  Migianu-Griffoni</span>, <span class="hlFld-ContribAuthor ">Mohamed Abdenour  Redouane</span>, <span class="hlFld-ContribAuthor ">Aurélie  Descamps</span>, <span class="hlFld-ContribAuthor ">Julia  Deschamp</span>, <span class="hlFld-ContribAuthor ">Olivier  Gager</span>, <span class="hlFld-ContribAuthor ">Maëlle  Monteil</span>, <span class="hlFld-ContribAuthor ">Florent  Barbault</span>, <span class="hlFld-ContribAuthor ">Marc  Lecouvey</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and preliminary anticancer evaluation of new triazole bisphosphonate-based isoprenoid biosynthesis inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>214 </em>, 113241. <a href="https://doi.org/10.1016/j.ejmech.2021.113241" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113241</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113241%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bpreliminary%252Banticancer%252Bevaluation%252Bof%252Bnew%252Btriazole%252Bbisphosphonate-based%252Bisoprenoid%252Bbiosynthesis%252Binhibitors%26aulast%3DLegigan%26aufirst%3DThibaut%26date%3D2021%26volume%3D214%26spage%3D113241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Min  Li</span>, <span class="hlFld-ContribAuthor ">Wei  Min</span>, <span class="hlFld-ContribAuthor ">Jianbo  Wang</span>, <span class="hlFld-ContribAuthor ">Lu  Wang</span>, <span class="hlFld-ContribAuthor ">Yan  Li</span>, <span class="hlFld-ContribAuthor ">Naihui  Zhou</span>, <span class="hlFld-ContribAuthor ">Ziliang  Yang</span>, <span class="hlFld-ContribAuthor ">Qihong  Qian</span>. </span><span class="cited-content_cbyCitation_article-title">Effects of mevalonate kinase interference on cell differentiation, apoptosis, prenylation and geranylgeranylation of human keratinocytes are attenuated by farnesyl pyrophosphate or geranylgeranyl pyrophosphate. </span><span class="cited-content_cbyCitation_journal-name">Experimental and Therapeutic Medicine</span><span> <strong>2020,</strong> <em> </em><a href="https://doi.org/10.3892/etm.2020.8569" title="DOI URL">https://doi.org/10.3892/etm.2020.8569</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3892/etm.2020.8569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3892%2Fetm.2020.8569%26sid%3Dliteratum%253Aachs%26jtitle%3DExperimental%2520and%2520Therapeutic%2520Medicine%26atitle%3DEffects%252Bof%252Bmevalonate%252Bkinase%252Binterference%252Bon%252Bcell%252Bdifferentiation%25252C%252Bapoptosis%25252C%252Bprenylation%252Band%252Bgeranylgeranylation%252Bof%252Bhuman%252Bkeratinocytes%252Bare%252Battenuated%252Bby%252Bfarnesyl%252Bpyrophosphate%252Bor%252Bgeranylgeranyl%252Bpyrophosphate%26aulast%3DLi%26aufirst%3DMin%26date%3D2020%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pimyupa  Manaswiyoungkul</span>, <span class="hlFld-ContribAuthor ">Elvin D.  de Araujo</span>, <span class="hlFld-ContribAuthor ">Patrick T.  Gunning</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting prenylation inhibition through the mevalonate pathway. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2020,</strong> <em>11 </em>
                                    (1)
                                     , 51-71. <a href="https://doi.org/10.1039/C9MD00442D" title="DOI URL">https://doi.org/10.1039/C9MD00442D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9MD00442D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9MD00442D%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252Bprenylation%252Binhibition%252Bthrough%252Bthe%252Bmevalonate%252Bpathway%26aulast%3DManaswiyoungkul%26aufirst%3DPimyupa%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D1%26spage%3D51%26epage%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Melanie J.  Blanden</span>, <span class="hlFld-ContribAuthor ">Sudhat  Ashok</span>, <span class="hlFld-ContribAuthor ">James L.  Hougland</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanisms of CaaX Protein Processing: Protein Prenylation by FTase and GGTase-I. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 497-527. <a href="https://doi.org/10.1016/B978-0-12-409547-2.14837-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.14837-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.14837-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.14837-1%26sid%3Dliteratum%253Aachs%26atitle%3DMechanisms%252Bof%252BCaaX%252BProtein%252BProcessing%25253A%252BProtein%252BPrenylation%252Bby%252BFTase%252Band%252BGGTase-I%26aulast%3DBlanden%26aufirst%3DMelanie%2BJ.%26date%3D2020%26spage%3D497%26epage%3D527%26pub%3DElsevier%26atitle%3DComprehensive%252BNatural%252BProducts%252BIII%26date%3D2020%26volume%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ghulam  Mohammad</span>, <span class="hlFld-ContribAuthor ">Arul J.  Duraisamy</span>, <span class="hlFld-ContribAuthor ">Anjan  Kowluru</span>, <span class="hlFld-ContribAuthor ">Renu A.  Kowluru</span>. </span><span class="cited-content_cbyCitation_article-title">Functional Regulation of an Oxidative Stress Mediator, Rac1, in Diabetic Retinopathy. </span><span class="cited-content_cbyCitation_journal-name">Molecular Neurobiology</span><span> <strong>2019,</strong> <em>56 </em>
                                    (12)
                                     , 8643-8655. <a href="https://doi.org/10.1007/s12035-019-01696-5" title="DOI URL">https://doi.org/10.1007/s12035-019-01696-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12035-019-01696-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12035-019-01696-5%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Neurobiology%26atitle%3DFunctional%252BRegulation%252Bof%252Ban%252BOxidative%252BStress%252BMediator%25252C%252BRac1%25252C%252Bin%252BDiabetic%252BRetinopathy%26aulast%3DMohammad%26aufirst%3DGhulam%26date%3D2019%26date%3D2019%26volume%3D56%26issue%3D12%26spage%3D8643%26epage%3D8655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Staci L.  Haney</span>, <span class="hlFld-ContribAuthor ">Yashpal S.  Chhonker</span>, <span class="hlFld-ContribAuthor ">Michelle L.  Varney</span>, <span class="hlFld-ContribAuthor ">Geoffrey  Talmon</span>, <span class="hlFld-ContribAuthor ">Lynette M.  Smith</span>, <span class="hlFld-ContribAuthor ">Daryl J.  Murry</span>, <span class="hlFld-ContribAuthor ">Sarah A.  Holstein</span>. </span><span class="cited-content_cbyCitation_article-title">In Vivo Evaluation of Isoprenoid Triazole Bisphosphonate Inhibitors of Geranylgeranyl Diphosphate Synthase: Impact of Olefin Stereochemistry on Toxicity and Biodistribution. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacology and Experimental Therapeutics</span><span> <strong>2019,</strong> <em>371 </em>
                                    (2)
                                     , 327-338. <a href="https://doi.org/10.1124/jpet.119.258624" title="DOI URL">https://doi.org/10.1124/jpet.119.258624</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/jpet.119.258624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fjpet.119.258624%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacology%2520and%2520Experimental%2520Therapeutics%26atitle%3DIn%252BVivo%252BEvaluation%252Bof%252BIsoprenoid%252BTriazole%252BBisphosphonate%252BInhibitors%252Bof%252BGeranylgeranyl%252BDiphosphate%252BSynthase%25253A%252BImpact%252Bof%252BOlefin%252BStereochemistry%252Bon%252BToxicity%252Band%252BBiodistribution%26aulast%3DHaney%26aufirst%3DStaci%2BL.%26date%3D2019%26date%3D2019%26volume%3D371%26issue%3D2%26spage%3D327%26epage%3D338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michal  Lisnyansky</span>, <span class="hlFld-ContribAuthor ">Elon  Yariv</span>, <span class="hlFld-ContribAuthor ">Omri  Segal</span>, <span class="hlFld-ContribAuthor ">Milit  Marom</span>, <span class="hlFld-ContribAuthor ">Anat  Loewenstein</span>, <span class="hlFld-ContribAuthor ">Nir  Ben-Tal</span>, <span class="hlFld-ContribAuthor ">Moshe  Giladi</span>, <span class="hlFld-ContribAuthor ">Yoni  Haitin</span>. </span><span class="cited-content_cbyCitation_article-title">Metal Coordination Is Crucial for Geranylgeranyl Diphosphate Synthase–Bisphosphonate Interactions: A Crystallographic and Computational Analysis. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmacology</span><span> <strong>2019,</strong> <em>96 </em>
                                    (5)
                                     , 580-588. <a href="https://doi.org/10.1124/mol.119.117499" title="DOI URL">https://doi.org/10.1124/mol.119.117499</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/mol.119.117499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fmol.119.117499%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmacology%26atitle%3DMetal%252BCoordination%252BIs%252BCrucial%252Bfor%252BGeranylgeranyl%252BDiphosphate%252BSynthase%2525E2%252580%252593Bisphosphonate%252BInteractions%25253A%252BA%252BCrystallographic%252Band%252BComputational%252BAnalysis%26aulast%3DLisnyansky%26aufirst%3DMichal%26date%3D2019%26date%3D2019%26volume%3D96%26issue%3D5%26spage%3D580%26epage%3D588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nazmul H.  Bhuiyan</span>, <span class="hlFld-ContribAuthor ">Michelle L.  Varney</span>, <span class="hlFld-ContribAuthor ">Deep S.  Bhattacharya</span>, <span class="hlFld-ContribAuthor ">William M.  Payne</span>, <span class="hlFld-ContribAuthor ">Aaron M.  Mohs</span>, <span class="hlFld-ContribAuthor ">Sarah A.  Holstein</span>, <span class="hlFld-ContribAuthor ">David F.  Wiemer</span>. </span><span class="cited-content_cbyCitation_article-title">ω-Hydroxy isoprenoid bisphosphonates as linkable GGDPS inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (19)
                                     , 126633. <a href="https://doi.org/10.1016/j.bmcl.2019.126633" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.126633</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.126633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.126633%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3D%2525CF%252589-Hydroxy%252Bisoprenoid%252Bbisphosphonates%252Bas%252Blinkable%252BGGDPS%252Binhibitors%26aulast%3DBhuiyan%26aufirst%3DNazmul%2BH.%26date%3D2019%26volume%3D29%26issue%3D19%26spage%3D126633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sherry S.  Agabiti</span>, <span class="hlFld-ContribAuthor ">Jin  Li</span>, <span class="hlFld-ContribAuthor ">Willie  Dong</span>, <span class="hlFld-ContribAuthor ">Michael M.  Poe</span>, <span class="hlFld-ContribAuthor ">Andrew J.  Wiemer</span>. </span><span class="cited-content_cbyCitation_article-title">Regulation of the Notch-ATM-abl axis by geranylgeranyl diphosphate synthase inhibition. </span><span class="cited-content_cbyCitation_journal-name">Cell Death & Disease</span><span> <strong>2019,</strong> <em>10 </em>
                                    (10)
                                     <a href="https://doi.org/10.1038/s41419-019-1973-7" title="DOI URL">https://doi.org/10.1038/s41419-019-1973-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41419-019-1973-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41419-019-1973-7%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Death%2520%2526%2520Disease%26atitle%3DRegulation%252Bof%252Bthe%252BNotch-ATM-abl%252Baxis%252Bby%252Bgeranylgeranyl%252Bdiphosphate%252Bsynthase%252Binhibition%26aulast%3DAgabiti%26aufirst%3DSherry%2BS.%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Taoda  Shi</span>, <span class="hlFld-ContribAuthor ">ChristopherJ.  Zerio</span>, <span class="hlFld-ContribAuthor ">Jared  Sivinski</span>, <span class="hlFld-ContribAuthor ">Andrew J.  Ambrose</span>, <span class="hlFld-ContribAuthor ">Kohlson T.  Moore</span>, <span class="hlFld-ContribAuthor ">Thomas  Buckley</span>, <span class="hlFld-ContribAuthor ">Lynn  Kaneko</span>, <span class="hlFld-ContribAuthor ">Mae  Zhang</span>, <span class="hlFld-ContribAuthor ">Donna D.  Zhang</span>, <span class="hlFld-ContribAuthor ">Eli  Chapman</span>. </span><span class="cited-content_cbyCitation_article-title">A One-Step, Atom Economical Synthesis of Thieno[2,3-
              d
              ]pyrimidin-4-amine Derivatives by a Four-Component Reaction. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>2019 </em>
                                    (20)
                                     , 3269-3272. <a href="https://doi.org/10.1002/ejoc.201900414" title="DOI URL">https://doi.org/10.1002/ejoc.201900414</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201900414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201900414%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DA%252BOne-Step%25252C%252BAtom%252BEconomical%252BSynthesis%252Bof%252BThieno%25255B2%25252C3-%252Bd%252B%25255Dpyrimidin-4-amine%252BDerivatives%252Bby%252Ba%252BFour-Component%252BReaction%26aulast%3DShi%26aufirst%3DTaoda%26date%3D2019%26date%3D2019%26volume%3D2019%26issue%3D20%26spage%3D3269%26epage%3D3272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sarah A.  Holstein</span>. </span><span class="cited-content_cbyCitation_article-title">A patent review of bisphosphonates in treating bone disease. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2019,</strong> <em>29 </em>
                                    (5)
                                     , 315-325. <a href="https://doi.org/10.1080/13543776.2019.1608180" title="DOI URL">https://doi.org/10.1080/13543776.2019.1608180</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2019.1608180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2019.1608180%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DA%252Bpatent%252Breview%252Bof%252Bbisphosphonates%252Bin%252Btreating%252Bbone%252Bdisease%26aulast%3DHolstein%26aufirst%3DSarah%2BA.%26date%3D2019%26date%3D2019%26volume%3D29%26issue%3D5%26spage%3D315%26epage%3D325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel D.  Waller</span>, <span class="hlFld-ContribAuthor ">Jaeok  Park</span>, <span class="hlFld-ContribAuthor ">Youla S.  Tsantrizos</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of farnesyl pyrophosphate (FPP) and/or geranylgeranyl pyrophosphate (GGPP) biosynthesis and its implication in the treatment of cancers. </span><span class="cited-content_cbyCitation_journal-name">Critical Reviews in Biochemistry and Molecular Biology</span><span> <strong>2019,</strong> <em>54 </em>
                                    (1)
                                     , 41-60. <a href="https://doi.org/10.1080/10409238.2019.1568964" title="DOI URL">https://doi.org/10.1080/10409238.2019.1568964</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/10409238.2019.1568964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F10409238.2019.1568964%26sid%3Dliteratum%253Aachs%26jtitle%3DCritical%2520Reviews%2520in%2520Biochemistry%2520and%2520Molecular%2520Biology%26atitle%3DInhibition%252Bof%252Bfarnesyl%252Bpyrophosphate%252B%252528FPP%252529%252Band%25252For%252Bgeranylgeranyl%252Bpyrophosphate%252B%252528GGPP%252529%252Bbiosynthesis%252Band%252Bits%252Bimplication%252Bin%252Bthe%252Btreatment%252Bof%252Bcancers%26aulast%3DWaller%26aufirst%3DDaniel%2BD.%26date%3D2019%26date%3D2019%26volume%3D54%26issue%3D1%26spage%3D41%26epage%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexios N.  Matralis</span>, <span class="hlFld-ContribAuthor ">Dimitrios  Xanthopoulos</span>, <span class="hlFld-ContribAuthor ">Geneviève  Huot</span>, <span class="hlFld-ContribAuthor ">Stéphane  Lopes-Paciencia</span>, <span class="hlFld-ContribAuthor ">Charles  Cole</span>, <span class="hlFld-ContribAuthor ">Hugo  de Vries</span>, <span class="hlFld-ContribAuthor ">Gerardo  Ferbeyre</span>, <span class="hlFld-ContribAuthor ">Youla S.  Tsantrizos</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular tools that block maturation of the nuclear lamin A and decelerate cancer cell migration. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (20)
                                     , 5547-5554. <a href="https://doi.org/10.1016/j.bmc.2018.10.001" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.10.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.10.001%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DMolecular%252Btools%252Bthat%252Bblock%252Bmaturation%252Bof%252Bthe%252Bnuclear%252Blamin%252BA%252Band%252Bdecelerate%252Bcancer%252Bcell%252Bmigration%26aulast%3DMatralis%26aufirst%3DAlexios%2BN.%26date%3D2018%26volume%3D26%26issue%3D20%26spage%3D5547%26epage%3D5554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/medium/jm-2018-00886c_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00886&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/medium/jm-2018-00886c_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Isoprenoid substrates and inhibitors of prenylation. (a) Sequence of biochemical steps involved in the biosynthesis of isoprenoids. (b) Structures of inhibitors zoledronic acid (<b>1</b>) and risedronic acid (<b>2</b>) of hFPPS. L-778,123 (<b>3</b>) is a dual inhibitor of FTase and GGTase I. Compound <b>4</b> is a dual inhibitor of hFPPS and hGGPPS. Compounds <b>5</b> and <b>6</b> are selective inhibitors of hGGPPS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00886&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/medium/jm-2018-00886c_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Examples of thienopyrimidine-based inhibitors of hFPPS/hGGPPS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00886&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/medium/jm-2018-00886c_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0007.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Parallel Synthesis of a 60-Member Compound Library<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00886&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Pathway A: Synthesis of key intermediates <b>17a,b</b>. Pathway B: Synthesis of compound library, including analogs <b>10a</b>–<b>d</b> and <b>11a</b>–<b>c</b>. Conditions: (a) MeSCN, HCl, dioxane, 70 °C, 63%; (b) diethyl phosphite, CH(OEt)<sub>3</sub>, toluene, 130 °C, 40%; (c) arylboronic acid, Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, CuTC, dioxane, 50 °C, 80–83%; (d) SnCl<sub>2</sub>·H<sub>2</sub>O, EtOH, 80 °C, 83%; (e) aryl/heteroaryl acid chloride, Et<sub>3</sub>N, DCM, 0 °C to rt or aryl/heteroaryl carboxylic acid, HBTU, DIPEA, DMF, rt, 60–80%; (f) TMSBr, DCM, 0 °C to rt, then MeOH; (g) TFA, 80 °C; >95%; (h) H<sub>2</sub>N-aryl/heteroaryl, HBTU, DIPEA, DMF, rt, 60–80%.</p></p></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/medium/jm-2018-00886c_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Crystal structure of wild type and mutant hGGPS. (a) Hexameric wild type hGGPPS (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2Q80">2Q80</a>). Monomer units are indicated by different colors. (b) Dimeric hGGPPS mutant (Y246D; cyan and green; PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6C56">6C56</a>). A dimer of the wild type enzyme (gray) is superposed (the inset highlights the single amino acid mutation disrupting the dimer–dimer contact). (c) Dimeric hGGPPS in complex with <b>10d</b> (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6C57">6C57</a>). The green and orange meshes represent the ligand discovery map (<i>F</i><sub>o</sub> - <i>F</i><sub>c</sub> contoured at 3σ) and the anomalous signal map (3σ), respectively. (d) Superposition of <b>10d</b>. GGPPS substrate with the structure of a sulfur derivative of FPP (FsPP) and IPP bound to the yeast enzyme (ligands in magenta; protein in semitransparent wheat; PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2E8T">2E8T</a>) are superimposed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00886&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/medium/jm-2018-00886c_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Antimyeloma properties of thienopyrimidine-based hGGPPS inhibitors. (a) Comparison of hGGPPS inhibitor <b>11c</b>, selective hFPPS inhibitor <b>13</b>, and inactive ThP-BP compound <b>12</b>. Doxorubicin was used as a positive control. (b) Toxicity effects on normal human bronchial cells (NHBE) induced by inhibitors <b>11b</b>, <b>11c</b>, and doxorubicin. Apoptosis of MM RPMI-8226 cells after 72 h of incubation with (c) vehicle, (d) inhibitor <b>11c</b>, (e) GGOH and inhibitor <b>11c</b>, (f) GGOH alone, (g) ZOL (<b>1</b>) at the same concentration as <b>11c</b>, and (h) bortezomib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00886&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/medium/jm-2018-00886c_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. RNA transcript level (RNAseq) of hFPPS and hGGPPS. (a) mRNA expression (Log<sub>2</sub> RPKM) of hFPPS and hGGPPS in various human MM cell lines. (b) mRNA expression levels (FPKM) of hFPPS and hGGPPS in CD138-selected MM cells from patients’ bone marrow specimens obtained at diagnosis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00886&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/medium/jm-2018-00886c_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (a) Western blot analysis of two representative PBMC samples from vehicle (lanes 1 and 2) and inhibitor <b>11c</b> treated mice (lanes 3 and 4). (b) Serum protein electrophoresis from animals treated with vehicle or inhibitor <b>11c</b>. Arrows indicated location of M-protein. (c) Analysis of M-protein as a percentage of total serum protein and expressed as a change from baseline (day 0) to day 14 for each respective mouse. Statistical analysis was performed using unpaired two-tailed Student’s <i>t</i> test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00886/20180802/images/large/jm-2018-00886c_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00886&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08257" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08257" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 62 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, U. T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deraeve, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fränzel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bon, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blankenfeldt, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goody, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolters, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexandrov, K.</span></span> <span> </span><span class="NLM_article-title">Analysis of the eukaryotic prenylome by isoprenoid affinity tagging <i>Nature</i></span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">227</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.1038/nchembio.149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1038%2Fnchembio.149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=19219049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvFKju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=227-235&author=U.+T.+T.+Nguyenauthor=Z.+Guoauthor=C.+Delonauthor=Y.+Wuauthor=C.+Deraeveauthor=B.+Fr%C3%A4nzelauthor=R.+S.+Bonauthor=W.+Blankenfeldtauthor=R.+S.+Goodyauthor=H.+Waldmannauthor=D.+Woltersauthor=K.+Alexandrov&title=Analysis+of+the+eukaryotic+prenylome+by+isoprenoid+affinity+tagging+Nature&doi=10.1038%2Fnchembio.149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of the eukaryotic prenylome by isoprenoid affinity tagging</span></div><div class="casAuthors">Nguyen, Uyen T. T.; Guo, Zhong; Delon, Christine; Wu, Yaowen; Deraeve, Celine; Fraenzel, Benjamin; Bon, Robin S.; Blankenfeldt, Wulf; Goody, Roger S.; Waldmann, Herbert; Wolters, Dirk; Alexandrov, Kirill</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">227-235</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein prenylation is a widespread phenomenon in eukaryotic cells that affects many important signaling mols.  The authors describe the structure-guided design of engineered protein prenyltransferases and their universal synthetic substrate, biotin-geranylpyrophosphate.  These new tools allowed the authors to detect femtomolar amts. of prenylatable proteins in cells and organs and to identify their cognate protein prenyltransferases.  Using this approach, the authors analyzed the in vivo effects of protein prenyltransferase inhibitors.  Whereas some of the inhibitors displayed the expected activities, others lacked in vivo activity or targeted a broader spectrum of prenyltransferases than previously believed.  To quantitate the in vivo effect of the prenylation inhibitors, the authors profiled biotin-geranyl-tagged Rab-GTPases across the proteome by mass spectrometry.  The authors also demonstrate that sites of active vesicular transport carry most of the Rab-GTPases.  This approach enables a quant. proteome-wide anal. of the regulation of protein prenylation and its modulation by therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtjML3f4rJZLVg90H21EOLACvtfcHk0lg_EkQ61UKPKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvFKju7g%253D&md5=55c806fee6cd3e6276bf9e5f92571352</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.149%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DU.%2BT.%2BT.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DDelon%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DDeraeve%26aufirst%3DC.%26aulast%3DFr%25C3%25A4nzel%26aufirst%3DB.%26aulast%3DBon%26aufirst%3DR.%2BS.%26aulast%3DBlankenfeldt%26aufirst%3DW.%26aulast%3DGoody%26aufirst%3DR.%2BS.%26aulast%3DWaldmann%26aufirst%3DH.%26aulast%3DWolters%26aufirst%3DD.%26aulast%3DAlexandrov%26aufirst%3DK.%26atitle%3DAnalysis%2520of%2520the%2520eukaryotic%2520prenylome%2520by%2520isoprenoid%2520affinity%2520tagging%2520Nature%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D5%26spage%3D227%26epage%3D235%26doi%3D10.1038%2Fnchembio.149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kho, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaunbergs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinbaum, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamanoi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span> <span> </span><span class="NLM_article-title">A tagging-via-substrate technology for detection and proteomics of farnesylated proteins</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">12479</span>– <span class="NLM_lpage">12484</span>, <span class="refDoi"> DOI: 10.1073/pnas.0403413101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1073%2Fpnas.0403413101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=15308774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsVens7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=12479-12484&author=Y.+Khoauthor=S.+C.+Kimauthor=C.+Jiangauthor=D.+Barmaauthor=S.+W.+Kwonauthor=J.+Chengauthor=J.+Jaunbergsauthor=C.+Weinbaumauthor=F.+Tamanoiauthor=J.+Falckauthor=Y.+Zhao&title=A+tagging-via-substrate+technology+for+detection+and+proteomics+of+farnesylated+proteins&doi=10.1073%2Fpnas.0403413101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">A tagging-via-substrate technology for detection and proteomics of farnesylated proteins</span></div><div class="casAuthors">Kho, Yoonjung; Kim, Sung Chan; Jiang, Chen; Barma, Deb; Kwon, Sung Won; Cheng, Jinke; Jaunbergs, Janis; Weinbaum, Carolyn; Tamanoi, Fuyuhiko; Falck, John; Zhao, Yingming</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">12479-12484</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A recently developed proteomics strategy, designated tagging-via-substrate (TAS) approach, is described for the detection and proteomic anal. of farnesylated proteins.  TAS technol. involves metabolic incorporation of a synthetic azido-farnesyl analog and chemoselective derivatization of azido-farnesyl-modified proteins by an elegant version of Staudinger reaction, pioneered by the Bertozzi group, using a biotinylated phosphine capture reagent.  The resulting protein conjugates can be specifically detected and/or affinity-purified by streptavidin-linked horseradish peroxidase or agarose beads, resp.  Thus, the technol. enables global profiling of farnesylated proteins by enriching farnesylated proteins and reducing the complexity of farnesylation subproteome.  Azido-farnesylated proteins maintain the properties of protein farnesylation, including promoting membrane assocn., Ras-dependent mitogen-activated protein kinase k activation, and inhibition of lovastatin-induced apoptosis.  A proteomic anal. of farnesylated proteins by TAS technol. revealed 18 farnesylated proteins, including those with potentially novel farnesylation motifs, suggesting that future use of this method is likely to yield novel insight into protein farnesylation.  TAS technol. can be extended to other posttranslational modifications, such as geranylgeranylation and myristoylation, thus providing powerful tools for detection, quantification, and proteomic anal. of posttranslationally modified proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6gC0ZaOzxhbVg90H21EOLACvtfcHk0lg_EkQ61UKPKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsVens7Y%253D&md5=e0c77d3d0eadf7c244402094e7de62a4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0403413101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0403413101%26sid%3Dliteratum%253Aachs%26aulast%3DKho%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DS.%2BC.%26aulast%3DJiang%26aufirst%3DC.%26aulast%3DBarma%26aufirst%3DD.%26aulast%3DKwon%26aufirst%3DS.%2BW.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DJaunbergs%26aufirst%3DJ.%26aulast%3DWeinbaum%26aufirst%3DC.%26aulast%3DTamanoi%26aufirst%3DF.%26aulast%3DFalck%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DY.%26atitle%3DA%2520tagging-via-substrate%2520technology%2520for%2520detection%2520and%2520proteomics%2520of%2520farnesylated%2520proteins%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26spage%3D12479%26epage%3D12484%26doi%3D10.1073%2Fpnas.0403413101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stark, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehla, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaika, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acton, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montelione, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, R.</span></span> <span> </span><span class="NLM_article-title">Structure and function of human DnaJ homologues subfamily A member 1 (DNAJA1) and its relationship to pancreatic cancer</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1360</span>– <span class="NLM_lpage">1372</span>, <span class="refDoi"> DOI: 10.1021/bi401329a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi401329a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=1360-1372&author=J.+L.+Starkauthor=K.+Mehlaauthor=N.+Chaikaauthor=T.+B.+Actonauthor=R.+Xiaoauthor=P.+K.+Singhauthor=G.+T.+Montelioneauthor=R.+Powers&title=Structure+and+function+of+human+DnaJ+homologues+subfamily+A+member+1+%28DNAJA1%29+and+its+relationship+to+pancreatic+cancer&doi=10.1021%2Fbi401329a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fbi401329a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi401329a%26sid%3Dliteratum%253Aachs%26aulast%3DStark%26aufirst%3DJ.%2BL.%26aulast%3DMehla%26aufirst%3DK.%26aulast%3DChaika%26aufirst%3DN.%26aulast%3DActon%26aufirst%3DT.%2BB.%26aulast%3DXiao%26aufirst%3DR.%26aulast%3DSingh%26aufirst%3DP.%2BK.%26aulast%3DMontelione%26aufirst%3DG.%2BT.%26aulast%3DPowers%26aufirst%3DR.%26atitle%3DStructure%2520and%2520function%2520of%2520human%2520DnaJ%2520homologues%2520subfamily%2520A%2520member%25201%2520%2528DNAJA1%2529%2520and%2520its%2520relationship%2520to%2520pancreatic%2520cancer%26jtitle%3DBiochemistry%26date%3D2014%26volume%3D53%26spage%3D1360%26epage%3D1372%26doi%3D10.1021%2Fbi401329a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kampinga, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craig, E. A.</span></span> <span> </span><span class="NLM_article-title">The HSP70 chaperone machinery J proteins as drivers of functional specificity</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">579</span>– <span class="NLM_lpage">592</span>, <span class="refDoi"> DOI: 10.1038/nrm2941</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1038%2Fnrm2941" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=20651708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1arsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=579-592&author=H.+H.+Kampingaauthor=E.+A.+Craig&title=The+HSP70+chaperone+machinery+J+proteins+as+drivers+of+functional+specificity&doi=10.1038%2Fnrm2941"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The HSP70 chaperone machinery: J proteins as drivers of functional specificity</span></div><div class="casAuthors">Kampinga, Harm H.; Craig, Elizabeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">579-592</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Heat-shock 70-kDa proteins (HSP70s) are ubiquitous mol. chaperones that function in a myriad of biol. processes, modulating polypeptide folding, degrdn., and translocation across membranes, and protein-protein interactions.  This multitude of roles is not easily reconciled with the universality of the activity of HSP70s in ATP-dependent client protein-binding and release cycles.  Much of the functional diversity of the HSP70s is driven by a diverse class of cofactors: J proteins.  Often, multiple J proteins function with a single HSP70.  Some target HSP70 activity to clients at precise locations in cells and others bind client proteins directly, thereby delivering specific clients to HSP70 and directly detg. their fate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqr-hItdN33vLVg90H21EOLACvtfcHk0lgER7bo11bsEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1arsLo%253D&md5=06ca9d96bfb6878abbb9facadebc32c8</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrm2941&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2941%26sid%3Dliteratum%253Aachs%26aulast%3DKampinga%26aufirst%3DH.%2BH.%26aulast%3DCraig%26aufirst%3DE.%2BA.%26atitle%3DThe%2520HSP70%2520chaperone%2520machinery%2520J%2520proteins%2520as%2520drivers%2520of%2520functional%2520specificity%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2010%26volume%3D11%26spage%3D579%26epage%3D592%26doi%3D10.1038%2Fnrm2941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaelis, S.</span></span> <span> </span><span class="NLM_article-title">Prelamin A, Zmpste24, misshapen cell nuclei, and progeria – new evidence suggesting that protein farnesylation could be important for diseases pathogenesis</span>. <i>J. Lipid Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">2531</span>– <span class="NLM_lpage">2558</span>, <span class="refDoi"> DOI: 10.1194/jlr.R500011-JLR200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1194%2Fjlr.R500011-JLR200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2005&pages=2531-2558&author=S.+G.+Youngauthor=L.+G.+Fongauthor=S.+Michaelis&title=Prelamin+A%2C+Zmpste24%2C+misshapen+cell+nuclei%2C+and+progeria+%E2%80%93+new+evidence+suggesting+that+protein+farnesylation+could+be+important+for+diseases+pathogenesis&doi=10.1194%2Fjlr.R500011-JLR200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1194%2Fjlr.R500011-JLR200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1194%252Fjlr.R500011-JLR200%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DS.%2BG.%26aulast%3DFong%26aufirst%3DL.%2BG.%26aulast%3DMichaelis%26aufirst%3DS.%26atitle%3DPrelamin%2520A%252C%2520Zmpste24%252C%2520misshapen%2520cell%2520nuclei%252C%2520and%2520progeria%2520%25E2%2580%2593%2520new%2520evidence%2520suggesting%2520that%2520protein%2520farnesylation%2520could%2520be%2520important%2520for%2520diseases%2520pathogenesis%26jtitle%3DJ.%2520Lipid%2520Res.%26date%3D2005%26volume%3D46%26spage%3D2531%26epage%3D2558%26doi%3D10.1194%2Fjlr.R500011-JLR200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matozaki, T.</span></span> <span> </span><span class="NLM_article-title">Small GTP-binding roteins</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1152/physrev.2001.81.1.153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1152%2Fphysrev.2001.81.1.153" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2001&pages=153-208&author=Y.+Takaiauthor=T.+Sasakiauthor=T.+Matozaki&title=Small+GTP-binding+roteins&doi=10.1152%2Fphysrev.2001.81.1.153"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.2001.81.1.153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.2001.81.1.153%26sid%3Dliteratum%253Aachs%26aulast%3DTakai%26aufirst%3DY.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DMatozaki%26aufirst%3DT.%26atitle%3DSmall%2520GTP-binding%2520roteins%26jtitle%3DPhysiol.%2520Rev.%26date%3D2001%26volume%3D81%26spage%3D153%26epage%3D208%26doi%3D10.1152%2Fphysrev.2001.81.1.153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mullen, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archer, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penn, L. Z.</span></span> <span> </span><span class="NLM_article-title">The interplay between cell signaling and the mevalonate pathway in cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">718</span>– <span class="NLM_lpage">731</span>, <span class="refDoi"> DOI: 10.1038/nrc.2016.76</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1038%2Fnrc.2016.76" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=27562463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVSrur%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=718-731&author=P.+J.+Mullenauthor=R.+Yuauthor=J.+Longoauthor=M.+C.+Archerauthor=L.+Z.+Penn&title=The+interplay+between+cell+signaling+and+the+mevalonate+pathway+in+cancer&doi=10.1038%2Fnrc.2016.76"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The interplay between cell signalling and the mevalonate pathway in cancer</span></div><div class="casAuthors">Mullen, Peter J.; Yu, Rosemary; Longo, Joseph; Archer, Michael C.; Penn, Linda Z.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">718-731</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The mevalonate (MVA) pathway is an essential metabolic pathway that uses acetyl-CoA to produce sterols and isoprenoids that are integral to tumor growth and progression.  In recent years, many oncogenic signalling pathways have been shown to increase the activity and/or the expression of MVA pathway enzymes.  This Review summarizes recent advances and discusses unique opportunities for immediately targeting this metabolic vulnerability in cancer with agents that have been approved for other therapeutic uses, such as the statin family of drugs, to improve outcomes for cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprCFV9_aKCv7Vg90H21EOLACvtfcHk0lgER7bo11bsEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVSrur%252FN&md5=4a692b82d8eb6fc1547db5c45a36cae4</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2016.76&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2016.76%26sid%3Dliteratum%253Aachs%26aulast%3DMullen%26aufirst%3DP.%2BJ.%26aulast%3DYu%26aufirst%3DR.%26aulast%3DLongo%26aufirst%3DJ.%26aulast%3DArcher%26aufirst%3DM.%2BC.%26aulast%3DPenn%26aufirst%3DL.%2BZ.%26atitle%3DThe%2520interplay%2520between%2520cell%2520signaling%2520and%2520the%2520mevalonate%2520pathway%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2016%26volume%3D16%26spage%3D718%26epage%3D731%26doi%3D10.1038%2Fnrc.2016.76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clendening, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandyra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boutros, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghamrasni, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khosravi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trentin, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martirosyan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakem, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakem, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurisica, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penn, L. Z.</span></span> <span> </span><span class="NLM_article-title">Dysregulation of the mevalonate pathway promotes transformation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">15051</span>– <span class="NLM_lpage">15056</span>, <span class="refDoi"> DOI: 10.1073/pnas.0910258107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1073%2Fpnas.0910258107" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=15051-15056&author=J.+W.+Clendeningauthor=A.+Pandyraauthor=P.+C.+Boutrosauthor=S.+E.+Ghamrasniauthor=F.+Khosraviauthor=G.+A.+Trentinauthor=A.+Martirosyanauthor=A.+Hakemauthor=R.+Hakemauthor=I.+Jurisicaauthor=L.+Z.+Penn&title=Dysregulation+of+the+mevalonate+pathway+promotes+transformation&doi=10.1073%2Fpnas.0910258107"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0910258107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0910258107%26sid%3Dliteratum%253Aachs%26aulast%3DClendening%26aufirst%3DJ.%2BW.%26aulast%3DPandyra%26aufirst%3DA.%26aulast%3DBoutros%26aufirst%3DP.%2BC.%26aulast%3DGhamrasni%26aufirst%3DS.%2BE.%26aulast%3DKhosravi%26aufirst%3DF.%26aulast%3DTrentin%26aufirst%3DG.%2BA.%26aulast%3DMartirosyan%26aufirst%3DA.%26aulast%3DHakem%26aufirst%3DA.%26aulast%3DHakem%26aufirst%3DR.%26aulast%3DJurisica%26aufirst%3DI.%26aulast%3DPenn%26aufirst%3DL.%2BZ.%26atitle%3DDysregulation%2520of%2520the%2520mevalonate%2520pathway%2520promotes%2520transformation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D15051%26epage%3D15056%26doi%3D10.1073%2Fpnas.0910258107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sorrentino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Specchia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordenonsi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupont, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfrin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingallina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommaggio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piazza, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccolo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Sal, G.</span></span> <span> </span><span class="NLM_article-title">Metabolic control of YAP and TAZ by the mevalonate pathway</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">366</span>, <span class="refDoi"> DOI: 10.1038/ncb2936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1038%2Fncb2936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=24658687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC2cXks12rtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=357-366&author=G.+Sorrentinoauthor=N.+Ruggeriauthor=V.+Specchiaauthor=M.+Cordenonsiauthor=M.+Manoauthor=S.+Dupontauthor=A.+Manfrinauthor=E.+Ingallinaauthor=R.+Sommaggioauthor=S.+Piazzaauthor=A.+Rosatoauthor=S.+Piccoloauthor=G.+Del+Sal&title=Metabolic+control+of+YAP+and+TAZ+by+the+mevalonate+pathway&doi=10.1038%2Fncb2936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic control of YAP and TAZ by the mevalonate pathway</span></div><div class="casAuthors">Sorrentino, Giovanni; Ruggeri, Naomi; Specchia, Valeria; Cordenonsi, Michelangelo; Mano, Miguel; Dupont, Sirio; Manfrin, Andrea; Ingallina, Eleonora; Sommaggio, Roberta; Piazza, Silvano; Rosato, Antonio; Piccolo, Stefano; Del Sal, Giannino</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">357-366</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The YAP and TAZ mediators of the Hippo pathway (hereafter called YAP/TAZ) promote tissue proliferation and organ growth.  However, how their biol. properties intersect with cellular metab. remains unexplained.  Here, we show that YAP/TAZ activity is controlled by the SREBP/mevalonate pathway.  Inhibition of the rate-limiting enzyme of this pathway (HMG-CoA reductase) by statins opposes YAP/TAZ nuclear localization and transcriptional responses.  Mechanistically, the geranylgeranyl pyrophosphate produced by the mevalonate cascade is required for activation of Rho GTPases that, in turn, activate YAP/TAZ by inhibiting their phosphorylation and promoting their nuclear accumulation.  The mevalonate-YAP/TAZ axis is required for proliferation and self-renewal of breast cancer cells.  In Drosophila melanogaster, inhibition of mevalonate biosynthesis and geranylgeranylation blunts the eye overgrowth induced by Yorkie, the YAP/TAZ orthologue.  In tumor cells, YAP/TAZ activation is promoted by increased levels of mevalonic acid produced by SREBP transcriptional activity, which is induced by its oncogenic cofactor mutant p53.  These findings reveal an addnl. layer of YAP/TAZ regulation by metabolic cues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXxh8AtqF2PbVg90H21EOLACvtfcHk0lhYr8ClJQzzhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXks12rtLY%253D&md5=417c52cd08ff2d532f10875140445bdd</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fncb2936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb2936%26sid%3Dliteratum%253Aachs%26aulast%3DSorrentino%26aufirst%3DG.%26aulast%3DRuggeri%26aufirst%3DN.%26aulast%3DSpecchia%26aufirst%3DV.%26aulast%3DCordenonsi%26aufirst%3DM.%26aulast%3DMano%26aufirst%3DM.%26aulast%3DDupont%26aufirst%3DS.%26aulast%3DManfrin%26aufirst%3DA.%26aulast%3DIngallina%26aufirst%3DE.%26aulast%3DSommaggio%26aufirst%3DR.%26aulast%3DPiazza%26aufirst%3DS.%26aulast%3DRosato%26aufirst%3DA.%26aulast%3DPiccolo%26aufirst%3DS.%26aulast%3DDel%2BSal%26aufirst%3DG.%26atitle%3DMetabolic%2520control%2520of%2520YAP%2520and%2520TAZ%2520by%2520the%2520mevalonate%2520pathway%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2014%26volume%3D16%26spage%3D357%26epage%3D366%26doi%3D10.1038%2Fncb2936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordestgaard, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bojesen, S. E.</span></span> <span> </span><span class="NLM_article-title">Statin use and reduced cancer-related mortality</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">1792</span>– <span class="NLM_lpage">1802</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1201735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1056%2FNEJMoa1201735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=23134381" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1ekt73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=1792-1802&author=S.+F.+Nielsenauthor=B.+G.+Nordestgaardauthor=S.+E.+Bojesen&title=Statin+use+and+reduced+cancer-related+mortality&doi=10.1056%2FNEJMoa1201735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Statin use and reduced cancer-related mortality</span></div><div class="casAuthors">Nielsen, Sune F.; Nordestgaard, Boerge G.; Bojesen, Stig E.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1792-1802</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A redn. in the availability of cholesterol may limit the cellular proliferation required for cancer growth and metastasis.  We tested the hypothesis that statin use begun before a cancer diagnosis is assocd. with reduced cancer-related mortality.  We assessed mortality among patients from the entire Danish population who had received a diagnosis of cancer between 1995 and 2007, with follow-up until Dec. 31, 2009.  Among patients 40 years of age or older, 18,721 had used statins regularly before the cancer diagnosis and 277,204 had never used statins.  Multivariable-adjusted hazard ratios for statin users, as compared with patients who had never used statins, were 0.85 (95% confidence interval [CI], 0.83 to 0.87) for death from any cause and 0.85 (95% CI, 0.82 to 0.87) for death from cancer.  Adjusted hazard ratios for death from any cause according to the defined daily statin dose (the assumed av. maintenance dose per day) were 0.82 (95% CI, 0.81 to 0.85) for a dose of 0.01 to 0.75 defined daily dose per day, 0.87 (95% CI, 0.83 to 0.89) for 0.76 to 1.50 defined daily dose per day, and 0.87 (95% CI, 0.81 to 0.91) for higher than 1.50 defined daily dose per day; the corresponding hazard ratios for death from cancer were 0.83 (95% CI, 0.81 to 0.86), 0.87 (95% CI, 0.83 to 0.91), and 0.87 (95% CI, 0.81 to 0.92).  The reduced cancer-related mortality among statin users as compared with those who had never used statins was obsd. for each of 13 cancer types.  Statin use in patients with cancer is assocd. with reduced cancer-related mortality.  This suggests a need for trials of statins in patients with cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRi4ePb4X5TbVg90H21EOLACvtfcHk0lhYr8ClJQzzhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1ekt73N&md5=cb3c50e51082614338f3c11f0078252e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1201735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1201735%26sid%3Dliteratum%253Aachs%26aulast%3DNielsen%26aufirst%3DS.%2BF.%26aulast%3DNordestgaard%26aufirst%3DB.%2BG.%26aulast%3DBojesen%26aufirst%3DS.%2BE.%26atitle%3DStatin%2520use%2520and%2520reduced%2520cancer-related%2520mortality%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D1792%26epage%3D1802%26doi%3D10.1056%2FNEJMoa1201735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garwood, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baehner, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Au, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hylton, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flowers, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnikoski, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olopade, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Port, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esserman, L. J.</span></span> <span> </span><span class="NLM_article-title">Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.1007/s10549-009-0507-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1007%2Fs10549-009-0507-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=19728082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFaqtrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2010&pages=137-144&author=E.+R.+Garwoodauthor=A.+S.+Kumarauthor=F.+L.+Baehnerauthor=D.+H.+Mooreauthor=A.+Auauthor=N.+Hyltonauthor=C.+I.+Flowersauthor=J.+Garberauthor=B.+A.+Lesnikoskiauthor=E.+S.+Hwangauthor=O.+Olopadeauthor=E.+R.+Portauthor=M.+Campbellauthor=L.+J.+Esserman&title=Fluvastatin+reduces+proliferation+and+increases+apoptosis+in+women+with+high+grade+breast+cancer&doi=10.1007%2Fs10549-009-0507-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer</span></div><div class="casAuthors">Garwood, Elisabeth R.; Kumar, Anjali S.; Baehner, Frederick L.; Moore, Dan H.; Au, Alfred; Hylton, Nola; Flowers, Chris I.; Garber, Judy; Lesnikoski, Beth-Ann; Hwang, E. Shelley; Olopade, Olofunmilao; Port, Elisa Rush; Campbell, Michael; Esserman, Laura J.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">137-144</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The purpose of this study is to det. the biol. impact of short-term lipophilic statin exposure on in situ and invasive breast cancer through paired tissue, blood and imaging-based biomarkers.  A perioperative window trial of fluvastatin was conducted in women with a diagnosis of DCIS or stage 1 breast cancer.  Patients were randomized to high dose (80 mg/day) or low dose (20 mg/day) fluvastatin for 3-6 wk before surgery.  Tissue (diagnostic core biopsy/final surgical specimen), blood, and magnetic resonance images were obtained before/after treatment.  The primary endpoint was Ki-67 (proliferation) redn.  Secondary endpoints were change in cleaved caspase-3 (CC3, apoptosis), MRI tumor vol., and serum C-reactive protein (CRP, inflammation).  Planned subgroup analyses compared disease grade, statin dose, and estrogen-receptor status.  Forty of 45 patients who enrolled completed the protocol; 29 had paired Ki-67 primary endpoint data.  Proliferation of high grade tumors decreased by a median of 7.2% (P = 0.008), which was statistically greater than the 0.3% decrease for low grade tumors.  Paired data for CC3 showed tumor apoptosis increased in 38%, remained stable in 41%, and decreased in 21% of subjects.  More high grade tumors had an increase in apoptosis (60 vs. 13%; P = 0.015).  Serum CRP did not change, but cholesterol levels were significantly lower post statin exposure (P < 0.001).  Fluvastatin showed measurable biol. changes by reducing tumor proliferation and increasing apoptotic activity in high-grade, stage 0/1 breast cancer.  Effects were only evident in high grade tumors.  These results support further evaluation of statins as chemoprevention for ER-neg. high grade breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYjyXK6k7NN7Vg90H21EOLACvtfcHk0lhYr8ClJQzzhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFaqtrrO&md5=0376bbe6cebf6545ff9b1066c43ee240</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs10549-009-0507-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-009-0507-x%26sid%3Dliteratum%253Aachs%26aulast%3DGarwood%26aufirst%3DE.%2BR.%26aulast%3DKumar%26aufirst%3DA.%2BS.%26aulast%3DBaehner%26aufirst%3DF.%2BL.%26aulast%3DMoore%26aufirst%3DD.%2BH.%26aulast%3DAu%26aufirst%3DA.%26aulast%3DHylton%26aufirst%3DN.%26aulast%3DFlowers%26aufirst%3DC.%2BI.%26aulast%3DGarber%26aufirst%3DJ.%26aulast%3DLesnikoski%26aufirst%3DB.%2BA.%26aulast%3DHwang%26aufirst%3DE.%2BS.%26aulast%3DOlopade%26aufirst%3DO.%26aulast%3DPort%26aufirst%3DE.%2BR.%26aulast%3DCampbell%26aufirst%3DM.%26aulast%3DEsserman%26aufirst%3DL.%2BJ.%26atitle%3DFluvastatin%2520reduces%2520proliferation%2520and%2520increases%2520apoptosis%2520in%2520women%2520with%2520high%2520grade%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2010%26volume%3D119%26spage%3D137%26epage%3D144%26doi%3D10.1007%2Fs10549-009-0507-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kubatka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruzliak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotrekl, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jelinkova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mladosievicova, B.</span></span> <span> </span><span class="NLM_article-title">Statins in oncological research: from experimental studies to clinical practice</span>. <i>Crit. Rev. Oncol. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">296</span>– <span class="NLM_lpage">311</span>, <span class="refDoi"> DOI: 10.1016/j.critrevonc.2014.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1016%2Fj.critrevonc.2014.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=25220658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A280%3ADC%252BC2M7htl2lsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2014&pages=296-311&author=P.+Kubatkaauthor=P.+Kruzliakauthor=V.+Rotreklauthor=S.+Jelinkovaauthor=B.+Mladosievicova&title=Statins+in+oncological+research%3A+from+experimental+studies+to+clinical+practice&doi=10.1016%2Fj.critrevonc.2014.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Statins in oncological research: from experimental studies to clinical practice</span></div><div class="casAuthors">Kubatka Peter; Kruzliak Peter; Rotrekl Vladimir; Jelinkova Sarka; Mladosievicova Beata</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">296-311</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Statins, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors are commonly used drugs in the treatment of dyslipidemias, primarily raised cholesterol.  Recently, many epidemiological and preclinical studies pointed to anti-tumor properties of statins, including anti-proliferative activities, apoptosis, decreased angiogenesis and metastasis.  These processes play an important role in carcinogenesis and, therefore, the role of statins in cancer disease is being seriously discussed among oncologists.  Anti-neoplastic properties of statins combined with an acceptable toxicity profile in the majority of individuals support their further development as anti-tumor drugs.  The mechanism of action, current preclinical studies and clinical efficacy of statins are reviewed in this paper.  Moreover, promising results have been reported regarding the statins' efficacy in some cancer types, especially in esophageal and colorectal cancers, and hepatocellular carcinoma.  Statins' hepatotoxicity has traditionally represented an obstacle to the prescription of this class of drugs and this issue is also discussed in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRlg2H7p3p9vEewzGPswiWOfW6udTcc2eYOdO7oNAQ5mrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M7htl2lsg%253D%253D&md5=d8aa97da1562828e3917630c41b1cd75</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2014.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2014.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DKubatka%26aufirst%3DP.%26aulast%3DKruzliak%26aufirst%3DP.%26aulast%3DRotrekl%26aufirst%3DV.%26aulast%3DJelinkova%26aufirst%3DS.%26aulast%3DMladosievicova%26aufirst%3DB.%26atitle%3DStatins%2520in%2520oncological%2520research%253A%2520from%2520experimental%2520studies%2520to%2520clinical%2520practice%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2014%26volume%3D92%26spage%3D296%26epage%3D311%26doi%3D10.1016%2Fj.critrevonc.2014.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanfilippo, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gage, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moskowitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gumbel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blue, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brian, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, K.</span></span> <span> </span><span class="NLM_article-title">Statins are associated with reduced mortality in multiple myeloma</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">4008</span>– <span class="NLM_lpage">4014</span>, <span class="refDoi"> DOI: 10.1200/JCO.2016.68.3482</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1200%2FJCO.2016.68.3482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=27646948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmtlGh" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=4008-4014&author=K.+M.+Sanfilippoauthor=J.+Kellerauthor=B.+F.+Gageauthor=S.+Luoauthor=T.-F.+Wangauthor=G.+Moskowitzauthor=J.+Gumbelauthor=B.+Blueauthor=K.+O%E2%80%99Brianauthor=K.+Carson&title=Statins+are+associated+with+reduced+mortality+in+multiple+myeloma&doi=10.1200%2FJCO.2016.68.3482"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Statins are associated with reduced mortality in multiple myeloma</span></div><div class="casAuthors">Sanfilippo, Kristen Marie; Keller, Jesse; Gage, Brian F.; Luo, Suhong; Wang, Tzu-Fei; Moskowitz, Gerald; Gumbel, Jason; Blue, Brandon; O'Brian, Katiuscia; Carson, Kenneth R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">4008-4014</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) have activity in one of the pathways influenced by nitrogen-contg. bisphosphonates, which are assocd. with improved survival in multiple myeloma (MM).  To understand the benefit of statins in MM, we evaluated the assocn. between statin use and mortality in a large cohort of patients with MM.  Patients and Methods From the Veterans Administration Central Cancer Registry, we identified patients diagnosed with MM between 1999 and 2013.  We defined statin use as the presence of any prescription for a statin within 3 mo before or any time after MM diagnosis.  Cox proportional hazards regression assessed the assocn. of statin use with mortality, while controlling for known MM prognostic factors.  Results We identified a cohort of 4,957 patients, of whom 2,294 received statin therapy.  Statin use was assocd. with a 21% decrease in all-cause mortality (adjusted hazard ratio, 0.79; 95% CI, 0.73 to 0.86; P < .001) as well as a 24% decrease in MM-specific mortality (adjusted hazard ratio, 0.76; 95% CI, 0.67 to 0.86; P < .001).  This assocn. remained significant across all sensitivity analyses.  In addn. to redns. in mortality, statin use was assocd. with a 31% decreased risk of developing a skeletal-related event.  Conclusion In this cohort study of US veterans with MM, statin therapy was assocd. with a reduced risk of both all-cause and MM-specific mortality.  Our findings suggest a potential role for statin therapy in patients with MM.  The putative benefit of statin therapy in MM should be corroborated in prospective studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBKXz8mCQuDrVg90H21EOLACvtfcHk0ljXS5ZsBZXTNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmtlGh&md5=4e499c400e7a33c7e187b7b515a5c759</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.68.3482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.68.3482%26sid%3Dliteratum%253Aachs%26aulast%3DSanfilippo%26aufirst%3DK.%2BM.%26aulast%3DKeller%26aufirst%3DJ.%26aulast%3DGage%26aufirst%3DB.%2BF.%26aulast%3DLuo%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DT.-F.%26aulast%3DMoskowitz%26aufirst%3DG.%26aulast%3DGumbel%26aufirst%3DJ.%26aulast%3DBlue%26aufirst%3DB.%26aulast%3DO%25E2%2580%2599Brian%26aufirst%3DK.%26aulast%3DCarson%26aufirst%3DK.%26atitle%3DStatins%2520are%2520associated%2520with%2520reduced%2520mortality%2520in%2520multiple%2520myeloma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26spage%3D4008%26epage%3D4014%26doi%3D10.1200%2FJCO.2016.68.3482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dunford, J. E.</span></span> <span> </span><span class="NLM_article-title">Molecular targets of the nitrogen containing bisphosphonates: The molecular pharmacology of prenyl synthase inhibition</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2961</span>– <span class="NLM_lpage">2969</span>, <span class="refDoi"> DOI: 10.2174/138161210793563617</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.2174%2F138161210793563617" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=2961-2969&author=J.+E.+Dunford&title=Molecular+targets+of+the+nitrogen+containing+bisphosphonates%3A+The+molecular+pharmacology+of+prenyl+synthase+inhibition&doi=10.2174%2F138161210793563617"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2174%2F138161210793563617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161210793563617%26sid%3Dliteratum%253Aachs%26aulast%3DDunford%26aufirst%3DJ.%2BE.%26atitle%3DMolecular%2520targets%2520of%2520the%2520nitrogen%2520containing%2520bisphosphonates%253A%2520The%2520molecular%2520pharmacology%2520of%2520prenyl%2520synthase%2520inhibition%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2010%26volume%3D16%26spage%3D2961%26epage%3D2969%26doi%3D10.2174%2F138161210793563617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ebetino, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogan, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsoumpra, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triffitt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwaasi, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunford, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnett, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oppermann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundy, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashemirov, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenna, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, R. G.</span></span> <span> </span><span class="NLM_article-title">The relationship between the chemistry and biological activity of the bisphosphonates</span>. <i>Bone</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1016/j.bone.2011.03.774</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1016%2Fj.bone.2011.03.774" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=21497677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsVSgsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2011&pages=20-33&author=F.+H.+Ebetinoauthor=A.-M.+Hoganauthor=S.+Sunauthor=M.+K.+Tsoumpraauthor=X.+Duanauthor=J.+T.+Triffittauthor=A.+A.+Kwaasiauthor=J.+E.+Dunfordauthor=B.+L.+Barnettauthor=U.+Oppermannauthor=M.+W.+Lundyauthor=A.+Boydeauthor=B.+A.+Kashemirovauthor=C.+E.+McKennaauthor=R.+G.+Russell&title=The+relationship+between+the+chemistry+and+biological+activity+of+the+bisphosphonates&doi=10.1016%2Fj.bone.2011.03.774"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The relationship between the chemistry and biological activity of the bisphosphonates</span></div><div class="casAuthors">Ebetino, Frank H.; Hogan, Anne-Marie L.; Sun, Shuting; Tsoumpra, Maria K.; Duan, Xuchen; Triffitt, James T.; Kwaasi, Aaron A.; Dunford, James E.; Barnett, Bobby L.; Oppermann, Udo; Lundy, Mark W.; Boyde, Alan; Kashemirov, Boris A.; McKenna, Charles E.; Russell, R. Graham G.</div><div class="citationInfo"><span class="NLM_cas:title">Bone (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-33</span>CODEN:
                <span class="NLM_cas:coden">BONEDL</span>;
        ISSN:<span class="NLM_cas:issn">8756-3282</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The ability of bisphosphonates ((HO)2P(O)CR1R2P(O)(OH)2) to inhibit bone resorption has been known since the 1960s, but it is only recently that a detailed mol. understanding of the relationship between chem. structures and biol. activity has begun to emerge.  The early development of chem. in this area was largely empirical and based on modifying R2 groups in a variety of ways.  Apart from the general ability of bisphosphonates to chelate Ca2+ and thus target the calcium phosphate mineral component of bone, attempts to refine clear structure-activity relationships had led to ambiguous or seemingly contradictory results.  However, there was increasing evidence for cellular effects, and eventually the earliest bisphosphonate drugs, such as clodronate (R1 = R2 = Cl) and etidronate (R1 = OH, R2 = CH3), were shown to exert intracellular actions via the formation in vivo of drug derivs. of ATP.  The observation that pamidronate, a bisphosphonate with R1 = OH and R2 = CH2CH2NH2, exhibited higher potency than previously known bisphosphonate drugs represented the first step towards the later recognition of the crit. importance of having nitrogen in the R2 side chain.  The synthesis and biol. evaluation of a large no. of nitrogen-contg. bisphosphonates took place particularly in the 1980s, but still with an incomplete understanding of their structure-activity relationships.  A major advance was the discovery that the anti-resorptive effects of the nitrogen-contg. bisphosphonates (including alendronate, risedronate, ibandronate, and zoledronate) on osteoclasts appear to result from their potency as inhibitors of the enzyme farnesyl pyrophosphate synthase (FPPS), a key branch-point enzyme in the mevalonate pathway.  FPPS generates isoprenoid lipids utilized in sterol synthesis and for the post-translational modification of small GTP-binding proteins essential for osteoclast function.  Effects on other cellular targets, such as osteocytes, may also be important.  Over the years many hundreds of bisphosphonates have been synthesized and studied.  Interest in expanding the structural scope of the bisphosphonate class has also motivated new approaches to the chem. synthesis of these compds.  Recent chem. innovations include the synthesis of fluorescently labeled bisphosphonates, which has enabled studies of the biodistribution of these drugs.  As a class, bisphosphonates share common properties.  However, as with other classes of drugs, there are chem., biochem., and pharmacol. differences among the individual compds.  Differences in mineral binding affinities among bisphosphonates influence their differential distribution within bone, their biol. potency, and their duration of action.  The overall pharmacol. effects of bisphosphonates on bone, therefore, appear to depend upon these two key properties of affinity for bone mineral and inhibitory effects on osteoclasts.  The relative contributions of these properties differ among individual bisphosphonates and help det. their clin. behavior and effectiveness.  This article is part of a Special Issue entitled Bisphosphonates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkW3DAKvbJe7Vg90H21EOLACvtfcHk0lhhFhdkEE9coQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsVSgsLk%253D&md5=0bba79f40512f2df89bd0ee36459e264</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bone.2011.03.774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bone.2011.03.774%26sid%3Dliteratum%253Aachs%26aulast%3DEbetino%26aufirst%3DF.%2BH.%26aulast%3DHogan%26aufirst%3DA.-M.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DTsoumpra%26aufirst%3DM.%2BK.%26aulast%3DDuan%26aufirst%3DX.%26aulast%3DTriffitt%26aufirst%3DJ.%2BT.%26aulast%3DKwaasi%26aufirst%3DA.%2BA.%26aulast%3DDunford%26aufirst%3DJ.%2BE.%26aulast%3DBarnett%26aufirst%3DB.%2BL.%26aulast%3DOppermann%26aufirst%3DU.%26aulast%3DLundy%26aufirst%3DM.%2BW.%26aulast%3DBoyde%26aufirst%3DA.%26aulast%3DKashemirov%26aufirst%3DB.%2BA.%26aulast%3DMcKenna%26aufirst%3DC.%2BE.%26aulast%3DRussell%26aufirst%3DR.%2BG.%26atitle%3DThe%2520relationship%2520between%2520the%2520chemistry%2520and%2520biological%2520activity%2520of%2520the%2520bisphosphonates%26jtitle%3DBone%26date%3D2011%26volume%3D49%26spage%3D20%26epage%3D33%26doi%3D10.1016%2Fj.bone.2011.03.774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodwell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkinshaw, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houston, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grieve, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett-Lee, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pugh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaunt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rea, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiley, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, R.</span></span> <span> </span><span class="NLM_article-title">Breast-cancer adjuvant therapy with zoledronic acid</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">1396</span>– <span class="NLM_lpage">1405</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1105195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1056%2FNEJMoa1105195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=21995387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlals7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2011&pages=1396-1405&author=R.+E.+Colemanauthor=H.+Marshallauthor=D.+Cameronauthor=D.+Dodwellauthor=R.+Burkinshawauthor=M.+Keaneauthor=M.+Gilauthor=S.+J.+Houstonauthor=R.+J.+Grieveauthor=P.+J.+Barrett-Leeauthor=D.+Ritchieauthor=J.+Pughauthor=C.+Gauntauthor=U.+Reaauthor=J.+Petersonauthor=C.+Daviesauthor=V.+Hileyauthor=W.+Gregoryauthor=R.+Bell&title=Breast-cancer+adjuvant+therapy+with+zoledronic+acid&doi=10.1056%2FNEJMoa1105195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Breast-cancer adjuvant therapy with zoledronic acid</span></div><div class="casAuthors">Coleman, Robert E.; Marshall, Helen; Cameron, David; Dodwell, David; Burkinshaw, Roger; Keane, Maccon; Gil, Miguel; Houston, Stephen.; Grieve, Robert J.; Barrett-Lee, Peter J.; Ritchie, Diana; Pugh, Julia; Gaunt, Claire; Rea, Una; Peterson, Jennifer; Davies, Claire; Hiley, Victoria; Gregory, Walter; Bell, Richard</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1396-1405</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Data suggest that the adjuvant use of bisphosphonates reduces rates of recurrence and death in patients with early-stage breast cancer.  We conducted a study to det. whether treatment with zoledronic acid, in addn. to std. adjuvant therapy, would improve disease outcomes in such patients.  METHODS: In this open-label phase 3 study, we randomly assigned 3360 patients to receive std. adjuvant systemic therapy either with or without zoledronic acid.  The zoledronic acid was administered every 3 to 4 wk for 6 doses and then every 3 to 6 mo to complete 5 years of treatment.  The primary end point of the study was disease-free survival.  A second interim anal. revealed that a prespecified boundary for lack of benefit had been crossed.  RESULTS: At a median follow-up of 59 mo, there was no significant between-group difference in the primary end point, with a rate of disease-free survival of 77% in each group (adjusted hazard ratio in the zoledronic acid group, 0.98; 95% confidence interval [CI], 0.85 to 1.13; P = 0.79). Disease recurrence or death occurred in 377 patients in the zoledronic acid group and 375 of those in the control group.  The nos. of deaths - 243 in the zoledronic acid group and 276 in the control group - were also similar, resulting in rates of overall survival of 85.4% in the zoledronic acid group and 83.1% in the control group (adjusted hazard ratio, 0.85; 95% CI, 0.72 to 1.01; P = 0.07).  In the zoledronic acid group, there were 17 confirmed cases of osteonecrosis of the jaw (cumulative incidence, 1.1%; 95% CI, 0.6 to 1.7; P < 0.001) and 9 suspected cases; there were no cases in the control group.  Rates of other adverse effects were similar in the two study groups.  CONCLUSIONS: These findings do not support the routine use of zoledronic acid in the adjuvant management of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpISmlJLPnAebVg90H21EOLACvtfcHk0lhhFhdkEE9coQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlals7jP&md5=3c61150ab39db154b5370ea59896c73f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1105195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1105195%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DR.%2BE.%26aulast%3DMarshall%26aufirst%3DH.%26aulast%3DCameron%26aufirst%3DD.%26aulast%3DDodwell%26aufirst%3DD.%26aulast%3DBurkinshaw%26aufirst%3DR.%26aulast%3DKeane%26aufirst%3DM.%26aulast%3DGil%26aufirst%3DM.%26aulast%3DHouston%26aufirst%3DS.%2BJ.%26aulast%3DGrieve%26aufirst%3DR.%2BJ.%26aulast%3DBarrett-Lee%26aufirst%3DP.%2BJ.%26aulast%3DRitchie%26aufirst%3DD.%26aulast%3DPugh%26aufirst%3DJ.%26aulast%3DGaunt%26aufirst%3DC.%26aulast%3DRea%26aufirst%3DU.%26aulast%3DPeterson%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DC.%26aulast%3DHiley%26aufirst%3DV.%26aulast%3DGregory%26aufirst%3DW.%26aulast%3DBell%26aufirst%3DR.%26atitle%3DBreast-cancer%2520adjuvant%2520therapy%2520with%2520zoledronic%2520acid%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D365%26spage%3D1396%26epage%3D1405%26doi%3D10.1056%2FNEJMoa1105195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gnant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mlineritsch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoeger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luschin-Ebengreuth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heck, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakesz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seifert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubalek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pristauz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauernhofer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eidtmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiermann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwasny, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochreiner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forsthuber, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fesl, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greil, R.</span></span> <span> </span><span class="NLM_article-title">Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">631</span>– <span class="NLM_lpage">641</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(11)70122-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1016%2FS1470-2045%2811%2970122-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=21641868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC3MXot1ejtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=631-641&author=M.+Gnantauthor=B.+Mlineritschauthor=H.+Stoegerauthor=G.+Luschin-Ebengreuthauthor=D.+Heckauthor=C.+Menzelauthor=R.+Jakeszauthor=M.+Seifertauthor=M.+Hubalekauthor=G.+Pristauzauthor=T.+Bauernhoferauthor=H.+Eidtmannauthor=W.+Eiermannauthor=G.+Stegerauthor=W.+Kwasnyauthor=P.+Dubskyauthor=G.+Hochreinerauthor=E.+P.+Forsthuberauthor=C.+Feslauthor=R.+Greil&title=Adjuvant+endocrine+therapy+plus+zoledronic+acid+in+premenopausal+women+with+early-stage+breast+cancer%3A+62-month+follow-up+from+the+ABCSG-12+randomised+trial&doi=10.1016%2FS1470-2045%2811%2970122-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial</span></div><div class="casAuthors">Gnant, Michael; Mlineritsch, Brigitte; Stoeger, Herbert; Luschin-Ebengreuth, Gero; Heck, Dietmar; Menzel, Christian; Jakesz, Raimund; Seifert, Michael; Hubalek, Michael; Pristauz, Gunda; Bauernhofer, Thomas; Eidtmann, Holger; Eiermann, Wolfgang; Steger, Guenther; Kwasny, Werner; Dubsky, Peter; Hochreiner, Gerhard; Forsthuber, Ernst-Pius; Fesl, Christian; Greil, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">631-641</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Anal. of the Austrian Breast and Colorectal Cancer Study Group trial-12 (ABCSG-12) at 48 mo' follow-up showed that addn. of zoledronic acid to adjuvant endocrine therapy significantly improved disease-free survival.  We have now assessed long-term clin. efficacy including disease-free survival and disease outcomes in patients receiving anastrozole or tamoxifen with or without zoledronic acid.  ABSCG-12 is a randomised, controlled, open-label, two-by-two factorial, multicentre trial in 1803 premenopausal women with endocrine-receptor-pos. early-stage (stage I-II) breast cancer receiving goserelin (3.6 mg every 28 days), comparing the efficacy and safety of anastrozole (1 mg per day) or tamoxifen (20 mg per day) with or without zoledronic acid (4 mg every 6 mo) for 3 years.  Randomisation (1:1:1:1 ratio) was computerized and based on the Pocock and Simon minimisation method to balance the four treatment arms across eight prognostic variables (age, neoadjuvant chemotherapy, pathol. tumor stage; lymph-node involvement, type of surgery or locoregional therapy, complete axillary dissection, intraoperative radiation therapy, and geog. region).  Treatment allocation was not masked.  The primary endpoint was disease-free survival (defined as disease recurrence or death) and anal. was by intention to treat.  This trial is registered with ClinicalTrials.gov, no. NCT00295646; follow-up is ongoing.  At a median follow-up of 62 mo (range 0-114.4 mo), more than 2 years after treatment completion, 186 disease-free survival events had been reported (53 events in 450 patients on tamoxifen alone, 57 in 453 patients on anastrozole alone, 36 in 450 patients on tamoxifen plus zoledronic acid, and 40 in 450 patients on anastrozole plus zoledronic acid).  Zoledronic acid reduced risk of disease-free survival events overall (HR 0.68, 95% CI 0.51-0.91; p=0.009), although the difference was not significant in the tamoxifen (HR 0.67, 95% CI 0.44-1.03; p=0.067) and anastrozole arms (HR 0.68, 95% CI 0.45-1.02; p=0.061) assessed sep.  Zoledronic acid did not significantly affect risk of death (30 deaths with zoledronic acid vs 43 deaths without; HR 0.67, 95% CI 0.41-1.07; p=0.09).  There was no difference in disease-free survival between patients on tamoxifen alone vs. anastrozole alone (HR 1.08, 95% CI 0.81-1.44; p=0.591), but overall survival was worse with anastrozole than with tamoxifen (46 vs 27 deaths; HR 1.75, 95% CI 1.08-2.83; p=0.02).  Treatments were generally well tolerated, with no reports of renal failure or osteonecrosis of the jaw.  Bone pain was reported in 601 patients (33%; 349 patients on zoledronic acid vs 252 not on the drug), fatigue in 361 (20%; 192 vs 169), headache in 280 (16%; 147 vs 133), and arthralgia in 266 (15%; 145 vs 121).  Addn. of zoledronic acid improved disease-free survival in the patients taking anastrozole or tamoxifen.  There was no difference in disease-free survival between patients receiving anastrozole and tamoxifen overall, but those on anastrozole alone had inferior overall survival.  These data show persistent benefits with zoledronic acid and support its addn. to adjuvant endocrine therapy in premenopausal patients with early-stage breast cancer.  Funding: AstraZeneca; Novartis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgMLLmua064rVg90H21EOLACvtfcHk0ljqtCPcXbF8Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXot1ejtLc%253D&md5=4755e1a85528b14accc4cc95bfa3d6b3</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2811%2970122-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252811%252970122-X%26sid%3Dliteratum%253Aachs%26aulast%3DGnant%26aufirst%3DM.%26aulast%3DMlineritsch%26aufirst%3DB.%26aulast%3DStoeger%26aufirst%3DH.%26aulast%3DLuschin-Ebengreuth%26aufirst%3DG.%26aulast%3DHeck%26aufirst%3DD.%26aulast%3DMenzel%26aufirst%3DC.%26aulast%3DJakesz%26aufirst%3DR.%26aulast%3DSeifert%26aufirst%3DM.%26aulast%3DHubalek%26aufirst%3DM.%26aulast%3DPristauz%26aufirst%3DG.%26aulast%3DBauernhofer%26aufirst%3DT.%26aulast%3DEidtmann%26aufirst%3DH.%26aulast%3DEiermann%26aufirst%3DW.%26aulast%3DSteger%26aufirst%3DG.%26aulast%3DKwasny%26aufirst%3DW.%26aulast%3DDubsky%26aufirst%3DP.%26aulast%3DHochreiner%26aufirst%3DG.%26aulast%3DForsthuber%26aufirst%3DE.%2BP.%26aulast%3DFesl%26aufirst%3DC.%26aulast%3DGreil%26aufirst%3DR.%26atitle%3DAdjuvant%2520endocrine%2520therapy%2520plus%2520zoledronic%2520acid%2520in%2520premenopausal%2520women%2520with%2520early-stage%2520breast%2520cancer%253A%252062-month%2520follow-up%2520from%2520the%2520ABCSG-12%2520randomised%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2011%26volume%3D12%26spage%3D631%26epage%3D641%26doi%3D10.1016%2FS1470-2045%2811%2970122-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gnant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mlineritsch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schippinger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luschin-Ebengreuth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pöstlberger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakesz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seifert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubalek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjelic-Radisic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samonigg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tausch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eidtmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwasny, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridrik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzal, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stierer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rücklinger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greil, R.</span></span> <span> </span><span class="NLM_article-title">Endocrine therapy plus zoledronic acid in premenopaisal breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">691</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa0806285</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1056%2FNEJMoa0806285" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=19213681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVyisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2009&pages=679-691&author=M.+Gnantauthor=B.+Mlineritschauthor=W.+Schippingerauthor=G.+Luschin-Ebengreuthauthor=S.+P%C3%B6stlbergerauthor=C.+Menzelauthor=R.+Jakeszauthor=M.+Seifertauthor=M.+Hubalekauthor=V.+Bjelic-Radisicauthor=H.+Samoniggauthor=C.+Tauschauthor=H.+Eidtmannauthor=G.+Stegerauthor=W.+Kwasnyauthor=P.+Dubskyauthor=M.+Fridrikauthor=F.+Fitzalauthor=M.+Stiererauthor=E.+R%C3%BCcklingerauthor=R.+Greil&title=Endocrine+therapy+plus+zoledronic+acid+in+premenopaisal+breast+cancer&doi=10.1056%2FNEJMoa0806285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Endocrine therapy plus zoledronic acid in premenopausal breast cancer</span></div><div class="casAuthors">Gnant, Michael; Mlineritsch, Brigitte; Schippinger, Walter; Luschin-Ebengreuth, Gero; Postlberger, Sabine; Menzel, Christian; Jakesz, Raimund; Seifert, Michael; Hubalek, Michael; Bjelic-Radisic, Vesna; Samonigg, Hellmut; Tausch, Christoph; Eidtmann, Holger; Steger, Gunther; Kwasny, Werner; Dubsky, Peter; Fridrik, Michael; Fitzal, Florian; Stierer, Michael; Rucklinger, Ernst; Greil, Richard</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">679-691</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Ovarian suppression plus tamoxifen is a std. adjuvant treatment in premenopausal women with endocrine-responsive breast cancer.  Aromatase inhibitors are superior to tamoxifen in postmenopausal patients, and preclin. data suggest that zoledronic acid has antitumor properties.  We examd. the effect of adding zoledronic acid to a combination of either goserelin and tamoxifen or goserelin and anastrozole in premenopausal women with endocrine-responsive early breast cancer.  We randomly assigned 1803 patients to receive goserelin (3.6 mg given s.c. every 28 days) plus tamoxifen (20 mg per day given orally) or anastrozole (1 mg per day given orally) with or without zoledronic acid (4 mg given i.v. every 6 mo) for 3 years.  The primary end point was disease-free survival; recurrence-free survival and overall survival were secondary end points.  After a median follow-up of 47.8 mo, 137 events had occurred, with disease-free survival rates of 92.8% in the tamoxifen group, 92.0% in the anastrozole group, 90.8% in the group that received endocrine therapy alone, and 94.0% in the group that received endocrine therapy with zoledronic acid.  There was no significant difference in disease-free survival between the anastrozole and tamoxifen groups (hazard ratio for disease progression in the anastrozole group, 1.10; 95% confidence interval [CI], 0.78 to 1.53; P = 0.59).  The addn. of zoledronic acid to endocrine therapy, as compared with endocrine therapy without zoledronic acid, resulted in an abs. redn. of 3.2 percentage points and a relative redn. of 36% in the risk of disease progression (hazard ratio, 0.64; 95% CI, 0.46 to 0.91; P = 0.01); the addn. of zoledronic acid did not significantly reduce the risk of death (hazard ratio, 0.60; 95% CI, 0.32 to 1.11; P = 0.11).  Adverse events were consistent with known drug-safety profiles.  The addn. of zoledronic acid to adjuvant endocrine therapy improves disease-free survival in premenopausal patients with estrogen-responsive early breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqWZL1vqoy7LVg90H21EOLACvtfcHk0ljqtCPcXbF8Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVyisbk%253D&md5=f2c9103a7cfd4b4d14bf30f8a2e679d7</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0806285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0806285%26sid%3Dliteratum%253Aachs%26aulast%3DGnant%26aufirst%3DM.%26aulast%3DMlineritsch%26aufirst%3DB.%26aulast%3DSchippinger%26aufirst%3DW.%26aulast%3DLuschin-Ebengreuth%26aufirst%3DG.%26aulast%3DP%25C3%25B6stlberger%26aufirst%3DS.%26aulast%3DMenzel%26aufirst%3DC.%26aulast%3DJakesz%26aufirst%3DR.%26aulast%3DSeifert%26aufirst%3DM.%26aulast%3DHubalek%26aufirst%3DM.%26aulast%3DBjelic-Radisic%26aufirst%3DV.%26aulast%3DSamonigg%26aufirst%3DH.%26aulast%3DTausch%26aufirst%3DC.%26aulast%3DEidtmann%26aufirst%3DH.%26aulast%3DSteger%26aufirst%3DG.%26aulast%3DKwasny%26aufirst%3DW.%26aulast%3DDubsky%26aufirst%3DP.%26aulast%3DFridrik%26aufirst%3DM.%26aulast%3DFitzal%26aufirst%3DF.%26aulast%3DStierer%26aufirst%3DM.%26aulast%3DR%25C3%25BCcklinger%26aufirst%3DE.%26aulast%3DGreil%26aufirst%3DR.%26atitle%3DEndocrine%2520therapy%2520plus%2520zoledronic%2520acid%2520in%2520premenopaisal%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D360%26spage%3D679%26epage%3D691%26doi%3D10.1056%2FNEJMoa0806285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Boer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eidtmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llombart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neven, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Minckwitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sleeboom, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forbes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrios, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frassoldati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paija, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bundred, N.</span></span> <span> </span><span class="NLM_article-title">Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): 60-months results</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">398</span>– <span class="NLM_lpage">405</span>, <span class="refDoi"> DOI: 10.1093/annonc/mds277</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1093%2Fannonc%2Fmds277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=23047045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A280%3ADC%252BC3s%252FjsFGjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=398-405&author=R.+E.+Colemanauthor=R.+de+Boerauthor=H.+Eidtmannauthor=A.+Llombartauthor=N.+Davidsonauthor=P.+Nevenauthor=G.+von+Minckwitzauthor=H.+P.+Sleeboomauthor=J.+Forbesauthor=C.+Barriosauthor=A.+Frassoldatiauthor=I.+Campbellauthor=O.+Paijaauthor=N.+Martinauthor=A.+Modiauthor=N.+Bundred&title=Zoledronic+acid+%28zoledronate%29+for+postmenopausal+women+with+early+breast+cancer+receiving+adjuvant+letrozole+%28ZO-FAST+study%29%3A+60-months+results&doi=10.1093%2Fannonc%2Fmds277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results</span></div><div class="casAuthors">Coleman R; de Boer R; Eidtmann H; Llombart A; Davidson N; Neven P; von Minckwitz G; Sleeboom H P; Forbes J; Barrios C; Frassoldati A; Campbell I; Paija O; Martin N; Modi A; Bundred N</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">398-405</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Aromatase inhibitors are the preferred adjuvant endocrine therapy for the majority of postmenopausal women with hormone-responsive early breast cancer.  Although generally more effective than tamoxifen, aromatase inhibitor therapy is associated with increased bone loss and fracture risk.  PATIENTS AND METHODS:  Postmenopausal women receiving adjuvant letrozole (2.5 mg/day for 5 years; N = 1065) were randomly assigned to immediate zoledronic acid (zoledronate) 4 mg every 6 months for 5 years, or delayed zoledronate (initiated for fracture or on-study bone mineral density [BMD] decrease).  The primary end point was the change in lumbar spine BMD at 12 months.  Lumbar spine and total hip BMD at subsequent follow-up, disease-free survival (DFS), and overall survival were assessed as secondary end points.  RESULTS:  At 60 months (final analysis), the mean change in lumbar spine BMD was +4.3% with immediate zoledronate and -5.4% with delayed intervention (P < 0.0001).  Immediate zoledronate reduced the risk of DFS events by 34% (hazard ratio [HR] = 0.66; P = 0.0375) with fewer local (0.9% versus 2.3%) and distant (5.5% versus 7.7%) recurrences versus delayed zoledronate.  In the delayed group, delayed initiation of zoledronate substantially improved DFS versus no zoledronate (HR = 0.46; P = 0.0334).  CONCLUSIONS:  Immediate zoledronate in postmenopausal women receiving letrozole preserved BMD and is associated with improved DFS compared with letrozole alone.  Clinical Trials Registration No NCT00171340.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSrF__4n9ssxlHFYivNCdPRfW6udTcc2ebs6LU4ioSIArntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s%252FjsFGjsg%253D%253D&md5=8c3ee5dd7ea24a157be353eca918044e</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmds277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmds277%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DR.%2BE.%26aulast%3Dde%2BBoer%26aufirst%3DR.%26aulast%3DEidtmann%26aufirst%3DH.%26aulast%3DLlombart%26aufirst%3DA.%26aulast%3DDavidson%26aufirst%3DN.%26aulast%3DNeven%26aufirst%3DP.%26aulast%3Dvon%2BMinckwitz%26aufirst%3DG.%26aulast%3DSleeboom%26aufirst%3DH.%2BP.%26aulast%3DForbes%26aufirst%3DJ.%26aulast%3DBarrios%26aufirst%3DC.%26aulast%3DFrassoldati%26aufirst%3DA.%26aulast%3DCampbell%26aufirst%3DI.%26aulast%3DPaija%26aufirst%3DO.%26aulast%3DMartin%26aufirst%3DN.%26aulast%3DModi%26aufirst%3DA.%26aulast%3DBundred%26aufirst%3DN.%26atitle%3DZoledronic%2520acid%2520%2528zoledronate%2529%2520for%2520postmenopausal%2520women%2520with%2520early%2520breast%2520cancer%2520receiving%2520adjuvant%2520letrozole%2520%2528ZO-FAST%2520study%2529%253A%252060-months%2520results%26jtitle%3DAnn.%2520Oncol.%26date%3D2013%26volume%3D24%26spage%3D398%26epage%3D405%26doi%3D10.1093%2Fannonc%2Fmds277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocks, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szubert, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro-Coy, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drayson, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feyler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashcroft, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roddie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Child, J. A.</span></span> <span> </span><span class="NLM_article-title">First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomized controlled trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">1989</span>– <span class="NLM_lpage">1999</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(10)62051-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1016%2FS0140-6736%2810%2962051-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=21131037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFCqsLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2010&pages=1989-1999&author=G.+J.+Morganauthor=F.+E.+Daviesauthor=W.+M.+Gregoryauthor=K.+Cocksauthor=S.+E.+Bellauthor=A.+J.+Szubertauthor=N.+Navarro-Coyauthor=M.+T.+Draysonauthor=R.+G.+Owenauthor=S.+Feylerauthor=A.+J.+Ashcroftauthor=F.+Rossauthor=J.+Byrneauthor=H.+Roddieauthor=C.+Rudinauthor=G.+Cookauthor=G.+H.+Jacksonauthor=J.+A.+Child&title=First-line+treatment+with+zoledronic+acid+as+compared+with+clodronic+acid+in+multiple+myeloma+%28MRC+Myeloma+IX%29%3A+a+randomized+controlled+trial&doi=10.1016%2FS0140-6736%2810%2962051-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial</span></div><div class="casAuthors">Morgan, Gareth J.; Davies, Faith E.; Gregory, Walter M.; Cocks, Kim; Bell, Sue E.; Szubert, Alex J.; Navarro-Coy, Nuria; Drayson, Mark T.; Owen, Roger G.; Feyler, Sylvia; Ashcroft, A. John; Ross, Fiona; Byrne, Jennifer; Roddie, Huw; Rudin, Claudius; Cook, Gordon; Jackson, Graham H.; Child, J. Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">9757</span>),
    <span class="NLM_cas:pages">1989-1999</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Bisphosphonates reduce the risk of skeletal events in patients with malignant bone disease, and zoledronic acid has shown potential anticancer effects in preclin. and clin. studies.  We aimed to establish whether bisphosphonates can affect clin. outcomes in patients with multiple myeloma.  Patients of age 18 years or older with newly diagnosed multiple myeloma were enrolled from 120 centers in the UK.  Computer-generated randomisation sequence was used to allocate patients equally, via an automated telephone service, to receive 4 mg zoledronic acid as an infusion every 3-4 wk or 1600 mg oral clodronic acid daily.  Patients also received intensive or non-intensive induction chemotherapy.  No investigators, staff, or patients were masked to treatment allocation, and bisphosphonate and maintenance therapy continued at least until disease progression.  The primary endpoints were overall survival, progression-free survival, and overall response rate.  We assessed between-group differences with Cox proportional hazards models for progression-free survival and overall survival, and with logistic regression models for overall response rate.  Anal. was by intention to treat.  This trial is registered, no. ISRCTN68454111.  1970 patients were enrolled between May, 2003, and Nov., 2007, of whom 1960 were eligible for intention-to-treat anal.: 981 in the zoledronic acid group (555 on intensive chemotherapy, 426 on non-intensive chemotherapy); and 979 on clodronic acid (556 on intensive chemotherapy, 423 on non-intensive chemotherapy).  The treatment cutoff was Oct 5, 2009, with patients receiving bisphosphonates for a median of 350 days (IQR 137-632) before disease progression, with a median of 3.7 years' follow-up (IQR 2.9-4.7).  Zoledronic acid reduced mortality by 16% (95% CI 4-26) vs. clodronic acid (hazard ratio [HR] 0.84, 95% CI 0.74-0.96; p=0.0118), and extended median overall survival by 5.5 mo (50.0 mo, IQR 21.0 to not reached vs 44.5 mo, IQR 16.5 to not reached; p=0.04).  Zoledronic acid also significantly improved progression-free survival by 12% (95% CI 2-20) vs. clodronic acid (HR 0.88, 95% CI 0.80-0.98; p=0.0179), and increased median progression-free survival by 2.0 mo (19.5 mo, IQR 9.0-38.0 vs 17.5 mo, IQR 8.5-34.0; p=0.07).  Rates of complete, very good partial, or partial response did not differ significantly between the zoledronic acid and clodronic acid groups for patients receiving intensive induction chemotherapy (432 patients [78%] vs 422 [76%]; p=0.43) or non-intensive induction chemotherapy (215 [50%] vs 195 [46%]; p=0.18).  Both bisphosphonates were generally well tolerated, with similar occurrence of acute renal failure and treatment-emergent serious adverse events, but zoledronic acid was assocd. with higher rates of confirmed osteonecrosis of the jaw (35 [4%]) than was clodronic acid (3 [<1%]).  Consistent with the potential anticancer activity of zoledronic acid, overall survival improved independently of prevention of skeletal-related events, showing that zoledronic acid has treatment benefits beyond bone health.  These findings support immediate treatment with zoledronic acid in patients with newly diagnosed multiple myeloma, not only for prevention of skeletal-related events, but also for potential antimyeloma benefits.  Funding: Medical Research Council (London, UK), with unrestricted educational grants from Novartis, Schering Health Care, Chugai, Pharmion, Celgene, and Ortho Biotech.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXS5ilaeyX3rVg90H21EOLACvtfcHk0liO_2Buq2gUAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFCqsLnL&md5=53e25efc3a82b57d286c73f7fba6a611</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2810%2962051-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252810%252962051-X%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DG.%2BJ.%26aulast%3DDavies%26aufirst%3DF.%2BE.%26aulast%3DGregory%26aufirst%3DW.%2BM.%26aulast%3DCocks%26aufirst%3DK.%26aulast%3DBell%26aufirst%3DS.%2BE.%26aulast%3DSzubert%26aufirst%3DA.%2BJ.%26aulast%3DNavarro-Coy%26aufirst%3DN.%26aulast%3DDrayson%26aufirst%3DM.%2BT.%26aulast%3DOwen%26aufirst%3DR.%2BG.%26aulast%3DFeyler%26aufirst%3DS.%26aulast%3DAshcroft%26aufirst%3DA.%2BJ.%26aulast%3DRoss%26aufirst%3DF.%26aulast%3DByrne%26aufirst%3DJ.%26aulast%3DRoddie%26aufirst%3DH.%26aulast%3DRudin%26aufirst%3DC.%26aulast%3DCook%26aufirst%3DG.%26aulast%3DJackson%26aufirst%3DG.%2BH.%26aulast%3DChild%26aufirst%3DJ.%2BA.%26atitle%3DFirst-line%2520treatment%2520with%2520zoledronic%2520acid%2520as%2520compared%2520with%2520clodronic%2520acid%2520in%2520multiple%2520myeloma%2520%2528MRC%2520Myeloma%2520IX%2529%253A%2520a%2520randomized%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2010%26volume%3D376%26spage%3D1989%26epage%3D1999%26doi%3D10.1016%2FS0140-6736%2810%2962051-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szubert, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drayson, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashcroft, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Child, J. A.</span></span> <span> </span><span class="NLM_article-title">Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">5374</span>– <span class="NLM_lpage">5383</span>, <span class="refDoi"> DOI: 10.1182/blood-2011-11-392522</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1182%2Fblood-2011-11-392522" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=22498739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFantLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2012&pages=5374-5383&author=G.+J.+Morganauthor=F.+E.+Daviesauthor=W.+M.+Gregoryauthor=A.+J.+Szubertauthor=S.+E.+Bellauthor=M.+T.+Draysonauthor=R.+G.+Owenauthor=A.+J.+Ashcroftauthor=G.+H.+Jacksonauthor=J.+A.+Child&title=Effects+of+induction+and+maintenance+plus+long-term+bisphosphonates+on+bone+disease+in+patients+with+multiple+myeloma%3A+the+Medical+Research+Council+Myeloma+IX+Trial&doi=10.1182%2Fblood-2011-11-392522"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial</span></div><div class="casAuthors">Morgan, Gareth J.; Davies, Faith E.; Gregory, Walter M.; Szubert, Alex J.; Bell, Sue E.; Drayson, Mark T.; Owen, Roger G.; Ashcroft, A. John; Jackson, Graham H.; Child, J. Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5374-5383</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The Medical Research Council Myeloma IX Trial (ISRCTNG8454111) examd. traditional and thalidomide-based induction and maintenance regimens and IV zoledronic acid (ZOL) and oral clodronate (CLO) in 1960 patients with newly diagnosed multiple myeloma.  Overall survival (OS) and skeletal-related event (SRE) data have been reported for the overall trial population.  The present anal. investigated optimal therapy regimens for different patient populations in Myeloma IX.  Patients were assigned to intensive or nonintensive treatment pathways and randomized to induction cyclophosphamide, vincristine, doxorubicin, and dexamethasone (CVAD) vs. cyclophosphamide, thalidomide, and dexamethasone (CTD; intensive) or melphalan and prednisolone vs. attenuated oral CTD (CTDa; nonintensive).  Patients were also randomized to ZOL or CLO.  In the nonintensive pathway, CTDa produced better responses and lower SRE rates than melphalan and prednisolone.  ZOL improved OS compared with CLO independently of sex, stage, or myeloma subtype, most profoundly in patients with baseline bone disease or other SREs.  In patients treated for ≥ 2 years, ZOL improved OS compared with CLO from randomization (median not reached for either; P = .02) and also from first on-study disease progression (median, 34 mo for ZOL vs 27 mo for CLO; P = .03).  Thalidomide-contg. regimens had better efficacy than traditional regimens, and ZOL demonstrated greater benefits than CLO.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn6bsYwhGflrVg90H21EOLACvtfcHk0liO_2Buq2gUAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFantLg%253D&md5=b908fa4236bbad0d7585647e43a02fbf</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-11-392522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-11-392522%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DG.%2BJ.%26aulast%3DDavies%26aufirst%3DF.%2BE.%26aulast%3DGregory%26aufirst%3DW.%2BM.%26aulast%3DSzubert%26aufirst%3DA.%2BJ.%26aulast%3DBell%26aufirst%3DS.%2BE.%26aulast%3DDrayson%26aufirst%3DM.%2BT.%26aulast%3DOwen%26aufirst%3DR.%2BG.%26aulast%3DAshcroft%26aufirst%3DA.%2BJ.%26aulast%3DJackson%26aufirst%3DG.%2BH.%26aulast%3DChild%26aufirst%3DJ.%2BA.%26atitle%3DEffects%2520of%2520induction%2520and%2520maintenance%2520plus%2520long-term%2520bisphosphonates%2520on%2520bone%2520disease%2520in%2520patients%2520with%2520multiple%2520myeloma%253A%2520the%2520Medical%2520Research%2520Council%2520Myeloma%2520IX%2520Trial%26jtitle%3DBlood%26date%3D2012%26volume%3D119%26spage%3D5374%26epage%3D5383%26doi%3D10.1182%2Fblood-2011-11-392522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skerjanec, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berenson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Major, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. H.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schran, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seaman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldmeier, F.</span></span> <span> </span><span class="NLM_article-title">The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">154</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1177/0091270002239824</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1177%2F0091270002239824" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=12616668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD3sXht1eqsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2003&pages=154-162&author=A.+Skerjanecauthor=J.+Berensonauthor=C.+Hsuauthor=P.+Majorauthor=W.+H.+Millerauthor=C.+Raveraauthor=H.+Schranauthor=J.+Seamanauthor=F.+Waldmeier&title=The+pharmacokinetics+and+pharmacodynamics+of+zoledronic+acid+in+cancer+patients+with+varying+degrees+of+renal+function&doi=10.1177%2F0091270002239824"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function</span></div><div class="casAuthors">Skerjanec, Andrej; Berenson, James; Hsu, ChyiHung; Major, Pierre; Miller, Wilson H., Jr.; Ravera, Christina; Schran, Horst; Seaman, John; Waldmeier, Felix</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">154-162</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">An open-label pharmacokinetic and pharmacodynamic study of zoledronic acid (Zometa) was performed in 19 cancer patients with bone metastases and known, varying levels of renal function.  Patients were stratified according to creatinine clearance (CLcr) into different groups of normal (CLcr > 80 mL/min), mildly (CLcr = 50-80 mL/min), or moderately/severely impaired (CLcr = 10-50 mL/min) renal function.  Three i.v. infusions of 4 mg zoledronic acid were administered at 1-mo intervals between doses.  Plasma concns. and amts. excreted in urine were detd. in all subjects, and 4 patients were administered 14C-labeled zoledronic acid to assess excretion and distribution of drug in whole blood.  In general, the drug was well tolerated by the patients.  Mean area under the plasma concn. vs. time curve and mean concn. immediately after cessation of drug infusion were lower, and mean amts. excreted in urine over 24 h from start of infusion were higher in normal subjects than in those with impaired renal function (36% vs. 28% of excreted dose), although the differences were not significant.  Furthermore, with repeated doses, there was no evidence of drug accumulation in plasma or changes in drug exposure in any of the groups, nor was there any evidence of changes in renal function status.  Serum levels of markers of bone resorption (serum C-telopeptide and N-telopeptide) were noticeably reduced after each dose of zoledronic acid across all three renal groups.  It was concluded that in patients with mildly to moderately reduced renal function, dosage adjustment of zoledronic acid is likely not necessary.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVyx9dbcD7JbVg90H21EOLACvtfcHk0lg0uGCLqZ6Y-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXht1eqsLo%253D&md5=48a5725e25414d6532f3f7d68ffbbd76</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1177%2F0091270002239824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270002239824%26sid%3Dliteratum%253Aachs%26aulast%3DSkerjanec%26aufirst%3DA.%26aulast%3DBerenson%26aufirst%3DJ.%26aulast%3DHsu%26aufirst%3DC.%26aulast%3DMajor%26aufirst%3DP.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26aulast%3DRavera%26aufirst%3DC.%26aulast%3DSchran%26aufirst%3DH.%26aulast%3DSeaman%26aufirst%3DJ.%26aulast%3DWaldmeier%26aufirst%3DF.%26atitle%3DThe%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520zoledronic%2520acid%2520in%2520cancer%2520patients%2520with%2520varying%2520degrees%2520of%2520renal%2520function%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2003%26volume%3D43%26spage%3D154%26epage%3D162%26doi%3D10.1177%2F0091270002239824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfaar, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweitzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiegand, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skerjanec, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schran, H.</span></span> <span> </span><span class="NLM_article-title">Biodistribution and plasma protein binding of zoledronic acid</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">2043</span>– <span class="NLM_lpage">2049</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.021071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1124%2Fdmd.108.021071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=18625688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtF2jtLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=2043-2049&author=H.+M.+Weissauthor=U.+Pfaarauthor=A.+Schweitzerauthor=H.+Wiegandauthor=A.+Skerjanecauthor=H.+Schran&title=Biodistribution+and+plasma+protein+binding+of+zoledronic+acid&doi=10.1124%2Fdmd.108.021071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Biodistribution and plasma protein binding of zoledronic acid</span></div><div class="casAuthors">Weiss, H. Markus; Pfaar, Ulrike; Schweitzer, Alain; Wiegand, Hansjorg; Skerjanec, Andrej; Schran, Horst</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2043-2049</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The bisphosphonate zoledronic acid is a potent inhibitor of osteoclast-mediated bone resorption.  To investigate drug biodistribution and elimination, 14C-zoledronic acid was administered i.v. to rats and dogs in single or multiple doses and assessed for its in vitro blood distribution and plasma protein binding in rat, dog, and human.  Drug exposure in plasma, bones, and noncalcified tissues was investigated up to 240 days in rats and 96 h in dogs using radiometry after dissection.  Drug biodistribution in the rat and within selected bones from dog was assessed by autoradiog.  Concns. of radioactivity showed a rapid decline in plasma and noncalcified tissue but only a slow decline in bone, to ∼50% of peak at 240 days post dose, whereas the terminal half-lives (50-200 days) were similar in bone and noncalcified tissues, suggesting redistribution of drug from the former rather than prolonged retention in the latter.  Uptake was highest in cancellous bone and axial skeleton.  At 96 h after dose, the fraction of dose excreted was 36% in rat and 60% in dog; 94 to 96% of the excreted radioactivity was found in urine.  Blood/plasma concn. ratios were 0.52 to 0.59, and plasma protein binding of zoledronic acid was moderate to low in all species.  The results suggest that a fraction of zoledronic acid is reversibly taken up by the skeleton, the elimination of drug is mainly by renal excretion, and the disposition in blood and noncalcified tissue is governed by extensive uptake into and slow release from bone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhdoRU-4CE8bVg90H21EOLACvtfcHk0lg0uGCLqZ6Y-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtF2jtLbF&md5=50e294a82b4649e2951f759d4788c7f8</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.021071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.021071%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DH.%2BM.%26aulast%3DPfaar%26aufirst%3DU.%26aulast%3DSchweitzer%26aufirst%3DA.%26aulast%3DWiegand%26aufirst%3DH.%26aulast%3DSkerjanec%26aufirst%3DA.%26aulast%3DSchran%26aufirst%3DH.%26atitle%3DBiodistribution%2520and%2520plasma%2520protein%2520binding%2520of%2520zoledronic%2520acid%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26spage%3D2043%26epage%3D2049%26doi%3D10.1124%2Fdmd.108.021071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rondeau, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotesta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzinzik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellé, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geiser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strauss, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Götte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitsch, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemmig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glickman, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roddy, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stout, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J. R.</span></span> <span> </span><span class="NLM_article-title">Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">660</span>– <span class="NLM_lpage">666</span>, <span class="refDoi"> DOI: 10.1038/nchembio.421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1038%2Fnchembio.421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=20711197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVaisLzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=660-666&author=W.+Jahnkeauthor=J.-M.+Rondeauauthor=S.+Cotestaauthor=A.+Marzinzikauthor=X.+Pell%C3%A9author=M.+Geiserauthor=A.+Straussauthor=M.+G%C3%B6tteauthor=F.+Bitschauthor=R.+Hemmigauthor=C.+Henryauthor=S.+Lehmannauthor=J.+F.+Glickmanauthor=T.+P.+Roddyauthor=S.+J.+Stoutauthor=J.+R.+Green&title=Allosteric+non-bisphosphonate+FPPS+inhibitors+identified+by+fragment-based+discovery&doi=10.1038%2Fnchembio.421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery</span></div><div class="casAuthors">Jahnke, Wolfgang; Rondeau, Jean-Michel; Cotesta, Simona; Marzinzik, Andreas; Pelle, Xavier; Geiser, Martin; Strauss, Andre; Goette, Marjo; Bitsch, Francis; Hemmig, Rene; Henry, Chrystele; Lehmann, Sylvie; Glickman, J. Fraser; Roddy, Thomas P.; Stout, Steven J.; Green, Jonathan R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">660-666</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bisphosphonates are potent inhibitors of farnesyl pyrophosphate synthase (FPPS) and are highly efficacious in the treatment of bone diseases such as osteoporosis, Paget's disease and tumor-induced osteolysis.  In addn., the potential for direct antitumor effects has been postulated on the basis of in vitro and in vivo studies and has recently been demonstrated clin. in early breast cancer patients treated with the potent bisphosphonate zoledronic acid.  However, the high affinity of bisphosphonates for bone mineral seems suboptimal for the direct treatment of soft-tissue tumors.  Here we report the discovery of the first potent non-bisphosphonate FPPS inhibitors.  These new inhibitors bind to a previously unknown allosteric site on FPPS, which was identified by fragment-based approaches using NMR and X-ray crystallog.  This allosteric and druggable pocket allows the development of a new generation of FPPS inhibitors that are optimized for direct antitumor effects in soft tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZFyA6x-XeY7Vg90H21EOLACvtfcHk0lg0uGCLqZ6Y-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVaisLzO&md5=72e1bc45a05733c2748a2138d0e0824f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.421%26sid%3Dliteratum%253Aachs%26aulast%3DJahnke%26aufirst%3DW.%26aulast%3DRondeau%26aufirst%3DJ.-M.%26aulast%3DCotesta%26aufirst%3DS.%26aulast%3DMarzinzik%26aufirst%3DA.%26aulast%3DPell%25C3%25A9%26aufirst%3DX.%26aulast%3DGeiser%26aufirst%3DM.%26aulast%3DStrauss%26aufirst%3DA.%26aulast%3DG%25C3%25B6tte%26aufirst%3DM.%26aulast%3DBitsch%26aufirst%3DF.%26aulast%3DHemmig%26aufirst%3DR.%26aulast%3DHenry%26aufirst%3DC.%26aulast%3DLehmann%26aufirst%3DS.%26aulast%3DGlickman%26aufirst%3DJ.%2BF.%26aulast%3DRoddy%26aufirst%3DT.%2BP.%26aulast%3DStout%26aufirst%3DS.%2BJ.%26aulast%3DGreen%26aufirst%3DJ.%2BR.%26atitle%3DAllosteric%2520non-bisphosphonate%2520FPPS%2520inhibitors%2520identified%2520by%2520fragment-based%2520discovery%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D6%26spage%3D660%26epage%3D666%26doi%3D10.1038%2Fnchembio.421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Schutter, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gormley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berghuis, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poirier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsantrizos, Y. S.</span></span> <span> </span><span class="NLM_article-title">Multistage screening reveals chameleon ligands of human farnesyl pyrophosphate synthase: Implications to drug discovery for neurodegenerative diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5764</span>– <span class="NLM_lpage">5776</span>, <span class="refDoi"> DOI: 10.1021/jm500629e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500629e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5764-5776&author=J.+W.+De%0ASchutterauthor=J.+Parkauthor=C.+Y.+Leungauthor=P.+Gormleyauthor=Y.+S.+Linauthor=Z.+Huauthor=A.+M.+Berghuisauthor=J.+Poirierauthor=Y.+S.+Tsantrizos&title=Multistage+screening+reveals+chameleon+ligands+of+human+farnesyl+pyrophosphate+synthase%3A+Implications+to+drug+discovery+for+neurodegenerative+diseases&doi=10.1021%2Fjm500629e"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm500629e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500629e%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSchutter%26aufirst%3DJ.%2BW.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DLeung%26aufirst%3DC.%2BY.%26aulast%3DGormley%26aufirst%3DP.%26aulast%3DLin%26aufirst%3DY.%2BS.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DBerghuis%26aufirst%3DA.%2BM.%26aulast%3DPoirier%26aufirst%3DJ.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26atitle%3DMultistage%2520screening%2520reveals%2520chameleon%2520ligands%2520of%2520human%2520farnesyl%2520pyrophosphate%2520synthase%253A%2520Implications%2520to%2520drug%2520discovery%2520for%2520neurodegenerative%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5764%26epage%3D5776%26doi%3D10.1021%2Fjm500629e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marzinzik, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amstutz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bold, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourgier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotesta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glickman, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Götte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartwieg, J. C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ofner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellé, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roddy, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rondeau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stout, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel allostetic non-bisphosphonate inhibitors of farnesyl pyrophosphate synthase by integrated lead finding</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1884</span>– <span class="NLM_lpage">1891</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1002%2Fcmdc.201500338" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1884-1891&author=A.+L.+Marzinzikauthor=R.+Amstutzauthor=G.+Boldauthor=E.+Bourgierauthor=S.+Cotestaauthor=J.+F.+Glickmanauthor=M.+G%C3%B6tteauthor=C.+Henryauthor=S.+Lehmannauthor=J.+C.+D.+Hartwiegauthor=S.+Ofnerauthor=X.+Pell%C3%A9author=T.+P.+Roddyauthor=M.+Rondeauauthor=F.+Staufferauthor=S.+J.+Stoutauthor=A.+Widmerauthor=J.+Zimmermannauthor=T.+Zollerauthor=W.+Jahnke&title=Discovery+of+novel+allostetic+non-bisphosphonate+inhibitors+of+farnesyl+pyrophosphate+synthase+by+integrated+lead+finding&doi=10.1002%2Fcmdc.201500338"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500338%26sid%3Dliteratum%253Aachs%26aulast%3DMarzinzik%26aufirst%3DA.%2BL.%26aulast%3DAmstutz%26aufirst%3DR.%26aulast%3DBold%26aufirst%3DG.%26aulast%3DBourgier%26aufirst%3DE.%26aulast%3DCotesta%26aufirst%3DS.%26aulast%3DGlickman%26aufirst%3DJ.%2BF.%26aulast%3DG%25C3%25B6tte%26aufirst%3DM.%26aulast%3DHenry%26aufirst%3DC.%26aulast%3DLehmann%26aufirst%3DS.%26aulast%3DHartwieg%26aufirst%3DJ.%2BC.%2BD.%26aulast%3DOfner%26aufirst%3DS.%26aulast%3DPell%25C3%25A9%26aufirst%3DX.%26aulast%3DRoddy%26aufirst%3DT.%2BP.%26aulast%3DRondeau%26aufirst%3DM.%26aulast%3DStauffer%26aufirst%3DF.%26aulast%3DStout%26aufirst%3DS.%2BJ.%26aulast%3DWidmer%26aufirst%3DA.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DZoller%26aufirst%3DT.%26aulast%3DJahnke%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520novel%2520allostetic%2520non-bisphosphonate%2520inhibitors%2520of%2520farnesyl%2520pyrophosphate%2520synthase%2520by%2520integrated%2520lead%2520finding%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D1884%26epage%3D1891%26doi%3D10.1002%2Fcmdc.201500338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matralis, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacbay, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsakos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez De Troconiz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berghuis, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsantrizos, Y. S.</span></span> <span> </span><span class="NLM_article-title">Pharmacophore mapping of thienopyrimidine-based monophosphonate (ThP-MP) inhibitors of the human farnesyl pyrophosphate synthase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2119</span>– <span class="NLM_lpage">2134</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01888</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01888" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC2sXivFSru74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2119-2134&author=J.+Parkauthor=C.+Y.+Leungauthor=A.+N.+Matralisauthor=C.+M.+Lacbayauthor=M.+Tsakosauthor=G.+Fernandez+De+Troconizauthor=A.+M.+Berghuisauthor=Y.+S.+Tsantrizos&title=Pharmacophore+mapping+of+thienopyrimidine-based+monophosphonate+%28ThP-MP%29+inhibitors+of+the+human+farnesyl+pyrophosphate+synthase&doi=10.1021%2Facs.jmedchem.6b01888"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacophore Mapping of Thienopyrimidine-Based Monophosphonate (ThP-MP) Inhibitors of the Human Farnesyl Pyrophosphate Synthase</span></div><div class="casAuthors">Park, Jaeok; Leung, Chun Yuen; Matralis, Alexios N.; Lacbay, Cyrus M.; Tsakos, Michail; Fernandez De Troconiz, Guillermo; Berghuis, Albert M.; Tsantrizos, Youla S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2119-2134</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The human farnesyl pyrophosphate synthase (hFPPS), a key regulatory enzyme in the mevalonate pathway, catalyzes the biosynthesis of the C-15 isoprenoid farnesyl pyrophosphate (FPP).  FPP plays a crucial role in the post-translational prenylation of small GTPases that perform a plethora of cellular functions.  Although hFPPS is a well-established therapeutic target for lytic bone diseases, the currently available bisphosphonate drugs exhibit poor cellular uptake and distribution into non-skeletal tissues.  Recent drug discovery efforts have focused primarily on allosteric inhibition of hFPPS and the discovery of non-bisphosphonate drugs for potentially treating non-skeletal diseases.  Hit-to-lead optimization of a new series of thienopyrimidine-based monosphosphonates (ThP-MPs) led to the identification of analogs with nanomolar potency in inhibiting hFPPS.  Their interactions with the allosteric pocket of the enzyme were characterized by crystallog. and the results provide further insight into the pharmacophore requirements for allosteric inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyhrW7fwd66bVg90H21EOLACvtfcHk0liZjMTDH7TX8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXivFSru74%253D&md5=ac44083a7b20a199cd1cfb59bec71be1</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01888%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DLeung%26aufirst%3DC.%2BY.%26aulast%3DMatralis%26aufirst%3DA.%2BN.%26aulast%3DLacbay%26aufirst%3DC.%2BM.%26aulast%3DTsakos%26aufirst%3DM.%26aulast%3DFernandez%2BDe%2BTroconiz%26aufirst%3DG.%26aulast%3DBerghuis%26aufirst%3DA.%2BM.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26atitle%3DPharmacophore%2520mapping%2520of%2520thienopyrimidine-based%2520monophosphonate%2520%2528ThP-MP%2529%2520inhibitors%2520of%2520the%2520human%2520farnesyl%2520pyrophosphate%2520synthase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2119%26epage%3D2134%26doi%3D10.1021%2Facs.jmedchem.6b01888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lobell, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buser, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davide, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePuy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblan, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motzel, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbruzzese, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowinsky, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deutsch, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazina, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildonger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, S.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohl, N. E.</span></span> <span> </span><span class="NLM_article-title">Preclinical and clinical pharmacodynamic assessment of L-778, 123, a dual inhibitor of farnesyl:protein transfgerase and geranylgeranyl:ptotein tansferase type-I</span>. <i>Mol. Cancer Ther</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">747</span>– <span class="NLM_lpage">758</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=12479371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsFSmtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=747-758&author=R.+B.+Lobellauthor=D.+Liuauthor=C.+A.+Buserauthor=J.+P.+Davideauthor=E.+DePuyauthor=K.+Hamiltonauthor=K.+S.+Koblanauthor=Y.+Leeauthor=S.+Mosserauthor=S.+L.+Motzelauthor=J.+L.+Abbruzzeseauthor=C.+S.+Fuchsauthor=E.+K.+Rowinskyauthor=E.+H.+Rubinauthor=S.+Sharmaauthor=P.+J.+Deutschauthor=K.+E.+Mazinaauthor=B.+W.+Morrisonauthor=L.+Wildongerauthor=S.-L.+Yaoauthor=N.+E.+Kohl&title=Preclinical+and+clinical+pharmacodynamic+assessment+of+L-778%2C+123%2C+a+dual+inhibitor+of+farnesyl%3Aprotein+transfgerase+and+geranylgeranyl%3Aptotein+tansferase+type-I"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I</span></div><div class="casAuthors">Lobell, Robert B.; Liu, Dongming; Buser, Carolyn A.; Davide, Joseph P.; DePuy, Elizabeth; Hamilton, Kelly; Koblan, Kenneth S.; Lee, Yih; Mosser, Scott; Motzel, Sherri L.; Abbruzzese, James L.; Fuchs, Charles S.; Rowinsky, Eric K.; Rubin, Eric H.; Sharma, Sunil; Deutsch, Paul J.; Mazina, Kathryn E.; Morrison, Briggs W.; Wildonger, Lynne; Yao, Siu-Long; Kohl, Nancy E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">747-758</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Farnesyl:protein transferase (FPTase) inhibitors were developed as anti-Ras drugs, but they fail to inhibit Ki-Ras activity because Ki-Ras can be modified by geranylgeranyl:protein transferase type-I (GGPTase-I).  L-778,123, an inhibitor of FPTase and GGPTase-I, was developed in part because it can completely inhibit Ki-Ras prenylation.  To support the clin. development of L-778,123, we developed pharmacodynamic assays using peripheral blood mononuclear cells (PBMCs) to measure the inhibition of prenylation of HDJ2 and Rap1A, proteins that are FPTase- and GGPTase-I substrates, resp.  We validated these assays in animal models and show that inhibition of HDJ2 prenylation in mouse PBMCs correlates with the concn. of FPTase inhibitors in blood.  In dogs, continuous infusion of L-778,123 inhibited both HDJ2 and Rap1A prenylation in PBMCs, but we did not detect inhibition of Ki-Ras prenylation.  We reported previously results from the first L-778,123 Phase I trial that showed a dose-dependent inhibition of HDJ2 farnesylation in PBMCs.  In this report, we present addnl. anal. of patient samples from this trial and a second Phase I trial of L-778, 123, and demonstrate the inhibition of both HDJ2 and Rap1A prenylation in PBMC samples.  This study represents the first demonstration of GGPTase-I inhibition in humans.  However, no inhibition of Ki-Ras prenylation by L-778,123 was detected in patient samples.  These results confirm the pharmacol. profile of L-778, 123 in humans as a dual inhibitor of FPTase and GGPTase-I, but indicate that the intended target of the drug, Ki-Ras, was not inhibited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogSDhxZmacjrVg90H21EOLACvtfcHk0li7W6bWh_V9rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsFSmtb8%253D&md5=082f75d70280294811cdf665b880b692</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLobell%26aufirst%3DR.%2BB.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DBuser%26aufirst%3DC.%2BA.%26aulast%3DDavide%26aufirst%3DJ.%2BP.%26aulast%3DDePuy%26aufirst%3DE.%26aulast%3DHamilton%26aufirst%3DK.%26aulast%3DKoblan%26aufirst%3DK.%2BS.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DMosser%26aufirst%3DS.%26aulast%3DMotzel%26aufirst%3DS.%2BL.%26aulast%3DAbbruzzese%26aufirst%3DJ.%2BL.%26aulast%3DFuchs%26aufirst%3DC.%2BS.%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26aulast%3DRubin%26aufirst%3DE.%2BH.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DDeutsch%26aufirst%3DP.%2BJ.%26aulast%3DMazina%26aufirst%3DK.%2BE.%26aulast%3DMorrison%26aufirst%3DB.%2BW.%26aulast%3DWildonger%26aufirst%3DL.%26aulast%3DYao%26aufirst%3DS.-L.%26aulast%3DKohl%26aufirst%3DN.%2BE.%26atitle%3DPreclinical%2520and%2520clinical%2520pharmacodynamic%2520assessment%2520of%2520L-778%252C%2520123%252C%2520a%2520dual%2520inhibitor%2520of%2520farnesyl%253Aprotein%2520transfgerase%2520and%2520geranylgeranyl%253Aptotein%2520tansferase%2520type-I%26jtitle%3DMol.%2520Cancer%2520Ther%26date%3D2002%26volume%3D1%26spage%3D747%26epage%3D758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiel, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLaney, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regine, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohiuddin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosato, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haller, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pramanik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tepper, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deutsch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muschel, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenna, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhard, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, S. M.</span></span> <span> </span><span class="NLM_article-title">A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">5447</span>– <span class="NLM_lpage">5454</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-04-0248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1158%2F1078-0432.CCR-04-0248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=15328183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvFSltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=5447-5454&author=N.+E.+Martinauthor=T.+B.+Brunnerauthor=K.+D.+Kielauthor=T.+F.+DeLaneyauthor=W.+F.+Regineauthor=M.+Mohiuddinauthor=E.+F.+Rosatoauthor=D.+G.+Hallerauthor=J.+P.+Stevensonauthor=D.+Smithauthor=B.+Pramanikauthor=J.+Tepperauthor=W.+K.+Tanakaauthor=B.+Morrisonauthor=P.+Deutschauthor=A.+K.+Guptaauthor=R.+J.+Muschelauthor=G.+McKennaauthor=E.+J.+Bernhardauthor=S.+M.+Hahn&title=A+phase+I+trial+of+the+dual+farnesyltransferase+and+geranylgeranyltransferase+inhibitor+L-778%2C123+and+radiotherapy+for+locally+advanced+pancreatic+cancer&doi=10.1158%2F1078-0432.CCR-04-0248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer</span></div><div class="casAuthors">Martin, Neil E.; Brunner, Thomas B.; Kiel, Krystina D.; DeLaney, Thomas F.; Regine, William F.; Mohiuddin, Mohammed; Rosato, Ernest F.; Haller, Daniel G.; Stevenson, James P.; Smith, Debbie; Pramanik, Barnali; Tepper, Joel; Tanaka, Wesley K.; Morrison, Briggs; Deutsch, Paul; Gupta, Anjali K.; Muschel, Ruth J.; McKenna, W. Gillies; Bernhard, Eric J.; Hahn, Stephen M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5447-5454</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Preclin. and clin. studies have demonstrated that inhibition of prenylation can radiosensitize cell lines with activation of Ras and produce clin. response in patients with cancer.  The aim of this study was to det. the maximally tolerated dose of the dual farnesyltransferase and geranylgeranyltransferase I inhibitor L-778,123 in combination with radiotherapy for patients with locally advanced pancreatic cancer.  L-778,123 was given by continuous i.v. infusion with concomitant radiotherapy to 59.4 Gy in std. fractions.  Two L-778,123 dose levels were tested: 280 mg/m2/day over weeks 1, 2, 4, and 5 for dose level 1; and 560 mg/m2/day over weeks 1, 2, 4, 5, and 7 for dose level 2.  There were no dose-limiting toxicities obsd. in the eight patients treated on dose level 1.  Two of the four patients on dose level 2 experienced dose-limiting toxicities consisting of grade 3 diarrhea in one case and grade 3 gastrointestinal hemorrhage assocd. with grade 3 thrombocytopenia and neutropenia in the other case.  Other common toxicities were mild neutropenia, dehydration, hyperglycemia, and nausea/vomiting.  One patient on dose level 1 showed a partial response of 6 mo in duration.  Both reversible inhibition of HDJ2 farnesylation and radiosensitization of a study patient-derived cell line were demonstrated in the presence of L-778,123.  K-RAS mutations were found in three of the four patients evaluated.  The combination of L-778,123 and radiotherapy at dose level 1 showed acceptable toxicity in patients with locally advanced pancreatic cancer.  Radiosensitization of a patient-derived pancreatic cancer cell line was obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-CjOMRzk8JLVg90H21EOLACvtfcHk0li7W6bWh_V9rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvFSltLg%253D&md5=cb80a9340dbafafced681366cceaf51c</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-0248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-0248%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DN.%2BE.%26aulast%3DBrunner%26aufirst%3DT.%2BB.%26aulast%3DKiel%26aufirst%3DK.%2BD.%26aulast%3DDeLaney%26aufirst%3DT.%2BF.%26aulast%3DRegine%26aufirst%3DW.%2BF.%26aulast%3DMohiuddin%26aufirst%3DM.%26aulast%3DRosato%26aufirst%3DE.%2BF.%26aulast%3DHaller%26aufirst%3DD.%2BG.%26aulast%3DStevenson%26aufirst%3DJ.%2BP.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DPramanik%26aufirst%3DB.%26aulast%3DTepper%26aufirst%3DJ.%26aulast%3DTanaka%26aufirst%3DW.%2BK.%26aulast%3DMorrison%26aufirst%3DB.%26aulast%3DDeutsch%26aufirst%3DP.%26aulast%3DGupta%26aufirst%3DA.%2BK.%26aulast%3DMuschel%26aufirst%3DR.%2BJ.%26aulast%3DMcKenna%26aufirst%3DG.%26aulast%3DBernhard%26aufirst%3DE.%2BJ.%26aulast%3DHahn%26aufirst%3DS.%2BM.%26atitle%3DA%2520phase%2520I%2520trial%2520of%2520the%2520dual%2520farnesyltransferase%2520and%2520geranylgeranyltransferase%2520inhibitor%2520L-778%252C123%2520and%2520radiotherapy%2520for%2520locally%2520advanced%2520pancreatic%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D5447%26epage%3D5454%26doi%3D10.1158%2F1078-0432.CCR-04-0248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelb, M. H.</span></span> <span> </span><span class="NLM_article-title">Differential prenyl pyrophosphate binding to mammalian protein geranylgeranyltransferase-I and protein farnesyltransferase and its consequence on the specificity of protein prenylation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>272</i></span>,  <span class="NLM_fpage">3944</span>– <span class="NLM_lpage">3952</span>, <span class="refDoi"> DOI: 10.1074/jbc.272.7.3944</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1074%2Fjbc.272.7.3944" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=9020098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADyaK2sXht1Oltr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=3944-3952&author=K.+Yokoyamaauthor=K.+Zimmermanauthor=J.+Scholtenauthor=M.+H.+Gelb&title=Differential+prenyl+pyrophosphate+binding+to+mammalian+protein+geranylgeranyltransferase-I+and+protein+farnesyltransferase+and+its+consequence+on+the+specificity+of+protein+prenylation&doi=10.1074%2Fjbc.272.7.3944"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Differential prenyl pyrophosphate binding to mammalian protein geranylgeranyltransferase-I and protein farnesyltransferase and its consequence on the specificity of protein prenylation</span></div><div class="casAuthors">Yokoyama, Kohei; Zimmerman, Karen; Scholten, Jeffrey; Gelb, Michael H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3944-3952</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Protein geranylgeranyltransferase-I (PGGT-I) and protein farnesyltransferase (PET) attach geranylgeranyl and farnesyl groups, resp., to the C termini of eukaryotic cell proteins.  In vitro, PGGT-I and PFT can transfer both geranylgeranyl and farnesyl groups from geranylgeranyl pyrophosphate (GGPP) and farnesyl pyrophosphate (FPP) to their protein or peptide prenyl acceptor substrates.  In the present study it is shown that PGGT-I binds GGPP 330-fold tighter than FPP and that PFT binds FPP 15-fold tighter than GGPP.  Therefore, in vivo, where both GGPP and FPP compete for the binding to prenyltransferases, PGGT-I and PFT will likely be bound predominantly to GGPP and FPP, resp.  Previous studies have shown that K-Ras4B and the Ras-related GTPase TC21 are substrates for both PGGT-I and PFT in vitro.  It is shown that TC21 can compete with the C-terminal peptide of the γ subunit of heterotrimeric G proteins and with the C-terminal peptide of lamin B for geranylgeranylation by PGGT-I and for farnesylation by PFT, resp.  K-Ras4B competes in both cases but is almost exclusively farnesylated by PFT in the presence of the lamin B peptide competitor.  Rapid and single turnover kinetic studies indicate that the rate const. for the PGGT-I-catalyzed geranylgeranyl transfer step of the reaction cycle is 14-fold larger than the steady-state turnover no., which indicates that the rate of the overall reaction is limited by a step subsequent to prenyl transfer such as release of products from the enzyme.  PGGT-I-catalyzed farnesylation is 37-fold slower than geranylgeranylation and is limited by the farnesyl transfer step.  These results together with earlier studies provide a paradigm for the substrate specificity of PGGT-I and PFT and provide information that is crit. for the design of prenyltransferase inhibitors as anti-cancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFtK1IiaHPBbVg90H21EOLACvtfcHk0li7W6bWh_V9rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXht1Oltr4%253D&md5=4e6ccafc175458dc5306c58288ac10c6</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1074%2Fjbc.272.7.3944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.272.7.3944%26sid%3Dliteratum%253Aachs%26aulast%3DYokoyama%26aufirst%3DK.%26aulast%3DZimmerman%26aufirst%3DK.%26aulast%3DScholten%26aufirst%3DJ.%26aulast%3DGelb%26aufirst%3DM.%2BH.%26atitle%3DDifferential%2520prenyl%2520pyrophosphate%2520binding%2520to%2520mammalian%2520protein%2520geranylgeranyltransferase-I%2520and%2520protein%2520farnesyltransferase%2520and%2520its%2520consequence%2520on%2520the%2520specificity%2520of%2520protein%2520prenylation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26spage%3D3944%26epage%3D3952%26doi%3D10.1074%2Fjbc.272.7.3944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rowinsky, E. K.</span></span> <span> </span><span class="NLM_article-title">Lately, it occurs to me what a long, strange trip it’s been for the farnesyltransferase inhibitors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2981</span>– <span class="NLM_lpage">2984</span>, <span class="refDoi"> DOI: 10.1200/JCO.2006.05.9808</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1200%2FJCO.2006.05.9808" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=16769983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD28XnslKhsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=2981-2984&author=E.+K.+Rowinsky&title=Lately%2C+it+occurs+to+me+what+a+long%2C+strange+trip+it%E2%80%99s+been+for+the+farnesyltransferase+inhibitors&doi=10.1200%2FJCO.2006.05.9808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors</span></div><div class="casAuthors">Rowinsky, Eric K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2981-2984</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The research of Sparano et al. (2006) entitled "Targeted inhibition of farnesyltransferase in locally advanced breast cancer: A phase I and II trial incorporating tipifarnib plus dose-dense doxorubicin and cyclophosphamide", is reviewed with commentary and refs.  The study of Sparano et al. have shown that the farnesyltransferase (FTase) inhibitors are capable of inhibiting FTase in tumors.  The pathol. complete response rate of 33% reported by Sparano et al. exceeds the threshold rate of 15% defined a priori for proceeding to the next stage of the study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq39i56qUmuhbVg90H21EOLACvtfcHk0ljNEirVjXFO7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnslKhsro%253D&md5=02a13916c995ebf1cbccfc783a32aae6</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1200%2FJCO.2006.05.9808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2006.05.9808%26sid%3Dliteratum%253Aachs%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26atitle%3DLately%252C%2520it%2520occurs%2520to%2520me%2520what%2520a%2520long%252C%2520strange%2520trip%2520it%25E2%2580%2599s%2520been%2520for%2520the%2520farnesyltransferase%2520inhibitors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D2981%26epage%3D2984%26doi%3D10.1200%2FJCO.2006.05.9808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krysiak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">No, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukkamala, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houlihan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldfield, E.</span></span> <span> </span><span class="NLM_article-title">Lipophilic pyridinium bisphosphonates: Potent γδ T cell stimulators</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1136</span>– <span class="NLM_lpage">1138</span>, <span class="refDoi"> DOI: 10.1002/anie.200905933</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1002%2Fanie.200905933" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=1136-1138&author=Y.+Zhangauthor=R.+Caoauthor=F.+Yinauthor=F.-Y.+Linauthor=H.+Wangauthor=K.+Krysiakauthor=J.-H.+Noauthor=D.+Mukkamalaauthor=K.+Houlihanauthor=J.+Liauthor=C.+T.+Moritaauthor=E.+Oldfield&title=Lipophilic+pyridinium+bisphosphonates%3A+Potent+%CE%B3%CE%B4+T+cell+stimulators&doi=10.1002%2Fanie.200905933"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fanie.200905933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200905933%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DR.%26aulast%3DYin%26aufirst%3DF.%26aulast%3DLin%26aufirst%3DF.-Y.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DKrysiak%26aufirst%3DK.%26aulast%3DNo%26aufirst%3DJ.-H.%26aulast%3DMukkamala%26aufirst%3DD.%26aulast%3DHoulihan%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMorita%26aufirst%3DC.%2BT.%26aulast%3DOldfield%26aufirst%3DE.%26atitle%3DLipophilic%2520pyridinium%2520bisphosphonates%253A%2520Potent%2520%25CE%25B3%25CE%25B4%2520T%2520cell%2520stimulators%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2010%26volume%3D49%26spage%3D1136%26epage%3D1138%26doi%3D10.1002%2Fanie.200905933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudock, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, R.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krysiak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">No, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cass, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goddard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, T.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Beek, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papapoulos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukkamala, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldfield, E.</span></span> <span> </span><span class="NLM_article-title">Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: An X-ray and NMR investigation</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">5153</span>– <span class="NLM_lpage">5162</span>, <span class="refDoi"> DOI: 10.1021/ja808285e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja808285e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjsFKnsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2009&pages=5153-5162&author=Y.+Zhangauthor=R.+Caoauthor=F.+Yinauthor=M.+P.+Hudockauthor=R.-T.+Guoauthor=K.+Krysiakauthor=S.+Mukherjeeauthor=Y.-G.+Gaoauthor=H.+Robinsonauthor=Y.+Songauthor=J.+H.+Noauthor=K.+Berganauthor=A.+Leonauthor=L.+Cassauthor=A.+Goddardauthor=T.-K.+Changauthor=F.-Y.+Linauthor=E.+Van+Beekauthor=S.+Papapoulosauthor=A.H.-J.+Wangauthor=T.+Kuboauthor=M.+Ochiauthor=D.+Mukkamalaauthor=E.+Oldfield&title=Lipophilic+bisphosphonates+as+dual+farnesyl%2Fgeranylgeranyl+diphosphate+synthase+inhibitors%3A+An+X-ray+and+NMR+investigation&doi=10.1021%2Fja808285e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Lipophilic Bisphosphonates as Dual Farnesyl/Geranylgeranyl Diphosphate Synthase Inhibitors: An X-ray and NMR Investigation</span></div><div class="casAuthors">Zhang, Yonghui; Cao, Rong; Yin, Fenglin; Hudock, Michael P.; Guo, Rey-Ting; Krysiak, Kilannin; Mukherjee, Sujoy; Gao, Yi-Gui; Robinson, Howard; Song, Yongcheng; No, Joo Hwan; Bergan, Kyle; Leon, Annette; Cass, Lauren; Goddard, Amanda; Chang, Ting-Kai; Lin, Fu-Yang; Van Beek, Ermond; Papapoulos, Socrates; Wang, Andrew H.-J.; Kubo, Tadahiko; Ochi, Mitsuo; Mukkamala, Dushyant; Oldfield, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5153-5162</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Considerable effort has focused on the development of selective protein farnesyl transferase (FTase) and protein geranylgeranyl transferase (GGTase) inhibitors as cancer chemotherapeutics.  Here, we report a new strategy for anticancer therapeutic agents involving inhibition of farnesyl diphosphate synthase (FPPS) and geranylgeranyl diphosphate synthase (GGPPS), the two enzymes upstream of FTase and GGTase, by lipophilic bisphosphonates.  Due to dual site targeting and decreased polarity, the compds. have activities far greater than do current bisphosphonate drugs in inhibiting tumor cell growth and invasiveness, both in vitro and in vivo.  We explore how these compds. inhibit cell growth and how cell activity can be predicted based on enzyme inhibition data, and using X-ray diffraction, solid state NMR, and isothermal titrn. calorimetry, we show how these compds. bind to FPPS and/or GGPPS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHhFMAMouc-rVg90H21EOLACvtfcHk0ljNEirVjXFO7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjsFKnsLw%253D&md5=373a71c889ed9f0ae6510d2503127e94</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fja808285e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja808285e%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DR.%26aulast%3DYin%26aufirst%3DF.%26aulast%3DHudock%26aufirst%3DM.%2BP.%26aulast%3DGuo%26aufirst%3DR.-T.%26aulast%3DKrysiak%26aufirst%3DK.%26aulast%3DMukherjee%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DY.-G.%26aulast%3DRobinson%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DNo%26aufirst%3DJ.%2BH.%26aulast%3DBergan%26aufirst%3DK.%26aulast%3DLeon%26aufirst%3DA.%26aulast%3DCass%26aufirst%3DL.%26aulast%3DGoddard%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DT.-K.%26aulast%3DLin%26aufirst%3DF.-Y.%26aulast%3DVan%2BBeek%26aufirst%3DE.%26aulast%3DPapapoulos%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DA.H.-J.%26aulast%3DKubo%26aufirst%3DT.%26aulast%3DOchi%26aufirst%3DM.%26aulast%3DMukkamala%26aufirst%3DD.%26aulast%3DOldfield%26aufirst%3DE.%26atitle%3DLipophilic%2520bisphosphonates%2520as%2520dual%2520farnesyl%252Fgeranylgeranyl%2520diphosphate%2520synthase%2520inhibitors%253A%2520An%2520X-ray%2520and%2520NMR%2520investigation%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2009%26volume%3D131%26spage%3D5153%26epage%3D5162%26doi%3D10.1021%2Fja808285e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shull, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiemer, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohl, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiemer, D. F.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological activity of isoprenoid bisphosphonates</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">4130</span>– <span class="NLM_lpage">4136</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2006.02.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1016%2Fj.bmc.2006.02.010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=4130-4136&author=L.+W.+Shullauthor=A.+J.+Wiemerauthor=R.+J.+Hohlauthor=D.+F.+Wiemer&title=Synthesis+and+biological+activity+of+isoprenoid+bisphosphonates&doi=10.1016%2Fj.bmc.2006.02.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2006.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2006.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DShull%26aufirst%3DL.%2BW.%26aulast%3DWiemer%26aufirst%3DA.%2BJ.%26aulast%3DHohl%26aufirst%3DR.%2BJ.%26aulast%3DWiemer%26aufirst%3DD.%2BF.%26atitle%3DSynthesis%2520and%2520biological%2520activity%2520of%2520isoprenoid%2520bisphosphonates%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D4130%26epage%3D4136%26doi%3D10.1016%2Fj.bmc.2006.02.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wills, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holstein, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiemer, D. F.</span></span> <span> </span><span class="NLM_article-title">Potent triazole bisphosphonate inhibitor of geranylgeranyl diphosphate synthase</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1195</span>– <span class="NLM_lpage">1198</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00334</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00334" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1195-1198&author=V.+S.+Willsauthor=C.+Allenauthor=S.+A.+Holsteinauthor=D.+F.+Wiemer&title=Potent+triazole+bisphosphonate+inhibitor+of+geranylgeranyl+diphosphate+synthase&doi=10.1021%2Facsmedchemlett.5b00334"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00334%26sid%3Dliteratum%253Aachs%26aulast%3DWills%26aufirst%3DV.%2BS.%26aulast%3DAllen%26aufirst%3DC.%26aulast%3DHolstein%26aufirst%3DS.%2BA.%26aulast%3DWiemer%26aufirst%3DD.%2BF.%26atitle%3DPotent%2520triazole%2520bisphosphonate%2520inhibitor%2520of%2520geranylgeranyl%2520diphosphate%2520synthase%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D1195%26epage%3D1198%26doi%3D10.1021%2Facsmedchemlett.5b00334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wills, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzger, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varney, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiemer, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holstein, S. A.</span></span> <span> </span><span class="NLM_article-title">Bishomoisoprenoid triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2437</span>– <span class="NLM_lpage">2444</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.02.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1016%2Fj.bmc.2017.02.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=28302510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1OnsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=2437-2444&author=V.+S.+Willsauthor=J.+I.+Metzgerauthor=C.+Allenauthor=M.+L.+Varneyauthor=D.+F.+Wiemerauthor=S.+A.+Holstein&title=Bishomoisoprenoid+triazole+bisphosphonates+as+inhibitors+of+geranylgeranyl+diphosphate+synthase&doi=10.1016%2Fj.bmc.2017.02.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Bishomoisoprenoid triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase</span></div><div class="casAuthors">Wills, Veronica S.; Metzger, Joseph I.; Allen, Cheryl; Varney, Michelle L.; Wiemer, David F.; Holstein, Sarah A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2437-2444</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Protein geranylgeranylation reactions are dependent on the availability of geranylgeranyl diphosphate (GGDP), which serves as the isoprenoid donor.  Inhibition of GGDP synthase (GGDPS) is of interest from a drug development perspective as GGDPS inhibition results in impaired protein geranylgeranylation, which in multiple myeloma, disrupts monoclonal protein trafficking and induces apoptosis.  We have recently reported a series of isoprenoid triazole bisphosphonates and have demonstrated that a 3:1 mixt. of homogeranyl and homoneryl isomers potently, and in a synergistic manner, inhibits GGDPS.  We now present the synthesis and biol. evaluation of a novel series of bishomoisoprenoid triazoles which furthers our understanding of the structure-function relationship of this class.  These studies demonstrate the importance of chain length and olefin stereochem. on inhibitory activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa9eWy7qvSRbVg90H21EOLACvtfcHk0lgH-pke8L_64w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1OnsL4%253D&md5=8aaa35d9ab8ae37bf288169d749eb10c</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.02.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.02.066%26sid%3Dliteratum%253Aachs%26aulast%3DWills%26aufirst%3DV.%2BS.%26aulast%3DMetzger%26aufirst%3DJ.%2BI.%26aulast%3DAllen%26aufirst%3DC.%26aulast%3DVarney%26aufirst%3DM.%2BL.%26aulast%3DWiemer%26aufirst%3DD.%2BF.%26aulast%3DHolstein%26aufirst%3DS.%2BA.%26atitle%3DBishomoisoprenoid%2520triazole%2520bisphosphonates%2520as%2520inhibitors%2520of%2520geranylgeranyl%2520diphosphate%2520synthase%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D2437%26epage%3D2444%26doi%3D10.1016%2Fj.bmc.2017.02.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guenther, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakker, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roelofs, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gramatzki, M.</span></span> <span> </span><span class="NLM_article-title">The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">246</span>, <span class="refDoi"> DOI: 10.1002/ijc.24758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1002%2Fijc.24758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=19621390" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVamt7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2010&pages=239-246&author=A.+Guentherauthor=S.+Gordonauthor=M.+Tiemannauthor=R.+Burgerauthor=F.+Bakkerauthor=J.+R.+Greenauthor=W.+Baumauthor=A.+J.+Roelofsauthor=M.+J.+Rogersauthor=M.+Gramatzki&title=The+bisphosphonate+zoledronic+acid+has+antimyeloma+activity+in+vivo+by+inhibition+of+protein+prenylation&doi=10.1002%2Fijc.24758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation</span></div><div class="casAuthors">Guenther, Andreas; Gordon, Sharon; Tiemann, Markus; Burger, Renate; Bakker, Frank; Green, Jonathan R.; Baum, Wolfgang; Roelofs, Anke J.; Rogers, Michael J.; Gramatzki, Martin</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">239-246</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Nitrogen-contg. bisphosphonates (N-BPs) are effective antiosteolytic agents in patients with multiple myeloma.  Preclin. studies have also demonstrated that these agents have direct antitumor effects in vitro and can reduce tumor burden in a variety of animal models, although it is not clear whether such effects are caused by direct actions on tumor cells or by inhibition of bone resorption.  N-BPs prevent bone destruction in myeloma by inhibiting the enzyme farnesyl pyrophosphate synthase in osteoclasts, thereby preventing the prenylation of small GTPase signaling proteins.  In this study, utilizing a plasmacytoma xenograft model without complicating skeletal lesions, treatment with zoledronic acid (ZOL) led to significant prolongation of survival in severe combined immunodeficiency mice inoculated with human INA-6 plasma cells.  Following treatment with a clin. relevant dose of ZOL, histol. anal. of INA-6 tumors from the peritoneal cavity revealed extensive areas of apoptosis assocd. with poly (ADP-ribose) polymerase cleavage.  Furthermore, Western blot anal. of tumor homogenates demonstrated the accumulation of unprenylated Rap1A, indicative of the uptake of ZOL by nonskeletal tumors and inhibition of farnesyl pyrophosphate synthase.  These studies provide, for the first time, clear evidence that N-BPs have direct antitumor effects in plasma cell tumors in vivo and this is executed by a mol. mechanism similar to that obsd. in osteoclasts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHg7sfa313ubVg90H21EOLACvtfcHk0lgH-pke8L_64w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVamt7nJ&md5=7c58cef58f4cb5c7aab14bbd03a3058d</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2Fijc.24758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.24758%26sid%3Dliteratum%253Aachs%26aulast%3DGuenther%26aufirst%3DA.%26aulast%3DGordon%26aufirst%3DS.%26aulast%3DTiemann%26aufirst%3DM.%26aulast%3DBurger%26aufirst%3DR.%26aulast%3DBakker%26aufirst%3DF.%26aulast%3DGreen%26aufirst%3DJ.%2BR.%26aulast%3DBaum%26aufirst%3DW.%26aulast%3DRoelofs%26aufirst%3DA.%2BJ.%26aulast%3DRogers%26aufirst%3DM.%2BJ.%26aulast%3DGramatzki%26aufirst%3DM.%26atitle%3DThe%2520bisphosphonate%2520zoledronic%2520acid%2520has%2520antimyeloma%2520activity%2520in%2520vivo%2520by%2520inhibition%2520of%2520protein%2520prenylation%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2010%26volume%3D126%26spage%3D239%26epage%3D246%26doi%3D10.1002%2Fijc.24758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langille, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancuso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsantrizos, Y. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of thienopyrimidine-based inhibitors of the human farnesyl pyrophosphate synthase – Parallel synthesis of analogs via a thrimethylsilyl ylidene intermediate</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2229</span>– <span class="NLM_lpage">2240</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1016%2Fj.bmc.2013.02.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2229-2240&author=C.-Y.+Leungauthor=A.+M.+Langilleauthor=J.+Mancusoauthor=Y.+S.+Tsantrizos&title=Discovery+of+thienopyrimidine-based+inhibitors+of+the+human+farnesyl+pyrophosphate+synthase+%E2%80%93+Parallel+synthesis+of+analogs+via+a+thrimethylsilyl+ylidene+intermediate&doi=10.1016%2Fj.bmc.2013.02.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DC.-Y.%26aulast%3DLangille%26aufirst%3DA.%2BM.%26aulast%3DMancuso%26aufirst%3DJ.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26atitle%3DDiscovery%2520of%2520thienopyrimidine-based%2520inhibitors%2520of%2520the%2520human%2520farnesyl%2520pyrophosphate%2520synthase%2520%25E2%2580%2593%2520Parallel%2520synthesis%2520of%2520analogs%2520via%2520a%2520thrimethylsilyl%2520ylidene%2520intermediate%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D2229%26epage%3D2240%26doi%3D10.1016%2Fj.bmc.2013.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kavanagh, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunford, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunkoczi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, R. G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oppermann, U. J.</span></span> <span> </span><span class="NLM_article-title">The crystal structure of human geranylgeranyl pyrophosphate synthase reveals a novel hexameric arrangement and inhibitory product binding</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>281</i></span>,  <span class="NLM_fpage">22004</span>– <span class="NLM_lpage">22012</span>, <span class="refDoi"> DOI: 10.1074/jbc.M602603200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1074%2Fjbc.M602603200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=16698791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsVOmsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=22004-22012&author=K.+L.+Kavanaghauthor=J.+E.+Dunfordauthor=G.+Bunkocziauthor=R.+G.+G.+Russellauthor=U.+J.+Oppermann&title=The+crystal+structure+of+human+geranylgeranyl+pyrophosphate+synthase+reveals+a+novel+hexameric+arrangement+and+inhibitory+product+binding&doi=10.1074%2Fjbc.M602603200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The Crystal Structure of Human Geranylgeranyl Pyrophosphate Synthase Reveals a Novel Hexameric Arrangement and Inhibitory Product Binding</span></div><div class="casAuthors">Kavanagh, Kathryn L.; Dunford, James E.; Bunkoczi, Gabor; Russell, R. Graham G.; Oppermann, Udo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">22004-22012</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Modification of GTPases with isoprenoid mols. derived from geranylgeranyl pyrophosphate (GGPP) or farnesyl pyrophosphate (FPP) is an essential requisite for cellular signaling pathways.  The synthesis of these isoprenoids proceeds in mammals through the mevalonate pathway, and the final steps in the synthesis are catalyzed by the related enzymes farnesyl pyrophosphate synthase (FPPS) and geranylgeranyl pyrophosphate synthase (GGPS).  Both enzymes play crucial roles in cell survival, and inhibition of farnesyl pyrophosphate synthase by nitrogen-contg. bisphosphonates is an established concept in the treatment of bone disorders such as osteoporosis or certain forms of cancer in bone.  Here we report the crystal structure of human geranylgeranyl pyrophosphate synthase, the first mammalian ortholog to have its x-ray structure detd.  It reveals that three dimers join together to form a propeller-bladed hexameric mol. with a mass of ∼200 kDa.  Structure-based sequence alignments predict this quaternary structure to be restricted to mammalian and insect orthologs, whereas fungal, bacterial, archaeal, and plant forms exhibit the dimeric organization also obsd. in farnesyl pyrophosphate synthase.  Geranylgeranyl pyrophosphate derived from heterologous bacterial expression is tightly bound in a cavity distinct from the chain elongation site described for farnesyl pyrophosphate synthase.  The structure most likely represents an inhibitory complex, which is further corroborated by steady-state kinetics, suggesting a possible feedback mechanism for regulating enzyme activity.  Structural comparisons between members of this enzyme class give deeper insights into conserved features important for catalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppWvup7XisV7Vg90H21EOLACvtfcHk0lixaYJbRj7Ppw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsVOmsLY%253D&md5=416cd4f9643c65dc1427cb70fac1c873</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M602603200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M602603200%26sid%3Dliteratum%253Aachs%26aulast%3DKavanagh%26aufirst%3DK.%2BL.%26aulast%3DDunford%26aufirst%3DJ.%2BE.%26aulast%3DBunkoczi%26aufirst%3DG.%26aulast%3DRussell%26aufirst%3DR.%2BG.%2BG.%26aulast%3DOppermann%26aufirst%3DU.%2BJ.%26atitle%3DThe%2520crystal%2520structure%2520of%2520human%2520geranylgeranyl%2520pyrophosphate%2520synthase%2520reveals%2520a%2520novel%2520hexameric%2520arrangement%2520and%2520inhibitory%2520product%2520binding%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D22004%26epage%3D22012%26doi%3D10.1074%2Fjbc.M602603200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Schutter, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebag, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berghuis, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsantrizos, Y. S.</span></span> <span> </span><span class="NLM_article-title">Thienopyrimidine bisphosphomates (ThPBP) inhibitors of the human farnesyl pyrophosphate synthase: Optimization and characterization of the mode of inhibition</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7939</span>– <span class="NLM_lpage">7950</span>, <span class="refDoi"> DOI: 10.1021/jm400946f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400946f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7939-7950&author=C.+Y.+Leungauthor=J.+Parkauthor=J.+W.+De+Schutterauthor=M.+Sebagauthor=A.+M.+Berghuisauthor=Y.+S.+Tsantrizos&title=Thienopyrimidine+bisphosphomates+%28ThPBP%29+inhibitors+of+the+human+farnesyl+pyrophosphate+synthase%3A+Optimization+and+characterization+of+the+mode+of+inhibition&doi=10.1021%2Fjm400946f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm400946f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400946f%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DC.%2BY.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DDe%2BSchutter%26aufirst%3DJ.%2BW.%26aulast%3DSebag%26aufirst%3DM.%26aulast%3DBerghuis%26aufirst%3DA.%2BM.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26atitle%3DThienopyrimidine%2520bisphosphomates%2520%2528ThPBP%2529%2520inhibitors%2520of%2520the%2520human%2520farnesyl%2520pyrophosphate%2520synthase%253A%2520Optimization%2520and%2520characterization%2520of%2520the%2520mode%2520of%2520inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7939%26epage%3D7950%26doi%3D10.1021%2Fjm400946f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span>For details
on the characterization
of MM cells lines, refer to Keats lab Web site: <a href="http://www.keatslab.org/projects/mm-cell-line-characterization/cell-line-characterization-status" class="extLink">http://www.keatslab.org/projects/mm-cell-line-characterization/cell-line-characterization-status</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=For+details%0Aon+the+characterization%0Aof+MM+cells+lines%2C+refer+to+Keats+lab+Web+site%3A+http%3A%2F%2Fwww.keatslab.org%2Fprojects%2Fmm-cell-line-characterization%2Fcell-line-characterization-status."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nozawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, H.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samur, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirstea, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massefski, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utsugi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhe-Paganon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span> <span> </span><span class="NLM_article-title">p53-Related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">1308</span>– <span class="NLM_lpage">1319</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-09-738500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1182%2Fblood-2016-09-738500" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=1308-1319&author=T.+Hideshimaauthor=F.+Cottiniauthor=Y.+Nozawaauthor=H.-S.+Seoauthor=H.+Ohguchiauthor=M.+K.+Samurauthor=D.+Cirsteaauthor=N.+Mimuraauthor=Y.+Iwasawaauthor=P.+G.+Richardsonauthor=N.+C.+Munshiauthor=D.+Chauhanauthor=W.+Massefskiauthor=T.+Utsugiauthor=S.+Dhe-Paganonauthor=K.+C.+Anderson&title=p53-Related+protein+kinase+confers+poor+prognosis+and+represents+a+novel+therapeutic+target+in+multiple+myeloma&doi=10.1182%2Fblood-2016-09-738500"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-09-738500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-09-738500%26sid%3Dliteratum%253Aachs%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DCottini%26aufirst%3DF.%26aulast%3DNozawa%26aufirst%3DY.%26aulast%3DSeo%26aufirst%3DH.-S.%26aulast%3DOhguchi%26aufirst%3DH.%26aulast%3DSamur%26aufirst%3DM.%2BK.%26aulast%3DCirstea%26aufirst%3DD.%26aulast%3DMimura%26aufirst%3DN.%26aulast%3DIwasawa%26aufirst%3DY.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DMunshi%26aufirst%3DN.%2BC.%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DMassefski%26aufirst%3DW.%26aulast%3DUtsugi%26aufirst%3DT.%26aulast%3DDhe-Paganon%26aufirst%3DS.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3Dp53-Related%2520protein%2520kinase%2520confers%2520poor%2520prognosis%2520and%2520represents%2520a%2520novel%2520therapeutic%2520target%2520in%2520multiple%2520myeloma%26jtitle%3DBlood%26date%3D2017%26volume%3D129%26spage%3D1308%26epage%3D1319%26doi%3D10.1182%2Fblood-2016-09-738500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shipman, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croucher, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russel, R. G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helfrich, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, M. J.</span></span> <span> </span><span class="NLM_article-title">The bisphosphnate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5294</span>– <span class="NLM_lpage">5297</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=5294-5297&author=C.+M.+Shipmanauthor=P.+I.+Croucherauthor=R.+G.+G.+Russelauthor=M.+H.+Helfrichauthor=M.+J.+Rogers&title=The+bisphosphnate+incadronate+%28YM175%29+causes+apoptosis+of+human+myeloma+cells+in+vitro+by+inhibiting+the+mevalonate+pathway"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShipman%26aufirst%3DC.%2BM.%26aulast%3DCroucher%26aufirst%3DP.%2BI.%26aulast%3DRussel%26aufirst%3DR.%2BG.%2BG.%26aulast%3DHelfrich%26aufirst%3DM.%2BH.%26aulast%3DRogers%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520bisphosphnate%2520incadronate%2520%2528YM175%2529%2520causes%2520apoptosis%2520of%2520human%2520myeloma%2520cells%2520in%2520vitro%2520by%2520inhibiting%2520the%2520mevalonate%2520pathway%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26spage%3D5294%26epage%3D5297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jagdev, S.
P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipman, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rostami-H, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croucher, P. I.</span></span> <span> </span><span class="NLM_article-title">The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">1126</span>– <span class="NLM_lpage">1134</span>, <span class="refDoi"> DOI: 10.1054/bjoc.2001.1727</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1054%2Fbjoc.2001.1727" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=11308265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktFymu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2001&pages=1126-1134&author=S.%0AP.+Jagdevauthor=R.+E.+Colemanauthor=C.+M.+Shipmanauthor=A.+Rostami-Hauthor=P.+I.+Croucher&title=The+bisphosphonate%2C+zoledronic+acid%2C+induces+apoptosis+of+breast+cancer+cells%3A+evidence+for+synergy+with+paclitaxel&doi=10.1054%2Fbjoc.2001.1727"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel</span></div><div class="casAuthors">Jagdev, S. P.; Coleman, R. E.; Shipman, C. M.; Rostami-H, A.; Croucher, P. I.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1126-1134</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Harcourt Publishers Ltd.</span>)
        </div><div class="casAbstract">Bisphosphonates are well established in the management of breast-cancer-induced bone disease.  Recent studies have suggested that these compds. are effective in preventing the development of bone metastases.  However, it is unclear whether this reflects an indirect effect via an inhibition of bone resorption or a direct antitumor effect.  The breast cancer cell lines, MCF-7 and MDA-MB-231 cells were treated with increasing concns. of the bisphosphonate, zoledronic acid, for varying time periods, in the presence or absence of paclitaxel.  The effects of zoledronic acid were detd. by assessing cell no. and rate of apoptosis by evaluating changes in nuclear morphol. and using a fluorescence nick translation assay.  Zoledronic acid caused a dose- and time-dependent decrease in cell no. (P < 0.001) and a concomitant increase in tumor cell apoptosis (P < 0.005).  Short-term exposure to zoledronic acid was sufficient to cause a significant redn. in cell no. and increase in apoptosis (P < 0.05).  These effects could be prevented by incubation with geranyl geraniol, suggesting that zoledronic acid-induced apoptosis is mediated by inhibiting the mevalonate pathway.  Treatment with zoledronic acid and clin. achievable concns. of paclitaxel resulted in a 4-5-fold increase in tumor cell apoptosis (P < 0.02).  Isobologram anal. revealed synergistic effects on tumor cell no. and apoptosis when zoledronic acid and paclitaxel were combined.  Short-term treatment with zoledronic acid, which closely resembles the clin. setting, has a clear antitumor effect on breast cancer cells.  Importantly, the commonly used anti-neoplastic agent, paclitaxel, potentiates the antitumor effects of zoledronic acid.  These data suggest that, in addn. to inhibiting bone resorption, zoledronic acid has a direct antitumor activity on breast cancer cells in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-FMJ3yV5xCrVg90H21EOLACvtfcHk0ljO-sRfwNk1gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktFymu7w%253D&md5=5cda9ff95bb2441029802c717eee076b</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1054%2Fbjoc.2001.1727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1054%252Fbjoc.2001.1727%26sid%3Dliteratum%253Aachs%26aulast%3DJagdev%26aufirst%3DS.%2BP.%26aulast%3DColeman%26aufirst%3DR.%2BE.%26aulast%3DShipman%26aufirst%3DC.%2BM.%26aulast%3DRostami-H%26aufirst%3DA.%26aulast%3DCroucher%26aufirst%3DP.%2BI.%26atitle%3DThe%2520bisphosphonate%252C%2520zoledronic%2520acid%252C%2520induces%2520apoptosis%2520of%2520breast%2520cancer%2520cells%253A%2520evidence%2520for%2520synergy%2520with%2520paclitaxel%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2001%26volume%3D84%26spage%3D1126%26epage%3D1134%26doi%3D10.1054%2Fbjoc.2001.1727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tohi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamura, N.</span></span> <span> </span><span class="NLM_article-title">Involvement of the mevalonate pathway in the antiproliferative effects of zoledronate on ACHN renal cell carcinoma cells</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1371</span>– <span class="NLM_lpage">1376</span>, <span class="refDoi"> DOI: 10.3892/or.2012.1683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.3892%2For.2012.1683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=22322451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt1Squ7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2012&pages=1371-1376&author=M.+Fujitaauthor=M.+Tohiauthor=K.+Sawadaauthor=Y.+Yamamotoauthor=T.+Nakamuraauthor=T.+Yagamiauthor=M.+Yamamoriauthor=N.+Okamura&title=Involvement+of+the+mevalonate+pathway+in+the+antiproliferative+effects+of+zoledronate+on+ACHN+renal+cell+carcinoma+cells&doi=10.3892%2For.2012.1683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of the mevalonate pathway in the antiproliferative effect of zoledronate on ACHN renal cell carcinoma cells</span></div><div class="casAuthors">Fujita, Megumi; Tohi, Makiko; Sawada, Kyoko; Yamamoto, Yasuhiro; Nakamura, Tsutomu; Yagami, Tatsurou; Yamamori, Motohiro; Okamura, Noboru</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1371-1376</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Oncology Reports</span>)
        </div><div class="casAbstract">Renal cell carcinoma (RCC) has been shown to be resistant to chemotherapy and radiotherapy.  In order to examine the potential of zoledronate(ZOL), abisphosphonate, as an anticancer agent, we investigated the effects of ZOL on RCC cells and the involvement of the mevalonate pathway in antiproliferative effects, as well as the effects of ZOL administration on mice inoculated with RCC.  ACHN cells were used and cell viability was measured via intracellular reductase activity.  Chromatin condensation was detected by Hoechst 33342 staining.  Proteins were detected by western blot anal.  Tumor vol. was measured bidimensionally in mice inoculated with ACHN cells after vehicle or ZOL s.c. administration.  ZOL exhibited antiproliferative effects with an IC50 value of 2.29±0.53 μM in ACHN cells and chromatin condensation was obsd. when treated with ZOL.  Farnesol (FOH) and geranylgeraniol (GGOH), precursors of farnesyl pyrophosphate and geranylgeranyl pyrophosphate, exhibited potency to rescue cells treated with ZOL.  Addnl., Ras and RhoA proteins located in the membrane fraction decreased when treated with ZOL and recovered by FOH or GGOH treatment, suggesting that ZOL inhibited the mevalonate pathway, thereby suppressing the translocation of prenylated Ras and RhoA proteins to membrane fractions.  An in vivo study showed the inhibitory potential of ZOL on tumor growth in mice without changes in body wt.  Our study showed that ZOL could be useful as an anticancer agent for the treatment of RCC, and the mevalonate pathway could be an efficient target for novel therapeutic agents against RCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRS_uSYJsrVrVg90H21EOLACvtfcHk0ljO-sRfwNk1gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt1Squ7w%253D&md5=31745485b904a62a3f6008f92d258712</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.3892%2For.2012.1683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2012.1683%26sid%3Dliteratum%253Aachs%26aulast%3DFujita%26aufirst%3DM.%26aulast%3DTohi%26aufirst%3DM.%26aulast%3DSawada%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DYagami%26aufirst%3DT.%26aulast%3DYamamori%26aufirst%3DM.%26aulast%3DOkamura%26aufirst%3DN.%26atitle%3DInvolvement%2520of%2520the%2520mevalonate%2520pathway%2520in%2520the%2520antiproliferative%2520effects%2520of%2520zoledronate%2520on%2520ACHN%2520renal%2520cell%2520carcinoma%2520cells%26jtitle%3DOncol.%2520Rep.%26date%3D2012%26volume%3D27%26spage%3D1371%26epage%3D1376%26doi%3D10.3892%2For.2012.1683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shingyoji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekine, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takiguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatsumi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiroshima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tagawa, M.</span></span> <span> </span><span class="NLM_article-title">Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e1517</span>, <span class="refDoi"> DOI: 10.1038/cddis.2014.475</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1038%2Fcddis.2014.475" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=25393473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFCiu7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=e1517&author=S.+Okamotoauthor=Y.+Jiangauthor=K.+Kawamuraauthor=M.+Shingyojiauthor=Y.+Tadaauthor=I.+Sekineauthor=Y.+Takiguchiauthor=K.+Tatsumiauthor=H.+Kobayashiauthor=H.+Shimadaauthor=K.+Hiroshimaauthor=M.+Tagawa&title=Zoledronic+acid+induces+apoptosis+and+S-phase+arrest+in+mesothelioma+through+inhibiting+Rab+family+proteins+and+topoisomerase+II+actions&doi=10.1038%2Fcddis.2014.475"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions</span></div><div class="casAuthors">Okamoto, S.; Jiang, Y.; Kawamura, K.; Shingyoji, M.; Tada, Y.; Sekine, I.; Takiguchi, Y.; Tatsumi, K.; Kobayashi, H.; Shimada, H.; Hiroshima, K.; Tagawa, M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e1517</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Zoledronic acid (ZOL), a nitrogen-contg. bisphosphonate, produced anti-tumor effects through apoptosis induction or S-phase arrest depending on human mesothelioma cells tested.  An addn. of isoprenoid, geranylgeraniol but not farnesol, negated these ZOL-induced effects, indicating that the ZOL-mediated effects were attributable to depletion of geranylgeranyl pyrophosphates which were substrates for prenylation processes of small guanine-nucleotide-binding regulatory proteins (small G proteins).  ZOL-treated cells decreased a ratio of membrane to cytoplasmic fractions in RhoA, Cdc42 and Rab6 but less significantly Rac1 proteins, indicating that these proteins were possible targets for ZOL-induced actions.  We further analyzed which small G proteins were responsible for the three ZOL-induced effects, caspase-mediated apoptosis, S-phase arrest and morphol. changes, using inhibitors for resp. small G proteins and siRNA for Cdc42.  ZOL-induced apoptosis is due to insufficient prenylation of Rab proteins because an inhibitor of geranlygeranyl transferase II that was specific for Rab family proteins prenylation, but not others inhibitors, activated the same apoptotic pathways that ZOL did.  ZOL suppressed an endogenous topoisomerase II activity, which was assocd. with apoptosis and S-phase arrest in resp. cells because we detected the same cell cycle changes in etoposide-treated cells.  Inhibitors for geranlygeranyl transferase I and for RhoA produced morphol. changes and disrupted actin fiber structures, both of which were similar to those by ZOL treatments.  These data demonstrated that anti-tumor effects by ZOL were attributable to inhibited functions of resp. small G proteins and topoisomerase II activity, and suggested that cellular factors were involved in the differential cell cycle changes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1V4pcnt-Xr7Vg90H21EOLACvtfcHk0ljO-sRfwNk1gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFCiu7%252FM&md5=58d19666aee80a93af63ffec9c373602</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2014.475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2014.475%26sid%3Dliteratum%253Aachs%26aulast%3DOkamoto%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DKawamura%26aufirst%3DK.%26aulast%3DShingyoji%26aufirst%3DM.%26aulast%3DTada%26aufirst%3DY.%26aulast%3DSekine%26aufirst%3DI.%26aulast%3DTakiguchi%26aufirst%3DY.%26aulast%3DTatsumi%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DH.%26aulast%3DShimada%26aufirst%3DH.%26aulast%3DHiroshima%26aufirst%3DK.%26aulast%3DTagawa%26aufirst%3DM.%26atitle%3DZoledronic%2520acid%2520induces%2520apoptosis%2520and%2520S-phase%2520arrest%2520in%2520mesothelioma%2520through%2520inhibiting%2520Rab%2520family%2520proteins%2520and%2520topoisomerase%2520II%2520actions%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2014%26volume%3D5%26spage%3De1517%26doi%3D10.1038%2Fcddis.2014.475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
de Donk, N. W. C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lokhorst, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nijhuis, E. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamphuis, M. M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloem, A. C.</span></span> <span> </span><span class="NLM_article-title">Geranylgeranylated proteins are involved in the regulation of myeloma cell growth</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">439</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=15701825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD2MXislWgtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=429-439&author=N.+W.+C.+J.+Van%0Ade+Donkauthor=H.+M.+Lokhorstauthor=E.+H.+J.+Nijhuisauthor=M.+M.+J.+Kamphuisauthor=A.+C.+Bloem&title=Geranylgeranylated+proteins+are+involved+in+the+regulation+of+myeloma+cell+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Geranylgeranylated proteins are involved in the regulation of myeloma cell growth</span></div><div class="casAuthors">van de Donk, Niels W. C. J.; Lokhorst, Henk M.; Nijhuis, Evert H. J.; Kamphuis, Marloes M. J.; Bloem, Andries C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2, Pt. 1</span>),
    <span class="NLM_cas:pages">429-439</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Prenylation is essential for membrane localization and participation of proteins in various signaling pathways.  This study examd. the role of farnesylated and geranylgeranylated proteins in the regulation of myeloma cell proliferation.  Antiproliferative and apoptotic effects of various modulators of farnesylated and geranylgeranylated proteins were investigated in myeloma cells.  Depletion of geranylgeranylpyrophosphate inhibited myeloma cell proliferation through accumulation of cells in G1 phase of the cell cycle and loss of cells in S phase.  In contrast, depletion of farnesylpyrophosphate had no or only minor effects.  Furthermore, inhibition of geranylgeranyl transferase I activity was more effective in reducing myeloma cell growth when compared with inhibition of farnesyl transferase activity.  This indicates that protein geranylgeranylation is important for myeloma cell proliferation and cell cycle progression through G1.  Geranylgeranylated target proteins involved in the control of proliferation include GTPases, such as Rac-1, Cdc42, and RhoA.  Inhibition of Rho, Rac, and Cdc42 GTPases by toxin B reduced proliferation, without affecting cell viability, whereas specific inhibition of Rho GTPases by C3 exoenzyme was without effect.  This suggests a role for Rac and/or Cdc42 GTPases in myeloma cell growth.  Rac-1 activity was found in all myeloma cell lines and was suppressed by the depletion of intracellular pools of geranylgeranylpyrophosphate, whereas interleukin-6 rapidly induced Rac-1 activation.  Furthermore, dominant-neg. Tat-Rac-1 reduced myeloma cell proliferation, whereas constitutively active Tat-Rac-1 enhanced proliferation.  These results indicate that protein geranylgeranylation is essential for myeloma cell proliferation and suggest that Rac-1 is a regulator of myeloma cell growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWXGCjQMNcbLVg90H21EOLACvtfcHk0lhUNFLKPETu0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXislWgtrs%253D&md5=16cb7b0245ce22f3ee703e6adccbe4be</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bde%2BDonk%26aufirst%3DN.%2BW.%2BC.%2BJ.%26aulast%3DLokhorst%26aufirst%3DH.%2BM.%26aulast%3DNijhuis%26aufirst%3DE.%2BH.%2BJ.%26aulast%3DKamphuis%26aufirst%3DM.%2BM.%2BJ.%26aulast%3DBloem%26aufirst%3DA.%2BC.%26atitle%3DGeranylgeranylated%2520proteins%2520are%2520involved%2520in%2520the%2520regulation%2520of%2520myeloma%2520cell%2520growth%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D429%26epage%3D439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holstein, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohl, R. J.</span></span> <span> </span><span class="NLM_article-title">Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">551</span>– <span class="NLM_lpage">559</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2010.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1016%2Fj.leukres.2010.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=20828814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtV2ru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2011&pages=551-559&author=S.+A.+Holsteinauthor=R.+J.+Hohl&title=Isoprenoid+biosynthetic+pathway+inhibition+disrupts+monoclonal+protein+secretion+and+induces+the+unfolded+protein+response+pathway+in+multiple+myeloma+cells&doi=10.1016%2Fj.leukres.2010.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells</span></div><div class="casAuthors">Holstein, Sarah A.; Hohl, Raymond J.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">551-559</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Myeloma is characterized by the overprodn. and secretion of monoclonal protein.  Inhibitors of the isoprenoid biosynthetic pathway (IBP) have pleiotropic effects in myeloma cells.  To investigate whether IBP inhibition interferes with monoclonal protein secretion, human myeloma cells were treated with specific inhibitors of the IBP or prenyltransferases.  These studies demonstrate that agents that inhibit Rab geranylgeranylation disrupt light chain trafficking, lead to accumulation of light chain in the endoplasmic reticulum, activate the unfolded protein response pathway and induce apoptosis.  These studies provide a novel mechanism of action for IBP inhibitors and suggest that further exploration of Rab-targeted agents in myeloma is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoveCupAqPavrVg90H21EOLACvtfcHk0lhUNFLKPETu0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtV2ru7g%253D&md5=c7c2c8ba4025668eb4c83cba8c57b7d3</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2010.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2010.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DHolstein%26aufirst%3DS.%2BA.%26aulast%3DHohl%26aufirst%3DR.%2BJ.%26atitle%3DIsoprenoid%2520biosynthetic%2520pathway%2520inhibition%2520disrupts%2520monoclonal%2520protein%2520secretion%2520and%2520induces%2520the%2520unfolded%2520protein%2520response%2520pathway%2520in%2520multiple%2520myeloma%2520cells%26jtitle%3DLeuk.%2520Res.%26date%3D2011%26volume%3D35%26spage%3D551%26epage%3D559%26doi%3D10.1016%2Fj.leukres.2010.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">The
Cancer Cell Line Encyclopedia and Genomics of Drug Sensitivity in
Cancer Consortium.</span> <span> </span><span class="NLM_article-title">Pharmacogenomic
agreement between two cancer cell line data sets</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>528</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">87</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=528&publication_year=2015&pages=84-87&author=The%0ACancer+Cell+Line+Encyclopedia+and+Genomics+of+Drug+Sensitivity+in%0ACancer+Consortium.&title=Pharmacogenomic%0Aagreement+between+two+cancer+cell+line+data+sets"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DPharmacogenomic%250Aagreement%2520between%2520two%2520cancer%2520cell%2520line%2520data%2520sets%26jtitle%3DNature%26date%3D2015%26volume%3D528%26spage%3D84%26epage%3D87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craig, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurdoglu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auclair, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kidd, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagannath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vij, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orloff, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, T. M.</span></span>; <span class="NLM_contrib-group">Mmrf CoMMpass Network</span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capone, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonial, S.</span></span> <span> </span><span class="NLM_article-title">Interim analysis of the mmrf commpass trial, a longitudinal study in multiple myeloma relating clinical outcomes to genomic and immunophenotypic profiles</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">532</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=532&author=J.+J.+Keatsauthor=D.+W.+Craigauthor=W.+Liangauthor=Y.+Venkataauthor=A.+Kurdogluauthor=J.+Aldrichauthor=D.+Auclairauthor=K.+Allenauthor=B.+Harrisonauthor=S.+Jewellauthor=P.+G.+Kiddauthor=M.+Correllauthor=S.+Jagannathauthor=D.+S.+Siegelauthor=R.+Vijauthor=G.+Orloffauthor=T.+M.+Zimmermanauthor=Mmrf+CoMMpass+Networkauthor=W.+Caponeauthor=J.+Carptenauthor=S.+Lonial&title=Interim+analysis+of+the+mmrf+commpass+trial%2C+a+longitudinal+study+in+multiple+myeloma+relating+clinical+outcomes+to+genomic+and+immunophenotypic+profiles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKeats%26aufirst%3DJ.%2BJ.%26aulast%3DCraig%26aufirst%3DD.%2BW.%26aulast%3DLiang%26aufirst%3DW.%26aulast%3DVenkata%26aufirst%3DY.%26aulast%3DKurdoglu%26aufirst%3DA.%26aulast%3DAldrich%26aufirst%3DJ.%26aulast%3DAuclair%26aufirst%3DD.%26aulast%3DAllen%26aufirst%3DK.%26aulast%3DHarrison%26aufirst%3DB.%26aulast%3DJewell%26aufirst%3DS.%26aulast%3DKidd%26aufirst%3DP.%2BG.%26aulast%3DCorrell%26aufirst%3DM.%26aulast%3DJagannath%26aufirst%3DS.%26aulast%3DSiegel%26aufirst%3DD.%2BS.%26aulast%3DVij%26aufirst%3DR.%26aulast%3DOrloff%26aufirst%3DG.%26aulast%3DZimmerman%26aufirst%3DT.%2BM.%26aulast%3D%26aulast%3DCapone%26aufirst%3DW.%26aulast%3DCarpten%26aufirst%3DJ.%26aulast%3DLonial%26aufirst%3DS.%26atitle%3DInterim%2520analysis%2520of%2520the%2520mmrf%2520commpass%2520trial%252C%2520a%2520longitudinal%2520study%2520in%2520multiple%2520myeloma%2520relating%2520clinical%2520outcomes%2520to%2520genomic%2520and%2520immunophenotypic%2520profiles%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26spage%3D532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lonial, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yellapantula, V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurdoglu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legendre, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephenson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adkins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christofferson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuyugan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohrer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodges, M.</span></span>; <span class="NLM_contrib-group">Mmrf CoMMpass Network</span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derome, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auclair, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kidd, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craig, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J. J.</span></span> <span> </span><span class="NLM_article-title">Interim analysis of the Mmrf Commpass Trial: identification of novel rearrangements potentially associated with disease initiation and progression</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">722</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=722&author=S.+Lonialauthor=V.+D.+Yellapantulaauthor=W.+Liangauthor=A.+Kurdogluauthor=J.+Aldrichauthor=C.+M.+Legendreauthor=K.+Stephensonauthor=J.+Adkinsauthor=J.+McDonaldauthor=A.+Hellandauthor=M.+Russellauthor=A.+Christoffersonauthor=L.+Cuyuganauthor=D.+Rohrerauthor=A.+Blanskiauthor=M.+Hodgesauthor=Mmrf+CoMMpass+Networkauthor=M.+Deromeauthor=D.+Auclairauthor=P.+G.+Kiddauthor=S.+Jewellauthor=D.+Craigauthor=J.+Carptenauthor=J.+J.+Keats&title=Interim+analysis+of+the+Mmrf+Commpass+Trial%3A+identification+of+novel+rearrangements+potentially+associated+with+disease+initiation+and+progression"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLonial%26aufirst%3DS.%26aulast%3DYellapantula%26aufirst%3DV.%2BD.%26aulast%3DLiang%26aufirst%3DW.%26aulast%3DKurdoglu%26aufirst%3DA.%26aulast%3DAldrich%26aufirst%3DJ.%26aulast%3DLegendre%26aufirst%3DC.%2BM.%26aulast%3DStephenson%26aufirst%3DK.%26aulast%3DAdkins%26aufirst%3DJ.%26aulast%3DMcDonald%26aufirst%3DJ.%26aulast%3DHelland%26aufirst%3DA.%26aulast%3DRussell%26aufirst%3DM.%26aulast%3DChristofferson%26aufirst%3DA.%26aulast%3DCuyugan%26aufirst%3DL.%26aulast%3DRohrer%26aufirst%3DD.%26aulast%3DBlanski%26aufirst%3DA.%26aulast%3DHodges%26aufirst%3DM.%26aulast%3D%26aulast%3DDerome%26aufirst%3DM.%26aulast%3DAuclair%26aufirst%3DD.%26aulast%3DKidd%26aufirst%3DP.%2BG.%26aulast%3DJewell%26aufirst%3DS.%26aulast%3DCraig%26aufirst%3DD.%26aulast%3DCarpten%26aufirst%3DJ.%26aulast%3DKeats%26aufirst%3DJ.%2BJ.%26atitle%3DInterim%2520analysis%2520of%2520the%2520Mmrf%2520Commpass%2520Trial%253A%2520identification%2520of%2520novel%2520rearrangements%2520potentially%2520associated%2520with%2520disease%2520initiation%2520and%2520progression%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speyer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christofferson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legendre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuyugan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adkins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodges, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohrer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagannath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vij, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orloff, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niesvizky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fay, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rifkin, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, N. C.</span></span>; <span class="NLM_contrib-group">Mmrf CoMMpass Network</span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yesil, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derome, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kidd, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpten, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auclair, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonial, S.</span></span> <span> </span><span class="NLM_article-title">Molecular predictors of outcome and drug response in multiple myeloma: An interim analysis of the Mmrf CoMMpass study</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">194</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=194&author=J.+J.+Keatsauthor=G.+Speyerauthor=A.+Christoffersonauthor=C.+Legendreauthor=J.+Aldrichauthor=M.+Russellauthor=L.+Cuyuganauthor=J.+Adkinsauthor=A.+Blanskiauthor=M.+Hodgesauthor=D.+Rohrerauthor=S.+Jagannathauthor=R.+Vijauthor=G.+Orloffauthor=T.+Zimmermanauthor=R.+Niesvizkyauthor=D.+Lilesauthor=J.+W.+Fayauthor=J.+L.+Wolfauthor=R.+M.+Rifkinauthor=N.+C.+Gutierrezauthor=Mmrf+CoMMpass+Networkauthor=J.+Yesilauthor=M.+Deromeauthor=S.+Kimauthor=W.+Liangauthor=P.+G.+Kiddauthor=S.+Jewellauthor=J.+D.+Carptenauthor=D.+Auclairauthor=S.+Lonial&title=Molecular+predictors+of+outcome+and+drug+response+in+multiple+myeloma%3A+An+interim+analysis+of+the+Mmrf+CoMMpass+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKeats%26aufirst%3DJ.%2BJ.%26aulast%3DSpeyer%26aufirst%3DG.%26aulast%3DChristofferson%26aufirst%3DA.%26aulast%3DLegendre%26aufirst%3DC.%26aulast%3DAldrich%26aufirst%3DJ.%26aulast%3DRussell%26aufirst%3DM.%26aulast%3DCuyugan%26aufirst%3DL.%26aulast%3DAdkins%26aufirst%3DJ.%26aulast%3DBlanski%26aufirst%3DA.%26aulast%3DHodges%26aufirst%3DM.%26aulast%3DRohrer%26aufirst%3DD.%26aulast%3DJagannath%26aufirst%3DS.%26aulast%3DVij%26aufirst%3DR.%26aulast%3DOrloff%26aufirst%3DG.%26aulast%3DZimmerman%26aufirst%3DT.%26aulast%3DNiesvizky%26aufirst%3DR.%26aulast%3DLiles%26aufirst%3DD.%26aulast%3DFay%26aufirst%3DJ.%2BW.%26aulast%3DWolf%26aufirst%3DJ.%2BL.%26aulast%3DRifkin%26aufirst%3DR.%2BM.%26aulast%3DGutierrez%26aufirst%3DN.%2BC.%26aulast%3D%26aulast%3DYesil%26aufirst%3DJ.%26aulast%3DDerome%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLiang%26aufirst%3DW.%26aulast%3DKidd%26aufirst%3DP.%2BG.%26aulast%3DJewell%26aufirst%3DS.%26aulast%3DCarpten%26aufirst%3DJ.%2BD.%26aulast%3DAuclair%26aufirst%3DD.%26aulast%3DLonial%26aufirst%3DS.%26atitle%3DMolecular%2520predictors%2520of%2520outcome%2520and%2520drug%2520response%2520in%2520multiple%2520myeloma%253A%2520An%2520interim%2520analysis%2520of%2520the%2520Mmrf%2520CoMMpass%2520study%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26spage%3D194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Beek, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löwik, C. W. G.
M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papapoulos, S. E.</span></span> <span> </span><span class="NLM_article-title">Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors</span>. <i>Bone</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">64</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/S8756-3282(01)00655-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1016%2FS8756-3282%2801%2900655-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=64-70&author=E.+R.+Van%0ABeekauthor=C.+W.+G.%0AM.+L%C3%B6wikauthor=S.+E.+Papapoulos&title=Bisphosphonates+suppress+bone+resorption+by+a+direct+effect+on+early+osteoclast+precursors+without+affecting+the+osteoclastogenic+capacity+of+osteogenic+cells%3A+the+role+of+protein+geranylgeranylation+in+the+action+of+nitrogen-containing+bisphosphonates+on+osteoclast+precursors&doi=10.1016%2FS8756-3282%2801%2900655-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2FS8756-3282%2801%2900655-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS8756-3282%252801%252900655-X%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BBeek%26aufirst%3DE.%2BR.%26aulast%3DL%25C3%25B6wik%26aufirst%3DC.%2BW.%2BG.%2BM.%26aulast%3DPapapoulos%26aufirst%3DS.%2BE.%26atitle%3DBisphosphonates%2520suppress%2520bone%2520resorption%2520by%2520a%2520direct%2520effect%2520on%2520early%2520osteoclast%2520precursors%2520without%2520affecting%2520the%2520osteoclastogenic%2520capacity%2520of%2520osteogenic%2520cells%253A%2520the%2520role%2520of%2520protein%2520geranylgeranylation%2520in%2520the%2520action%2520of%2520nitrogen-containing%2520bisphosphonates%2520on%2520osteoclast%2520precursors%26jtitle%3DBone%26date%3D2002%26volume%3D30%26spage%3D64%26epage%3D70%26doi%3D10.1016%2FS8756-3282%2801%2900655-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, C.</span></span> <span> </span><span class="NLM_article-title">An <i>in vitro</i> assay to measure targeted drug delivery to bone mineral</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">770</span>– <span class="NLM_lpage">776</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201000016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1002%2Fcmdc.201000016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=770-776&author=W.+Jahnkeauthor=C.+Henry&title=An+in+vitro+assay+to+measure+targeted+drug+delivery+to+bone+mineral&doi=10.1002%2Fcmdc.201000016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201000016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201000016%26sid%3Dliteratum%253Aachs%26aulast%3DJahnke%26aufirst%3DW.%26aulast%3DHenry%26aufirst%3DC.%26atitle%3DAn%2520in%2520vitro%2520assay%2520to%2520measure%2520targeted%2520drug%2520delivery%2520to%2520bone%2520mineral%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D770%26epage%3D776%26doi%3D10.1002%2Fcmdc.201000016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chesi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbitt, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shortt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefebure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergsagel, P. L.</span></span> <span> </span><span class="NLM_article-title">Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">376</span>– <span class="NLM_lpage">385</span>, <span class="refDoi"> DOI: 10.1182/blood-2012-02-412783</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1182%2Fblood-2012-02-412783" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2012&pages=376-385&author=M.+Chesiauthor=G.+M.+Matthewsauthor=V.+M.+Garbittauthor=S.+E.+Palmerauthor=J.+Shorttauthor=M.+Lefebureauthor=A.+K.+Stewartauthor=R.+W.+Johnstoneauthor=P.+L.+Bergsagel&title=Drug+response+in+a+genetically+engineered+mouse+model+of+multiple+myeloma+is+predictive+of+clinical+efficacy&doi=10.1182%2Fblood-2012-02-412783"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1182%2Fblood-2012-02-412783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2012-02-412783%26sid%3Dliteratum%253Aachs%26aulast%3DChesi%26aufirst%3DM.%26aulast%3DMatthews%26aufirst%3DG.%2BM.%26aulast%3DGarbitt%26aufirst%3DV.%2BM.%26aulast%3DPalmer%26aufirst%3DS.%2BE.%26aulast%3DShortt%26aufirst%3DJ.%26aulast%3DLefebure%26aufirst%3DM.%26aulast%3DStewart%26aufirst%3DA.%2BK.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26aulast%3DBergsagel%26aufirst%3DP.%2BL.%26atitle%3DDrug%2520response%2520in%2520a%2520genetically%2520engineered%2520mouse%2520model%2520of%2520multiple%2520myeloma%2520is%2520predictive%2520of%2520clinical%2520efficacy%26jtitle%3DBlood%26date%3D2012%26volume%3D120%26spage%3D376%26epage%3D385%26doi%3D10.1182%2Fblood-2012-02-412783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Palou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebag, M.</span></span> <span> </span><span class="NLM_article-title">A transgenic model of multiple myeloma bone disease shows profound mesenchymal stem cell impairment</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">130</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2013&pages=130&author=M.+Gomez-Palouauthor=H.+Fangauthor=R.+Kremerauthor=M.+Sebag&title=A+transgenic+model+of+multiple+myeloma+bone+disease+shows+profound+mesenchymal+stem+cell+impairment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGomez-Palou%26aufirst%3DM.%26aulast%3DFang%26aufirst%3DH.%26aulast%3DKremer%26aufirst%3DR.%26aulast%3DSebag%26aufirst%3DM.%26atitle%3DA%2520transgenic%2520model%2520of%2520multiple%2520myeloma%2520bone%2520disease%2520shows%2520profound%2520mesenchymal%2520stem%2520cell%2520impairment%26jtitle%3DBlood%26date%3D2013%26volume%3D112%26spage%3D130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vieira, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajewsky, K.</span></span> <span> </span><span class="NLM_article-title">The half-lives of serum immunoglobulins in adult mice</span>. <i>Eur. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">313</span>– <span class="NLM_lpage">316</span>, <span class="refDoi"> DOI: 10.1002/eji.1830180221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1002%2Feji.1830180221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=3350037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADyaL1cXhvVCrs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1988&pages=313-316&author=P.+Vieiraauthor=K.+Rajewsky&title=The+half-lives+of+serum+immunoglobulins+in+adult+mice&doi=10.1002%2Feji.1830180221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">The half-lives of serum immunoglobulins in adult mice</span></div><div class="casAuthors">Vieira, Paulo; Rajewsky, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Immunology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">313-16</span>CODEN:
                <span class="NLM_cas:coden">EJIMAF</span>;
        ISSN:<span class="NLM_cas:issn">0014-2980</span>.
    </div><div class="casAbstract">The half-lives were detd. of several sets of murine monoclonal antibodies spanning all Ig isotypes in the serum.  The antibodies in each set possess the same V region.  With this approach, the differences in half-life obsd. between the different isotypes are independent of the V region carried by the monoclonal antibodies and therefore must relate to each other in the same way as the half-lives of each class of serum Igs.  The half-life of a monoclonal antibody of the γ2a isotype is identical to the av. half-life of serum IgG2a as previously detd. (6-8 days).  Therefore, the half-lives detd. with monoclonal antibodies possessing the same V region represent the half-life of the serum Igs.  In this way, the half-life of IgM was calcd. to be 2 days, IgG3 and IgG1 was 6-8 days, and IgG2b was 4-6 days.  IgE has a half-life of 12 h.  A polymeric form of IgA was eliminated from the serum with a half-life of 17-22 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0z6mWARTG1rVg90H21EOLACvtfcHk0ljs1tubX9LLfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXhvVCrs7Y%253D&md5=2c644134b8964794b3391b7c796f8537</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Feji.1830180221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Feji.1830180221%26sid%3Dliteratum%253Aachs%26aulast%3DVieira%26aufirst%3DP.%26aulast%3DRajewsky%26aufirst%3DK.%26atitle%3DThe%2520half-lives%2520of%2520serum%2520immunoglobulins%2520in%2520adult%2520mice%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D1988%26volume%3D18%26spage%3D313%26epage%3D316%26doi%3D10.1002%2Feji.1830180221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span> For a recent review
on the biology/physiology and clinical characteristics of multiply
myeloma, refer to the following:<span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, N.</span></span> <span> </span><span class="NLM_article-title">Pathogenesis beyond the cancer clone(s) in multiple myeloma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">3049</span>– <span class="NLM_lpage">3058</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-11-568881</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1182%2Fblood-2014-11-568881" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=25838343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFGqsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=3049-3058&author=G.+Bianchiauthor=N.+Munshi&title=Pathogenesis+beyond+the+cancer+clone%28s%29+in+multiple+myeloma&doi=10.1182%2Fblood-2014-11-568881"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Pathogenesis beyond the cancer clone(s) in multiple myeloma</span></div><div class="casAuthors">Bianchi, Giada; Munshi, Nikhil C.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3049-3058</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  Over the past 4 decades, basic research has provided crucial information regarding the cellular and mol. biol. of cancer.  In particular, the relevance of cancer microenvironment (including both cellular and noncellular elements) and the concept of clonal evolution and heterogeneity have emerged as important in cancer pathogenesis, immunol. escape, and resistance to therapy.  Multiple myeloma (MM), a cancer of terminally differentiated plasma cells, is emblematic of the impact of cancer microenvironment and the role of clonal evolution.  Although genetic and epigenetic aberrations occur in MM and evolve over time under the pressure of exogenous stimuli, they are also largely present in premalignant plasma cell dyscrasia such as monoclonal gammopathy of undetd. significance (MGUS) and smoldering multiple myeloma (SMM), suggesting that genetic mutations alone are necessary, but not sufficient, for myeloma transformation.  The role of bone marrow microenvironment in mediating survival, proliferation, and resistance to therapy in myeloma is well established; and although an appealing speculation, its role in fostering the evolution of MGUS or SMM into MM is yet to be proven.  In this review, we discuss MM pathogenesis with a particular emphasis on the role of bone marrow microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrltD2PWpKFIbVg90H21EOLACvtfcHk0ljs1tubX9LLfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFGqsLY%253D&md5=f82070898f2c44ea219884e64dc8f5c3</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-11-568881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-11-568881%26sid%3Dliteratum%253Aachs%26aulast%3DBianchi%26aufirst%3DG.%26aulast%3DMunshi%26aufirst%3DN.%26atitle%3DPathogenesis%2520beyond%2520the%2520cancer%2520clone%2528s%2529%2520in%2520multiple%2520myeloma%26jtitle%3DBlood%26date%3D2015%26volume%3D125%26spage%3D3049%26epage%3D3058%26doi%3D10.1182%2Fblood-2014-11-568881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coxon, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helfrich, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van’t
Hof, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ralston, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, M. J.</span></span> <span> </span><span class="NLM_article-title">Protein geranylgeranylation is required for osteoclast formation, function and survival: Inhibition by bisphosphonates and GGTI-298</span>. <i>J. Bone Miner. Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1467</span>– <span class="NLM_lpage">1476</span>, <span class="refDoi"> DOI: 10.1359/jbmr.2000.15.8.1467</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1359%2Fjbmr.2000.15.8.1467" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10934645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlvVSjsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2000&pages=1467-1476&author=F.+P.+Coxonauthor=M.+H.+Helfrichauthor=R.+van%E2%80%99t%0AHofauthor=S.+Sebtiauthor=S.+H.+Ralstonauthor=A.+Hamiltonauthor=M.+J.+Rogers&title=Protein+geranylgeranylation+is+required+for+osteoclast+formation%2C+function+and+survival%3A+Inhibition+by+bisphosphonates+and+GGTI-298&doi=10.1359%2Fjbmr.2000.15.8.1467"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298</span></div><div class="casAuthors">Coxon, Fraser P.; Helfrich, Miep H.; Van't Hof, Robert; Sebti, Said; Ralston, Stuart H.; Hamilton, Andrew; Rogers, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bone and Mineral Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1467-1476</span>CODEN:
                <span class="NLM_cas:coden">JBMREJ</span>;
        ISSN:<span class="NLM_cas:issn">0884-0431</span>.
    
            (<span class="NLM_cas:orgname">American Society for Bone and Mineral Research</span>)
        </div><div class="casAbstract">Bisphosphonates are the important class of antiresorptive drugs used in the treatment of metabolic bone diseases.  Although their mol. mechanism of action has not been fully elucidated, recent studies have shown that the nitrogen-contg. bisphosphonates can inhibit protein prenylation in macrophages in vitro.  In this study, we show that the nitrogen-contg. bisphosphonates risedronate, zoledronate, ibandronate, alendronate, and pamidronate (but not the non nitrogen-contg. bisphosphonates clodronate, etidronate, and tiludronate) prevent the incorporation of [14C]mevalonate into prenylated (farnesylated and geranylgeranylated) proteins in purified rabbit osteoclasts.  The inhibitory effect of nitrogen-contg. bisphosphonates on bone resorption is likely to result largely from the loss of geranylgeranylated proteins rather than loss of farnesylated proteins in osteoclasts, because concns. of GGTI-298 (a specific inhibitor of geranylgeranyl transferase I) that inhibited protein geranylgeranylation in purified rabbit osteoclasts prevented osteoclast formation in murine bone marrow cultures, disrupted the osteoclast cytoskeleton, inhibited bone resorption, and induced apoptosis in isolated chick and rabbit osteoclasts in vitro.  By contrast, concns. of FTI-277 (a specific inhibitor of farnesyl transferase) that prevented protein farnesylation in purified rabbit osteoclasts had little effect on osteoclast morphol. or apoptosis and did not inhibit bone resorption.  These results therefore show the mol. mechanism of action of nitrogen-contg. bisphosphonate drugs in osteoclasts and highlight the fundamental importance of geranylgeranylated proteins in osteoclast formation and function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDC_HEW6PkGrVg90H21EOLACvtfcHk0ljs1tubX9LLfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlvVSjsLw%253D&md5=6dfe84e31fc6e121470fbd0185d993e5</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1359%2Fjbmr.2000.15.8.1467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1359%252Fjbmr.2000.15.8.1467%26sid%3Dliteratum%253Aachs%26aulast%3DCoxon%26aufirst%3DF.%2BP.%26aulast%3DHelfrich%26aufirst%3DM.%2BH.%26aulast%3Dvan%25E2%2580%2599t%2BHof%26aufirst%3DR.%26aulast%3DSebti%26aufirst%3DS.%26aulast%3DRalston%26aufirst%3DS.%2BH.%26aulast%3DHamilton%26aufirst%3DA.%26aulast%3DRogers%26aufirst%3DM.%2BJ.%26atitle%3DProtein%2520geranylgeranylation%2520is%2520required%2520for%2520osteoclast%2520formation%252C%2520function%2520and%2520survival%253A%2520Inhibition%2520by%2520bisphosphonates%2520and%2520GGTI-298%26jtitle%3DJ.%2520Bone%2520Miner.%2520Res.%26date%3D2000%26volume%3D15%26spage%3D1467%26epage%3D1476%26doi%3D10.1359%2Fjbmr.2000.15.8.1467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbay, J. K.</span>; <span class="NLM_string-name">Chakravarty, D.</span>; <span class="NLM_string-name">Shook, B.
C.</span>; <span class="NLM_string-name">Wang, A.</span></span> <span> </span><span class="NLM_article-title">Methylene Amines of Thieno[2,3-<i>d</i>]pyrimidine and Their Use as Adenosine a2a Receptor Antagonists</span>. <span class="NLM_patent">WO2010/045006 A1</span>, April 22, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+K.+Barbay&author=D.+Chakravarty&author=B.%0AC.+Shook&author=A.+Wang&title=Methylene+Amines+of+Thieno%5B2%2C3-d%5Dpyrimidine+and+Their+Use+as+Adenosine+a2a+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBarbay%26aufirst%3DJ.%2BK.%26atitle%3DMethylene%2520Amines%2520of%2520Thieno%255B2%252C3-d%255Dpyrimidine%2520and%2520Their%2520Use%2520as%2520Adenosine%2520a2a%2520Receptor%2520Antagonists%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liebeskind, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srogl, J.</span></span> <span> </span><span class="NLM_article-title">Heteroaromatic thioether-boronic acid cross-coupling under neutral reaction conditions</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">979</span>– <span class="NLM_lpage">981</span>, <span class="refDoi"> DOI: 10.1021/ol0200091</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol0200091" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=1%3ACAS%3A528%3ADC%252BD38Xht1Gktb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2002&pages=979-981&author=L.+S.+Liebeskindauthor=J.+Srogl&title=Heteroaromatic+thioether-boronic+acid+cross-coupling+under+neutral+reaction+conditions&doi=10.1021%2Fol0200091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Heteroaromatic Thioether-Boronic Acid Cross-Coupling under Neutral Reaction Conditions</span></div><div class="casAuthors">Liebeskind, Lanny S.; Srogl, Jiri</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">979-981</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">π-Deficient heteroarom. thioethers undergo efficient palladium-catalyzed cross-coupling with boronic acids, mediated by copper(I) thiophene-2-carboxylate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowmqoxHMYfLbVg90H21EOLACvtfcHk0likUoyLxSG4Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xht1Gktb0%253D&md5=ce42d2952572e0b36f0f60e6037a18f6</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fol0200091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol0200091%26sid%3Dliteratum%253Aachs%26aulast%3DLiebeskind%26aufirst%3DL.%2BS.%26aulast%3DSrogl%26aufirst%3DJ.%26atitle%3DHeteroaromatic%2520thioether-boronic%2520acid%2520cross-coupling%2520under%2520neutral%2520reaction%2520conditions%26jtitle%3DOrg.%2520Lett.%26date%3D2002%26volume%3D4%26spage%3D979%26epage%3D981%26doi%3D10.1021%2Fol0200091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wetzel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchais-Oberwinkler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, R.-W.</span></span> <span> </span><span class="NLM_article-title">17b-HSD2 inhibitors for the treatment of osteoporosis: Identification of a promising scaffold</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">807</span>– <span class="NLM_lpage">815</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.12.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;key=10.1016%2Fj.bmc.2010.12.013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=807-815&author=M.+Wetzelauthor=S.+Marchais-Oberwinklerauthor=R.-W.+Hartmann&title=17b-HSD2+inhibitors+for+the+treatment+of+osteoporosis%3A+Identification+of+a+promising+scaffold&doi=10.1016%2Fj.bmc.2010.12.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.12.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.12.013%26sid%3Dliteratum%253Aachs%26aulast%3DWetzel%26aufirst%3DM.%26aulast%3DMarchais-Oberwinkler%26aufirst%3DS.%26aulast%3DHartmann%26aufirst%3DR.-W.%26atitle%3D17b-HSD2%2520inhibitors%2520for%2520the%2520treatment%2520of%2520osteoporosis%253A%2520Identification%2520of%2520a%2520promising%2520scaffold%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D807%26epage%3D815%26doi%3D10.1016%2Fj.bmc.2010.12.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6C56" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6C56','PDB','6C56'); return false;">PDB: 6C56</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6C57" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6C57','PDB','6C57'); return false;">PDB: 6C57</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2Q80" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2Q80','PDB','2Q80'); return false;">PDB: 2Q80</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2E8T" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2E8T','PDB','2E8T'); return false;">PDB: 2E8T</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i31"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00886">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_88384"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the ACS Publications Web site at DOI:10.1021/acs.jmedchem- .  (CSV). The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b00886">10.1021/acs.jmedchem.8b00886</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Experimental procedures for (a) the expression, purification, and in vitro assay of recombinant hGGPPS, (b) creation of the dimeric Y246D mutant of hGGPPS and crystallographic studies with inhibitor <b>10d</b>, (c) cell culture and viability assays for MM cell lines, (d) cell culture for various other cancer cell lines (non-MM), (e) determination of cancer cell viability for non-MM cancer cells, (f) annexin-V apoptosis assays, (g) Western blot analysis, (h) XBP1 mRNA splicing, (i) metabolic stability, (j) in vivo experiments with MM mouse diseases model, (k) serum protein electrophoresis (SPEP), (l) isolation of peripheral blood mononuclear cells (PBMCs), (m) DSF studies; Figures S1–S8; Tables S1–S3; <sup>1</sup>H, <sup>31</sup>C, <sup>31</sup>P NMR spectra and HPLC chromatograms for inhibitors <b>10a</b>–<b>d</b> and <b>11a</b>–<b>c</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00886/suppl_file/jm8b00886_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and biological data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00886/suppl_file/jm8b00886_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00886/suppl_file/jm8b00886_si_001.pdf">jm8b00886_si_001.pdf (2.61 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00886/suppl_file/jm8b00886_si_002.csv">jm8b00886_si_002.csv (1.25 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The PDB accession codes for the X-ray structures of the dimeric hGGPPS Y245D mutant and the structure of <b>10d</b> bound to this mutant are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6C56">6C56</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6C57">6C57</a>, respectively. Authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b00886&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b00886%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-15%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b00886" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799817d0b773c9a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
